| Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial 2023 · calcifediol · Adults receiving ChAdOx1 nCoV-19 vaccine; age range and sex not specified | 50 mcg | 26 weeks | 262 |
| A 2-Year Follow-Up After a 2-Year RCT with Vitamin D and Exercise: Effects on Falls, Injurious Falls and Physical Functioning Among Older Women 2017 · D+ Ex− (vitamin D without exercise) · Home-dwelling women aged 70–80 years | 20 mcg | 2 years | 102 |
| A 2-Year Follow-Up After a 2-Year RCT with Vitamin D and Exercise: Effects on Falls, Injurious Falls and Physical Functioning Among Older Women 2017 · D+ Ex+ (vitamin D with exercise) · Home-dwelling women aged 70–80 years | 20 mcg | 2 years | 102 |
| Improved Healing of Diabetic Foot Ulcers After High-dose Vitamin D: A Randomized Double-blinded Clinical Trial 2023 · high-dose vitamin D3 · People with diabetes and one or more foot ulcers lasting more than 6 weeks | 170 mcg | 48 weeks | 24 |
| Improved Healing of Diabetic Foot Ulcers After High-dose Vitamin D: A Randomized Double-blinded Clinical Trial 2023 · low-dose vitamin D3 · People with diabetes and one or more foot ulcers lasting more than 6 weeks | 20 mcg | 48 weeks | 24 |
| Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial 2006 · D(+) group · Patients with congestive heart failure; age and sex not specified | 50 mcg | 270 days | — |
| Effects of Vitamin D on Cardiac Function in Patients With Chronic HF: The VINDICATE Study 2016 · Vitamin D · Adults with vitamin D-deficient chronic heart failure due to left ventricular systolic dysfunction; stable NYHA class II or III symptoms | 100 mcg | 1 year | 80 |
| Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients 2004 · 100 mcg (4000 IU)/day · Adults attending an endocrinology clinic with low serum 25(OH)D; age and sex varied | 100 mcg | 1 year | 66 |
| Vitamin D Status and Physical Activity during Wintertime in Forensic Inpatients-A Randomized Clinical Trial 2021 · Intervention group (vitamin D) · Male forensic inpatients; age range 31–81 years in the analysed sample | 40 mcg | 135 days | 43 |
| A 12-week double-blind randomized clinical trial of vitamin D₃ supplementation on body fat mass in healthy overweight and obese women 2012 · vitamin D group · Women aged 18–50 with BMI ≥25 kg/m², apparently healthy and overweight or obese | 25 mcg | 90 days | 42 |
| Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial 2017 · calcitriol · Patients with non-alcoholic fatty liver disease (NAFLD) following an energy-restricted weight-loss program; age and sex not stated | 25 mcg | 12 weeks | 37 |
| Effects of vitamin D supplementation on depressive symptoms in type 2 diabetes mellitus patients: Randomized placebo-controlled double-blind clinical trial 2019 · Vitamin D group · Adults with type 2 diabetes mellitus and mild to moderate depressive symptoms | 100 mcg | 12 weeks | 32 |
| A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D(3) supplementation in adult patients with migraine 2019 · D3-Vitamin · Adults aged 18–65 with migraine | 100 mcg | 24 weeks | 24 |
| A 12-week double-blind randomised controlled trial investigating the effect of dietary supplementation with 125 μg/d vitamin D in adults with asthma 2024 · vitamin D group · Adults aged 20–62 with mild to moderate asthma | 125 mcg | 12 weeks | 13 |
| Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers 2009 · vitamin D group · Healthy overweight adults with mean baseline 25(OH)D concentration of 30 nmol/L (12 ng/mL); age and sex distribution not stated | 83 mcg | 1 year | — |
| Bone Microstructure in Response to Vitamin D3 Supplementation: A Randomized Placebo-Controlled Trial 2019 · Vitamin D3 supplementation · Healthy postmenopausal women with low 25(OH)D at screening; age range not reported | 70 mcg | 90 days | — |
| Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial 2024 · Vitamin D · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses | 2,000 IU | 1936 days | 12,927 |
| Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial 2025 · Vitamin D · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults | 2,000 IU | 1935 days | 11,062 |
| Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial 2011 · Vitamin D group · Indian term infants with birth weight 1.8–2.5 kg, enrolled before 48 hours of age | 5 mcg | 26 weeks | 1,039 |
| Vitamin D supplementation and incidence of major depressive disorder - A randomized clinical trial 2026 · 3200 IU/day vitamin D3 · Adults with a mean age of 68.2 years; 42.5% of the overall trial population were women. No specific condition was required. | 3,200 IU | 5 years | 817 |
| Vitamin D supplementation and incidence of major depressive disorder - A randomized clinical trial 2026 · 1600 IU/day vitamin D3 · Adults with a mean age of 68.2 years; 42.5% of the overall trial population were women. No specific condition was required. | 1,600 IU | 5 years | 814 |
| Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population 2022 · Eldecalcitol group · Adults aged 30–78 years, men and women, with impaired glucose tolerance in Japan | 0.75 mcg | 3 years | 630 |
| Active vitamin D treatment in the prevention of sarcopenia in adults with prediabetes (DPVD ancillary study): a randomised controlled trial 2024 · eldecalcitol group · Adults with prediabetes; mean age 60.8 years; both sexes | 0.75 mcg | 1059 days | 548 |
| Does antenatal cholecalciferol supplementation affect the mode or timing of delivery? Post hoc analyses of the MAVIDOS randomized controlled trial 2023 · Cholecalciferol · Pregnant women aged over 18 years with singleton pregnancies and baseline 25(OH)D of 25–100 nmol/l | 1,000 IU | — | 479 |
| The Association of Prenatal Vitamin D Sufficiency With Aeroallergen Sensitization and Allergic Rhinitis in Early Childhood 2021 · high-dose vitamin D · Pregnant women aged 18–39 years at 10–18 weeks of gestation, nonsmoking, with a personal or partner history of asthma or atopy | 4,400 IU | — | 440 |
| Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial 2019 · vitamin D alone · Adults aged 45–75 with at least one adenomatous polyp detected and removed within the preceding 4 months | 1,000 IU | 5 years | 420 |
| Early pregnancy vitamin D status and risk of preeclampsia 2016 · treatment group · Pregnant women; age and condition beyond pregnancy not reported | 4,400 IU | — | 408 |
| Early pregnancy vitamin D status and risk of preeclampsia 2016 · control group · Pregnant women; age and condition beyond pregnancy not reported | 400 IU | — | 408 |
| Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial 2022 · Cholecalciferol (1000 IU daily) · Pregnant women aged over 18 years with a singleton pregnancy under 17 weeks’ gestation and baseline serum 25(OH)D of 25–100 nmol/L | 1,000 IU | — | 352 |
| High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10: A randomized clinical trial 2024 · high-dose · Pregnant women; the abstract does not give an age range or report a diagnosed condition | 2,800 IU | — | 315 |
| High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10: A randomized clinical trial 2024 · standard dose · Pregnant women; the abstract does not give an age range or report a diagnosed condition | 400 IU | — | 308 |
| Vitamin D3 Supplementation at 5000 IU Daily for the Prevention of Influenza-like Illness in Healthcare Workers: A Pragmatic Randomized Clinical Trial 2022 · vitamin D3 supplementation intervention group · Healthcare workers aged 18 years or older; no specific diagnosis or deficiency required | 5,000 IU | 270 days | 299 |
| Fish Oil and Vitamin D Supplementations in Pregnancy Protect Against Childhood Croup 2023 · High-dose vitamin D group · Pregnant women in the Danish population-based Copenhagen Prospective Studies on Asthma in Childhood 2010 mother-child cohort | 2,800 IU | 32 weeks | 295 |
| Fish Oil and Vitamin D Supplementations in Pregnancy Protect Against Childhood Croup 2023 · Standard-dose vitamin D group · Pregnant women in the Danish population-based Copenhagen Prospective Studies on Asthma in Childhood 2010 mother-child cohort | 400 IU | 32 weeks | 286 |
| Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial 2019 · vitamin D supplements · Adults aged 30 to 90 with stage I to III digestive tract cancer who underwent curative surgery | 2,000 IU | — | 251 |
| Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation 2023 · vitamin D group · Adults aged 30–90 years with resected stage I–III epithelial cancer of the digestive tract, including colorectal cancer | 2,000 IU | 1205 days | 251 |
| Effect of Vitamin D Supplements on Relapse or Death in a p53-Immunoreactive Subgroup With Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial 2023 · Vitamin D group · Adults aged 35–90 with stage I–III digestive tract cancer after curative surgery; the p53-immunoreactive subgroup had serum p53-Ab positivity and p53-IHC [3+] cancer cells | 2,000 IU | — | 241 |
| Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren 2010 · vitamin D(3) group · schoolchildren | 1,200 IU | 120 days | 167 |
| Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial 2022 · Vitamin D group (VDG) · Frontline healthcare workers caring for hospitalized patients with COVID-19, SARS-CoV-2-free at enrollment; adults, both sexes | 4,000 IU | 30 days | 160 |
| Effect of Vitamin D Supplementation on Recurrent Wheezing in Black Infants Who Were Born Preterm: The D-Wheeze Randomized Clinical Trial 2018 · sustained supplementation group · Black infants born at 28 to 36 weeks’ gestation | 400 IU | — | 153 |
| Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial 2014 · Vitamin D and gargling · University students aged 17 years or older; both sexes; no specific diagnosed condition stated | 1,429 IU | 8 weeks | 150 |
| Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial 2014 · Vitamin D and no gargling · University students aged 17 years or older; both sexes; no specific diagnosed condition stated | 1,429 IU | 8 weeks | 150 |
| Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial 2011 · 17.5 mg risedronate once a week · Older women with Parkinson's disease | 1,000 IU | 2 years | 136 |
| Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial 2011 · Placebo · Older women with Parkinson's disease | 1,000 IU | 2 years | 136 |
| Maternal vitamin D intakes during pregnancy and child health outcome 2023 · 2000 IU/day · Pregnant women receiving vitamin D during pregnancy; age and condition beyond pregnancy not reported. | 2,000 IU | — | 121 |
| Maternal vitamin D intakes during pregnancy and child health outcome 2023 · 4000 IU/day · Pregnant women receiving vitamin D during pregnancy; age and condition beyond pregnancy not reported. | 4,000 IU | — | 120 |
| Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease 2019 · Vitamin D group · Adults aged 18–80 with ulcerative colitis or Crohn’s disease in stable condition | 500 IU | 26 weeks | 119 |
| Maternal vitamin D intakes during pregnancy and child health outcome 2023 · 600 IU/day · Pregnant women receiving vitamin D during pregnancy; age and condition beyond pregnancy not reported. | 600 IU | — | 119 |
| Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial 2025 · study group - vitamin D intake · Adult women aged 18–74 with primary breast cancer receiving neoadjuvant systemic therapy | 7,143 IU | — | 114 |
| Treatment of vitamin D deficiency is an effective method in the elimination of asymptomatic bacterial vaginosis: A placebo-controlled randomized clinical trial 2015 · intervention group · Women aged 18–35 with vitamin D deficiency and asymptomatic bacterial vaginosis | 2,000 IU | 15 weeks | 103 |
| In "High-Risk" Infants with Sufficient Vitamin D Status at Birth, Infant Vitamin D Supplementation Had No Effect on Allergy Outcomes: A Randomized Controlled Trial 2020 · vitamin D group · Term infants with sufficient maternal vitamin D status late in pregnancy and a family history of allergic disease in at least one parent or sibling; infants were followed for allergy outcomes | 400 IU | 26 weeks | 97 |
| The effects of vitamin D supplementation on postoperative atrial fibrillation after coronary artery bypass grafting in patients with vitamin D deficiency 2022 · Group B · Patients with vitamin D insufficiency undergoing coronary artery bypass grafting | 600,000 IU | 1 day | 93 |
| Effect of isolated vitamin D supplementation on the rate of falls and postural balance in postmenopausal women fallers: a randomized, double-blind, placebo-controlled trial 2016 · VITD group · Brazilian postmenopausal women aged 50–65 years with at least 12 months of amenorrhea and a history of falls in the previous 12 months | 1,000 IU | 274 days | 80 |
| Vitamin D supplementation improves the metabolic syndrome risk profile in postmenopausal women 2020 · VD group · Postmenopausal women aged 50–65 years with vitamin D deficiency | 1,000 IU | 274 days | 80 |
| Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial 2018 · vitamin D · Patients with non-small cell lung cancer (NSCLC) after operation; age and sex not specified | 1,200 IU | 1 year | 77 |
| Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial 2015 · vitD3 · Adults aged 18 years or older, male and female, with newly diagnosed sputum smear-positive pulmonary tuberculosis; most had deficient or insufficient vitamin D status | 5,000 IU | 8 weeks | 72 |
| Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial 2015 · PBA+vitD3 · Adults aged 18 years or older, male and female, with newly diagnosed sputum smear-positive pulmonary tuberculosis; most had deficient or insufficient vitamin D status | 5,000 IU | 8 weeks | 72 |
| High-dose preoperative cholecalciferol to prevent post-thyroidectomy hypocalcaemia: A randomized, double-blinded placebo-controlled trial 2019 · cholecalciferol · Patients undergoing thyroidectomy for Graves' disease, malignancy or goitre | 300,000 IU | 1 day | 72 |
| Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer 2025 · Treatment group · Adults with advanced-stage cervical cancer, FIGO stages IIB–IVA, eligible for radiotherapy; sex and age range not stated | 10,000 IU | 19 weeks | 69 |
| Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE) 2019 · cholecalciferol group · Adults aged 18–65 with relapsing-remitting multiple sclerosis, low serum 25OHD, and receiving interferon beta-1a | 50,000 IU | 96 weeks | 64 |
| Vitamin D supplementation to patients with frequent respiratory tract infections: a post hoc analysis of a randomized and placebo-controlled trial 2015 · vitamin D group · Adults aged 18–75 with primary immunodeficiency or increased susceptibility to respiratory tract infections | 4,000 IU | 1 year | 62 |
| Vitamin D supplementation reduces the risk of acute otitis media in otitis-prone children 2013 · VD group · Children with a history of recurrent acute otitis media | 1,000 IU | 120 days | 58 |
| Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial 2022 · Group 1 (low-dose vitamin D) · Adults aged 18 years or older hospitalized with moderate-to-severe COVID-19 and hyperinflammation | 1 mcg | — | 58 |
| The effect of vitamin D on recurrence of uterine fibroids: A randomized, double-blind, placebo-controlled pilot study 2022 · vitamin D · Women who had undergone hysteroscopic myomectomy; mean age 37.9 ± 6.5 years | 1,000 IU | 1 year | 55 |
| Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial 2013 · paricalcitol · Incident kidney transplant recipients | 2 mcg | 1 year | 50 |
| "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study" 2020 · Group receiving Calcifediol · Adults hospitalized with confirmed COVID-19; women and men, aged 18 years or older, with acute respiratory infection and viral pneumonia | 532 mcg | — | 50 |
| Randomized trial of activated vitamin D for acute kidney injury prevention in critically ill patients 2025 · calcitriol group · Critically ill adults aged 18 years or older in an ICU, at high risk of moderate-to-severe acute kidney injury within 7 days or with mild AKI at enrollment | 4 mcg | 5 days | 50 |
| Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study 2010 · vitamin D3 · Patients with Crohn's disease in remission | 1,200 IU | 1 year | 46 |
| Vitamin D Intake May Reduce SARS-CoV-2 Infection Morbidity in Health Care Workers 2022 · Group II · Health care workers aged 18–65 years, women and men, with negative SARS-CoV-2 PCR and occupational exposure to infected patients | 2,000 IU | 90 days | 46 |
| A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD 2014 · calcitriol · Patients with stages 3–4 CKD and PTH >120 pg/ml | 0.25 mcg | 24 weeks | 45 |
| A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD 2014 · paricalcitol · Patients with stages 3–4 CKD and PTH >120 pg/ml | 1 mcg | 24 weeks | 45 |
| Association of vitamin D with functional cure in chronic hepatitis B: Insights from a retrospective cohort study and an intervention study 2024 · VD group · Patients with chronic hepatitis B and baseline vitamin D insufficiency | 800 IU | — | 45 |
| The effect of standard-dose wintertime vitamin D supplementation on influenza infection in immunized nursing home elderly residents 2021 · experimental group · Adults aged 65 years or older who were frail residents of nursing homes and had received influenza vaccination | 800 IU | 90 days | 41 |
| Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial 2025 · VD group · Women aged ≥45 years with breast cancer eligible for neoadjuvant chemotherapy | 2,000 IU | 26 weeks | 40 |
| Vitamin D supplementation to persistent carriers of MRSA-a randomized and placebo-controlled clinical trial 2018 · Vitamin D · Men and women aged 18–75 with persistent MRSA carriage and serum 25OHD below 75 nmol/L | 4,000 IU | 1 year | 32 |
| Comparison of 300,000 and 600,000 IU Oral Vitamin-D Bolus for Vitamin-D Deficiency in Young Children 2017 · 600,000 IU group · Children aged 3 months to 3 years with vitamin-D deficiency | 600,000 IU | 1 day | 30 |
| Comparison of 300,000 and 600,000 IU Oral Vitamin-D Bolus for Vitamin-D Deficiency in Young Children 2017 · 300,000 IU group · Children aged 3 months to 3 years with vitamin-D deficiency | 300,000 IU | 1 day | 30 |
| Calcitriol supplementation accelerates the recovery of patients with tuberculosis who have vitamin D deficiency: a randomized, single-blind, controlled clinical trial 2022 · Low-25(OH)D-Calcitriol group · Adults aged 18–70 with tuberculosis and serum 25(OH)D below 75 nmol/L | 0.5 mcg | 24 weeks | 30 |
| Long-Term Vitamin D Supplementation and the Effects on Recurrence and Metabolic Status of Cervical Intraepithelial Neoplasia Grade 2 or 3: A Randomized, Double-Blind, Placebo-Controlled Trial 2018 · vitamin D group · Women diagnosed with cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) | 25,000 IU | 26 weeks | 29 |
| A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study 2007 · 200 IU group · Nursing home residents; average age 89; sex not specified | 200 IU | 150 days | 26 |
| A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study 2007 · 400 IU group · Nursing home residents; average age 89; sex not specified | 400 IU | 150 days | 25 |
| A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study 2007 · 600 IU group · Nursing home residents; average age 89; sex not specified | 600 IU | 150 days | 25 |
| A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study 2007 · 800 IU group · Nursing home residents; average age 89; sex not specified | 800 IU | 150 days | 23 |
| Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients 2012 · Treatment group · Adults with chronic hepatitis C virus genotype 2–3, ages 48 ± 14 years; 65% male | 2,000 IU | 24 weeks | 20 |
| Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females 2013 · Maxmarvil group · Postmenopausal Korean females aged 50–70 with osteoporosis | 0.5 mcg | 2 weeks | 20 |
| Randomized Controlled Trial Assessing Vitamin D's Role in Reducing BPPV Recurrence in Older Adults 2025 · Group A · Adults aged 50 and above with vitamin D <30 ng/mL and idiopathic BPPV | 2,000 IU | 26 weeks | 19 |
| Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial 2013 · treatment group (cases) · Patients aged 20–40 years with optic neuritis and serum 25 (OH) D levels below 30 ng/ml | 7,143 IU | 1 year | 15 |
| Exploring the synergistic effects of vitamin D and synbiotics on cytokines profile, and treatment response in breast cancer: a pilot randomized clinical trial 2024 · Vitamin D group (VitD) · Adult women with histologically confirmed, non-metastatic primary invasive breast cancer who were candidates for neoadjuvant therapy | 1,000 IU | 18 weeks | 15 |
| Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily 2004 · Alfacalcidol · Community-dwelling elderly men and women; the abstract does not give an age range | 1 mcg | 36 weeks | — |
| Prospective study of vitamin D supplementation and rickets in China 1992 · 100 IU/day group · Term infants during the first 6 months of life | 100 IU | 26 weeks | — |
| Prospective study of vitamin D supplementation and rickets in China 1992 · 200 IU/day group · Term infants during the first 6 months of life | 200 IU | 26 weeks | — |
| Prospective study of vitamin D supplementation and rickets in China 1992 · 400 IU/day group · Term infants during the first 6 months of life | 400 IU | 26 weeks | — |
| Falls are associated with decreased renal function and insufficient calcitriol production by the kidney 2007 · calcitriol · Women aged 65–77 years; generally healthy, with some analyses focused on women with creatinine clearance below 60 ml/min | 0.5 mcg | 3 years | — |
| Falls are associated with decreased renal function and insufficient calcitriol production by the kidney 2007 · calcitriol + estrogen · Women aged 65–77 years; generally healthy, with some analyses focused on women with creatinine clearance below 60 ml/min | 0.5 mcg | 3 years | — |
| Treatment of postmenopausal osteoporosis with calcitriol or calcium 1992 · calcitriol · Postmenopausal women with osteoporosis and one or more vertebral compression fractures | 0.5 mcg | 3 years | — |
| Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial 2010 · Cholecalciferol 2000 IU/d · Patients aged 65 years or older recovering from acute hip fracture; 79.2% were women | 2,000 IU | 1 year | — |
| Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial 2010 · Cholecalciferol 800 IU/d · Patients aged 65 years or older recovering from acute hip fracture; 79.2% were women | 800 IU | 1 year | — |
| Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial 2012 · vitamin D group · Mongolian school-age children | 800 IU | 26 weeks | — |
| Low-dose calcitriol versus calcium in established postmenopausal osteoporosis 1990 · calcitriol · Women under 80 with at least 3 years of postmenopausal osteoporosis | 0.5 mcg | 3 years | — |
| Comprehensive Safety Monitoring of 12-Month Daily 7000-IU Vitamin D3 Supplementation in Human Immunodeficiency Virus-Infected Children and Young Adults 2016 · 7000-IU/d vitD3 · HIV-infected children and young adults aged 9–24.9 years | 7,000 IU | 1 year | — |
| Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial 2017 · Vitamin D3 · Adults aged 45–75 with at least one large-bowel adenoma removed before enrollment | 1,000 IU | 1376 days | — |
| Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal Asthma Reduction Trial 2017 · 4400 international units/d vitamin D · Pregnant women at risk of having children with asthma; race-specific age range not reported | 4,400 IU | — | — |
| Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal Asthma Reduction Trial 2017 · Placebo plus 400 international units/d vitamin D · Pregnant women at risk of having children with asthma; race-specific age range not reported | 400 IU | — | — |
| Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial 2017 · 800 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American | 800 IU | 1 year | — |
| Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial 2017 · 1600 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American | 1,600 IU | 1 year | — |
| Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial 2017 · 2400 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American | 2,400 IU | 1 year | — |
| Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial 2017 · 3200 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American | 3,200 IU | 1 year | — |
| Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial 2017 · 4000 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American | 4,000 IU | 1 year | — |
| Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial 2017 · 4800 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American | 4,800 IU | 1 year | — |
| Vitamin D-supplemented yogurt drink reduces Candida infections in a paediatric intensive care unit: a randomised, placebo-controlled clinical trial 2019 · VD group · Children aged 12 months to 5 years admitted to a paediatric intensive care unit and receiving broad-spectrum antibiotic therapy | 300 IU | 2 weeks | — |
| Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure 2020 · vitamin D group · older adults; mean age 67.1 years, 50.6% women; no condition specified | 2,000 IU | 1935 days | — |
| Effect of Vitamin D on Relapse-Free Survival in a Subgroup of Patients with p53 Protein-Positive Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Trial 2020 · vitamin D group · Patients with p53-positive digestive tract cancer | 2,000 IU | — | — |
| Effect of early and late prenatal vitamin D and maternal asthma status on offspring asthma or recurrent wheeze 2021 · intervention · Pregnant women aged 18–39 years at 10–18 weeks’ gestation, at increased risk of offspring asthma or atopy due to their own or their partner’s history of asthma or atopy | 4,400 IU | — | — |
| Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial 2020 · Vitamin D3 · Men and women aged 45–75 recently diagnosed with a colorectal adenoma | 1,000 IU | 5 years | — |
| Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial 2020 · Vitamin D3 active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry | 2,000 IU | 1937 days | — |
| The effects of vitamin D supplementation on types of falls 2021 · 200 IU/d control · Community-dwelling adults aged 70 years or older with elevated fall risk and serum 25-hydroxyvitamin D of 10–29 ng/mL; men and women | 200 IU | 2 years | — |
| The effects of vitamin D supplementation on types of falls 2021 · 1000 IU/d group · Community-dwelling adults aged 70 years or older with elevated fall risk and serum 25-hydroxyvitamin D of 10–29 ng/mL; men and women | 1,000 IU | 2 years | — |
| The effects of vitamin D supplementation on types of falls 2021 · 2000 IU/d group · Community-dwelling adults aged 70 years or older with elevated fall risk and serum 25-hydroxyvitamin D of 10–29 ng/mL; men and women | 2,000 IU | 2 years | — |
| The effects of vitamin D supplementation on types of falls 2021 · 4000 IU/d group · Community-dwelling adults aged 70 years or older with elevated fall risk and serum 25-hydroxyvitamin D of 10–29 ng/mL; men and women | 4,000 IU | 2 years | — |
| Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial 2021 · Vitamin D arm · Adults aged 75 years or younger with recently resected stage II cutaneous malignant melanoma | 2,000 IU | 3 years | — |
| Short-Term Hypocalcemia Prophylaxis With Calcitriol Before Thyroidectomy 2021 · intervention group · Patients about to undergo total thyroidectomy for thyroid disease | 1 mcg | 3 days | — |
| Effects of early vitamin D supplementation on the prevention of bronchopulmonary dysplasia in preterm infants 2022 · vitamin D supplementation (VD) group · Preterm infants; age range and sex not reported. | 800 IU | 4 weeks | — |
| Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial 2022 · Vitamin D active/omega 3 placebo · Men aged 50 years or older and women aged 55 years or older; general older-adult population, not selected for vitamin D deficiency | 2,000 IU | 5 years | — |
| Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial 2022 · Vitamin D supplementation (with or without omega-3 supplementation; exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years | 2,000 IU | 3 years | — |
| Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization 2022 · vitamin D3 group · Adults enrolled in VITAL; mean age 67.1 years, 50.6% women, with and without type 2 diabetes | 2,000 IU | 1935 days | — |
| Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial 2023 · Vitamin D3 · Adults with a recently diagnosed colorectal adenoma and no remaining polyps after complete colonoscopy; the analyzed subgroup consisted of non-Hispanic White participants | 1,000 IU | 5 years | — |
| Effect of intratrial mean 25(OH)D concentration on diabetes risk, by race and weight: an ancillary analysis in the D2d study 2023 · vitamin D3 group · people with prediabetes | 4,000 IU | 913 days | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes 2023 · vitamin D3 supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population | 2,000 IU | 1935 days | — |
| Maternal Vitamin D Supplementation and Infantile Rickets: Secondary Analysis of a Randomized Trial 2024 · vitamin D 4200 IU/week · Pregnant women in Bangladesh | 600 IU | — | — |
| Maternal Vitamin D Supplementation and Infantile Rickets: Secondary Analysis of a Randomized Trial 2024 · vitamin D 16 800 IU/week · Pregnant women in Bangladesh | 2,400 IU | — | — |
| Maternal Vitamin D Supplementation and Infantile Rickets: Secondary Analysis of a Randomized Trial 2024 · vitamin D 28 000 IU/week, prenatal · Pregnant women in Bangladesh | 4,000 IU | — | — |
| Maternal Vitamin D Supplementation and Infantile Rickets: Secondary Analysis of a Randomized Trial 2024 · vitamin D 28 000 IU/week, prenatal and postpartum · Pregnant women in Bangladesh, continuing supplementation postpartum | 4,000 IU | — | — |
| Early Vitamin D Supplementation in Infants Born Extremely Preterm and Fed Human Milk: A Randomized Controlled Trial 2025 · intervention · Infants born at 28 weeks of gestation or less and fed human milk | 800 IU | 2 weeks | — |
| Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial 2026 · high-dose · Pregnant women starting supplementation at pregnancy week 24; maternal tobacco exposure was assessed, with no restriction to a specific exposure group stated | 2,800 IU | — | — |
| Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial 2026 · standard-dose · Pregnant women starting supplementation at pregnancy week 24; maternal tobacco exposure was assessed, with no restriction to a specific exposure group stated | 400 IU | — | — |
| Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients 2004 · 15 mcg (600 IU)/day · Adults attending an endocrinology clinic with low serum 25(OH)D; age and sex varied | 13.6 mcg | 1 year | 65 |
| Effect of calcifediol and cholecalciferol on muscle function in postmenopausal women: a randomized controlled trial 2025 · Calcifediol · Postmenopausal women aged 50–70 with osteopenia or osteoporosis and serum 25(OH)D <30 ng/mL | 20 mcg | 26 weeks | 49 |
| The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal women 2022 · 500 ml water with added cholecalciferol · Postmenopausal women aged 60–80 years with vitamin D insufficiency at screening | 200 mcg | 1 day | 20 |
| Calcifediol versus vitamin D3 effects on gait speed and trunk sway in young postmenopausal women: a double-blind randomized controlled trial 2015 · calcifediol group · Postmenopausal women, mean age 61.5 years, with low average 25(OH)D levels | 20 mcg | 120 days | 10 |
| Calcifediol versus vitamin D3 effects on gait speed and trunk sway in young postmenopausal women: a double-blind randomized controlled trial 2015 · vitamin D3 group · Postmenopausal women, mean age 61.5 years, with low average 25(OH)D levels | 20 mcg | 120 days | 10 |
| Winter vitamin D(3) supplementation does not increase muscle strength, but modulates the IGF-axis in young children 2019 · 20 µg/day vitamin D3 · Healthy children aged 4–8 years | 20 mcg | 20 weeks | — |
| Effects of vitamin D supplementation on acute respiratory tract infections in 6-8-year-old children: a randomized clinical trial 2025 · vitamin D group · Healthy children aged 6–8 years | 20 mcg | 24 weeks | — |
| Changes in bone density and microarchitecture following treatment of Graves' disease and the effects of vitamin D supplementation. A randomized clinical trial 2024 · vitamin D group · Adults aged 18–80 with newly diagnosed Graves’ disease thyrotoxicosis | 70 mcg | 270 days | 44 |
| Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial 2012 · cholecalciferol group · Adults with hypertension in Denmark; mean age 61 ± 10 years. A subgroup had baseline vitamin D insufficiency. | 75 mcg | 20 weeks | — |
| Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements 2011 · CaD group · Postmenopausal women aged 50–79 years | 400 IU | 7 years | 18,176 |
| Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study 2013 · Calcium plus vitamin D (CaD) group · Postmenopausal women aged 50–79 years | 400 IU | 7 years | 18,176 |
| A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast 2021 · calcium plus vitamin D · Postmenopausal women aged 50–79 years at enrollment | 400 IU | 2592 days | 18,176 |
| Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation 2017 · active treatment · older women; median age 63 years | 400 IU | 7 years | 18,141 |
| Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative 2015 · intervention group · Postmenopausal women aged 50–79 years, free of heart failure at baseline, with and without pre-existing cardiovascular risk conditions | 400 IU | 2577 days | 18,023 |
| Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study 2004 · Calcium and Vitamin D Program · Community-dwelling residents aged 66 years and older | 400 IU | 3 years | 4,957 |
| Efficacy of vitamin D(3) supplementation for the prevention of pulmonary tuberculosis and mortality in HIV: a randomised, double-blind, placebo-controlled trial 2020 · vitamin D3 supplementation group · Tanzanian adults aged 18 years or older living with HIV, initiating ART, with serum 25(OH)D below 30 ng/mL | 9,143 IU | 1 year | 2,001 |
| Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial 2017 · vitamin D3 + calcium group · Healthy postmenopausal women aged 55 years or older | 2,000 IU | 1461 days | 1,156 |
| Zoledronic acid and clinical fractures and mortality after hip fracture 2007 · zoledronic acid group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture | 800 IU | 1826 days | 1,065 |
| Zoledronic acid and clinical fractures and mortality after hip fracture 2007 · placebo group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture | 800 IU | 1826 days | 1,062 |
| Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study 2015 · supplement group — women · Women aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China | 20 mcg | 6 years | 927 |
| Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study 2015 · supplement group — men · Men aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China | 20 mcg | 6 years | 726 |
| A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study 2011 · Eldecalcitol · Osteoporotic patients aged 46 to 92 years; patients with serum 25-hydroxyvitamin D below 50 nmol/L also received vitamin D3 | 0.75 mcg | 3 years | 528 |
| Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis 2013 · Eldecalcitol group · Japanese adults aged 46–92 with osteoporosis; predominantly women; patients with low baseline serum 25(OH)D also received vitamin D3 | 0.75 mcg | 3 years | 528 |
| A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study 2011 · Alfacalcidol · Osteoporotic patients aged 46 to 92 years; patients with serum 25-hydroxyvitamin D below 50 nmol/L also received vitamin D3 | 1 mcg | 3 years | 526 |
| Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis 2013 · Alfacalcidol group · Japanese adults aged 46–92 with osteoporosis; predominantly women; patients with low baseline serum 25(OH)D also received vitamin D3 | 1 mcg | 3 years | 526 |
| Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial 2020 · intervention · Patients with confirmed benign paroxysmal positional vertigo (BPPV); supplementation was given when serum vitamin D was below 20 ng/mL | 800 IU | 1 year | 518 |
| The Association of Prenatal Vitamin D Sufficiency With Aeroallergen Sensitization and Allergic Rhinitis in Early Childhood 2021 · placebo multivitamin with low-dose vitamin D · Pregnant women aged 18–39 years at 10–18 weeks of gestation, nonsmoking, with a personal or partner history of asthma or atopy | 400 IU | — | 441 |
| Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial 2019 · calcium and vitamin D · Adults aged 45–75 with at least one adenomatous polyp detected and removed within the preceding 4 months | 1,000 IU | 5 years | 421 |
| Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction 2020 · vitamin D group · Pregnant women aged 18–39 years with a personal history of asthma, eczema, or allergic rhinitis, or a partner with one of these conditions | 4,400 IU | — | 405 |
| Effect of Vitamin D3 Supplementation During Pregnancy on Risk of Persistent Wheeze in the Offspring: A Randomized Clinical Trial 2016 · Vitamin D3 group · Pregnant women enrolled at 24 weeks of pregnancy | 2,400 IU | — | 315 |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · 200-IU salmon calcitonin group · Postmenopausal women with established osteoporosis | 400 IU | 5 years | 287 |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · Placebo group · Postmenopausal women with established osteoporosis | 400 IU | 5 years | 270 |
| Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial 2014 · vitamin D3 group · Adults aged 18 years or older with symptomatic asthma and serum 25-hydroxyvitamin D below 30 ng/mL | 4,000 IU | 28 weeks | 201 |
| Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study 2009 · Risedronate group · Men with primary or secondary osteoporosis | 800 IU | 2 years | 158 |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Placebo (Ca-D group) · Postmenopausal women with osteoporosis and vertebral fractures | 800 IU | 2 years | 146 |
| Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial 2025 · active placebo group · Children aged 3–18 years with a documented history of recurrent respiratory tract infections | 10 mcg | 90 days | 113 |
| Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial 2025 · active group · Children aged 3–18 years with a documented history of recurrent respiratory tract infections | 10 mcg | 90 days | 104 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women | 0.5 mcg | 1 year | 99 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women | 800 IU | 1 year | 98 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · P-A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 72 years, predominantly women | 0.5 mcg | 1 year | 98 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · P-NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 70 years, predominantly women | 800 IU | 1 year | 97 |
| Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomised controlled trial 2015 · lower-dose vitamin D3 (1000 IU/400 IU) · Pregnant women from 27 weeks' gestation to birth and their infants from birth to age 6 months | 1,400 IU | — | 87 |
| Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomised controlled trial 2015 · higher-dose vitamin D3 (2000 IU/800 IU) · Pregnant women from 27 weeks' gestation to birth and their infants from birth to age 6 months | 2,800 IU | — | 86 |
| Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery 2018 · Control group · Adults undergoing total or completion thyroidectomy with at least one well-perfused parathyroid gland identified by indocyanine green angiography; men and women; thyroid disease requiring surgery | 1,600 IU | 15 days | 73 |
| Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial 2023 · Perioperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy | 1 mcg | 17 days | 68 |
| Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial 2023 · Postoperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy | 1 mcg | 2 weeks | 66 |
| A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis: phase II 2019 · Lertal® Group (LG) · Children aged 6–12 years with allergic rhinoconjunctivitis and sensitization to house dust mites or pollens | 5 mcg | 12 weeks | 64 |
| Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial 2003 · Cal+D-group · Elderly women aged 63–99 years in long-stay geriatric care | 800 IU | 12 weeks | 62 |
| Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study 2020 · experiment group · Men and women aged 80–93 years with osteopenia living independently | 125 IU | 548 days | 62 |
| Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study 2020 · control group · Men and women aged 80–93 years with osteopenia living independently | 125 IU | 548 days | 61 |
| Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection 2009 · Group A · Patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection; age and sex not specified | 1 mg | — | 49 |
| Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy 2006 · oral calcium/vitamin D group · patients who underwent total thyroidectomy; age and sex not specified | 1 g | 2 weeks | 45 |
| Vitamin D Intake May Reduce SARS-CoV-2 Infection Morbidity in Health Care Workers 2022 · Group I · Health care workers aged 18–65 years, women and men, with negative SARS-CoV-2 PCR and occupational exposure to infected patients | 12,143 IU | 90 days | 45 |
| Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial 2021 · Control group · Patients undergoing total thyroidectomy; age and sex not reported | 0.5 mcg | — | 44 |
| [Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia] 2014 · VD group · Men with idiopathic oligoasthenozoospermia | 200 IU | 90 days | 43 |
| Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial 2021 · Intervention group · Patients undergoing total thyroidectomy; age and sex not reported | 0.5 mcg | — | 38 |
| Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? 2006 · Vitamin D plus calcium · Institutionalized women aged 65–97 | 800 IU | 90 days | 33 |
| Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis 2012 · Cholecalciferol group · Postmenopausal women with osteoporosis | 300,800 IU | 7 days | 30 |
| Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis 2012 · Placebo group with shared supplementation · Postmenopausal women with osteoporosis | 800 IU | 7 days | 30 |
| Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial 2020 · juice-based TMN · Patients with non-small-cell lung cancer receiving first-line chemotherapy, with weight loss or low BMI | 20 mcg | 12 weeks | 26 |
| The efficacy of oral vitamin D supplements on fusion outcome in patients receiving elective lumbar spinal fusion-a randomized control trial 2022 · Experimental group · Adults aged 20–80 undergoing elective lumbar spinal fusion for spinal stenosis or degenerative spondylolisthesis | 800 IU | 90 days | 21 |
| Exploring the synergistic effects of vitamin D and synbiotics on cytokines profile, and treatment response in breast cancer: a pilot randomized clinical trial 2024 · Vitamin D + synbiotic group (VitD + Pro) · Adult women with histologically confirmed, non-metastatic primary invasive breast cancer who were candidates for neoadjuvant therapy | 1,000 IU | 18 weeks | 18 |
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 · risedronate 2.5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis | 500 IU | 2 years | — |
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 · risedronate 5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis | 500 IU | 3 years | — |
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 · placebo group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis | 500 IU | 3 years | — |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · 100-IU salmon calcitonin group · Postmenopausal women with established osteoporosis | 400 IU | 5 years | — |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · 400-IU salmon calcitonin group · Postmenopausal women with established osteoporosis | 400 IU | 5 years | — |
| The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial 2005 · risedronate group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency | 1,000 IU | 548 days | — |
| The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial 2005 · control group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency | 1,000 IU | 548 days | — |
| Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial 2006 · cholecalciferol-calcium · Ambulatory, community-dwelling men and women aged 65 years or older | 700 IU | 3 years | — |
| Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial 2007 · Ca + D · Healthy postmenopausal women aged over 55 years | 1,100 IU | 4 years | — |
| Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial 2008 · calcium plus vitamin-D supplementation · Women in the Women's Health Initiative; age and specific health conditions are not stated in the abstract | 400 IU | — | — |
| Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women 2008 · ergocalciferol group · Community-dwelling women aged 70–90 with serum 25-hydroxyvitamin D below 24.0 ng/mL and a history of falling in the previous year | 1,000 IU | 1 year | — |
| Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women 2008 · vitamin D3 plus calcium · Community-dwelling, healthy ambulatory men and women aged 65 years or older | 700 IU | 3 years | — |
| Calcium and vitamin d supplementation decreases incidence of stress fractures in female navy recruits 2008 · calcium and vitamin D group · female Navy recruits undergoing basic training | 800 IU | 8 weeks | — |
| Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals 2009 · calcium plus vitamin D · Community-dwelling women and men, mean age 77 years, with serum 25-hydroxyvitamin D below 78 nmol/l | 800 IU | 1 year | — |
| Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study 2009 · Control group without previous vertebral fractures · Men with primary or secondary osteoporosis without previous vertebral fractures | 800 IU | 2 years | — |
| Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial 2009 · CaD supplementation · Postmenopausal women aged 51–82 years | 400 IU | 2557 days | — |
| Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial 2011 · CaD (calcium plus vitamin D) · Postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative calcium/vitamin D trial | 400 IU | 7 years | — |
| Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set 2011 · Calcium and vitamin D (CaD) · Community-dwelling postmenopausal women | 400 IU | 2557 days | — |
| Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy 2014 · Active CaD + active hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis | 400 IU | 2628 days | — |
| Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy 2014 · Active CaD + placebo hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis | 400 IU | 2628 days | — |
| Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D 2014 · 1000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ | 1,000 IU | 90 days | — |
| Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D 2014 · 2000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ | 2,000 IU | 90 days | — |
| Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D 2014 · 4000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ | 4,000 IU | 90 days | — |
| The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. From the Women's Health Initiative Randomized Controlled Trial 2015 · calcium and vitamin D group · Postmenopausal women aged 50–79 years | 400 IU | 7 years | — |
| Effect of Calcium β-Hydroxy-β-Methylbutyrate (CaHMB), Vitamin D, and Protein Supplementation on Postoperative Immobilization in Malnourished Older Adult Patients With Hip Fracture: A Randomized Controlled Study 2016 · CaHMB/vitamin D/protein group · Older female patients with malnutrition and hip fracture | 1,000 IU | 30 days | — |
| Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials 2017 · Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause | 400 IU | — | — |
| Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials 2017 · HT + Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause | 400 IU | — | — |
| Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial 2017 · Vitamin D3 plus calcium · Adults aged 45–75 with at least one large-bowel adenoma removed before enrollment | 1,000 IU | 1376 days | — |
| The influence of genetic susceptibility and calcium plus vitamin D supplementation on fracture risk 2017 · calcium plus vitamin D group · White postmenopausal women | 400 IU | 339 weeks | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer 2019 · n-3 fatty acids plus vitamin D group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial | 2,000 IU | 1936 days | — |
| Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease 2019 · CaD-supplement group · Postmenopausal women in the Women's Health Initiative who entered the calcium and vitamin D trial after one year in a menopausal hormone therapy trial | 400 IU | 2264 days | — |
| Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial 2020 · Vitamin D3 plus calcium carbonate · Men and women aged 45–75 recently diagnosed with a colorectal adenoma | 1,000 IU | 5 years | — |
| Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial 2020 · Vitamin D3 and marine omega-3 fatty acids active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry | 2,000 IU | 1937 days | — |
| Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial 2022 · Vitamin D active/omega 3 active · Men aged 50 years or older and women aged 55 years or older; general older-adult population, not selected for vitamin D deficiency | 2,000 IU | 5 years | — |
| Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial 2022 · Vitamin D plus marine omega-3 supplementation (exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years | 2,000 IU | 3 years | — |
| Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial 2023 · Vitamin D3 and calcium · Adults with a recently diagnosed colorectal adenoma and no remaining polyps after complete colonoscopy; the analyzed subgroup consisted of non-Hispanic White participants | 1,000 IU | 5 years | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes 2023 · combination supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population | 2,000 IU | 1935 days | — |
| Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial 2024 · Vitamin D and n-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses | 2,000 IU | 1936 days | — |
| Long-Term Effect of Randomization to Calcium and Vitamin D Supplementation on Health in Older Women : Postintervention Follow-up of a Randomized Clinical Trial 2024 · CaD · Postmenopausal women with no history of breast or colorectal cancer | 400 IU | 7 years | — |
| Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial 2025 · Vitamin D plus marine omega-3 · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults | 2,000 IU | 1935 days | — |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Sodium fluoride · Postmenopausal women with osteoporosis and vertebral fractures | 800 IU | 2 years | — |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Monofluorophosphate, 200 mg/day · Postmenopausal women with osteoporosis and vertebral fractures | 800 IU | 2 years | — |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Monofluorophosphate, 150 mg/day · Postmenopausal women with osteoporosis and vertebral fractures | 800 IU | 2 years | — |
| A randomized clinical trial of omega-3 fatty acid and vitamin D supplementation on electrocardiographic risk profiles 2023 · Vitamin D3 active treatment · Men aged 50 years or older and women aged 55 years or older in the VITAL ECG substudy; no specific disease required | 2,000 IU | 2 years | 446 |
| Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial 2016 · 400 IU/d vitamin D group · Pregnant women aged 18–39 years, 10–18 weeks’ gestation, with a personal or partner history of asthma, eczema, or allergic rhinitis | 400 IU | — | 436 |
| Efficacy of High-Dose Supplementation With Oral Vitamin D3 on Depressive Symptoms in Dialysis Patients With Vitamin D3 Insufficiency: A Prospective, Randomized, Double-Blind Study 2016 · test group · Dialysis patients with depression and vitamin D3 insufficiency; age and sex not specified | 7,143 IU | 52 weeks | 362 |
| High-Dose Vitamin D Supplementation in Pregnancy and Neurodevelopment in Childhood: A Prespecified Secondary Analysis of a Randomized Clinical Trial 2020 · high-dose vitamin D3 group · pregnant Danish women recruited at 24 weeks of pregnancy | 2,800 IU | — | 315 |
| High-Dose Vitamin D Supplementation in Pregnancy and Neurodevelopment in Childhood: A Prespecified Secondary Analysis of a Randomized Clinical Trial 2020 · standard-dose vitamin D3 group · pregnant Danish women recruited at 24 weeks of pregnancy | 400 IU | — | 308 |
| Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years. Results from an RCT including 511 subjects 2016 · vitamin D group · People with prediabetes; age and sex not specified | 2,857 IU | 5 years | 256 |
| Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial 2010 · vitamin D3 · Children aged 1–36 months with non-severe or severe pneumonia | 100,000 IU | 1 day | 224 |
| Effect of Vitamin D3 Supplementation in the First 2 Years of Life on Psychiatric Symptoms at Ages 6 to 8 Years: A Randomized Clinical Trial 2023 · 1200-IU vitamin D group · Infants randomized at about 2 weeks of age; healthy infants of Northern European ancestry | 1,200 IU | 2 years | 177 |
| Effect of Vitamin D3 Supplementation in the First 2 Years of Life on Psychiatric Symptoms at Ages 6 to 8 Years: A Randomized Clinical Trial 2023 · 400-IU vitamin D group · Infants randomized at about 2 weeks of age; healthy infants of Northern European ancestry | 400 IU | 2 years | 169 |
| Vitamin D Supplementation for Treatment and Prevention of Pneumonia in Under-five Children: A Randomized Double-blind Placebo Controlled Trial 2016 · vitamin D group · Children aged 6 months to 5 years with WHO-defined severe pneumonia | 100,000 IU | 1 day | 162 |
| Impact of vitamin D supplementation on the clinical outcomes of COVID-19 pneumonia patients: a single-center randomized controlled trial 2024 · intervention group · Adults aged 18 years or older with COVID-19 pneumonia | 2 mcg | — | 147 |
| Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia 2012 · vitamin D group · Mongolian schoolchildren with vitamin D deficiency | 300 IU | 90 days | 143 |
| Once-weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency 2010 · 8400 IU vitamin D(3) group · Adults aged 70 years or older with vitamin D insufficiency | 1,200 IU | — | 114 |
| Repletion of vitamin D associated with deterioration of sleep quality among postmenopausal women 2016 · Vitamin D · Overweight or obese postmenopausal women aged 50–75 years with insufficient serum 25(OH)D (≥10 and <32 ng/mL) | 2,000 IU | 1 year | 109 |
| A parallel group double-blind RCT of vitamin D3 assessing physical function: is the biochemical response to treatment affected by overweight and obesity? 2014 · 400 I.U. vitamin D3 · Healthy postmenopausal women aged 60–70 years, BMI 18–45 kg/m² | 400 IU | 1 year | 102 |
| A parallel group double-blind RCT of vitamin D3 assessing physical function: is the biochemical response to treatment affected by overweight and obesity? 2014 · 1,000 I.U. vitamin D3 · Healthy postmenopausal women aged 60–70 years, BMI 18–45 kg/m² | 1,000 IU | 1 year | 101 |
| Efficacy and Safety of High-Dose Vitamin D Supplementation vs Solifenacin or Standard Urotherapy for Overactive Bladder Dry in Children: A Randomized Clinical Trial 2024 · VDS + SU group · Children with dry overactive bladder; median age 82.0 months | 2,400 IU | 8 weeks | 100 |
| Role of vitamin D supplementation and vitamin D receptor in drug-resistant epilepsy: A double-blind placebo-controlled trial conducted in India 2025 · Vitamin D group · Adults with drug-resistant epilepsy, serum vitamin D below 30 ng/mL, and at least 2 seizures per month | 8,571 IU | 26 weeks | 99 |
| Vitamin D Supplementation Improves Cognitive Function Through Reducing Oxidative Stress Regulated by Telomere Length in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized Controlled Trial 2020 · intervention group · Chinese adults aged 65 years and older with mild cognitive impairment | 800 IU | 1 year | 93 |
| Increased food allergy and vitamin D: randomized, double-blind, placebo-controlled trial 2014 · vitamin D3 supplements · Breastfeeding mothers of infants with facial eczema at the 1-month check-up | 800 IU | 6 weeks | 82 |
| Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study 2015 · Alfacalcidol · Adults with clinically definite multiple sclerosis and significant fatigue; mean age 41.1 years, 118 of 158 participants were female | 1 mcg | 26 weeks | 80 |
| Effect of vitamin D supplementation alone on muscle function in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial 2015 · VITD group · Postmenopausal women aged 50–65 years with a history of falls in the previous 12 months | 1,000 IU | 39 weeks | 80 |
| Vitamin D supplementation improves anxiety but not depression symptoms in patients with vitamin D deficiency 2020 · intervention group · Adults aged 18–60 with major depressive disorder and serum 25(OH)D ≤75 nmol/L | 1,600 IU | 26 weeks | 79 |
| A randomized controlled trial of vitamin D supplementation on perinatal depression: in Iranian pregnant mothers 2016 · vitamin D group · Pregnant women aged 18 years or older, at 26–28 weeks of gestation, without a history of mental illness or specified internal diseases and with baseline EPDS scores of 0–13 | 2,000 IU | 8 weeks | 75 |
| Muscle Cramps Do Not Improve With Correction of Vitamin D Insufficiency 2017 · low-dose vitamin D · Postmenopausal women aged 60 years or younger than 75 years, with baseline 25(OH)D levels of 14 to 27 ng/mL | 800 IU | 1 year | 75 |
| Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial 2022 · Higher dose of vitamin D3 · Women aged 21 and older with type 2 diabetes, significant depressive symptoms, and serum 25(OH)D below 32 ng/mL | 7,143 IU | 26 weeks | 65 |
| Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial 2022 · Lower dose of vitamin D3 · Women aged 21 and older with type 2 diabetes, significant depressive symptoms, and serum 25(OH)D below 32 ng/mL | 714 IU | 26 weeks | 64 |
| Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease 2013 · vitamin D3 supplements · Patients with Parkinson disease; age and sex not reported | 1,200 IU | 1 year | 56 |
| Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial 2018 · Group 1 · Adolescents aged 14–18 years with irritable bowel syndrome and vitamin D deficiency | 2,000 IU | 26 weeks | 56 |
| Effect of vitamin D deficiency on depressive symptoms in child and adolescent psychiatric patients: results of a randomized controlled trial 2020 · Verum group (VG) · Children and adolescents aged 11.0–18.9 years with vitamin D deficiency and at least mild depressive symptoms receiving psychiatric inpatient or daycare treatment | 2,640 IU | 4 weeks | 56 |
| Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial 2021 · intervention group · Adults with asthma and serum 25-hydroxyvitamin D3 below 30 ng/mL | 2,286 IU | 26 weeks | 56 |
| Improved control of childhood asthma with low-dose, short-term vitamin D supplementation: a randomized, double-blind, placebo-controlled trial 2016 · vitamin D group · Japanese schoolchildren with asthma; age and sex not specified | 800 IU | 60 days | 54 |
| Efficacy of vitamin D supplementation in reducing body mass index and lipid profile in healthy young adults in Colombia: a pilot randomised controlled clinical trial 2023 · 200 IU group · Healthy young adults from the SIMBA cohort in Colombia; mean age 22.6 years; men and women | 200 IU | 15 weeks | 54 |
| Effects of vitamin D and/or calcium intervention on sleep quality in individuals with prediabetes: a post hoc analysis of a randomized controlled trial 2024 · vitamin D group · Chinese individuals with prediabetes; age and sex not specified | 1,600 IU | 24 weeks | 54 |
| Protein-enriched diet, with the use of lean red meat, combined with progressive resistance training enhances lean tissue mass and muscle strength and reduces circulating IL-6 concentrations in elderly women: a cluster randomized controlled trial 2014 · resistance training plus lean red meat (RT+Meat) group · Women aged 60–90 years residing in retirement villages | 1,000 IU | 120 days | 53 |
| Effect of calcifediol and cholecalciferol on muscle function in postmenopausal women: a randomized controlled trial 2025 · Vitamin D3 · Postmenopausal women aged 50–70 with osteopenia or osteoporosis and serum 25(OH)D <30 ng/mL | 3,200 IU | 26 weeks | 52 |
| Effect of Vitamin D Supplementation on Body Composition and Physical Fitness in Healthy Adults: A Double-Blind, Randomized Controlled Trial 2019 · vitamin D group · healthy adults; age range and sex not specified | 420 IU | 1 year | 48 |
| Protein-enriched diet, with the use of lean red meat, combined with progressive resistance training enhances lean tissue mass and muscle strength and reduces circulating IL-6 concentrations in elderly women: a cluster randomized controlled trial 2014 · control resistance training (CRT) group · Women aged 60–90 years residing in retirement villages | 1,000 IU | 120 days | 47 |
| Efficacy of vitamin D supplementation in reducing body mass index and lipid profile in healthy young adults in Colombia: a pilot randomised controlled clinical trial 2023 · 1000 IU group · Healthy young adults from the SIMBA cohort in Colombia; mean age 22.6 years; men and women | 1,000 IU | 15 weeks | 47 |
| Oral vitamin D(3) supplementation for femtosecond LASIK-associated dry eye vitamin D for LASIK dry eye syndrome 2022 · experimental group · Patients with dry-eye symptoms one month after femtosecond LASIK surgery; ages and sex not reported | 2,000 IU | 12 weeks | 45 |
| The effect of vitamin D on urgent urinary incontinence in postmenopausal women 2023 · vitamin D group · Postmenopausal women with vitamin D deficiency and urge urinary incontinence or nocturia more than once at night | 7,143 IU | 8 weeks | 45 |
| Paricalcitol and endothelial function in chronic kidney disease trial 2014 · paricalcitol · Patients with stage 3 to 4 chronic kidney disease and parathormone >65 pg/mL | 2 mcg | 12 weeks | 44 |
| Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients 2016 · PCT · Adults with stage G3–4 chronic kidney disease; age and sex not specified | 2 mcg | 12 weeks | 44 |
| The impact of vitamin D supplementation as an adjuvant therapy on clinical outcomes in patients with severe atopic dermatitis: A randomized controlled trial 2020 · Treatment group · Children aged 5–16 years with severe atopic dermatitis | 1,600 IU | 90 days | 44 |
| Effect of alfacalcidol on the pulmonary function of adult asthmatic patients: A randomized trial 2017 · Alfacalcidol plus standard asthma treatment · Adults with asthma | 1 mcg | 120 days | 43 |
| The impact of exercise and vitamin D supplementation on physical function in community-dwelling elderly individuals: A randomized trial 2018 · exercise and vitamin D group · Community-dwelling adults aged 60 years or older who were not taking osteoporosis medications | 1,000 IU | 24 weeks | 43 |
| The effects of Vitamin D3 supplementation on Spermatogram and endocrine factors in asthenozoospermia infertile men: a randomized, triple blind, placebo-controlled clinical trial 2021 · Vitamin D3 group · Infertile men with asthenozoospermia and vitamin D3 levels below 30 ng/ml; mean age approximately 35 years | 4,000 IU | 90 days | 43 |
| The impact of exercise and vitamin D supplementation on physical function in community-dwelling elderly individuals: A randomized trial 2018 · vitamin D group · Community-dwelling adults aged 60 years or older who were not taking osteoporosis medications | 1,000 IU | 24 weeks | 42 |
| Efficacy of high-dose vs. low-dose vitamin D₃ supplementation in children with chronic tic disorders: a randomized controlled trial 2025 · low-dose vitamin D₃ supplementation group · Children aged 4–15 years with chronic tic disorders | 1,000 IU | 90 days | 42 |
| Efficacy of high-dose vs. low-dose vitamin D₃ supplementation in children with chronic tic disorders: a randomized controlled trial 2025 · high-dose vitamin D₃ supplementation group · Children aged 4–15 years with chronic tic disorders | 5,000 IU | 90 days | 41 |
| Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial 2020 · vitamin D3 supplemented group · Adults with episodic migraine; age and sex not stated | 2,000 IU | 12 weeks | 40 |
| The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial 2020 · Vitamin D group · Adults aged 18–45 with episodic migraine | 2,000 IU | 12 weeks | 40 |
| Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial 2024 · Vitamin D group · Patients with post-COVID fatigue or neuropsychiatric symptoms | 8,571 IU | 8 weeks | 40 |
| Effects of cholecalciferol supplementation on depressive symptoms, C-peptide, serotonin, and neurotrophin-3 in type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial 2024 · cholecalciferol · Adults with type 2 diabetes mellitus and mild to moderate depressive symptoms; mean age about 54 years; both sexes | 4,000 IU | 12 weeks | 40 |
| Effect of vitamin D as Nutrition Supplement on Patients with Prolonged Ventilation due to Ventilator Associated Pneumonia and Sepsis Followed Severe Traumatic Lung Contusion: A Randomized Controlled Trial 2026 · Group B · Adult ICU patients with severe traumatic lung contusion who remained mechanically ventilated for 10 consecutive days and subsequently developed ventilator-associated pneumonia and sepsis | 100,000 IU | 2 weeks | 40 |
| Vitamin D in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 or Vaccination: A Randomized Controlled Trial 2026 · Control group · Adults aged 18 years or older with ME/CFS following COVID-19 infection or vaccination and vitamin D insufficiency or deficiency | 1 mcg | 24 weeks | 39 |
| Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial 2017 · calcium carbonate + calcitriol · Patients with non-alcoholic fatty liver disease (NAFLD) following an energy-restricted weight-loss program; age and sex not stated | 25 mcg | 12 weeks | 37 |
| The effect of hormonal contraceptives combined with vitamin D3 supplements on sexual dysfunction in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled trial 2025 · OCP-treated · Women aged 18–40 with PCOS, vitamin D3 deficiency (<20 ng/ml), and sexual dysfunction | 7,143 IU | 90 days | 35 |
| The effect of hormonal contraceptives combined with vitamin D3 supplements on sexual dysfunction in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled trial 2025 · Placebo · Women aged 18–40 with PCOS, vitamin D3 deficiency (<20 ng/ml), and sexual dysfunction | 7,143 IU | 90 days | 35 |
| The Effect of Vitamin D Supplementation on Quality of Life in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy: A Single-Blind, Randomized Controlled Trial 2024 · vitamin D · Adults with stage II–III colorectal cancer undergoing adjuvant chemotherapy; age and sex not specified | 10,000 IU | 26 weeks | 34 |
| A randomised controlled trial evaluating the impact of targeted vitamin D supplementation on endothelial function in type 2 diabetes mellitus: The DIMENSION trial 2016 · vitamin D group · Adults with type 2 diabetes and hypovitaminosis D; mean age 53.5 years, 52% male | 4,000 IU | 16 weeks | 33 |
| Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study 2012 · Group D · Patients with atopic dermatitis; age and sex not reported | 1,600 IU | 60 days | 30 |
| The effect of vitamin D on primary dysmenorrhea with vitamin D deficiency: a randomized double-blind controlled clinical trial 2016 · treatment group · Women with primary dysmenorrhea and vitamin D deficiency; age range not stated | 7,143 IU | 8 weeks | 30 |
| Androgens and hirsutism score of overweight women with polycystic ovary syndrome improved after vitamin D treatment: A randomized placebo controlled clinical trial 2021 · treatment group · Overweight Jordanian females aged 18–49 years with vitamin D deficiency and PCOS | 7,143 IU | 12 weeks | 30 |
| Significant improvement of facial actinic keratoses after blue light photodynamic therapy with oral vitamin D pretreatment: An interventional cohort-controlled trial 2022 · Group 2 (VDAK) · Adults aged 18 years or older, male and nonpregnant female patients with at least 10 actinic keratoses on the face or scalp | 10,000 IU | 2 weeks | 29 |
| Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial 2015 · simvastatin plus vitamin D · Adults aged 18 or older with episodic migraine for at least 3 years and at least 4 migraine days per month | 2,000 IU | 24 weeks | 28 |
| Effect of physical activity and vitamin D compared with vitamin D alone on muscle strength, back flexibility and aerobic activity in patients with chronic kidney disease: A comparative study from Pakistan 2021 · VDPA arm · Patients with CKD stage 2–4 and vitamin D deficiency (<20 ng/mL); age and sex not reported | 4,000 IU | 90 days | 28 |
| Online positive-oriented counseling, taking vitamin D3 tablet, online lifestyle modification training on premenstrual syndrome: a 3-armed randomized clinical trial 2023 · vitamin D3 tablet group · Women aged 20–40 with premenstrual syndrome and serum 25-hydroxyvitamin D3 below 30 ng/ml | 7,143 IU | 6 weeks | 28 |
| Effects of Vitamin D Supplementation on Central Hemodynamic Parameters and Autonomic Nervous System in Obese or Overweight Individuals 2024 · Vitamin D group (VD) · Adults aged 40–70, both sexes, with overweight or obesity (BMI 25.0–39.9 kg/m²) and serum 25(OH)D below 30 ng/mL | 7,000 IU | 8 weeks | 28 |
| Randomized study of the effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammation, and SIRT1 in obese women with mild to moderate depressive symptoms 2022 · vitamin D group · Obese women with mild to moderate depressive symptoms | 7,143 IU | 8 weeks | 27 |
| Vitamin D supplementation and exercise for improving physical function, body composition and metabolic health in overweight or obese older adults with vitamin D deficiency: a pilot randomized, double-blind, placebo-controlled trial 2023 · Vitamin D · Adults aged 50–80 years with vitamin D deficiency who were overweight or obese | 4,000 IU | 24 weeks | 26 |
| Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: an open-label randomized controlled study 2016 · eldecalcitol group · Postmenopausal women, mean age 74 years, with osteoporosis treated with bisphosphonate | 0.75 mcg | 26 weeks | 25 |
| The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial 2024 · group 2: vitamin D supplementation (VitD) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment | 7,143 IU | 9 weeks | 24 |
| Baduanjin Exercise, With or Without Vitamin D, Outperforms Vitamin D Alone in Reducing Frailty Among Institutionalized Older Adults: A Cluster-Based Randomized Controlled Trial 2025 · Combined group · Adults aged 65 years or older living in long-term care facilities who could walk and perform activities independently; frailty was assessed, and vitamin D dosing was based on baseline levels and medical needs. | 800 IU | 90 days | 24 |
| Efficacy of ultraviolet B radiation versus vitamin D(3) on postural control and cognitive functions in relapsing-remitting multiple sclerosis: A randomized controlled study 2023 · vitamin D 3 group · Patients of both genders with relapsing-remitting multiple sclerosis (RRMS) | 7,143 IU | 12 weeks | 23 |
| Vitamin D(3) supplementation using an oral spray solution resolves deficiency but has no effect on VO(2) max in Gaelic footballers: results from a randomised, double-blind, placebo-controlled trial 2017 · Vitamin D (VD) group · Apparently healthy male and female Gaelic footballers over age 18 | 3,000 IU | 12 weeks | 22 |
| Efficacy of oral cholecalciferol on rhododendrol-induced vitiligo: A blinded randomized clinical trial 2018 · vitamin D (VD)-intervention group · female patients with rhododendrol-induced vitiligo | 5,000 IU | 150 days | 22 |
| Effects of vitamin D supplementation on metabolic parameters, serum irisin and obesity values in women with subclinical hypothyroidism: a double-blind randomized controlled trial 2023 · vitamin D supplement group · Women aged 20–65 with subclinical hypothyroidism (TSH 5–10 µIU/mL), normal fT4, and BMI 25–37 kg/m² | 7,143 IU | 12 weeks | 22 |
| Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties 2013 · low dose group · Adults aged 18 or older with relapsing-remitting multiple sclerosis, low 25-OH-D, and flu-like symptoms during interferon-beta treatment | 800 IU | 1 year | 21 |
| Prevalence of vitamin D deficiency and the effect of vitamin D3 supplementation on response to anti-tuberculosis therapy in patients with extrapulmonary tuberculosis 2024 · Vitamin D group · Adults aged 18 years or older with vitamin D deficiency and extrapulmonary tuberculosis | 7,143 IU | 1 year | 21 |
| Comparison of Vitamin D Levels in Patients with and without Acne: A Case-Control Study Combined with a Randomized Controlled Trial 2016 · Vitamin D group · Patients with acne and vitamin D deficiency; age and sex range not specified | 1,000 IU | 60 days | 20 |
| Correcting Vitamin D Insufficiency Improves Some But Not All Aspects of Physical Performance During Winter Training in Taekwondo Athletes 2018 · vitamin D group · Collegiate male and female taekwondo athletes aged 19–22 years with low serum 25(OH)D concentration | 5,000 IU | 4 weeks | 20 |
| The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial 2022 · Group 3 (vitamin D: 10–30 ng/ml + vitamin D supplementation), subgroup with baseline 25(OH)D 20–30 ng/ml · Adults with diabetic macular edema and vitamin D insufficiency, baseline 25(OH)D 20–30 ng/ml | 800 IU | 39 weeks | 20 |
| High- vs. routine-dose vitamin D3 in severe lupus on pulse methylprednisolone: a randomized, double-blind, placebo-controlled clinical trial 2025 · routine-dose (RD) · Inpatients with severe systemic lupus erythematosus receiving intravenous pulse methylprednisolone; age and sex not stated | 1,000 IU | 24 weeks | 20 |
| Comparative evaluation of the effects of diclofenac sodium and vitamin D supplementation on symptoms in individuals with myofascial pain and vitamin D deficiency: a randomized controlled clinical trial 2025 · Group B · Adults aged 18–40 with myofascial pain, bruxism, and vitamin D deficiency (25(OH)D below 20) | 10,000 IU | 8 weeks | 20 |
| Impact of Vitamin D Supplementation on Gross Motor Development of Healthy Term Infants: A Randomized Dose-Response Trial 2016 · 400 IU group · Healthy, term, breastfed infants; ages at motor assessments were 3 and 6 months | 400 IU | — | 19 |
| A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder 2019 · VID · Children aged 2.5–8 years with autism spectrum disorder | 2,000 IU | 1 year | 19 |
| The role of vitamin D in amelioration of oral lichen planus and its effect on salivary and tissue IFN-γ level: a randomized clinical trial 2024 · Group A · Middle-aged men and women with symptomatic oral lichen planus and vitamin D deficiency or insufficiency (serum vitamin D ≤30 ng/mL) | 8,571 IU | 30 days | 19 |
| Supplemental vitamin D and physical performance in COPD: a pilot randomized trial 2013 · vitamin D supplementation arm · Caucasian men with severe COPD, age 50 years or older; mean age 68 years | 2,000 IU | 6 weeks | 18 |
| Impact of Vitamin D Supplementation on Gross Motor Development of Healthy Term Infants: A Randomized Dose-Response Trial 2016 · 800 IU group · Healthy, term, breastfed infants; ages at motor assessments were 3 and 6 months | 800 IU | — | 18 |
| Impact of Vitamin D Supplementation on Gross Motor Development of Healthy Term Infants: A Randomized Dose-Response Trial 2016 · 1,200 IU group · Healthy, term, breastfed infants; ages at motor assessments were 3 and 6 months | 1,200 IU | — | 18 |
| Effect of physical activity and vitamin D compared with vitamin D alone on muscle strength, back flexibility and aerobic activity in patients with chronic kidney disease: A comparative study from Pakistan 2021 · VD arm · Patients with CKD stage 2–4 and vitamin D deficiency (<20 ng/mL); age and sex not reported | 4,000 IU | 90 days | 18 |
| Effectiveness of Vitamin D along with Splint therapy in the Vit D deficient patients with Temporomandibular disorder-A Randomized, double-blind, placebo-controlled clinical trial 2022 · Group S + D · Adults aged 18–45 with temporomandibular disorder and vitamin D levels below 30 ng/ml | 8,571 IU | 8 weeks | 18 |
| Baduanjin Exercise, With or Without Vitamin D, Outperforms Vitamin D Alone in Reducing Frailty Among Institutionalized Older Adults: A Cluster-Based Randomized Controlled Trial 2025 · Vitamin D group · Adults aged 65 years or older living in long-term care facilities who could walk and perform activities independently; frailty was assessed, and supplementation was adjusted according to baseline vitamin D levels and medical needs. | 800 IU | 90 days | 17 |
| Effect of vitamin D supplementation and isokinetic training on muscle strength, explosive strength, lean body mass and gait in severely burned children: A randomized controlled trial 2017 · VD group · Children aged 10–16 years with circumferential lower-extremity burns covering 40–55% of total body surface area | 1,000 IU | 12 weeks | 15 |
| Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡) 2020 · vitamin D (VID) · Children aged 2.5–8 years with autism spectrum disorder | 2,000 IU | 1 year | 15 |
| Efficacy of Vitamin D Supplementation in Addition to Aerobic Exercise Training in Obese Women with Perceived Myalgia: A Single-Blinded Randomized Controlled Clinical Trial 2021 · Group A · Women aged 30–40 with class I obesity, vitamin D deficiency, and nonspecific muscle pain | 7,143 IU | 12 weeks | 15 |
| Efficacy of Vitamin D Supplementation in Addition to Aerobic Exercise Training in Obese Women with Perceived Myalgia: A Single-Blinded Randomized Controlled Clinical Trial 2021 · Group B · Women aged 30–40 with class I obesity, vitamin D deficiency, and nonspecific muscle pain | 7,143 IU | 12 weeks | 15 |
| The role of rehabilitation and vitamin D supplementation on motor and psychological outcomes in poststroke patients 2021 · experimental group (EG) · Adults with ischemic or hemorrhagic stroke 30–60 days before enrollment, undergoing intensive neurorehabilitation | 2,000 IU | 12 weeks | 15 |
| Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients 2024 · Group I · Female patients with systemic lupus erythematosus (SLE); age not reported | 1,200 IU | 90 days | 15 |
| Impact of vitamin D3 supplementation on motor functionality and the immune response in Parkinson's disease patients with vitamin D deficiency 2025 · VitD3 group · Adults aged 45–80 with Parkinson’s disease and low vitamin D; mean age 73.4 years; men and women | 1,000 IU | 90 days | 15 |
| Supplementary zinc and vitamin D in management of symptomatic oral lichen planus: a three-arm randomized clinical trial 2025 · Group III (TA + VIT D) · Adults with symptomatic atrophic, erosive, or bullous oral lichen planus; age and sex ranges not specified | 400 IU | 8 weeks | 14 |
| Effects of six months of vitamin D supplementation in patients with heart failure: a randomized double-blind controlled trial 2014 · cholecalciferol · Elderly patients with chronic heart failure and plasma vitamin D levels below 30 ng/mL; mean age 74 years | 4,000 IU | 26 weeks | 13 |
| Vitamin D₃ Supplementation Reduces the Symptoms of Upper Respiratory Tract Infection during Winter Training in Vitamin D-Insufficient Taekwondo Athletes: A Randomized Controlled Trial 2018 · vitamin D group · Male collegiate taekwondo athletes aged 19–22 with vitamin D insufficiency | 5,000 IU | 4 weeks | 13 |
| Effect of vitamin D supplementation on microvascular reactivity in obese adolescents: A randomized controlled trial 2021 · fruit juice with vitamin D · obese adolescents | 4,000 IU | 90 days | 13 |
| Vitamin D Supplementation on Carotid Remodeling and Stiffness in Obese Adolescents 2022 · OS (with vitamin D supplementation) · Adolescents aged 12–17 with severe obesity | 4,000 IU | 90 days | 13 |
| Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis 2011 · group D · Patients with atopic dermatitis; age and sex not specified | 1,600 IU | 60 days | 12 |
| Insulin-sensitizing effects of vitamin D repletion mediated by adipocyte vitamin D receptor: Studies in humans and mice 2020 · vitamin D group · Overweight or obese adults with insulin resistance and vitamin D deficiency; age range and sex not specified | 5,444 IU | 26 weeks | 11 |
| Oral vitamin D versus acitretin in congenital non-syndromic ichthyosis: double blinded, randomized controlled trial 2022 · group A · Patients with congenital non-syndromic ichthyosis; age and sex not specified | 2,000 IU | 24 weeks | 11 |
| Serum and gene expression profile of cytokines following combination of yoga training and vitamin D supplementation in breast cancer survivors: a randomized controlled trial 2022 · HVD · Breast cancer survivors aged 47.90 ± 7.95 years on average, with stage 0 to IIA disease | 4,000 IU | 12 weeks | 10 |
| Serum and gene expression profile of cytokines following combination of yoga training and vitamin D supplementation in breast cancer survivors: a randomized controlled trial 2022 · Y-HVD · Breast cancer survivors aged 47.90 ± 7.95 years on average, with stage 0 to IIA disease | 4,000 IU | 12 weeks | 10 |
| Serum and gene expression profile of cytokines following combination of yoga training and vitamin D supplementation in breast cancer survivors: a randomized controlled trial 2022 · Y-LVD · Breast cancer survivors aged 47.90 ± 7.95 years on average, with stage 0 to IIA disease | 2,000 IU | 12 weeks | 10 |
| Effect of Vitamin D Supplementation on Obesity-Induced Insulin Resistance: A Double-Blind, Randomized, Placebo-Controlled Trial 2018 · vitamin D group · Men and women aged 18–70 years with obesity (BMI ≥30 kg/m²) and vitamin D deficiency, enrolled in a weight-loss program | 3,571 IU | 90 days | 9 |
| The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial 2022 · Group 3 (vitamin D: 10–30 ng/ml + vitamin D supplementation), subgroup with baseline 25(OH)D 10–20 ng/ml · Adults with diabetic macular edema and vitamin D levels of 10–20 ng/ml | 7,143 IU | 8 weeks | 8 |
| Maturation of primary and permanent teeth in preterm infants 2000 · 500 IU/day vitamin D; unsupplemented breast milk · Preterm infants | 500 IU | — | — |
| Maturation of primary and permanent teeth in preterm infants 2000 · 1000 IU/day vitamin D; unsupplemented breast milk · Preterm infants | 1,000 IU | — | — |
| Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial 2006 · Low-dose vitamin D · Girls aged 10–17 years; vitamin D deficiency status and other conditions not specified | 200 IU | 1 year | — |
| Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial 2006 · High-dose vitamin D · Girls aged 10–17 years; vitamin D deficiency status and other conditions not specified | 2,000 IU | 1 year | — |
| An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment 2007 · calcitriol · Women aged 65–77 years; generally healthy, ambulatory older women | 0.5 mcg | 3 years | — |
| An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment 2007 · calcitriol + ET/HT · Women aged 65–77 years; generally healthy, ambulatory older women | 0.5 mcg | 3 years | — |
| Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial 2008 · 20,000 IU vitamin D per week · Overweight and obese adults aged 21–70 years, both sexes | 2,857 IU | 1 year | — |
| Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial 2008 · 40,000 IU vitamin D per week · Overweight and obese adults aged 21–70 years, both sexes | 5,714 IU | 1 year | — |
| Vitamin C provision improves mood in acutely hospitalized patients 2011 · Vitamin D · Acutely hospitalized patients with hypovitaminosis D | 2,000 IU | — | — |
| Changes in balance, functional performance and fall risk following whole body vibration training and vitamin D supplementation in institutionalized elderly women. A 6 month randomized controlled trial 2011 · WBV training with conventional-dose vitamin D · Institutionalized women, mean age 79.6 years | 880 IU | 26 weeks | — |
| Changes in balance, functional performance and fall risk following whole body vibration training and vitamin D supplementation in institutionalized elderly women. A 6 month randomized controlled trial 2011 · WBV training with high-dose vitamin D · Institutionalized women, mean age 79.6 years | 1,600 IU | 26 weeks | — |
| Changes in balance, functional performance and fall risk following whole body vibration training and vitamin D supplementation in institutionalized elderly women. A 6 month randomized controlled trial 2011 · No-training group with conventional-dose vitamin D · Institutionalized women, mean age 79.6 years | 880 IU | 26 weeks | — |
| Changes in balance, functional performance and fall risk following whole body vibration training and vitamin D supplementation in institutionalized elderly women. A 6 month randomized controlled trial 2011 · No-training group with high-dose vitamin D · Institutionalized women, mean age 79.6 years | 1,600 IU | 26 weeks | — |
| Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial 2011 · Stratum A high-dose vitamin D2 group · Women with early breast cancer and aromatase inhibitor-induced musculoskeletal symptoms, receiving adjuvant anastrozole, with baseline 25-hydroxy vitamin D of 20–29 ng/ml | 7,143 IU | 26 weeks | — |
| Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial 2011 · Stratum B high-dose vitamin D2 group · Women with early breast cancer and aromatase inhibitor-induced musculoskeletal symptoms, receiving adjuvant anastrozole, with baseline 25-hydroxy vitamin D of 10–19 ng/ml | 7,143 IU | 26 weeks | — |
| Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial 2011 · Vitamin D group · Adults at high risk of type 2 diabetes; mean age 57 years | 2,000 IU | 16 weeks | — |
| Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality 2011 · Vitamin D · Women aged 50–60 years who refused hormonal therapy; postmenopausal women with climacteric symptoms | 400 IU | 1 year | — |
| Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder 2013 · vitamin D3 plus fluoxetine · Patients with major depressive disorder diagnosed using DSM-IV criteria; age and sex not reported | 1,500 IU | 8 weeks | — |
| Vitamin D supplementation for nonspecific musculoskeletal pain in non-Western immigrants: a randomized controlled trial 2012 · Vitamin D group (baseline allocation) · Vitamin D-deficient non-Western immigrants with nonspecific persistent musculoskeletal pain | 150,000 IU | 6 weeks | — |
| Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease 2012 · paricalcitol group · Adults with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved ejection fraction | 2 mcg | 48 weeks | — |
| The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial 2013 · oral cholecalciferol 2000 IU/day · Patients with systemic lupus erythematosus; age and sex not reported | 2,000 IU | 1 year | — |
| Anti-inflammatory effect of vitamin D on gingivitis: a dose-response randomised control trial 2013 · Group A · People with gingivitis; age and sex not reported | 2,000 IU | 90 days | — |
| Anti-inflammatory effect of vitamin D on gingivitis: a dose-response randomised control trial 2013 · Group B · People with gingivitis; age and sex not reported | 1,000 IU | 90 days | — |
| Anti-inflammatory effect of vitamin D on gingivitis: a dose-response randomised control trial 2013 · Group C · People with gingivitis; age and sex not reported | 500 IU | 90 days | — |
| Effects of vitamin C and vitamin D administration on mood and distress in acutely hospitalized patients 2013 · high-dose vitamin D · Acutely hospitalized patients with a high prevalence of hypovitaminosis C and D | 5,000 IU | 8 days | — |
| Maternal vitamin D3 supplementation during the third trimester of pregnancy: effects on infant growth in a longitudinal follow-up study in Bangladesh 2013 · maternal vitamin D3 · Pregnant women in Bangladesh receiving supplementation during the third trimester; age and specific condition not stated | 5,000 IU | — | — |
| Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial 2013 · vitamin D(3) · Adults aged 45–75 in good health, with a history of colorectal adenoma and serum 25-hydroxyvitamin D ≥12 ng/mL | 1,000 IU | — | — |
| Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study 2014 · High-dose vitamin D3 group · People with chronic urticaria; age and sex not specified | 4,000 IU | 12 weeks | — |
| Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study 2014 · Low-dose vitamin D3 group · People with chronic urticaria; age and sex not specified | 600 IU | 12 weeks | — |
| Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial 2014 · weight loss + 2000 IU oral vitamin D3/d · Overweight or obese postmenopausal women aged 50–75 years with serum 25(OH)D ≥10 ng/mL but <32 ng/mL | 2,000 IU | 1 year | — |
| Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children 2014 · oral cholecalciferol · Mongolian children aged 2–17 years with winter-related atopic dermatitis | 1,000 IU | 30 days | — |
| Effects of Calcium Plus Vitamin D Supplementation on Anthropometric Measurements and Blood Pressure in Vitamin D Insufficient People with Type 2 Diabetes: A Randomized Controlled Clinical Trial 2015 · 50,000 IU/wk vitamin D3 plus calcium placebo · People with type 2 diabetes and vitamin D insufficiency | 7,143 IU | 8 weeks | — |
| A randomized double-blind placebo-controlled study adding high dose vitamin D to analgesic regimens in patients with musculoskeletal pain 2015 · vitamin D group · patients with musculoskeletal pain; age and sex not reported | 4,000 IU | 90 days | — |
| A systems-based investigation into vitamin D and skeletal muscle repair, regeneration, and hypertrophy 2015 · vitamin D3 · males with insufficient serum 25(OH)D | 4,000 IU | 6 weeks | — |
| Acute Effects of Vitamin D3 Supplementation on Muscle Strength in Judoka Athletes: A Randomized Placebo-Controlled, Double-Blind Trial 2016 · treatment · adult male white national-level judoka athletes involved in full-time training; described as vitamin D insufficient | 150,000 IU | 8 days | — |
| The Effects of Oral Vitamin D Supplement on Atopic Dermatitis: A Clinical Trial with Staphylococcus aureus Colonization Determination 2015 · Vitamin D group · Patients with atopic dermatitis | 2,000 IU | 4 weeks | — |
| The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis 2016 · vitamin D group · Children aged 5–12 years with grass-pollen sensitivity and allergic rhinitis; some had concomitant asthma | 1,000 IU | 152 days | — |
| Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Increase Muscle Strength and Function in Frail Elderly Adults in a Randomized Controlled Trial 2016 · LD + MCT · Frail elderly nursing home residents; mean age 86.6 years; 11 men and 27 women enrolled across the study | 20 mcg | 90 days | — |
| Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Increase Muscle Strength and Function in Frail Elderly Adults in a Randomized Controlled Trial 2016 · LD + LCT · Frail elderly nursing home residents; mean age 86.6 years; 11 men and 27 women enrolled across the study | 20 mcg | 90 days | — |
| Effect of Lactobacillus rhamnosus GG and vitamin D supplementation on the immunologic effectiveness of grass-specific sublingual immunotherapy in children with allergy 2016 · SLIT-vitamin D group · Children aged 5–12 years with grass-pollen sensitivity and allergic rhinitis | 1,000 IU | 150 days | — |
| Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial 2017 · 600 IU group · Postmenopausal women, mean age 58 ± 6 years, with overweight or obesity, undergoing weight control | 600 IU | 1 year | — |
| Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial 2017 · 2000 IU group · Postmenopausal women, mean age 58 ± 6 years, with overweight or obesity, undergoing weight control | 2,000 IU | 1 year | — |
| Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial 2017 · 4000 IU group · Postmenopausal women, mean age 58 ± 6 years, with overweight or obesity, undergoing weight control | 4,000 IU | 1 year | — |
| High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial 2016 · vitamin D group · people with relapsing-remitting multiple sclerosis (RRMS) | 10,000 IU | 90 days | — |
| Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial 2018 · Vitamin D group · Children aged 5–12 years with ADHD | 2,000 IU | 8 weeks | — |
| Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Benefit Cognition in Frail Elderly Adults: A Randomized Controlled Trial 2017 · LD+MCT · Frail elderly nursing-home residents; mean age 86.6 years; sex not stated | 20 mcg | 90 days | — |
| Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Benefit Cognition in Frail Elderly Adults: A Randomized Controlled Trial 2017 · LD+LCT · Frail elderly nursing-home residents; mean age 86.6 years; sex not stated | 20 mcg | 90 days | — |
| Winter vitamin D(3) supplementation does not increase muscle strength, but modulates the IGF-axis in young children 2019 · 10 µg/day vitamin D3 · Healthy children aged 4–8 years | 10 mcg | 20 weeks | — |
| Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children 2018 · Group A · Children aged 7–15 with nocturnal enuresis | 1,000 IU | 60 days | — |
| Effect of vitamin D treatment in children with attention-deficit hyperactivity disorder 2019 · vitamin D group · Children aged 2–18 years with ADHD | 7,143 IU | 6 weeks | — |
| Changes in Dietary Intake and Adherence to the NU-AGE Diet Following a One-Year Dietary Intervention among European Older Adults-Results of the NU-AGE Randomized Trial 2018 · NU-AGE diet group · apparently healthy men and women aged 65–80 years | 10 mcg | 1 year | — |
| Effects of vitamin D supplementation on cognitive function and blood Aβ-related biomarkers in older adults with Alzheimer's disease: a randomised, double-blind, placebo-controlled trial 2019 · vitamin D group · Older adults with Alzheimer's disease | 800 IU | 1 year | — |
| Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial 2019 · vitamin D3 group · Adults at high risk of diabetes or with newly diagnosed type 2 diabetes | 5,000 IU | 26 weeks | — |
| Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial 2019 · oral nano vitamin D · Patients with active ulcerative colitis and vitamin D <40 ng/mL | 60,000 IU | 8 days | — |
| Effects of zinc, vitamin D, and their co-supplementation on mood, serum cortisol, and brain-derived neurotrophic factor in patients with obesity and mild to moderate depressive symptoms: A phase II, 12-wk, 2 × 2 factorial design, double-blind, randomized, placebo-controlled trial 2020 · Vitamin D group · Overweight or obese adults with depressive symptoms and BDI-II score ≥10; mean age 38.35 years | 2,000 IU | 12 weeks | — |
| Effect of High-Dose vs Standard-Dose Vitamin D Supplementation in Pregnancy on Bone Mineralization in Offspring Until Age 6 Years: A Prespecified Secondary Analysis of a Double-Blinded, Randomized Clinical Trial 2020 · High-dose vitamin D · Pregnant women; offspring were followed through age 6 years | 2,800 IU | — | — |
| Effect of High-Dose vs Standard-Dose Vitamin D Supplementation in Pregnancy on Bone Mineralization in Offspring Until Age 6 Years: A Prespecified Secondary Analysis of a Double-Blinded, Randomized Clinical Trial 2020 · Standard-dose vitamin D · Pregnant women; offspring were followed through age 6 years | 400 IU | — | — |
| Effect of eldecalcitol on muscle function and fall prevention in Japanese postmenopausal women: A randomized controlled trial 2021 · Eldecalcitol group · Japanese postmenopausal women with osteoporosis | 0.75 mcg | 24 weeks | — |
| Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 - A Randomized Clinical Trial 2020 · intervention group · Adults aged 18–65 with diarrhea-predominant irritable bowel syndrome and vitamin D deficiency and/or insufficiency | 7,143 IU | 9 weeks | — |
| Vitamin D Supplementation Improves Health-Related Quality of Life and Physical Performance in Children with Sickle Cell Disease and in Healthy Children 2020 · HbSS, 4000 IU/day · African American children aged 5–20 years with HbSS sickle cell disease | 4,000 IU | 12 weeks | — |
| Vitamin D Supplementation Improves Health-Related Quality of Life and Physical Performance in Children with Sickle Cell Disease and in Healthy Children 2020 · HbSS, 7000 IU/day · African American children aged 5–20 years with HbSS sickle cell disease | 7,000 IU | 12 weeks | — |
| Vitamin D Supplementation Improves Health-Related Quality of Life and Physical Performance in Children with Sickle Cell Disease and in Healthy Children 2020 · Healthy, 4000 IU/day · Healthy African American children aged 5–20 years without HbSS | 4,000 IU | 12 weeks | — |
| Vitamin D Supplementation Improves Health-Related Quality of Life and Physical Performance in Children with Sickle Cell Disease and in Healthy Children 2020 · Healthy, 7000 IU/day · Healthy African American children aged 5–20 years without HbSS | 7,000 IU | 12 weeks | — |
| The effect of multistrain synbiotic and vitamin D3 supplements on the severity of atopic dermatitis among infants under 1 year of age: a double-blind, randomized clinical trial study 2022 · Vitamin D3 group · Infants under 1 year of age with atopic dermatitis | 1,000 IU | 60 days | — |
| Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis 2020 · ELD group · Women aged 65 or over with osteoporosis | 0.75 mcg | 24 weeks | — |
| The effect of vitamin D add-on therapy on the improvement of quality of life and clinical symptoms of patients with chronic spontaneous urticaria 2023 · low (group 1) · Adults with chronic spontaneous urticaria; age range and sex not specified | 600 IU | 12 weeks | — |
| The effect of vitamin D add-on therapy on the improvement of quality of life and clinical symptoms of patients with chronic spontaneous urticaria 2023 · high (group 2) · Adults with chronic spontaneous urticaria; age range and sex not specified | 4,000 IU | 12 weeks | — |
| The Effects of 6-Month Vitamin D Supplementation during the Non-Surgical Treatment of Periodontitis in Vitamin-D-Deficient Patients: A Randomized Double-Blind Placebo-Controlled Study 2020 · Vitamin D group · Adults aged 30 years or older with generalized chronic periodontitis and serum 25(OH)D below 30 ng/mL | 3,571 IU | 26 weeks | — |
| Vitamin D in Children With Inflammatory Bowel Disease: A Randomized Controlled Clinical Trial 2021 · Vitamin D group · Children with inflammatory bowel disease and hypovitaminosis D | 2,000 IU | 26 weeks | — |
| Intake of 25-Hydroxyvitamin D(3) May Reduce the Severity of Upper Respiratory Tract Infection: Post hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study 2020 · 25OHD group · Japanese men and women with insufficient or deficient blood 25-hydroxyvitamin D levels (≤75 nmol/L) | 10 mcg | — | — |
| Vitamin D Supplementation Improves the Effects of the Rehabilitation Program on Balance and Pressure Distribution in Patients after Anterior Cervical Interbody Fusion-Randomized Control Trial 2020 · vitamin D supplemented (D3) group · Adults aged 31–68 with cervical spinal stenosis or degenerative disc disease undergoing anterior cervical interbody fusion | 3,200 IU | 5 weeks | — |
| Daily intake of yogurt drink fortified either with vitamin D alone or in combination with added calcium causes a thyroid-independent increase of resting metabolic rate in adults with type 2 diabetes: a randomized, double-blind, clinical trial 2021 · D-fortified yogurt drink (DY) · Adults with type 2 diabetes | 1,000 IU | 12 weeks | — |
| Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial 2021 · 5000 IU group · Adults aged 20–75 with mild to moderate, RT-PCR-confirmed COVID-19 and sub-optimal vitamin D status | 5,000 IU | 2 weeks | — |
| Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial 2021 · 1000 IU group · Adults aged 20–75 with mild to moderate, RT-PCR-confirmed COVID-19 and sub-optimal vitamin D status | 1,000 IU | 2 weeks | — |
| Vitamin D3 Supplementation Effects on Spermatogram and Oxidative Stress Biomarkers in Asthenozoospermia Infertile Men: a Randomized, Triple-Blind, Placebo-Controlled Clinical Trial 2022 · Group A · Men with asthenozoospermia, infertility, and serum 25-OH-D3 <30 ng/ml | 4,000 IU | 90 days | — |
| Vitamin D supplementation and gross motor development: A 3-year follow-up of a randomized trial 2022 · 400 IU/day (standard-of-care) · Healthy infants receiving supplementation from 1 to 12 months of age | 400 IU | 330 days | — |
| Vitamin D supplementation and gross motor development: A 3-year follow-up of a randomized trial 2022 · 800 IU/day · Healthy infants receiving supplementation from 1 to 12 months of age | 800 IU | 330 days | — |
| Vitamin D supplementation and gross motor development: A 3-year follow-up of a randomized trial 2022 · 1200 IU/day · Healthy infants receiving supplementation from 1 to 12 months of age | 1,200 IU | 330 days | — |
| Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial 2023 · vitamin D plus placebo · Men aged 50 and older without clinically apparent cardiovascular disease or cancer; this analysis excluded men with multiple sclerosis or Parkinson’s disease at baseline | 2,000 IU | 1935 days | — |
| A randomized controlled trial of Vitamin D supplementation in Iranian patients with schizophrenia: Effects on serum levels of glycogen synthase kinase-3β and symptom severity 2023 · vitamin D treatment group · adult men with chronic schizophrenia and vitamin D deficiency (≤20 ng/mL) | 2,000 IU | 8 weeks | — |
| Vitamin D and Child Neurodevelopment-A Post Hoc Analysis 2023 · 400 IU/day vitamin D3 group · Pregnant women with singleton pregnancies and no preexisting chronic diseases; good general health; recruited at 12–16 weeks of gestation | 400 IU | — | — |
| Vitamin D and Child Neurodevelopment-A Post Hoc Analysis 2023 · 2000 IU/day vitamin D3 group · Pregnant women with singleton pregnancies and no preexisting chronic diseases; good general health; recruited at 12–16 weeks of gestation | 2,000 IU | — | — |
| Vitamin D and Child Neurodevelopment-A Post Hoc Analysis 2023 · 4000 IU/day vitamin D3 group · Pregnant women with singleton pregnancies and no preexisting chronic diseases; good general health; recruited at 12–16 weeks of gestation | 4,000 IU | — | — |
| Effect of vitamin D supplementation on symptoms severity in vitamin D insufficient women with premenstrual syndrome: A randomized controlled trial 2024 · vitamin D group · Vitamin D-insufficient women with premenstrual syndrome; age range not reported | 3,571 IU | 16 weeks | — |
| Effect of Calcium and Vitamin D Supplementation (Dairy vs. Pharmacological) on Bone Health of Underprivileged Indian Children and Youth with Type-1 Diabetes: A Randomized Controlled Trial 2024 · Milk (group A) · Underprivileged Indian children and youth aged 5–23 years with type-1 diabetes mellitus; both sexes | 1,000 IU | 1 year | — |
| Effect of dairy products fortified with vitamin d(3) on restless legs syndrome in women with premenstrual syndrome, abdominal obesity and vitamin d deficiency: a pilot study 2024 · Fortified low-fat milk · Women aged 30–50 with premenstrual syndrome, abdominal obesity and vitamin D deficiency | 1,500 IU | 10 weeks | — |
| Effect of dairy products fortified with vitamin d(3) on restless legs syndrome in women with premenstrual syndrome, abdominal obesity and vitamin d deficiency: a pilot study 2024 · Fortified low-fat yogurt · Women aged 30–50 with premenstrual syndrome, abdominal obesity and vitamin D deficiency | 1,500 IU | 10 weeks | — |
| Weekly Vitamin D Supplementation to Prevent Acute Respiratory Infections in Young Children at Different Latitudes: A Randomized Controlled Trial 2024 · low-dose · Children aged 1.5–3.5 years without a stated condition | 800 IU | 26 weeks | — |
| Weekly Vitamin D Supplementation to Prevent Acute Respiratory Infections in Young Children at Different Latitudes: A Randomized Controlled Trial 2024 · high-dose · Children aged 1.5–3.5 years without a stated condition | 1,600 IU | 26 weeks | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Vitamin D3, without omega-3s · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 2,000 IU | 3 years | — |
| Rickets in very-low-birth-weight infants born at Baragwanath Hospital 1994 · Breast-milk only · Very-low-birth-weight neonates weighing less than 1,200 g at birth | 800 IU | 18 weeks | — |
| No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects 1997 · calcitriol · healthy male subjects; age not reported | 1.5 mcg | 7 days | — |
| Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60 2000 · 25OH vitamin D3 · Men and women over age 60; elderly volunteers | 15 mcg | 4 years | — |
| Effects of vitamin D and high dairy protein intake on bone mineralization and linear growth in 6- to 8-year-old children: the D-pro randomized trial 2021 · Vitamin D3 plus high-protein yogurt · Healthy Danish children aged 6–8 years with light skin | 20 mcg | 24 weeks | — |
| Effects of vitamin D and high dairy protein intake on bone mineralization and linear growth in 6- to 8-year-old children: the D-pro randomized trial 2021 · Vitamin D3 plus normal-protein yogurt · Healthy Danish children aged 6–8 years with light skin | 20 mcg | 24 weeks | — |
| Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study 2023 · intervention group · Adults aged 18 years or older hospitalized with PCR-confirmed COVID-19 who required more than 48 hours of admission | 0.75 mcg | — | 78 |
| The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial 2020 · Study group · Women undergoing ICSI | 50 mcg | 26 weeks | 50 |
| Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial 2018 · TMN · Adults aged 50 years or older with moderate-to-severe COPD and pre-cachexia or cachexia | 20 mcg | 12 weeks | 22 |
| Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren 2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified | 5 mcg | 335 days | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 10 mcg | — | — |
| Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial 2016 · 4400 IU/d vitamin D group · Pregnant women aged 18–39 years, 10–18 weeks’ gestation, with a personal or partner history of asthma, eczema, or allergic rhinitis | 4,400 IU | — | 440 |
| Daily adjunctive therapy with vitamin D(3) and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia 2018 · vitamin D3 + PBA · HIV-negative adults over 18 with newly diagnosed pulmonary tuberculosis | 5,000 IU | 16 weeks | 175 |
| Effects of Enhanced Exercise and Combined Vitamin D and Calcium Supplementation on Muscle Strength and Fracture Risk in Postmenopausal Chinese Women 2017 · group D · Postmenopausal women at high risk of osteoporosis | 0.25 mcg | 2 years | 131 |
| An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial 2016 · Active · Adults aged 65 years or older who had undergone hip fracture surgery; men and women with a recent surgically repaired hip fracture | 800 IU | 26 weeks | 111 |
| Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial 2025 · vitamin K2/D3 arm · Adults aged 18 years or older with at least two moderate-intensity long COVID symptoms persisting for at least three months after COVID-19 infection | 2,000 IU | 24 weeks | 98 |
| Role of Lactobacillus rhamnosus (FloraActive™) 19070-2 and Lactobacillus reuteri (FloraActive™) 12246 in Infant Colic: A Randomized Dietary Study 2018 · probiotic group · Exclusively breastfed infants aged 4–12 weeks with infant colic | 5 mcg | 4 weeks | 86 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · denosumab 60 mg Q6M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 400 IU | 1 year | 85 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · denosumab 60 mg Q2M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 400 IU | 1 year | 85 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · denosumab 60 mg Q3M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 400 IU | 1 year | 82 |
| Vitamin D Attenuates Left Atrial Volume Changes in African American Males with Obesity and Prediabetes 2016 · vitamin D group · African American male veterans aged 35–85 with obesity, prediabetes and vitamin D deficiency | 7,143 IU | 1 year | 81 |
| Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial 2017 · Placebo arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61 | 600 IU | 24 weeks | 80 |
| Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial 2017 · Vitamin D3 arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61 | 4,886 IU | 24 weeks | 80 |
| Improving rehabilitation in sarcopenia: a randomized-controlled trial utilizing a muscle-targeted food for special medical purposes 2020 · Experimental formula · Adults aged 65 years or older with sarcopenia admitted for inpatient rehabilitation | 1,600 IU | 8 weeks | 70 |
| High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women 2013 · aquatic exercise group (AEG) · Postmenopausal women, mean age 58.8 years | 1,000 IU | 24 weeks | 64 |
| Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial 2011 · Vitamin D group · Patients with treatment-naive early rheumatoid arthritis | 500 IU | 90 days | 59 |
| Effects of vitamin D and/or calcium intervention on sleep quality in individuals with prediabetes: a post hoc analysis of a randomized controlled trial 2024 · vitamin D + calcium group · Chinese individuals with prediabetes; age and sex not specified | 1,600 IU | 24 weeks | 53 |
| Combination of alfacalcidol and calcium improved handgrip strength and mobility among Indonesian older women: A randomized controlled trial 2018 · Alfacalcidol group · Indonesian older women with handgrip strength ≤22 kg | 0.5 mcg | 90 days | 47 |
| Vitamin D(3) supplementation does not enhance the effects of resistance training in older adults 2021 · Vitamin D3 arm · Men and women aged 56–77 years, older adults with normal lung function or moderate COPD; some had indications of sarcopenia | 12,000 IU | 25 weeks | 46 |
| Vitamin D in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 or Vaccination: A Randomized Controlled Trial 2026 · Intervention group · Adults aged 18 years or older with ME/CFS following COVID-19 infection or vaccination and vitamin D insufficiency or deficiency | 26 mcg | 24 weeks | 46 |
| High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women 2013 · control group (CG) · Postmenopausal women, mean age 58.8 years | 1,000 IU | 24 weeks | 44 |
| A Nutritionally Complete Oral Nutritional Supplement Powder Improved Nutritional Outcomes in Free-Living Adults at Risk of Malnutrition: A Randomized Controlled Trial 2022 · nutrition supplement (intervention group) · Chinese men and women aged 18 years or older, all classified as at risk of malnutrition; mean age 66.5 years, range 41–89 | 8 mcg | 12 weeks | 44 |
| Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV 2020 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy | 1,000 IU | 1 year | 41 |
| Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV 2020 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy | 3,000 IU | 1 year | 41 |
| [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women] 2010 · Group B · Perimenopausal or postmenopausal women with low bone mineral density or osteoporosis | 0.5 mcg | 48 weeks | 40 |
| Changes in body composition following a dietary and lifestyle intervention trial: the postmenopausal health study 2009 · dietary intervention group (DG) · Healthy postmenopausal women | 7.5 mcg | 1 year | 39 |
| [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women] 2010 · Group A · Perimenopausal or postmenopausal women with low bone mineral density or osteoporosis | 0.5 mcg | 48 weeks | 36 |
| Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial 2014 · combined calcium and vitamin D treatment · Multi-ethnic men and women aged 18 years or older, vitamin D-deficient and at risk of type 2 diabetes; BMI 25–40 kg/m² | 2,000 IU | 26 weeks | 35 |
| Co-administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double-blinded randomized controlled trial 2024 · Probiotic group · Adults aged 18–65 with schizophrenia | 400 IU | 12 weeks | 35 |
| [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women] 2010 · Group C · Perimenopausal or postmenopausal women with low bone mineral density or osteoporosis | 0.5 mcg | 48 weeks | 33 |
| A Novel Fortified Dairy Product and Sarcopenia Measures in Sarcopenic Older Adults: A Double-Blind Randomized Controlled Trial 2021 · intervention group · Community-recruited older adults with sarcopenia | 1,000 IU | 12 weeks | 33 |
| The effect of vitamin D and magnesium supplementation on the mental health status of attention-deficit hyperactive children: a randomized controlled trial 2021 · Intervention group · Children aged 6–12 years with ADHD and low serum 25-hydroxyvitamin D and magnesium levels | 7,143 IU | 8 weeks | 33 |
| A randomized controlled trial of high dose vitamin D3 in patients with heart failure 2013 · Vitamin D3 group · Adults aged 50 years or older with heart failure (NYHA class II–IV) and serum 25OHD ≤37.5 ng/ml | 7,143 IU | 26 weeks | 32 |
| Effects of progesterone and vitamin D on outcome of patients with acute traumatic spinal cord injury; a randomized, double-blind, placebo controlled study 2016 · progesterone and vitamin D · Adults with acute traumatic spinal cord injury | 0.01 mg/kg | 5 days | 32 |
| Calcium Plus Vitamin D Supplementation During the Third Trimester of Pregnancy in Adolescents Accustomed to Low Calcium Diets Does Not Affect Infant Bone Mass at Early Lactation in a Randomized Controlled Trial 2015 · calcium plus vitamin D supplementation · Brazilian adolescent mothers consuming low-calcium diets, from 26 weeks of gestation until parturition | 200 IU | — | 30 |
| Long-term Effects of Calcium β-Hydroxy-β-Methylbutyrate and Vitamin D3 Supplementation on Muscular Function in Older Adults With and Without Resistance Training: A Randomized, Double-blind, Controlled Study 2020 · HMB+D + exercise · Men and women aged 60 years or older with insufficient, but not clinically deficient, 25-hydroxyvitamin D levels (15–30 ng/mL) | 2,000 IU | 1 year | 30 |
| The Effect of Branched Chain Amino Acids-Enriched Nutritional Supplements on Activities of Daily Living and Muscle Mass in Inpatients with Gait Impairments: A Randomized Controlled Trial 2019 · RJ group · Adult inpatients aged 20 years or older with gait impairments admitted to acute and convalescent rehabilitation wards | 40 mcg | 58 days | 29 |
| Long-term Effects of Calcium β-Hydroxy-β-Methylbutyrate and Vitamin D3 Supplementation on Muscular Function in Older Adults With and Without Resistance Training: A Randomized, Double-blind, Controlled Study 2020 · HMB+D + no exercise · Men and women aged 60 years or older with insufficient, but not clinically deficient, 25-hydroxyvitamin D levels (15–30 ng/mL) | 2,000 IU | 1 year | 27 |
| Randomized study of the effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammation, and SIRT1 in obese women with mild to moderate depressive symptoms 2022 · co-supplementation group · Obese women with mild to moderate depressive symptoms | 7,143 IU | 8 weeks | 27 |
| Calcium plus vitamin D3 supplementation facilitated fat loss in overweight and obese college students with very-low calcium consumption: a randomized controlled trial 2013 · calcium+D group · Generally healthy overweight or obese college students aged 18–25 years with daily calcium intake below 600 mg; predominantly female | 125 IU | 12 weeks | 26 |
| The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial 2024 · group 3: both omega-3 and vitamin D supplementation (ω3+VitD) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment | 7,143 IU | 9 weeks | 24 |
| The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study 2009 · Group 1 · Infertile women with polycystic ovary syndrome (PCOS); age not stated | 400 IU | 90 days | 20 |
| The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study 2009 · Group 2 · Infertile women with polycystic ovary syndrome (PCOS); age not stated | 400 IU | 90 days | 20 |
| Effects of Vitamin D and Calcium Fortified Yogurts on Gait, Cognitive Performances, and Serum 25-Hydroxyvitamin D Concentrations in Older Community-Dwelling Females: Results from the GAit, MEmory, Dietary and Vitamin D (GAME-D2) Randomized Controlled Trial 2019 · intervention group (fortified yogurt) · Females aged 65 years or older with hypovitaminosis D (serum 25OHD <75 nmol/L), living independently at home or in an autonomous residence | 400 IU | 90 days | 20 |
| The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal women 2022 · 500 ml semi-skimmed milk with added cholecalciferol · Postmenopausal women aged 60–80 years with vitamin D insufficiency at screening | 200 mcg | 1 day | 20 |
| High- vs. routine-dose vitamin D3 in severe lupus on pulse methylprednisolone: a randomized, double-blind, placebo-controlled clinical trial 2025 · high-dose (HD) · Inpatients with severe systemic lupus erythematosus receiving intravenous pulse methylprednisolone; age and sex not stated | 1,000 IU | 24 weeks | 20 |
| Falls and physical function in older patients with Benign Paroxysmal Positional Vertigo (BPPV): findings from a placebo controlled, double blinded randomized control trial (RCT) investigating efficacy of vitamin D treatment in lowering the recurrence rate of BPPV 2025 · Group A · Adults aged 50 years or older with idiopathic BPPV and depleted baseline vitamin D | 3,000 IU | 26 weeks | 19 |
| Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial 2021 · Group B (vitamin D supplementation group) · Adults aged 20 years or older with decompensated cirrhosis, receiving oral branched-chain amino acid preparations for at least 6 months; serum 25(OH)D below 30 ng/mL | 2,000 IU | 1 year | 16 |
| A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder 2019 · VIDOM · Children aged 2.5–8 years with autism spectrum disorder | 2,000 IU | 1 year | 15 |
| Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡) 2020 · vitamin D and omega-3 LCPUFA (VIDOM) · Children aged 2.5–8 years with autism spectrum disorder | 2,000 IU | 1 year | 15 |
| Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients 2024 · Group III · Female patients with systemic lupus erythematosus (SLE); age not reported | 1,200 IU | 90 days | 15 |
| Muscle-Related Effect of Whey Protein and Vitamin D(3) Supplementation Provided before or after Bedtime in Males Undergoing Resistance Training 2022 · before bedtime (BB) · Males aged 18–24 years with vitamin D deficiency, healthy and untrained, undergoing resistance training | 4,000 IU | 6 weeks | 14 |
| Muscle-Related Effect of Whey Protein and Vitamin D(3) Supplementation Provided before or after Bedtime in Males Undergoing Resistance Training 2022 · after sleeping (AS) · Males aged 18–24 years with vitamin D deficiency, healthy and untrained, undergoing resistance training | 4,000 IU | 6 weeks | 14 |
| Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis 2011 · group DE · Patients with atopic dermatitis; age and sex not specified | 1,600 IU | 60 days | 11 |
| Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study 2012 · Group B (calcium and calcitriol; PTH <5) · Adults aged 18–82 undergoing completion or total thyroidectomy, with POD1 PTH <5 | 1 mcg | 15 days | 7 |
| Maturation of primary and permanent teeth in preterm infants 2000 · 500 IU/day vitamin D; calcium- and phosphorus-supplemented breast milk · Preterm infants | 500 IU | — | — |
| Maturation of primary and permanent teeth in preterm infants 2000 · 1000 IU/day vitamin D; calcium- and phosphorus-supplemented breast milk · Preterm infants | 1,000 IU | — | — |
| Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? 2002 · group C · Patients who underwent total thyroidectomy | 1 mg | 26 weeks | — |
| Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects 2006 · resistance training plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects | 400 IU | 270 days | — |
| Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects 2006 · control (no resistance training) plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects | 400 IU | 270 days | — |
| Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis 2007 · RE+ (reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture | 400 IU | 1 year | — |
| Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis 2007 · RE− (no reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture | 400 IU | 1 year | — |
| Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain 2007 · calcium plus cholecalciferol · Postmenopausal women aged 50 to 79 years | 400 IU | 7 years | — |
| Predictors of adherence in the Women's Health Initiative Calcium and Vitamin D Trial 2009 · active treatment · Postmenopausal women aged 50–79 years | 400 IU | — | — |
| Calcium plus vitamin D supplementation and fat mass loss in female very low-calcium consumers: potential link with a calcium-specific appetite control 2009 · calcium+D supplementation · Overweight or obese women, mean age 43 years, with daily calcium intake below 800 mg | 10 mcg | 15 weeks | — |
| A comparison between the efficacy of dydrogesterone and calcium plus vitamin D in improving women's general health 2010 · calcium plus vitamin D · Young women who were students at Shiraz University | 400 mg | — | — |
| A randomized controlled trial of the effects of vitamin D on muscle strength and mobility in older women with vitamin D insufficiency 2010 · Vitamin D group · Women aged 70 to 90 with vitamin D insufficiency, living in the community | 1,000 IU | 1 year | — |
| Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial 2011 · Vitamin D and calcium group · Adults at high risk of type 2 diabetes; mean age 57 years | 2,000 IU | 16 weeks | — |
| Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults 2012 · Calcium and vitamin D-fortified regular orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated | 300 IU | 16 weeks | — |
| Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults 2012 · Calcium and vitamin D-fortified lite orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated | 300 IU | 16 weeks | — |
| The effect of vitamin D on calcium absorption in older women 2012 · 400 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency | 400 IU | 1 year | — |
| The effect of vitamin D on calcium absorption in older women 2012 · 800 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency | 800 IU | 1 year | — |
| The effect of vitamin D on calcium absorption in older women 2012 · 1600 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency | 1,600 IU | 1 year | — |
| The effect of vitamin D on calcium absorption in older women 2012 · 2400 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency | 2,400 IU | 1 year | — |
| The effect of vitamin D on calcium absorption in older women 2012 · 3200 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency | 3,200 IU | 1 year | — |
| The effect of vitamin D on calcium absorption in older women 2012 · 4000 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency | 4,000 IU | 1 year | — |
| The effect of vitamin D on calcium absorption in older women 2012 · 4800 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency | 4,800 IU | 1 year | — |
| High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study 2012 · High-dose vitamin D group · Children and adolescents aged 7–21 years with sickle cell disease, including participants with and without chronic pain | 200 IU | 26 weeks | — |
| Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial 2013 · vitamin D(3) plus calcium · Adults aged 45–75 in good health, with a history of colorectal adenoma and serum 25-hydroxyvitamin D ≥12 ng/mL | 1,000 IU | — | — |
| Complementary treatment of obesity and overweight with salacia reticulata and vitamin d 2013 · Group B · Healthy, physically active adults aged 30–60 years with BMI 25–45 and overweight or obesity | 4.8 mcg | 4 weeks | — |
| Effects of Calcium Plus Vitamin D Supplementation on Anthropometric Measurements and Blood Pressure in Vitamin D Insufficient People with Type 2 Diabetes: A Randomized Controlled Clinical Trial 2015 · 50,000 IU/wk vitamin D3 plus 1000 mg/d calcium · People with type 2 diabetes and vitamin D insufficiency | 7,143 IU | 8 weeks | — |
| A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods 2015 · VDCa group · Adult male and female volunteers aged 50 years or older | 800 IU | 26 weeks | — |
| Effects of Calcium-Vitamin D and Calcium-Alone on Pain Intensity and Menstrual Blood Loss in Women with Primary Dysmenorrhea: A Randomized Controlled Trial 2017 · calcium-vitamin D group · Women students with moderate or severe primary dysmenorrhea | 5,000 IU | — | — |
| Calcium plus vitamin D supplementation and height loss: findings from the Women's Health Initiative Calcium and Vitamin D clinical trial 2016 · CaD group · Postmenopausal women aged 50–79, generally healthy | 400 IU | 8 years | — |
| High dose vitamin D may improve lower urinary tract symptoms in postmenopausal women 2017 · standard dose group · Postmenopausal women with low bone mineral density | 800 IU | 1 year | — |
| Supplementing Breakfast with a Vitamin D and Leucine-Enriched Whey Protein Medical Nutrition Drink Enhances Postprandial Muscle Protein Synthesis and Muscle Mass in Healthy Older Men 2017 · test group · Healthy older men; mean age 71 ± 4 years | 800 IU | 6 weeks | — |
| Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children 2018 · Group C · Children aged 7–15 with nocturnal enuresis | 1,000 IU | 60 days | — |
| Vitamin D supplementation may improve back pain disability in vitamin D deficient and overweight or obese adults 2019 · Vitamin D group · Overweight or obese adults with vitamin D deficiency; otherwise healthy | 4,000 IU | 16 weeks | — |
| A high weekly dose of cholecalciferol and calcium supplement enhances weight loss and improves health biomarkers in obese women 2018 · vitamin D3 plus Ca (Diet/Ca/D) · Obese women with vitamin D deficiency | 7,143 IU | 90 days | — |
| Low-Dose Omega-3 Fatty Acid and Vitamin D for Anthropometric, Biochemical Blood Indices and Respiratory Function. Does it work? 2020 · experimental group · Office workers aged 40–60 years; sex and health condition not stated | 5 mcg | 16 weeks | — |
| Effects of zinc, vitamin D, and their co-supplementation on mood, serum cortisol, and brain-derived neurotrophic factor in patients with obesity and mild to moderate depressive symptoms: A phase II, 12-wk, 2 × 2 factorial design, double-blind, randomized, placebo-controlled trial 2020 · Vitamin D plus zinc group · Overweight or obese adults with depressive symptoms and BDI-II score ≥10; mean age 38.35 years | 2,000 IU | 12 weeks | — |
| Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT 2021 · low-dose vitamin D · Men aged 60 years or older with stage I–IV prostate cancer receiving ADT and suboptimal vitamin D levels (<32 ng/ml) | 600 IU | 24 weeks | — |
| Randomized Study of the Effects of Vitamin D and Magnesium Co-Supplementation on Muscle Strength and Function, Body Composition, and Inflammation in Vitamin D-Deficient Middle-Aged Women 2021 · intervention · Women aged 40–55 years with vitamin D deficiency | 7,143 IU | 8 weeks | — |
| Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial 2020 · Group 1—fortified milk and early therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis | 1,000 IU | — | — |
| Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial 2020 · Group 3—fortified milk and late therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis | 1,000 IU | — | — |
| Calcium Carbonate Attenuates Withdrawal and Reduces Craving: A Randomized Controlled Trial in Alcohol-Dependent Patients 2021 · calcium carbonate group · Alcohol-dependent patients undergoing inpatient alcohol-withdrawal treatment; age and sex not specified | 5 mcg | 2 weeks | — |
| Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile 2021 · Fortified sachet and powdered milk plus periodontal treatment during pregnancy (early PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation | 1,000 IU | — | — |
| Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile 2021 · Fortified sachet and powdered milk plus periodontal treatment after delivery (late PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation | 1,000 IU | — | — |
| Daily intake of yogurt drink fortified either with vitamin D alone or in combination with added calcium causes a thyroid-independent increase of resting metabolic rate in adults with type 2 diabetes: a randomized, double-blind, clinical trial 2021 · Ca-D-fortified yogurt drink (CDY) · Adults with type 2 diabetes | 1,000 IU | 12 weeks | — |
| Functional improvements to 6 months of physical activity are not related to changes in size or density of multiple lower-extremity muscles in mobility-limited older individuals 2022 · nutritional supplement · Community-dwelling mobility-limited older men and women; mean age 77 ± 5 years | 800 IU | 26 weeks | — |
| Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial 2023 · vitamin D plus omega-3 fatty acids · Men aged 50 and older without clinically apparent cardiovascular disease or cancer; this analysis excluded men with multiple sclerosis or Parkinson’s disease at baseline | 2,000 IU | 1935 days | — |
| Vitamin D Supplementation Has No Impact on Cardiorespiratory Fitness, but Improves Inflammatory Status in Vitamin D Deficient Young Men Engaged in Resistance Training 2022 · Vitamin D supplemented (VD) group · Vitamin-D-deficient young men, mean age 23.7 years, without chronic disease, participating in resistance training | 8,000 IU | 12 weeks | — |
| Effects of vitamin D on sex steroids, luteinizing hormone, and testosterone to luteinizing hormone ratio in 307 infertile men 2024 · active group · infertile men | 301,400 IU | 150 days | — |
| Effect of Calcium and Vitamin D Supplementation (Dairy vs. Pharmacological) on Bone Health of Underprivileged Indian Children and Youth with Type-1 Diabetes: A Randomized Controlled Trial 2024 · Calcium supplement (group B) · Underprivileged Indian children and youth aged 5–23 years with type-1 diabetes mellitus; both sexes | 1,000 IU | 1 year | — |
| Alcohol use disorder and muscle weakness: Original study of the effect of vitamin D supplementation in ambulatory participants with alcohol use disorder 2024 · CAU (care as usual) · Community-dwelling adults with alcohol use disorder; ages and sex by arm not reported. The reported outcome subgroup had vitamin D concentrations below 50 nmol/L. | 800 IU | 1 year | — |
| Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial 2024 · cholecalciferol group · pre-frail older adults | 4,000 IU | 12 weeks | — |
| Evaluation of efficacy of cholecalciferol and silymarin in improving lower urinary tract symptoms of benign prostatic hyperplasia: A double-blind, randomized, controlled trial 2024 · Cholecalciferol and Silymarin combination · Men aged 50–80 with benign prostatic hyperplasia and lower urinary tract symptoms, with serum 25-(OH) vitamin D below 20 ng/ml | 7,143 IU | 90 days | — |
| The relationship between serum vitamin D, testosterone, and oxidative stress levels in women with sexual dysfunction: A case-controlled study 2024 · intervention group · Women aged 18–45 with female sexual dysfunction and low serum vitamin D | 7,143 IU | 4 weeks | — |
| The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial 2025 · ω3+VitD group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported | 7,143 IU | 9 weeks | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Vitamin D3 and omega-3s, without SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 2,000 IU | 3 years | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Vitamin D3 and omega-3s with SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 2,000 IU | 3 years | — |
| Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial 2025 · D12 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL | 4,286 IU | 12 weeks | — |
| Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial 2025 · D24 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL | 4,286 IU | 24 weeks | — |
| Rickets in very-low-birth-weight infants born at Baragwanath Hospital 1994 · Breast-milk and premature formula · Very-low-birth-weight neonates weighing less than 1,200 g at birth | 800 IU | 18 weeks | — |
| Effect of vitamin D supplementation on glucose control in mid-late gestation: A randomized controlled trial 2023 · 400 IU/d vitamin D3 · Pregnant women recruited at 24–28 weeks’ gestation | 400 IU | 60 days | 862 |
| Effect of vitamin D supplementation on glucose control in mid-late gestation: A randomized controlled trial 2023 · 1600 IU/d vitamin D3 · Pregnant women recruited at 24–28 weeks’ gestation | 1,600 IU | 60 days | 858 |
| Vitamin D supplementation for cardiometabolic risk markers in pregnant women based on the gestational diabetes mellitus or obesity status : a randomized clinical trial 2024 · control group · Pregnant women at 24–28 weeks' gestation with serum 25(OH)D <75 nmol/L; included women with or without GDM or overweight/obesity | 400 IU | 60 days | 771 |
| Vitamin D supplementation for cardiometabolic risk markers in pregnant women based on the gestational diabetes mellitus or obesity status : a randomized clinical trial 2024 · intervention group · Pregnant women at 24–28 weeks' gestation with serum 25(OH)D <75 nmol/L; included women with or without GDM or overweight/obesity | 1,600 IU | 60 days | 766 |
| A Mediterranean-like dietary pattern with vitamin D3 (10 µg/d) supplements reduced the rate of bone loss in older Europeans with osteoporosis at baseline: results of a 1-y randomized controlled trial 2018 · Mediterranean-like dietary intervention · Men and women aged 65–79 years; free-living older adults, including a subgroup with osteoporosis at baseline | 10 mcg | 1 year | 632 |
| Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density 2007 · alendronate 10 mg/calcium-placebo · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day | 400 IU | 2 years | 280 |
| Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis 2014 · ALN/D group · Postmenopausal women with osteoporosis; mean age 73 years | 800 IU | 1 year | 257 |
| The effect of high-dose vitamin D(3) supplementation on bone mineral density in subjects with prediabetes 2018 · vitamin D · Prediabetic adults; the abstract does not specify their age or sex distribution. The reported significant femoral-neck result was in males. | 2,857 IU | 5 years | 256 |
| Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial 1995 · vitamin D group · Women aged 70 years and older | 400 IU | 2 years | 177 |
| Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China 2018 · ALN/D5600 group · Chinese postmenopausal women older than 55 with osteoporosis | 800 IU | 1 year | 111 |
| Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis 2015 · ALN + ELD group · Japanese men and women aged 60–90 with primary osteoporosis or osteopenia and at least one vertebral fracture | 0.75 mcg | 48 weeks | 110 |
| Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males 2020 · 400 IU daily vitamin D3 · Healthy vitamin D-sufficient adults aged 55–70 years; males and females | 400 IU | 3 years | 109 |
| Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China 2018 · calcitriol group · Chinese postmenopausal women older than 55 with osteoporosis | 0.25 mcg | 1 year | 108 |
| Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males 2020 · 10,000 IU daily vitamin D3 · Healthy vitamin D-sufficient adults aged 55–70 years; males and females | 10,000 IU | 3 years | 102 |
| Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males 2020 · 4000 IU daily vitamin D3 · Healthy vitamin D-sufficient adults aged 55–70 years; males and females | 4,000 IU | 3 years | 100 |
| A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis 2006 · Placebo tablets and vitamin D group · Children and adolescents aged 6–18 years with juvenile rheumatoid arthritis who had not taken corticosteroids for at least 3 months | 400 IU | 2 years | 95 |
| Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults 1995 · Vitamin D supplementation · Men and women aged 63–76 years (mean age 70), recruited from general practitioner age-sex registers in Cambridge, UK; no stated condition | 2.5 mg | 5 weeks | 95 |
| Cholecalciferol Supplementation Attenuates Bone Loss in Incident Kidney Transplant Recipients: A Prespecified Secondary Endpoint Analysis of a Randomized Controlled Trial 2022 · cholecalciferol · Adults aged 20–80 years, 1 month after living kidney transplantation; most had vitamin D deficiency | 4,000 IU | 330 days | 92 |
| Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis 2006 · alfacalcidol group · Postmenopausal Caucasian patients with osteoporosis and normal vitamin D serum levels | 1 mcg | 547 days | 76 |
| Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis 1999 · alfacalcidol · Patients with diseases requiring long-term high-dose corticosteroid treatment who were steroid naive at study entry | 1 mcg | 1 year | 74 |
| Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: a randomized placebo-controlled trial 2014 · vitamin D supplementation group · Chinese patients with grades I-II essential hypertension | 2,000 IU | 26 weeks | 63 |
| Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease 1999 · treatment group · Elderly patients with Parkinson's disease; mean age 70.6 years | 1 mcg | 548 days | 43 |
| Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial 2015 · group 1 · Women with endometrial cancer after treatment and surgery | 1 mcg | 2 years | 39 |
| Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial 2015 · group 2 · Women with endometrial cancer after treatment and surgery | 1 mcg | 2 years | 37 |
| Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study 2016 · alfacalcidol plus alendronate · Adult women with systemic connective tissue diseases starting high-dose glucocorticoid therapy (prednisolone-equivalent dose at least 20 mg/day) | 1 mcg | 1 year | 36 |
| The effect of season and vitamin D supplementation on bone mineral density in healthy women: a double-masked crossover study 2001 · Group 1 (vitamin D; crossover) · Healthy women aged 24–70 years (mean age 47.2 years) | 800 IU | 1 year | 35 |
| Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D 1999 · vitamin D3 group · Elderly patients with hemiplegia after stroke and hypovitaminosis D | 1 mcg | 1 year | 34 |
| Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study 2016 · alfacalcidol · Adult women with systemic connective tissue diseases starting high-dose glucocorticoid therapy (prednisolone-equivalent dose at least 20 mg/day) | 1 mcg | 1 year | 33 |
| Combination of Calcitriol and Zoledronic Acid on PINP and β-CTX in Postoperative Patients with Diabetic Osteoporosis: A Randomized Controlled Trial 2022 · control group · Adults aged 40–78 with diabetic osteoporosis and surgically treated posterior cruciate ligament tibial avulsion fractures | 0.25 mcg | 1 year | 30 |
| Combination of Calcitriol and Zoledronic Acid on PINP and β-CTX in Postoperative Patients with Diabetic Osteoporosis: A Randomized Controlled Trial 2022 · observation group · Adults aged 43–78 with diabetic osteoporosis and surgically treated posterior cruciate ligament tibial avulsion fractures | 0.25 mcg | 1 year | 30 |
| Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis 2000 · D group · Postmenopausal women aged 55–81 years with osteoporosis, more than 5 years after menopause | 0.75 mcg | 2 years | 29 |
| Effects of 12 Weeks of Whole-Body Vibration Training and Vitamin D Supplementation on Bone Density and Muscle Quality in the Aged with Osteosarcopenia: A Randomized Controlled Trial 2025 · WBVT group · Older adults with osteosarcopenia; age range and sex not specified | 0.25 mcg | 90 days | 24 |
| Effects of calcium and vitamin D supplementation on blood pressure and serum lipids and carotenoids: a randomized, double-blind, placebo-controlled, clinical trial 2013 · vitamin D3 · Adults aged 30–75 with at least one pathology-confirmed adenomatous colorectal polyp in the previous 36 months | 800 IU | 26 weeks | 23 |
| Effect of Calcitriol Supplementation on Blood Pressure in Older Adults 2016 · calcitriol group · Older adults with hypertension; mean age 71.7 ± 10 years | 1,000 IU | 6 weeks | 22 |
| Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome 2010 · risedronate + alfacalcidol group · Patients with minimal-change nephrotic syndrome receiving prednisolone | 0.25 mcg | 1 year | 20 |
| Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome 2010 · alfacalcidol-alone group · Patients with minimal-change nephrotic syndrome receiving prednisolone | 0.25 mcg | 1 year | 20 |
| Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss 1993 · Group 3 · Women with postmenopausal bone loss | 2 mcg | 1 year | 20 |
| Bone mineral metabolism in full-term infants fed human milk, cow milk-based, and soy-based formulas 1992 · human milk-fed group · Normal, healthy, full-term infants | 400 IU | 120 days | 17 |
| Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol 2008 · group 3 (alendronate + alfacalcidol) · Kidney transplant recipients with low bone mineral density; 22 women and 42 men were recruited overall, but the arm's sex and age distribution are not reported. | 0.5 mcg | 1 year | 17 |
| Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol 2008 · alfacalcidol group · Japanese women with systemic autoimmune disease excluding rheumatoid arthritis, receiving glucocorticoids of at least 5 mg/day prednisolone equivalent for more than 6 months | 1 mcg | 2 years | 16 |
| Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine 2004 · vitamin D3 alone (group D) · Patients with chronic glomerulonephritis receiving prednisolone; age and sex distribution for this arm not reported | 0.5 mcg | 8 weeks | 15 |
| Treatment of osteopenia and osteoporosis in renal transplant children and adolescents 2004 · group 2 · Children and adolescents who had undergone renal transplantation at age 17 years or younger and had osteopenia or osteoporosis | 0.25 mcg | 1 year | 15 |
| A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents 2004 · group 2 · Children and adolescents with low bone mineral density after renal transplantation | 0.25 mcg | 1 year | 15 |
| Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure 1995 · calcitriol group · 13 patients in the predialysis phase of chronic renal failure | 0.25 mcg | 1 year | 13 |
| Randomised controlled trial of vitamin D supplementation on bone density and biochemical indices in preterm infants 1999 · Vitamin D 960 IU/day · Preterm infants born before 33 weeks of gestational age | 960 IU | 90 days | — |
| Calcitriol for bone loss in patients with primary biliary cirrhosis 1999 · calcitriol · Women with primary biliary cirrhosis | 1 mg | 187 weeks | — |
| Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3 1999 · 1alpha(OH)D3-treated group · Japanese women within 5 years of menopause | 1 mcg | 2 years | — |
| Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3 1999 · Combination-treated group (conjugated estrogens + 1alpha(OH)D3) · Japanese women within 5 years of menopause | 1 mcg | 2 years | — |
| Calcitriol for bone disease in patients with cirrhosis of the liver 1999 · calcitriol group · Men and women with cirrhosis of the liver | 1 mg | — | — |
| The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely 1999 · 500 IU/day vitamin D; unsupplemented breast milk · Preterm infants; sex and exact age range not stated | 500 IU | — | — |
| The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely 1999 · 1000 IU/day vitamin D; unsupplemented breast milk · Preterm infants; sex and exact age range not stated | 1,000 IU | — | — |
| Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate 2000 · group A · Heart transplant recipients; age and sex not specified | 0.5 mcg | 548 days | — |
| Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation 2001 · calcitriol · Patients undergoing cardiac or lung transplantation; age and sex not specified | 0.5 mcg | 26 weeks | — |
| Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss 2001 · calcitriol · Women aged 65–77 with normal bone density for their age | 0.5 mcg | 3 years | — |
| Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss 2001 · hormone replacement therapy/estrogen replacement therapy plus calcitriol · Women aged 65–77 with normal bone density for their age | 0.5 mcg | 3 years | — |
| Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study 2001 · calcitriol group · men with primary osteoporosis and at least one baseline fragility fracture | 0.5 mcg | 2 years | — |
| Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation 2004 · calcitriol · Cardiac transplant patients; age and sex not specified | 0.5 mcg | 1 year | — |
| Preventing wintertime bone loss: effects of vitamin D supplementation in healthy postmenopausal women 1992 · Vitamin D supplementation · Healthy postmenopausal women with low vitamin D intakes | 500 IU | 1 year | — |
| Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss 2006 · HRT/D group · Postmenopausal women aged 60 years or older with low lumbar bone mineral density (T-score less than -1) | 1 mcg | 2 years | — |
| A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: a double-blinded randomized placebo-controlled 1-year intervention 2006 · 5 microg vitamin D3 group · Adolescent girls, mean age 11.4 ± 0.4 years, with adequate dietary calcium intake | 5 mcg | 1 year | — |
| A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: a double-blinded randomized placebo-controlled 1-year intervention 2006 · 10 microg vitamin D3 group · Adolescent girls, mean age 11.4 ± 0.4 years, with adequate dietary calcium intake | 10 mcg | 1 year | — |
| Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone 2006 · Low-dose vitamin D, adults · Adults aged 18 to 54 years on long-term antiepileptic drug therapy | 400 IU | 1 year | — |
| Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone 2006 · High-dose vitamin D, adults · Adults aged 18 to 54 years on long-term antiepileptic drug therapy | 4,000 IU | 1 year | — |
| Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone 2006 · Low-dose vitamin D, children and adolescents · Children and adolescents aged 10 to 18 years on long-term antiepileptic drug therapy | 400 IU | 1 year | — |
| Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone 2006 · High-dose vitamin D, children and adolescents · Children and adolescents aged 10 to 18 years on long-term antiepileptic drug therapy | 2,000 IU | 1 year | — |
| ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects 2007 · 0.5 microg/day ED-71 group · Osteoporotic subjects | 0.5 mcg | 1 year | — |
| ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects 2007 · 0.75 microg/day ED-71 group · Osteoporotic subjects | 0.75 mcg | 1 year | — |
| ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects 2007 · 1.0 microg/day ED-71 group · Osteoporotic subjects | 1 mcg | 1 year | — |
| Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial 2007 · ALN 70 mg once a week plus calcitriol (1,25D3) 0.5 microg daily · Women aged 60 and older with osteoporosis, vitamin D insufficiency, and secondary hyperparathyroidism | 0.5 mcg | 1 year | — |
| Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial 2008 · placebo group · Children aged 6–18 years with juvenile rheumatoid arthritis, without systemic corticosteroid therapy in the 3 months before enrollment | 400 IU | 2 years | — |
| Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis 2009 · alfacalcidol · Patients with ulcerative colitis receiving glucocorticoids | 1 mcg | 1 year | — |
| What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year? 2013 · vitamin D(3) intervention group · Patients with multiple sclerosis; age and sex not reported | 2,857 IU | 96 weeks | — |
| Skeletal effects of vitamin D supplementation in postmenopausal black women 2012 · vitamin D · Postmenopausal Black women with serum 25(OH)D levels below 20 ng/mL | 1,000 IU | 2 years | — |
| Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women 2013 · 400 IU vitamin D group · White postmenopausal women aged 60–70 years | 400 IU | 1 year | — |
| Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women 2013 · 1000 IU vitamin D group · White postmenopausal women aged 60–70 years | 1,000 IU | 1 year | — |
| The effect of vitamin D supplementation on blood pressure in patients with elevated blood pressure and vitamin D deficiency: a randomized, double-blind, placebo-controlled trial 2015 · vitamin D-supplemented group (VDG) · Patients with elevated blood pressure and vitamin D deficiency; age and sex not specified | 7,143 IU | 8 weeks | — |
| 25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial 2018 · vitamin D 400 IU/d · Postmenopausal women; age range and baseline vitamin D status not specified | 400 IU | 1 year | — |
| 25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial 2018 · vitamin D 1000 IU/d · Postmenopausal women; age range and baseline vitamin D status not specified | 1,000 IU | 1 year | — |
| Alendronate/Vitamin D for attenuating bone mineral density loss during antiretroviral initiation: a pilot randomized controlled trial 2019 · concomitant treatment arm (CTA) · Treatment-naïve HIV-positive adults initiating antiretroviral therapy | 800 IU | 24 weeks | — |
| Alendronate/Vitamin D for attenuating bone mineral density loss during antiretroviral initiation: a pilot randomized controlled trial 2019 · delayed treatment arm (DTA) · Treatment-naïve HIV-positive adults initiating antiretroviral therapy | 800 IU | 24 weeks | — |
| Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA) 2020 · eldecalcitol · Patients with glucocorticoid-induced osteoporosis | 0.75 mcg | 2 years | — |
| Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA) 2020 · alfacalcidol · Patients with glucocorticoid-induced osteoporosis | 1 mcg | 2 years | — |
| The effects of vitamin D and curcuminoids supplementation on anthropometric measurements and blood pressure in type 2 diabetic patients with coexisting hypovitaminosis D: A double-blind, placebo-controlled randomized clinical trial 2020 · vitamin D3 · Adults with type 2 diabetes and insufficient vitamin D status | 7,143 IU | 12 weeks | — |
| Pregnancy vitamin D supplementation and offspring bone mineral density in childhood follow-up of a randomized controlled trial 2024 · Cholecalciferol · Pregnant adults aged 18 years or older with a singleton pregnancy and serum 25(OH)D of 25–100 nmol/L | 1,000 IU | — | — |
| Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients 2025 · eldecalcitol add-on therapy · Postmenopausal women with hormone receptor-positive early-stage breast cancer (TNM stage 0–3A), treated with aromatase inhibitors and risedronate for more than 12 months | 0.75 mcg | 2 years | — |
| Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3 1995 · B, Vitamin D3 · Postmenopausal women | 300 IU | 1 year | — |
| Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3 1995 · C, Climen+Vitamin D3 · Postmenopausal women | 300 IU | 1 year | — |
| Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss 1994 · placebo · Healthy white women 3 to 6 years after spontaneous menopause | 400 IU | 1059 days | — |
| Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation 1995 · vitamin D supplement · Out-patients aged 16–77 with Crohn's disease | 1,000 IU | 1 year | — |
| Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study 1997 · D group · Healthy postmenopausal women | 300 IU | 913 days | — |
| Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study 1997 · HRT+D group · Healthy postmenopausal women | 300 IU | 913 days | — |
| The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype 1997 · vitamin D group · Women aged 70 years and over participating in a trial of vitamin D supplementation | 400 IU | 2 years | — |
| Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids) 2024 · vitamin D arm · Schoolchildren aged 6–11 years in Cape Town, South Africa; children with chronic illness other than asthma and clinical evidence of rickets were excluded. | 35.7 mcg | 3 years | 829 |
| Vitamin D substrate-product relationship in idiopathic hypercalciuria 2009 · Controls receiving 25OHD · Age- and sex-matched controls; mean age 61.5 years | 25 mcg | 2 weeks | 57 |
| Vitamin D substrate-product relationship in idiopathic hypercalciuria 2009 · AH subjects receiving 25OHD · Adults with absorptive hypercalciuria; mean age 60.9 years | 25 mcg | 2 weeks | 52 |
| Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial 2013 · group receiving vitamin D2 · Healthy volunteers; age range and sex not reported. | 50 mcg | 8 weeks | 46 |
| Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial 2020 · Intervention group · Male forensic inpatients aged 31–81 with varied mental health and substance-use diagnoses | 40 mcg | 135 days | 43 |
| Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial 2013 · vitamin D3 group · Healthy volunteers; age range and sex not reported. | 50 mcg | 8 weeks | 42 |
| Effect of vitamin D fortified foods on bone markers and muscle strength in women of Pakistani and Danish origin living in Denmark: a randomised controlled trial 2019 · Pakistani fortified-food group · Pakistani-origin women aged 18–50 at risk of vitamin D deficiency | 29 mcg | 90 days | 33 |
| Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months 2013 · vitamin D3 · Healthy adults aged 18–50 years | 25 mcg | 25 weeks | 32 |
| Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months 2013 · vitamin D2 · Healthy adults aged 18–50 years | 25 mcg | 25 weeks | 31 |
| Vitamin D receptor Cdx-2-dependent response of central obesity to vitamin D intake in the subjects with type 2 diabetes: a randomised clinical trial 2015 · Vitamin D3-fortified doogh (FD) · Adults with type 2 diabetes | 25 mcg | 12 weeks | 31 |
| Effect of vitamin D fortified foods on bone markers and muscle strength in women of Pakistani and Danish origin living in Denmark: a randomised controlled trial 2019 · Danish fortified-food group · Danish-origin women aged 18–50 at risk of vitamin D deficiency | 29 mcg | 90 days | 31 |
| Vitamin D-Fortified Bread Is as Effective as Supplement in Improving Vitamin D Status: A Randomized Clinical Trial 2016 · fortified bread (FP) · Healthy adults aged 20–60 years | 25 mcg | 8 weeks | 30 |
| Vitamin D-Fortified Bread Is as Effective as Supplement in Improving Vitamin D Status: A Randomized Clinical Trial 2016 · supplement (SP) · Healthy adults aged 20–60 years | 25 mcg | 8 weeks | 30 |
| Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study 2024 · calcifediol group · People with multiple sclerosis; age and sex not reported | 50 mcg | — | 25 |
| Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study 2024 · cholecalciferol group · People with multiple sclerosis; age and sex not reported | 50 mcg | — | 25 |
| Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level 2001 · 25 microg vitamin D3/d group · Healthy men and women aged 41 +/- 9 years | 25 mcg | 152 days | — |
| Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level 2001 · 100 microg vitamin D3/d group · Healthy men and women aged 41 +/- 9 years | 100 mcg | 152 days | — |
| Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol 2003 · 25 micro g cholecalciferol · Healthy men living in Omaha; age not reported | 25 mcg | 20 weeks | — |
| Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol 2003 · 125 micro g cholecalciferol · Healthy men living in Omaha; age not reported | 125 mcg | 20 weeks | — |
| Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration 2008 · vitamin D3 supplementation · Adults; age range, sex, and health status not specified | 86 mcg | 26 weeks | — |
| High-dose vitamin d intervention in infants--effects on vitamin d status, calcium homeostasis, and bone strength 2012 · 30 μg group · Infants receiving supplementation from age 2 weeks to 3 months | 30 mcg | 10 weeks | — |
| High-dose vitamin d intervention in infants--effects on vitamin d status, calcium homeostasis, and bone strength 2012 · 40 μg group · Infants receiving supplementation from age 2 weeks to 3 months | 40 mcg | 10 weeks | — |
| A 250 μg/week dose of vitamin D was as effective as a 50 μg/d dose in healthy adults, but a regimen of four weekly followed by monthly doses of 1250 μg raised the risk of hypercalciuria 2013 · 50 μg/d · Healthy adults | 50 mcg | 90 days | — |
| A 250 μg/week dose of vitamin D was as effective as a 50 μg/d dose in healthy adults, but a regimen of four weekly followed by monthly doses of 1250 μg raised the risk of hypercalciuria 2013 · 250 μg/week · Healthy adults | 35.7 mcg | 90 days | — |
| Vitamin D supplementation in elderly nursing home residents increases 25(OH)D but not 1,25(OH)2D 1990 · Vitamin D group · Elderly nursing home residents | 50 mcg | 6 weeks | — |
| Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial 2014 · cholecalciferol group · Adults aged 29–77 with primary hyperparathyroidism; 76% of the enrolled participants were women | 70 mcg | 52 weeks | — |
| Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease 2014 · 30 µg MR calcifediol group · Adults with chronic kidney disease, vitamin D insufficiency and elevated intact parathyroid hormone | 30 mcg | 6 weeks | — |
| Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease 2014 · 60 µg MR calcifediol group · Adults with chronic kidney disease, vitamin D insufficiency and elevated intact parathyroid hormone | 60 mcg | 6 weeks | — |
| Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease 2014 · 90 µg MR calcifediol group · Adults with chronic kidney disease, vitamin D insufficiency and elevated intact parathyroid hormone | 90 mcg | 6 weeks | — |
| Maternal vitamin D₃ supplementation at 50 μg/d protects against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized controlled trial of 3 doses of vitamin D beginning in gestation and continued in lactation 2015 · 25 μg vitamin D₃/d group · Pregnant women, supplementation begun during gestation and continued through 8 weeks postpartum; breastfed infants received no supplementation | 25 mcg | — | — |
| Maternal vitamin D₃ supplementation at 50 μg/d protects against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized controlled trial of 3 doses of vitamin D beginning in gestation and continued in lactation 2015 · 50 μg vitamin D₃/d group · Pregnant women, supplementation begun during gestation and continued through 8 weeks postpartum; breastfed infants received no supplementation | 50 mcg | — | — |
| Oral High-Dose Vitamin D Dissolved in Oil Raised Serum 25-Hydroxy-Vitamin D to Physiological Levels in Obese Patients After Sleeve Gastrectomy-A Double-Blind, Randomized, and Placebo-Controlled Trial 2016 · Vitamin D3 in oil · Morbidly obese patients after sleeve gastrectomy | 80 mcg | 12 weeks | — |
| Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women 2016 · D2 supplement and regular bread · Healthy women aged 20–37 years | 25 mcg | 8 weeks | — |
| Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women 2016 · D3 supplement and regular bread · Healthy women aged 20–37 years | 25 mcg | 8 weeks | — |
| Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women 2016 · Placebo pill and D2-biofortified bread · Healthy women aged 20–37 years | 25 mcg | 8 weeks | — |
| Obese young adults exhibit lower total and lower free serum 25-hydroxycholecalciferol in a randomized vitamin D intervention 2016 · cholecalciferol group · Young people aged 15–25 years, including participants with severe childhood-onset obesity and normal-weight participants | 50 mcg | 12 weeks | — |
| Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease 2016 · ER calcifediol 30 µg · Adults with stage 3 or 4 chronic kidney disease, secondary hyperparathyroidism and vitamin D insufficiency | 30 mcg | 26 weeks | — |
| Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease 2016 · ER calcifediol 60 µg · Adults with stage 3 or 4 chronic kidney disease, secondary hyperparathyroidism and vitamin D insufficiency | 60 mcg | 26 weeks | — |
| Increased vitamin D intake differentiated according to skin color is needed to meet requirements in young Swedish children during winter: a double-blind randomized clinical trial 2017 · 25 μg/d vitamin D3 group · Children aged 5–7 years in Sweden with fair or dark skin | 25 mcg | 90 days | — |
| Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens 2017 · 40 μg/day · Postmenopausal women aged 55 years or older with vitamin D inadequacy | 40 mcg | 90 days | — |
| Genetic Variation of the Vitamin D Binding Protein Affects Vitamin D Status and Response to Supplementation in Infants 2019 · 30 μg/d vitamin D3 group · Healthy term infants | 30 mcg | 716 days | — |
| Effectiveness of vitamin D supplementation in Swedish children may be negatively impacted by BMI and serum fructose 2020 · 25 μg vitamin D group · children aged 5–7 years in northern and southern Sweden; no condition stated | 25 mcg | 90 days | — |
| Efficiency of Vitamin D Supplementation in Healthy Adults is Associated with Body Mass Index and Baseline Serum 25-Hydroxyvitamin D Level 2020 · Group A: capsules with starch-adsorbed vitamin D · Adults aged 18–65 with suboptimal serum 25-OH-vitamin D levels (30–50 nmol/L) | 25 mcg | 8 weeks | — |
| Efficiency of Vitamin D Supplementation in Healthy Adults is Associated with Body Mass Index and Baseline Serum 25-Hydroxyvitamin D Level 2020 · Group B: oil-based Valens vitamin D oral spray · Adults aged 18–65 with suboptimal serum 25-OH-vitamin D levels (30–50 nmol/L) | 25 mcg | 8 weeks | — |
| Efficiency of Vitamin D Supplementation in Healthy Adults is Associated with Body Mass Index and Baseline Serum 25-Hydroxyvitamin D Level 2020 · Group C: water-based Valens vitamin D oral spray · Adults aged 18–65 with suboptimal serum 25-OH-vitamin D levels (30–50 nmol/L) | 25 mcg | 8 weeks | — |
| Effects of High-Dose Vitamin D Supplementation on Placental Vitamin D Metabolism and Neonatal Vitamin D Status 2024 · 90 µg vitamin D group · Pregnant women enrolled at gestational weeks 11–16; no specific pregnancy complication required | 90 mcg | 26 weeks | — |
| Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men 1998 · vitamin D3 25 micrograms/day · healthy men, mean age 28 years | 25 mcg | 8 weeks | — |
| Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men 1998 · 25(OH)D3 50 micrograms/day · healthy men, mean age 28 years | 50 mcg | 4 weeks | — |
| The impact of supplemental n-3 long chain polyunsaturated fatty acids and dietary antioxidants on physical performance in postmenopausal women 2013 · n-3 LCPUFA group · Postmenopausal women over age 65 without the listed bone, cancer or liver diseases; most were prefrail or frail. | 1,000 IU | 180 days | 85 |
| Melatonin, vitamins and minerals supplements for the treatment of Covid-19 and Covid-like illness: A prospective, randomized, double-blind multicenter study 2024 · Treatment group · Adults younger than 60 years with COVID-19 or COVID-like illness, no previous medical history, and not hospitalized | 2.5 mcg | — | 82 |
| Effects of a 6-Month Multifaceted Diet and Exercise Intervention on Cognition in Older Adults at Risk of Cognitive Decline: The PONDER Double-Blind, Placebo-Controlled Randomized Trial 2022 · Multimodal exercise program with daily supplement · Community-dwelling older adults with subjective memory impairment; mean age 70.2 years, 70% female | 1,000 IU | 26 weeks | 73 |
| Effect of zinc plus multivitamin supplementation on growth in school children 2016 · Chelated zinc plus multivitamins · Healthy Thai schoolchildren aged 4–13 years | 200 IU | 26 weeks | 70 |
| Leucine-Enriched Protein Supplementation Increases Lean Body Mass in Healthy Korean Adults Aged 50 Years and Older: A Randomized, Double-Blind, Placebo-Controlled Trial 2020 · protein mixture powder (intervention group) · Healthy Korean adults aged 50–80 years, men and women, without sarcopenia | 1,600 IU | 12 weeks | 54 |
| The effect of 12-weeks Nutritional supplementation on Nutritional Intake and Status among Indonesian Older Outpatients with Malnutrition Risk, the Prolansia study: a randomized controlled trial 2025 · intervention group (standard care plus NDD) · Men and women aged 60 years and older with malnutrition or at risk of malnutrition, attending outpatient clinics in Indonesia | 800 IU | 12 weeks | 54 |
| Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study 2015 · GCQID group · Japanese women and men aged 40–74 years with knee pain | 5 mcg | 16 weeks | 50 |
| Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial 2023 · Supplement group (SG) · Adults aged 18–45 with acute sciatica due to lumbar disc herniation and low-back pain NRS 5–7 | 800 IU | 30 days | 41 |
| Effects of Low-Dose Dairy Protein Plus Micronutrient Supplementation during Resistance Exercise on Muscle Mass and Physical Performance in Older Adults: A Randomized, Controlled Trial 2018 · ExPM (resistance exercise plus low-dose dairy protein and micronutrient supplementation) · Adults aged 65–80 years, non-disabled and not exercising regularly | 5 mcg | 12 weeks | 40 |
| A novel oral nutritional supplement improves gait speed and mitochondrial functioning compared to standard care in older adults with (or at risk of) undernutrition: results from a randomized controlled trial 2021 · Novel supplement · Adults aged 65 years and older with or at risk of undernutrition | 10.8 mcg | 12 weeks | 40 |
| Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial 2024 · combo group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment | 38 mcg | 16 weeks | 36 |
| Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial 2024 · training group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment | 38 mcg | 16 weeks | 36 |
| Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial 2018 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS); age not reported | 400 IU | 12 weeks | 30 |
| The efficacy of Sarcomeal® oral supplementation plus vitamin D3 on muscle parameters, metabolic factors, and quality of life in diabetic sarcopenia: a randomized controlled clinical trial 2025 · Intervention group · Adults aged 50–75 years with type 2 diabetes and sarcopenia | 1,000 IU | 12 weeks | 30 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 5 mcg | 120 days | 26 |
| A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: A randomized controlled trial 2017 · SUPP (multi-ingredient nutritional supplement) · Healthy men aged 60 years or older | 1,000 IU | 20 weeks | 25 |
| A Five-Ingredient Nutritional Supplement and Home-Based Resistance Exercise Improve Lean Mass and Strength in Free-Living Elderly 2020 · Muscle5 (M5) · Sedentary or low-active, free-living men aged 65 years or older, with normal to class 1/low-risk obesity and varying degrees of age-related muscle loss | 1,000 IU | 12 weeks | 22 |
| A prospective randomized comparative trial evaluating postoperative nutritional intervention in patients with oral cancer 2022 · Intervention group · Adults with oral cancer after surgery; ages 18 and older, both sexes | 2,857 IU | 26 weeks | 22 |
| Supportive treatment of vascular dysfunction in pediatric subjects with obesity: the OBELIX study 2022 · Treatment group · Children aged 6–17 years with obesity (BMI above the 95th percentile for age) | 25 mcg | 26 weeks | 16 |
| Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management 2024 · Muscle 5 (M5) · Men aged 66–91 years; older, sedentary or low-active participants, with the subgroup analysis including overweight or obese men with at least one additional metabolic-syndrome risk factor | 1,000 IU | 12 weeks | 16 |
| Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up 2019 · AMD-M group · Adults with intermediate age-related macular degeneration; 9 male and 21 female enrolled overall, mean age 69.32 years | 800 IU | 26 weeks | 15 |
| The Effect of a Multi-ingredient Supplement on Resistance Training-induced Adaptations 2021 · SUPP group · Healthy young adults, male and female, mean age 22 ± 2 years, undertaking resistance exercise training | 2,000 IU | 10 weeks | 13 |
| Impact of vitamin D supplementation during a resistance training intervention on body composition, muscle function, and glucose tolerance in overweight and obese adults 2013 · VitD group · Overweight and obese adults, women and men, participating in resistance training; no metabolic disease or diabetes | 4,000 IU | 12 weeks | 10 |
| The Effect of Fish Oil, Vitamin D and Protein on URTI Incidence in Young Active People 2015 · supplementation · Young recreational athletes; age and sex not specified; healthy active population | 10 mcg | 16 weeks | — |
| Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT 2021 · high-dose vitamin D · Men aged 60 years or older with stage I–IV prostate cancer receiving ADT and suboptimal vitamin D levels (<32 ng/ml) | 7,743 IU | 24 weeks | — |
| Influence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (ViDiKids) 2024 · Vitamin D arm · Children aged 6–11 years in South African schools, without a stated chronic illness; the bone sub-study was restricted to grade 4 pupils | 35.7 mcg | 3 years | 829 |
| Phosphate Concentrations and Modifying Factors in Healthy Children From 12 to 24 Months of Age 2021 · Group30 · Healthy infants; sex not specified for this arm; no stated condition | 30 mcg | 670 days | 268 |
| Vitamin D status and cardiometabolic risk markers in young Swedish children: a double-blind randomized clinical trial comparing different doses of vitamin D supplements 2020 · 25 µg group · Healthy children aged 5–7 years, including fair- and dark-skinned children | 25 mcg | 90 days | 84 |
| Treatment With 25-Hydroxyvitamin D(3) (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial 2021 · 25(OH)D3 treatment group · Adults older than 18 years hospitalized with COVID-19 and vitamin D deficiency or insufficiency (25(OH)D3 <30 ng/mL) | 25 mcg | 60 days | 53 |
| Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial 2010 · vitamin D(3) · South Asian women aged 23–68 years living in Auckland, New Zealand, who were insulin resistant and vitamin D deficient | 100 mcg | 26 weeks | 42 |
| Effect of vitamin D supplementation on testosterone levels in men 2011 · vitamin D group · Overweight men with vitamin D deficiency and low-end reference-range testosterone, participating in a weight reduction program | 83 mcg | 1 year | 31 |
| Glucose Metabolism Effects of Vitamin D in Prediabetes: The VitDmet Randomized Placebo-Controlled Supplementation Study 2015 · 40 μg/day vitamin D3 group · Adults aged 60 years or older with impaired fasting glucose or impaired glucose tolerance, overweight but not severely obese, and serum 25(OH)D3 below 75 nmol/L | 40 mcg | 150 days | 24 |
| Effects of vitamin D supplementation on circulatory YKL-40 and MCP-1 biomarkers associated with vascular diabetic complications: A randomized, placebo-controlled, double-blind clinical trial 2019 · vitamin D group · Patients with type 2 diabetes; age and sex not specified | 100 mcg | 12 weeks | 24 |
| Glucose Metabolism Effects of Vitamin D in Prediabetes: The VitDmet Randomized Placebo-Controlled Supplementation Study 2015 · 80 μg/day vitamin D3 group · Adults aged 60 years or older with impaired fasting glucose or impaired glucose tolerance, overweight but not severely obese, and serum 25(OH)D3 below 75 nmol/L | 80 mcg | 150 days | 21 |
| Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome- a pilot study 2021 · Vitamin D3 · Healthy adult volunteers; age and sex range not specified | 60 mcg | 4 weeks | 12 |
| The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design 2010 · vitamin D3 plus placebo · Healthy men and women aged 20–80 years | 100 mcg | 90 days | — |
| Vitamin D3 and the risk of CVD in overweight and obese women: a randomised controlled trial 2012 · vitamin D group · Healthy premenopausal overweight and obese women; mean age 38 years | 25 mcg | 12 weeks | — |
| Calcium and vitamin d supplementation in postmenopausal women 2013 · vitamin D3 plus placebo · healthy postmenopausal white women | 100 mcg | 26 weeks | — |
| Prenatal vitamin D₃ supplementation suppresses LL-37 peptide expression in ex vivo activated neonatal macrophages but not their killing capacity 2014 · vitamin D group · Healthy pregnant women; gestational age 26 weeks or later | 125 mcg | — | — |
| Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial 2018 · vitamin D3 · Postmenopausal women with high parathyroid hormone levels and vitamin D insufficiency | 70 mcg | 2 weeks | — |
| Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial 2018 · valsartan plus vitamin D3 · Postmenopausal women with high parathyroid hormone levels and vitamin D insufficiency | 70 mcg | 2 weeks | — |
| Associations Between Change in Total and Free 25-Hydroxyvitamin D With 24,25-Dihydroxyvitamin D and Parathyroid Hormone 2018 · D3 group · Adults aged 18 years or older with 25(OH)D levels below 20 ng/mL | 60 mcg | 16 weeks | — |
| The effect of vitamin D3 supplementation on markers of cardiovascular health in hyperparathyroid, vitamin D insufficient women: a randomized placebo-controlled trial 2018 · vitamin D3 · Postmenopausal women with secondary hyperparathyroidism and 25-hydroxy-vitamin D levels below 50 nmol/l | 70 mcg | 12 weeks | — |
| Fibroblast growth factor 23 concentrations and modifying factors in children from age 12 to 24 months 2020 · 30 μg/day vitamin D3 group · Healthy infants, enrolled at approximately 2 weeks of age and followed to 24 months | 30 mcg | — | — |
| Low-grade inflammation from prenatal period to age 6-8 years in a Vitamin D trial 2024 · group 30 · Healthy full-term infants, from age 2 weeks to 2 years | 30 mcg | 2 years | — |
| Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status 2020 · placebo-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated | 400 IU | 2 years | 481 |
| Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status 2020 · denosumab-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated | 400 IU | 2 years | 475 |
| Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial 2014 · CaD · Postmenopausal women aged 50–79 years from the general community | 400 IU | — | 291 |
| Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS) 2010 · supplementation group · Ambulatory postmenopausal women aged 66 to 71 years | 800 IU | 3 years | 287 |
| Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density 2007 · alendronate 10 mg/elemental calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day | 400 IU | 2 years | 280 |
| Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial 2008 · vitamin K group · Postmenopausal women with osteopenia; mean age 59 years, range 40–82 | 800 IU | 4 years | 217 |
| The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease 2012 · calcium-vitamin D3 fixed combination group (Ca-D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency | 800 IU | 2 years | 206 |
| The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease 2012 · separate calcium and vitamin D3 supplements group (Ca + D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency | 800 IU | 2 years | 189 |
| Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density 2007 · alendronate-placebo/calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day | 400 IU | 2 years | 140 |
| Impact of Calcium and Two Doses of Vitamin D on Bone Metabolism in the Elderly: A Randomized Controlled Trial 2017 · Low dose group · Overweight, ambulatory adults aged 65 or older with screening serum 25OHD of 10–30 ng/ml | 500 IU | 1 year | 128 |
| Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial 2014 · Group A (alfacalcidol) · Women aged 45–75 years, postmenopausal for at least 5 years, with osteoporosis | 0.5 mcg | 1 year | 118 |
| Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension 2015 · ALN/D5600 · Postmenopausal women in China aged over 55 with osteoporosis | 800 IU | 1 year | 111 |
| Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis 2015 · ALN + VitD group · Japanese men and women aged 60–90 with primary osteoporosis or osteopenia and at least one vertebral fracture | 400 IU | 48 weeks | 109 |
| Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial 2019 · 400 IU group · Healthy community-dwelling adults aged 55 to 70 years without osteoporosis, with baseline 25(OH)D of 30 to 125 nmol/L | 400 IU | 3 years | 109 |
| Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension 2015 · Calcitriol · Postmenopausal women in China aged over 55 with osteoporosis | 0.25 mcg | 1 year | 108 |
| Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis 2004 · group A · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica | 1 mcg | 3 years | 103 |
| A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis 2006 · Calcium group · Children and adolescents aged 6–18 years with juvenile rheumatoid arthritis who had not taken corticosteroids for at least 3 months | 400 IU | 2 years | 103 |
| Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial 2019 · 10 000 IU group · Healthy community-dwelling adults aged 55 to 70 years without osteoporosis, with baseline 25(OH)D of 30 to 125 nmol/L | 10,000 IU | 3 years | 102 |
| Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis 2004 · group B · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica | 1,000 IU | 3 years | 101 |
| Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial 2019 · 4000 IU group · Healthy community-dwelling adults aged 55 to 70 years without osteoporosis, with baseline 25(OH)D of 30 to 125 nmol/L | 4,000 IU | 3 years | 100 |
| Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study 2025 · All patients · Patients aged 18–60 years with early active rheumatoid arthritis and no earlier use of disease-modifying anti-rheumatic drugs | 800 IU | — | 99 |
| Formula Milk Supplementation and Bone Acquisition in 4-6 Years Chinese Children: A 12-Month Cluster-Randomized Controlled Trial 2023 · formula milk group · Healthy Chinese children aged 4–6 years in rural Northwest China who were willing to drink milk but consumed little for economic reasons | 4.5 mcg | 1 year | 96 |
| Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation 2003 · supplementation · Ambulatory elderly women, mean age 75 years, with vitamin D insufficiency | 800 IU | 1 year | 95 |
| Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial 2015 · VitD/Cal group · HIV-infected adults initiating their first ART regimen with EFV/FTC/TDF | 4,000 IU | 48 weeks | 81 |
| Efficacy of strontium ranelate on bone mineral density in men with osteoporosis 2010 · Strontium ranelate group · Men with primary osteoporosis | 800 IU | 1 year | 76 |
| Efficacy of strontium ranelate on bone mineral density in men with osteoporosis 2010 · Alendronate group · Men with primary osteoporosis | 800 IU | 1 year | 76 |
| Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women 2001 · vitamin D(3) and calcium group · Elderly women with 25-hydroxycholecalciferol below 50 nmol/L; mean age 74 years | 800 IU | 8 weeks | 74 |
| The efficacy and safety of calcitriol and/or Caltrate D in elderly Chinese women with low bone mass 2009 · Rocaltrol+Caltrate D group · Chinese women aged over 65 years with osteopenia or osteoporosis | 0.25 mcg | 1 year | 74 |
| Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis 2006 · vitamin D plus calcium group · Postmenopausal Caucasian patients with osteoporosis and normal vitamin D serum levels | 880 IU | 547 days | 72 |
| Estimating the causal effect of milk powder supplementation on bone mineral density: a randomized controlled trial with both non-compliance and loss to follow-up 2015 · milk powder supplementation group · Healthy postmenopausal women | 800 IU | 2 years | 69 |
| The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women 2014 · Aquatic Exercise Group (AEG) · Postmenopausal women, mean age 58.8 ± 6.4 years | 1,000 IU | 24 weeks | 64 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D 2011 · group B · Patients with Crohn's disease and reduced BMD (T-score < -1) | 1,000 IU | 1278 days | 62 |
| Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium 2003 · simple vitamin D (ergocalciferol) plus calcium carbonate · Females and males commencing or already taking glucocorticoids | 4,286 IU | 2 years | 61 |
| Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study 2012 · 500 mg calcium with 400 international unis (iu) vitamin D daily · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0) | 400 IU | 1 year | 59 |
| Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study 2012 · 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0) | 400 IU | 1 year | 59 |
| Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients 2021 · bazedoxifene group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids | 800 IU | 56 weeks | 57 |
| Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients 2021 · control group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids | 800 IU | 56 weeks | 57 |
| Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study 1996 · 1 alpha(OH)D3 group · Female patients with osteoporosis; age range not reported | 0.75 mcg | 2 years | 57 |
| Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents 2019 · Ca6D group · Healthy Chinese adolescents aged 11.9–15.2 years | 400 IU | 548 days | 56 |
| Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial 2015 · Risedronate group · Postmenopausal women over age 55 with hormone receptor-positive breast cancer, low bone mass, and current aromatase inhibitor treatment | 200 IU | 2 years | 55 |
| Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation 2006 · Control group · Patients with orthotopic liver transplantation | 0.5 mcg | 2 years | 54 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D 2011 · group C · Patients with Crohn's disease and reduced BMD (T-score < -1) | 1,000 IU | 1278 days | 54 |
| Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial 2015 · Placebo group · Postmenopausal women over age 55 with hormone receptor-positive breast cancer, low bone mass, and current aromatase inhibitor treatment | 200 IU | 2 years | 54 |
| Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents 2019 · Ca9D group · Healthy Chinese adolescents aged 11.9–15.2 years | 400 IU | 548 days | 54 |
| Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients 2008 · experiment I group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified | 0.25 mcg | 1 year | 50 |
| Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients 2008 · experiment II group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified | 0.25 mcg | 1 year | 50 |
| Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride 2002 · calcium-vitamin D-placebo group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D | 800 IU | 1 year | 49 |
| Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents 2019 · Ca3D group · Healthy Chinese adolescents aged 11.9–15.2 years | 400 IU | 548 days | 49 |
| Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride 2002 · calcium-vitamin D-fluoride group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D | 800 IU | 1 year | 45 |
| Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation 2004 · calcitriol therapy (CT) · renal transplant recipients; age and sex not specified | 0.25 mcg | 90 days | 45 |
| Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study 2011 · Risedronate plus calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation | 800 IU | 1 year | 45 |
| Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation 2006 · ALN 70 mg weekly · Patients with orthotopic liver transplantation | 0.5 mcg | 2 years | 44 |
| Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study 2011 · Calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation | 800 IU | 1 year | 44 |
| The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women 2014 · Control Group (CG) · Postmenopausal women, mean age 58.8 ± 6.4 years | 1,000 IU | 24 weeks | 44 |
| A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV 2019 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy | 1,000 IU | 1 year | 43 |
| A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV 2019 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy | 3,000 IU | 1 year | 42 |
| The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis 2004 · Calcitriol and calcium group · Post-menopausal women with osteoporosis | 0.5 mcg | 26 weeks | 40 |
| The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study 2005 · Treatment group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures | 400 IU | 548 days | 40 |
| Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old 2011 · treatment group (vitamin K) · Postmenopausal Korean women over 60 years old | 400 IU | 26 weeks | 40 |
| Skeletal site-dependent response of bone mineral density and quantitative ultrasound parameters following a 12-month dietary intervention using dairy products fortified with calcium and vitamin D: the Postmenopausal Health Study 2006 · dairy group (DG) · Postmenopausal women aged 55–65 years | 7.5 mcg | 1 year | 39 |
| Changes in biochemical indexes of bone metabolism and bone mineral density after a 12-mo dietary intervention program: the Postmenopausal Health Study 2007 · dairy intervention group · postmenopausal women | 7.5 mcg | 1 year | 39 |
| Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old 2011 · control group · Postmenopausal Korean women over 60 years old | 400 IU | 26 weeks | 38 |
| Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women 2022 · Supplement group (S) · Overweight/obese, generally healthy postmenopausal women with dietary calcium intake of 800 mg/day or less | 200 IU | 26 weeks | 37 |
| Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial 2003 · Group 2 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis | 800 IU | 1 year | 36 |
| Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial 2003 · Group 1 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis | 800 IU | 1 year | 35 |
| Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial 2011 · Vitamin D3 · Adults aged 18–50 with clinically definite multiple sclerosis, fully ambulatory (EDSS ≤4.5) | 2,857 IU | 96 weeks | 35 |
| Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women 2002 · placebo · Postmenopausal African-American women aged 45–88 with osteoporosis | 500 IU | 2 years | 33 |
| The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis 2006 · raloxifene group · Postmenopausal women with diagnosed osteoporosis | 800 IU | 2 years | 33 |
| The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis 2006 · placebo group · Postmenopausal women with diagnosed osteoporosis | 800 IU | 2 years | 33 |
| The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis 2006 · continuation of open-label alendronate group · Postmenopausal women with diagnosed osteoporosis | 800 IU | 2 years | 33 |
| Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women 2002 · alendronate group · Postmenopausal African-American women aged 45–88 with osteoporosis | 500 IU | 2 years | 32 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D 2011 · group A · Patients with Crohn's disease and reduced BMD (T-score < -1) | 1,000 IU | 1278 days | 32 |
| The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study 2005 · Control group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures | 400 IU | 548 days | 31 |
| Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study 2006 · PTH250 · Adults aged 52–84 years with osteoporosis | 200 IU | 90 days | 31 |
| Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial 2004 · treatment group · Healthy adults; age and sex not specified | 500 IU | 213 days | 30 |
| [Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis] 2005 · Group A · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment | 1 mcg | 1 year | 30 |
| [Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis] 2005 · Group B · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment | 0.5 mcg | 1 year | 30 |
| Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study 2006 · PTH500 · Adults aged 52–84 years with osteoporosis | 200 IU | 90 days | 30 |
| Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) 2007 · group A · Adults with established postmenopausal or male osteoporosis | 1 mcg | 2 years | 30 |
| Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) 2007 · group B · Adults with established postmenopausal or male osteoporosis | 1,000 IU | 2 years | 30 |
| Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) 2007 · group C · Adults with established postmenopausal or male osteoporosis | 1 mcg | 2 years | 30 |
| Clodronic acid in the treatment of postmenopausal osteoporosis 2007 · clodronic acid group · Postmenopausal women aged 48–73 years with osteoporosis | 400 IU | 3 years | 30 |
| Effect of calcium plus vitamin D supplementation during pregnancy in Brazilian adolescent mothers: a randomized, placebo-controlled trial 2013 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low-calcium diets | 200 IU | — | 30 |
| Calcium plus vitamin D supplementation during pregnancy interacts with polymorphisms in the promoter region of the VDR gene to affect postpartum bone mass of Brazilian adolescent mothers: A randomized controlled trial 2016 · calcium plus cholecalciferol · Pregnant adolescents aged 14–19 years | 200 IU | — | 30 |
| Reduction in Bone Loss from 5 to 20 Weeks Postpartum in Adolescents Supplemented with Calcium Plus Vitamin D during Pregnancy Is Not Sustained at 1 Year Postpartum: Follow-up Study of a Randomized Controlled Trial 2021 · supplemented group · Pregnant adolescents aged 14–19 years with habitually low calcium intake | 200 IU | — | 30 |
| Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation 1997 · treatment group · Patients with hemiplegia after stroke; mean duration of illness 4.8 years; age and sex not reported | 1 mcg | 26 weeks | 30 |
| Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study 2006 · PTH1000 · Adults aged 52–84 years with osteoporosis | 200 IU | 90 days | 29 |
| Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial) 2008 · Control group · Adults aged 18 years or older with cystic fibrosis and low bone mass | 800 IU | 1 year | 29 |
| Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial 2015 · Resistance training (RT) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active | 10 mcg | 1 year | 29 |
| Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial 2015 · Jump training (JUMP) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active | 10 mcg | 1 year | 29 |
| Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study 2014 · B · Adults aged 61–96 years with a recent hip fracture | 800 IU | 1 year | 28 |
| Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial) 2008 · Alendronate group · Adults aged 18 years or older with cystic fibrosis and low bone mass | 800 IU | 1 year | 27 |
| Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss? 2009 · Group A · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion | 200 IU | 1 year | 26 |
| Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss? 2009 · Group B · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion | 200 IU | 1 year | 26 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaD group · Postmenopausal women | 10 mcg | 1 year | 26 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaDK1 group · Postmenopausal women | 10 mcg | 1 year | 26 |
| Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study 2014 · BN · Adults aged 61–96 years with a recent hip fracture | 800 IU | 26 weeks | 26 |
| Two-Month Consumption of Orange Juice Enriched with Vitamin D3 and Probiotics Decreases Body Weight, Insulin Resistance, Blood Lipids, and Arterial Blood Pressure in High-Cardiometabolic-Risk Patients on a Westernized Type Diet: Results from a Randomized Clinical Trial 2024 · Intervention group · Adults aged 18–70 with BMI >25 kg/m² and high cardiometabolic risk, including hyperglycemia and/or hyperlipidemia and/or hypertension | 2,000 IU | 8 weeks | 26 |
| Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study 2014 · C · Adults aged 61–96 years with a recent hip fracture | 800 IU | 1 year | 25 |
| Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial 2017 · multispecies probiotic supplement (GeriLact) · Postmenopausal women aged 50–72 years with osteopenia | 200 IU | 26 weeks | 25 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaDK2 group · Postmenopausal women | 10 mcg | 1 year | 24 |
| Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women 1998 · E + C group · Postmenopausal women with at least one non-traumatic vertebral fracture or z score < -1.5 | 0.5 mcg | 1 year | 24 |
| Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome 2009 · group 1 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia | 800 mg | 1 year | 23 |
| Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome 2009 · group 2 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia | 800 mg | 1 year | 23 |
| Effects of calcium and vitamin D supplementation on blood pressure and serum lipids and carotenoids: a randomized, double-blind, placebo-controlled, clinical trial 2013 · calcium plus vitamin D3 · Adults aged 30–75 with at least one pathology-confirmed adenomatous colorectal polyp in the previous 36 months | 800 IU | 26 weeks | 23 |
| Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis 2000 · DK group · Postmenopausal women aged 55–81 years with osteoporosis, more than 5 years after menopause | 0.75 mcg | 2 years | 21 |
| Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT 2012 · Algal oil containing DHA · Individuals with osteopenia | 1,000 IU | 1 year | 20 |
| Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT 2012 · Placebo group · Individuals with osteopenia | 1,000 IU | 1 year | 20 |
| Increase of bone mineral density with sodium fluoride in patients with Crohn's disease 2000 · calcium/vitamin D/fluoride group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year | 1,000 IU | 1 year | 18 |
| Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation 2000 · Control subjects · Patients with cystic fibrosis after lung transplantation | 800 IU | 2 years | 18 |
| Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation 2000 · treatment group · Long-term renal transplant recipients with serum creatinine levels less than 2.0 mg/dL | 0.25 mcg | 1 year | 16 |
| Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation 2000 · Pamidronate treatment group · Patients with cystic fibrosis after lung transplantation | 800 IU | 2 years | 16 |
| Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis 2014 · SrRan monotherapy · Postmenopausal women aged 54–73 with osteoporosis | 800 IU | 26 weeks | 16 |
| Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis 2014 · SrRan + AD3 · Postmenopausal women aged 54–73 with osteoporosis | 800 IU | 26 weeks | 16 |
| Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis 2014 · Control · Postmenopausal women aged 54–73 with osteoporosis | 800 IU | 26 weeks | 16 |
| Increase of bone mineral density with sodium fluoride in patients with Crohn's disease 2000 · calcium/vitamin D only group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year | 1,000 IU | 1 year | 15 |
| Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine 2004 · vitamins D3 plus K2 (group D + K) · Patients with chronic glomerulonephritis receiving prednisolone; age and sex distribution for this arm not reported | 0.5 mcg | 8 weeks | 15 |
| Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis 2004 · calcium and vitamin D treatment group · Adults with cystic fibrosis and a BMD Z score of -1 or less in the lumbar spine, proximal femur or distal forearm | 1,700 IU | 1 year | 15 |
| Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate 1994 · treated group · Adults with asthma undergoing long-term systemic corticosteroid treatment | 1,000 IU | 26 weeks | 14 |
| Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers 2000 · Vehicle group · Men aged 30–68 with idiopathic osteoporosis | 400 IU | 548 days | 13 |
| Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers 2000 · PTH-(1-34) group · Men aged 30–68 with idiopathic osteoporosis | 400 IU | 548 days | 10 |
| Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial 2020 · study group · Adults aged 18–50 with HIV infection, ART-naïve at enrollment and starting TDF/FTC/EFV; mostly men | 2,857 IU | 24 weeks | 9 |
| Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients 1997 · diet plus calcium and vitamin D · Adults with newly diagnosed, untreated celiac disease; 11 of the 14 patients had osteopenia at diagnosis | 4,571 IU | 1 year | 7 |
| Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women 1990 · Calcitriol-treated group · Women over 60 years of age with osteopenia | 0.5 mcg | 1 year | 4 |
| The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely 1999 · 500 IU/day vitamin D; mineral-supplemented breast milk · Preterm infants; sex and exact age range not stated | 500 IU | — | — |
| The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely 1999 · 1000 IU/day vitamin D; mineral-supplemented breast milk · Preterm infants; sex and exact age range not stated | 1,000 IU | — | — |
| Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen 2000 · calcium and calcitriol at 0.25 microg daily · Thai postmenopausal women no more than 6 years postmenopausal | 0.25 mcg | 2 years | — |
| Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen 2000 · calcium and calcitriol at 0.5 microg daily · Thai postmenopausal women no more than 6 years postmenopausal | 0.5 mcg | 2 years | — |
| Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study 2000 · Group 1 · Premenopausal women aged 31.1 ± 6 years with systemic lupus erythematosus taking chronic steroid therapy | 0.5 mcg | 2 years | — |
| Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis 2001 · HEBP group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain | 0.5 mcg | 2 years | — |
| Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis 2001 · Ca. D group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain | 0.5 mcg | 2 years | — |
| Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study 2002 · CaD group · Adult renal transplant recipients; 65 men and 46 women, mean age 47 years | 0.25 mcg | 26 weeks | — |
| Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate 2003 · group A · Patients with Crohn's disease and pathological bone mineral density findings | 1,000 IU | 821 days | — |
| A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density 2003 · HRT/D group · Postmenopausal women aged 53–79 years with osteoporosis, at least one minimal-trauma vertebral fracture, and low lumbar bone mineral density | 0.5 mcg | 2 years | — |
| Preventing bone loss in renal transplant recipients with vitamin D 2003 · group 1 · adult men who were recent renal transplant recipients | 0.5 mcg | — | — |
| A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease 2003 · calcium and vitamin D alone · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip | 400 IU | 1 year | — |
| A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease 2003 · calcium and vitamin D with intravenous pamidronate · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip | 400 IU | 1 year | — |
| An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis 2004 · Transdermal HRT group · Postmenopausal women with primary biliary cirrhosis | 0.25 mcg | 2 years | — |
| An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis 2004 · Control group · Postmenopausal women with primary biliary cirrhosis | 0.25 mcg | 2 years | — |
| Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension 2004 · alendronate 10 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT | 250 IU | 3 years | — |
| Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension 2004 · alendronate 5 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT | 250 IU | 3 years | — |
| Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension 2004 · placebo group · Women aged 60–86 years with low BMD who had received alendronate in FIT | 250 IU | 3 years | — |
| The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study 2004 · vitamin D3 plus calcium · Women aged 58–88 with a proximal humerus fracture and osteoporosis or osteopenia | 800 IU | 12 weeks | — |
| Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease 2005 · Etidronate group · Patients with Crohn's disease and decreased bone mineral density | 400 IU | 2 years | — |
| Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease 2005 · Non-etidronate group · Patients with Crohn's disease and decreased bone mineral density | 400 IU | 2 years | — |
| Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate 2005 · Calcium, vitamin D, and sex hormone replacement group · Adults who received an allogeneic stem cell transplant | 800 IU | 1 year | — |
| Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate 2005 · Calcium, vitamin D, sex hormone replacement, and pamidronate group · Adults who received an allogeneic stem cell transplant | 800 IU | 1 year | — |
| A prospective randomized study for prevention of postrenal transplantation bone loss 2005 · group I · adult male recent renal transplant recipients | 0.5 mcg | 1 year | — |
| A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial 2005 · 0.5 microg/d ED-71 · Osteoporotic patients aged 49–87 years receiving vitamin D supplementation | 0.5 mcg | 1 year | — |
| A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial 2005 · 0.75 microg/d ED-71 · Osteoporotic patients aged 49–87 years receiving vitamin D supplementation | 0.75 mcg | 1 year | — |
| A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial 2005 · 1.0 microg/d ED-71 · Osteoporotic patients aged 49–87 years receiving vitamin D supplementation | 1 mcg | 1 year | — |
| Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10-12-y-old girls: a 2-y randomized trial 2005 · calcium (1000 mg) + vitamin D3 (200 IU) · Healthy girls aged 10–12 years at Tanner stage I–II with dietary calcium intake below 900 mg/day | 200 IU | 2 years | — |
| Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome 2006 · treatment group · Children with nephrotic syndrome receiving prednisolone; mean age 4.6 years, 27 boys and 13 girls across the study | 400 IU | 60 days | — |
| Calcium plus vitamin D supplementation and the risk of fractures 2006 · calcium plus vitamin D group · Healthy postmenopausal women aged 50 to 79 years | 400 IU | 7 years | — |
| Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial 2006 · calcium- and vitamin D3-fortified milk group · Men older than 50 years living in the community; mean age 61.9 years | 800 IU | 2 years | — |
| Long-term effects of calcium-vitamin-D3-fortified milk on bone geometry and strength in older men 2006 · milk supplementation group · men aged over 50 years; older subgroup analyses included men over 62 years | 800 IU | 2 years | — |
| Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations 2007 · calcium + vitamin D supplement group · Healthy overweight or obese women with daily calcium intake below 800 mg | 400 IU | 15 weeks | — |
| Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women 2007 · vitamin D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older | 10 mcg | 2 years | — |
| Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women 2007 · combined vitamins K1 and D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older | 10 mcg | 2 years | — |
| Bone mineral density and bone markers in patients with a recent low-energy fracture: effect of 1 y of treatment with calcium and vitamin D 2007 · calcium and vitamin D intervention group · Patients with a recent low-energy fracture of the hip, forearm, shoulder, or spine; mean age 70 ± 11 years, 84% women | 1,400 IU | 1 year | — |
| Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis 2007 · Raloxifene group · Postmenopausal women with osteoporosis | 400 IU | 1 year | — |
| Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis 2007 · Low-dose HRT group · Postmenopausal women with osteoporosis | 400 IU | 1 year | — |
| Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial 2008 · CaD group · Community-dwelling women aged 70–80 years | 1,000 IU | 5 years | — |
| The remodeling transient and the calcium economy 2008 · Ca + D group · Ambulatory postmenopausal African-American women not receiving hormone replacement therapy | 20 mcg | 2 years | — |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study 2008 · 2 mg IV ibandronate every 2 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis | 400 IU | 2 years | — |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study 2008 · 3 mg IV ibandronate every 3 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis | 400 IU | 2 years | — |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study 2008 · 2.5 mg daily oral ibandronate · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis | 400 IU | 2 years | — |
| Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency 2008 · Calcium plus vitamin D · Elderly women, mean age 77.2 years, with vitamin D insufficiency (serum 25(OH)D <60 nM) | 1,000 IU | 1 year | — |
| Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women 1991 · Vitamin D group · Healthy, ambulatory postmenopausal women with usual vitamin D intakes of 100 IU/day | 400 IU | 1 year | — |
| Effect of alendronate in elderly patients after low trauma hip fracture repair 2009 · Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women | 400 IU | 1 year | — |
| Effect of alendronate in elderly patients after low trauma hip fracture repair 2009 · ALN + Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women | 400 IU | 1 year | — |
| Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial 2009 · exercise + fortified milk · Men aged 50–79 years; older, well-nourished men | 800 IU | 1 year | — |
| Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial 2009 · fortified milk · Men aged 50–79 years; older, well-nourished men | 800 IU | 1 year | — |
| Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial 2008 · calcium supplementation group · Children aged 6–18 years with juvenile rheumatoid arthritis, without systemic corticosteroid therapy in the 3 months before enrollment | 400 IU | 2 years | — |
| Vitamin D insufficiency does not affect response of bone mineral density to alendronate 2009 · Calcium and cholecalciferol recipients · Postmenopausal women with low bone mineral density | 250 IU | — | — |
| Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone 2009 · DHEA group · Men and women aged 65–75 years | 16 mcg | 2 years | — |
| Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone 2009 · Placebo group, then open-label DHEA in year 2 · Men and women aged 65–75 years | 16 mcg | 1 year | — |
| Phosphate and carbonate salts of calcium support robust bone building in osteoporosis 2010 · Tricalcium phosphate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day | 1,000 IU | 1 year | — |
| Phosphate and carbonate salts of calcium support robust bone building in osteoporosis 2010 · Calcium carbonate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day | 1,000 IU | 1 year | — |
| The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial 2012 · standard-dose vitamin D group · Postmenopausal women aged 50–80 years with reduced bone mass (BMD T-score ≤ −2.0 in the lumbar spine or total hip) | 800 IU | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Placebo group · Japanese postmenopausal women with osteoporosis | 400 IU | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Denosumab 14 mg group · Japanese postmenopausal women with osteoporosis | 400 IU | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Denosumab 60 mg group · Japanese postmenopausal women with osteoporosis | 400 IU | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Denosumab 100 mg group · Japanese postmenopausal women with osteoporosis | 400 IU | 1 year | — |
| Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study 1990 · calcitriol · Postmenopausal women with vertebral fractures; age range not reported | 0.62 mcg | 2 years | — |
| A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation 2012 · Ibandronate group · Renal transplant recipients with early stable renal function | 0.25 mcg | 1 year | — |
| A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation 2012 · Placebo group · Renal transplant recipients with early stable renal function | 0.25 mcg | 1 year | — |
| Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis 2013 · low-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis | 125 IU | 1 year | — |
| Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis 2013 · standard-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis | 125 IU | 1 year | — |
| Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study 2013 · 5-mg alendronate and 0.5-µg calcitriol (Maxmarvil®) group · Korean postmenopausal women with hormone receptor-positive early breast cancer receiving daily aromatase inhibitor | 0.5 mcg | 24 weeks | — |
| Effect of vitamin D supplementation on blood pressure in blacks 2013 · 1,000 IU vitamin D3 group · Black adults aged 30–80, described as healthy; vitamin D status varied | 1,000 IU | 90 days | — |
| Effect of vitamin D supplementation on blood pressure in blacks 2013 · 2,000 IU vitamin D3 group · Black adults aged 30–80, described as healthy; vitamin D status varied | 2,000 IU | 90 days | — |
| Effect of vitamin D supplementation on blood pressure in blacks 2013 · 4,000 IU vitamin D3 group · Black adults aged 30–80, described as healthy; vitamin D status varied | 4,000 IU | 90 days | — |
| Vitamin D supplementation after parathyroidectomy: effect on bone mineral density-a randomized double-blind study 2014 · D+ · Adults with primary hyperparathyroidism after successful parathyroidectomy; median age 60 years, range 30–80; 79% women | 1,600 IU | 1 year | — |
| Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial 2014 · Exemestane group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0 | 800 IU | 2 years | — |
| Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial 2014 · Anastrozole group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0 | 800 IU | 2 years | — |
| The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial 2014 · 100 g dried plum/d group · Osteopenic postmenopausal women | 400 IU | 1 year | — |
| The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial 2014 · 75 g dried apple/d comparative control group · Osteopenic postmenopausal women | 400 IU | 1 year | — |
| Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial 2014 · Low-Ca group · Girls and boys aged 12–14 years | 200 IU | 2 years | — |
| Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial 2014 · Mid-Ca group · Girls and boys aged 12–14 years | 200 IU | 2 years | — |
| Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial 2014 · High-Ca group · Girls and boys aged 12–14 years | 200 IU | 2 years | — |
| A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial 2015 · CC group · Postmenopausal women with osteopenia | 200 IU | 1 year | — |
| A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial 2015 · Control group · Postmenopausal women with osteopenia | 200 IU | 1 year | — |
| Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis 2016 · SrR group · Women with thalassemia major-related osteoporosis | 800 IU | 2 years | — |
| Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial 2016 · Group A · Postmenopausal women aged 50–65 years | 800 IU | 2 years | — |
| Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial 2016 · Group B · Postmenopausal women aged 50–65 years | 800 IU | 2 years | — |
| Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial 2016 · Group C · Postmenopausal women aged 50–65 years | 800 IU | 2 years | — |
| Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate 2017 · denosumab group · Men with prostate cancer and osteoporosis undergoing androgen deprivation therapy | 600 IU | 2 years | — |
| Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate 2017 · alendronate group · Men with prostate cancer and osteoporosis undergoing androgen deprivation therapy | 600 IU | 2 years | — |
| Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy 2017 · Cholecalciferol and calcium carbonate · Adults with primary hyperparathyroidism undergoing parathyroidectomy; median age 60 years, 119 women | 1,600 IU | 1 year | — |
| Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial 2019 · PATCH · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside hormone treatment | 800 IU | 1 year | — |
| Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial 2019 · PILL · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside combined oral contraceptive treatment | 800 IU | 1 year | — |
| Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial 2019 · NONE · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation and no oestrogen or progesterone | 800 IU | 1 year | — |
| Role of Calcium and Low-Fat Dairy Foods in Weight-Loss Outcomes Revisited: Results from the Randomized Trial of Effects on Bone and Body Composition in Overweight/Obese Postmenopausal Women 2019 · Supplement group (S) · Overweight or obese Caucasian women 2–10 years postmenopausal, generally healthy, with dietary calcium intake of 800 mg/day or less | 400 IU | 26 weeks | — |
| Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study 2020 · Co-supplementation group · Community-dwelling men and postmenopausal women aged 50–75 years | 10 mcg | 1 year | — |
| The effects of vitamin D and curcuminoids supplementation on anthropometric measurements and blood pressure in type 2 diabetic patients with coexisting hypovitaminosis D: A double-blind, placebo-controlled randomized clinical trial 2020 · vitamin D3 plus curcuminoids · Adults with type 2 diabetes and insufficient vitamin D status | 7,143 IU | 12 weeks | — |
| The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial 2021 · vitamin K2 (MK-7) group · Postmenopausal women with osteopenia | 38 mcg | 1096 days | — |
| The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial 2021 · Placebo group · Postmenopausal women with osteopenia | 38 mcg | 1096 days | — |
| Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial 2021 · standard-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART | 400 IU | 48 weeks | — |
| Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial 2021 · high-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART | 3,257 IU | 48 weeks | — |
| Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia 2022 · Group A · Postmenopausal women with osteopenia | 400 IU | 1 year | — |
| High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT 2024 · Arm 2 (placebo arm; daily supplements) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL | 800 IU | 24 weeks | — |
| Impact of high-dose vitamin D and calcium carbonate supplementation on bone density in adolescents living with HIV: a randomised, placebo-controlled trial 2026 · intervention · Adolescents aged 11–19 years with perinatally acquired HIV, taking antiretroviral therapy | 2,857 IU | 48 weeks | — |
| Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D 1995 · 2.5 micrograms (100 IU) vitamin D/d group · Healthy ambulatory postmenopausal women | 100 IU | 2 years | — |
| Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D 1995 · 17.5 micrograms (700 IU) vitamin D/d group · Healthy ambulatory postmenopausal women | 700 IU | 2 years | — |
| Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss 1994 · calcium augmentation · Healthy white women 3 to 6 years after spontaneous menopause | 400 IU | 1059 days | — |
| Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss 1994 · estrogen-progesterone-calcium · Healthy white women 3 to 6 years after spontaneous menopause | 400 IU | 1059 days | — |
| Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial 1996 · Calcium carbonate and vitamin D3 · Patients with rheumatoid arthritis; some were receiving corticosteroids and some were not | 500 IU | 2 years | — |
| Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older 1997 · calcium and vitamin D group · Men and women 65 years of age or older living at home | 700 IU | 3 years | — |
| Maternal obesity and baseline vitamin D insufficiency alter the response to vitamin D supplementation: a double-blind, randomized trial in pregnant women 2021 · 20 µg/d group · Pregnant women aged 18 years or older, from 12 gestational weeks through delivery; normal weight, overweight, and obese participants, including women with and without baseline vitamin D insufficiency. | 20 mcg | 28 weeks | 121 |
| Estimation of the maternal vitamin D intake that maintains circulating 25-hydroxyvitamin D in late gestation at a concentration sufficient to keep umbilical cord sera ≥25-30 nmol/L: a dose-response, double-blind, randomized placebo-controlled trial in pregnant women at northern latitude 2018 · 20 µg vitamin D3 group · White-skinned pregnant adults aged 21–41 years, enrolled by 18 weeks’ gestation and without a stated high-risk pregnancy | 20 mcg | 22 weeks | 48 |
| Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial 2026 · ERC group · Adults with end-stage kidney disease, advanced secondary hyperparathyroidism, and requiring regular hemodialysis; sex and age range not specified | 129 mcg | 26 weeks | 33 |
| Comparison of narrowband ultraviolet B exposure and oral vitamin D substitution on serum 25-hydroxyvitamin D concentration 2012 · oral cholecalciferol-treated · Healthy adults with serum 25(OH)D below 75 nmol/L | 20 mcg | 4 weeks | 30 |
| Influence of food matrix delivery system on the bioavailability of vitamin D(3): A randomized crossover trial in postmenopausal women 2023 · Apple juice · Postmenopausal women aged 60–80 years with vitamin D insufficiency | 200 mcg | 1 day | 30 |
| Influence of food matrix delivery system on the bioavailability of vitamin D(3): A randomized crossover trial in postmenopausal women 2023 · Semi-skim milk · Postmenopausal women aged 60–80 years with vitamin D insufficiency | 200 mcg | 1 day | 30 |
| Influence of food matrix delivery system on the bioavailability of vitamin D(3): A randomized crossover trial in postmenopausal women 2023 · Water with vitamin D3 · Postmenopausal women aged 60–80 years with vitamin D insufficiency | 200 mcg | 1 day | 30 |
| Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial 2016 · cholecalciferol · Adults with non-dialysis-dependent stage 3–5 chronic kidney disease and serum 25(OH)D below 30 ng/ml | 179 mcg | 12 weeks | 22 |
| Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial 2016 · ergocalciferol · Adults with non-dialysis-dependent stage 3–5 chronic kidney disease and serum 25(OH)D below 30 ng/ml | 179 mcg | 12 weeks | 22 |
| A 25-Hydroxycholecalciferol-Fortified Dairy Drink Is More Effective at Raising a Marker of Postprandial Vitamin D Status than Cholecalciferol in Men with Suboptimal Vitamin D Status 2017 · +HyD3 dairy drink · Men with suboptimal vitamin D status; mean age 49 years | 20 mcg | 1 day | 17 |
| A 25-Hydroxycholecalciferol-Fortified Dairy Drink Is More Effective at Raising a Marker of Postprandial Vitamin D Status than Cholecalciferol in Men with Suboptimal Vitamin D Status 2017 · +D3 dairy drink · Men with suboptimal vitamin D status; mean age 49 years | 20 mcg | 1 day | 17 |
| Serum 25-hydroxyvitamin D response to vitamin D supplementation using different lipid delivery systems in middle-aged and older adults: a randomised controlled trial 2023 · Vitamin D supplement · Healthy adults aged 50 years and older; middle-aged and older adults, men and women | 20 mcg | 4 weeks | 17 |
| Serum 25-hydroxyvitamin D response to vitamin D supplementation using different lipid delivery systems in middle-aged and older adults: a randomised controlled trial 2023 · Olive oil dairy drink · Healthy adults aged 50 years and older; middle-aged and older adults, men and women | 20 mcg | 4 weeks | 15 |
| Serum 25-hydroxyvitamin D response to vitamin D supplementation using different lipid delivery systems in middle-aged and older adults: a randomised controlled trial 2023 · Coconut oil dairy drink · Healthy adults aged 50 years and older; middle-aged and older adults, men and women | 20 mcg | 4 weeks | 15 |
| Pharmacokinetics of oral vitamin D(3) and calcifediol 2014 · daily calcifediol group · healthy females aged 50–70 years | 20 mcg | 15 weeks | 5 |
| Pharmacokinetics of oral vitamin D(3) and calcifediol 2014 · daily vitamin D(3) group · healthy females aged 50–70 years | 20 mcg | 15 weeks | 5 |
| Pharmacokinetics of oral vitamin D(3) and calcifediol 2014 · weekly calcifediol group · healthy females aged 50–70 years | 20 mcg | 15 weeks | 5 |
| Pharmacokinetics of oral vitamin D(3) and calcifediol 2014 · weekly vitamin D(3) group · healthy females aged 50–70 years | 20 mcg | 15 weeks | 5 |
| Pharmacokinetics of oral vitamin D(3) and calcifediol 2014 · single bolus calcifediol group · healthy females aged 50–70 years | 140 mcg | 1 day | 5 |
| Pharmacokinetics of oral vitamin D(3) and calcifediol 2014 · single bolus vitamin D(3) group · healthy females aged 50–70 years | 140 mcg | 1 day | 5 |
| Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3 2002 · Vitamin D3 supplementation, young men · Healthy men aged 18–35 | 20 mcg | 8 weeks | — |
| Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3 2002 · Vitamin D3 supplementation, older men · Healthy men aged 62–79 | 20 mcg | 8 weeks | — |
| Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol 2003 · 250 micro g cholecalciferol · Healthy men living in Omaha; age not reported | 250 mcg | 20 weeks | — |
| How much vitamin D3 do the elderly need? 2006 · 20 microg vitamin D3 group · Women aged 65–85 years | 20 mcg | 12 weeks | — |
| Wintertime vitamin D supplementation inhibits seasonal variation of calcitropic hormones and maintains bone turnover in healthy men 2009 · 20 microg (800 IU) group · Healthy white men aged 21–49 years | 20 mcg | 26 weeks | — |
| Estimation of the dietary requirement for vitamin D in healthy adults 2008 · 15 microg/d vitamin D3 · Men and women aged 20–40 years; healthy adults | 15 mcg | 22 weeks | — |
| Supplements of 20 microg/d cholecalciferol optimized serum 25-hydroxyvitamin D concentrations in 80% of premenopausal women in winter 2009 · 20 microg/d D3 group · Predominantly white premenopausal women living in Maine; mean age 22.2 ± 3.7 years | 20 mcg | 150 days | — |
| How much vitamin D for neonates? 1991 · 20 micrograms/d (800 IU/d) vitamin D · Neonates, including low-birth-weight and full-term well infants | 20 mcg | 16 weeks | — |
| Estimation of the dietary requirement for vitamin D in free-living adults >=64 y of age 2009 · 15 microg vitamin D(3)/d · men and women aged ≥64 years | 15 mcg | 22 weeks | — |
| Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults 2010 · Young adults, 15 microg/day · Healthy adults aged 20–40 years | 15 mcg | — | — |
| Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults 2010 · Elderly adults, 15 microg/day · Healthy adults aged 64 years or older | 15 mcg | — | — |
| Serum 25-hydroxyvitamin D concentrations of free-living subjects consuming olestra 1991 · Triglycerides (placebo) · Free-living adults; age range and sex not reported | 20 mcg | 6 weeks | — |
| Serum 25-hydroxyvitamin D concentrations of free-living subjects consuming olestra 1991 · Olestra · Free-living adults; age range and sex not reported | 20 mcg | 6 weeks | — |
| Effect of adiposity on vitamin D status and the 25-hydroxycholecalciferol response to supplementation in healthy young and older Irish adults 2012 · cholecalciferol supplementation · Healthy Irish adults aged 20–40 years and 64 years or older | 15 mcg | 22 weeks | — |
| Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity 2012 · HyD group · Healthy postmenopausal women, mean age 61.5 years, with a mean baseline 25(OH)D level of 13.2 ng/mL | 20 mcg | 120 days | — |
| Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity 2012 · vitamin D3 group · Healthy postmenopausal women, mean age 61.5 years, with a mean baseline 25(OH)D level of 13.2 ng/mL | 20 mcg | 120 days | — |
| Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults 2012 · 20 μg vitamin D3 group · Adults aged 50 years or older, apparently healthy | 20 mcg | 10 weeks | — |
| Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults 2012 · 20 μg 25-hydroxyvitamin D3 group · Adults aged 50 years or older, apparently healthy | 20 mcg | 10 weeks | — |
| Dietary calcium does not interact with vitamin D₃ in terms of determining the response and catabolism of serum 25-hydroxyvitamin D during winter in older adults 2014 · vitamin D₃ group · Free-living men and women aged 50 years or older, stratified by dietary calcium intake | 20 mcg | 15 weeks | — |
| Calcifediol improves lipid profile in osteopenicatorvastatin-treated postmenopausal women 2015 · calcifediol · Postmenopausal women aged about 59 years with low 25(OH)D, osteopenia and dyslipidemia, taking atorvastatin | 20 mcg | 24 weeks | — |
| Calcifediol improves lipid profile in osteopenicatorvastatin-treated postmenopausal women 2015 · cholecalciferol · Postmenopausal women aged about 59 years with low 25(OH)D, osteopenia and dyslipidemia, taking atorvastatin | 20 mcg | 24 weeks | — |
| Vitamin D3 supplementation: Response and predictors of vitamin D3 metabolites - A randomized controlled trial 2016 · vitamin D3 group · Adults aged 20–71 years | 20 mcg | 12 weeks | — |
| Estimation of the dietary requirement for vitamin D in adolescents aged 14-18 y: a dose-response, double-blind, randomized placebo-controlled trial 2016 · 20-μg/d group · White male and female adolescents aged 14–18 years in the United Kingdom during winter | 20 mcg | 20 weeks | — |
| Estimation of the dietary requirement for vitamin D in white children aged 4-8 y: a randomized, controlled, dose-response trial 2016 · 20 μg vitamin D3/d supplementation · White Danish children aged 4–8 years | 20 mcg | 20 weeks | — |
| Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone 2017 · 25D3 group · Adults aged 18 years or older with 25-hydroxyvitamin D levels below 20 ng/mL | 20 mcg | 16 weeks | — |
| Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults 2018 · 15 μg calcifediol group · Men and women aged 65 years or older; no condition specified | 15 mcg | 24 weeks | — |
| Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults 2018 · 20 μg vitamin D3 group · Men and women aged 65 years or older; no condition specified | 20 mcg | 24 weeks | — |
| Daily supplementation with 15 μg vitamin D(2) compared with vitamin D(3) to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial 2017 · juice supplemented with vitamin D2 · Healthy South Asian and white European women aged 20–64 years | 15 mcg | 12 weeks | — |
| Daily supplementation with 15 μg vitamin D(2) compared with vitamin D(3) to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial 2017 · biscuit supplemented with vitamin D2 · Healthy South Asian and white European women aged 20–64 years | 15 mcg | 12 weeks | — |
| Daily supplementation with 15 μg vitamin D(2) compared with vitamin D(3) to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial 2017 · juice supplemented with vitamin D3 · Healthy South Asian and white European women aged 20–64 years | 15 mcg | 12 weeks | — |
| Daily supplementation with 15 μg vitamin D(2) compared with vitamin D(3) to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial 2017 · biscuit supplemented with vitamin D3 · Healthy South Asian and white European women aged 20–64 years | 15 mcg | 12 weeks | — |
| Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens 2017 · 20 μg/day · Postmenopausal women aged 55 years or older with vitamin D inadequacy | 20 mcg | 90 days | — |
| Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens 2017 · 125 μg/week · Postmenopausal women aged 55 years or older with vitamin D inadequacy | 17.9 mcg | 90 days | — |
| Winter Cholecalciferol Supplementation at 55°N Has No Effect on Markers of Cardiometabolic Risk in Healthy Children Aged 4-8 Years 2018 · 20 µg/d vitamin D3 group · Healthy white Danish children aged 4–8 years | 20 mcg | 20 weeks | — |
| Vitamin D-fortified foods improve wintertime vitamin D status in women of Danish and Pakistani origin living in Denmark: a randomized controlled trial 2020 · Danish-fortified group · Women of Danish origin living in Denmark, at risk of vitamin D deficiency | 20 mcg | 12 weeks | — |
| Vitamin D-fortified foods improve wintertime vitamin D status in women of Danish and Pakistani origin living in Denmark: a randomized controlled trial 2020 · Pakistani-fortified group · Women of Pakistani origin living in Denmark, at risk of vitamin D deficiency | 20 mcg | 12 weeks | — |
| Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults 2020 · 25(OH)D3 15 µg group · Older adults, mean age 63.3 ± 7.9 years; no specific condition stated | 15 mcg | 26 weeks | — |
| Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults 2020 · 25(OH)D3 20 µg group · Older adults, mean age 63.3 ± 7.9 years; no specific condition stated | 20 mcg | 26 weeks | — |
| Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults 2020 · D3 20 µg group · Older adults, mean age 63.3 ± 7.9 years; no specific condition stated | 20 mcg | 26 weeks | — |
| Vitamin D Supplementation and Sunlight Exposure on Serum Vitamin D Concentrations in 2 Parallel, Double-Blind, Randomized, Placebo-Controlled Trials 2021 · Vitamin D supplement group with UVB exposure (Brazil) · Adult women living in Brazil (16°S); mean age 31.39 ± 8.7 years; no condition stated | 15 mcg | 12 weeks | — |
| Vitamin D Supplementation and Sunlight Exposure on Serum Vitamin D Concentrations in 2 Parallel, Double-Blind, Randomized, Placebo-Controlled Trials 2021 · Vitamin D supplement group without UVB exposure (England) · Adult women living in England (51°N); mean age 31.39 ± 8.7 years; no condition stated | 15 mcg | 12 weeks | — |
| Effects of high dairy protein intake and vitamin D supplementation on body composition and cardiometabolic markers in 6-8-y-old children-the D-pro trial 2022 · high-protein yogurt plus vitamin D3 · White Danish children aged 6–8 years, described as well-nourished | 20 mcg | 24 weeks | — |
| Effects of high dairy protein intake and vitamin D supplementation on body composition and cardiometabolic markers in 6-8-y-old children-the D-pro trial 2022 · normal-protein yogurt plus vitamin D3 · White Danish children aged 6–8 years, described as well-nourished | 20 mcg | 24 weeks | — |
| Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial 2024 · calcifediol 100 µg group · Adults aged 18 years or older with vitamin D deficiency, serum 25(OH)D >10 and <20 ng/mL; males and females | 14.3 mcg | 52 weeks | — |
| Olestra dose response on fat-soluble and water-soluble nutrients in humans 1997 · 0 g/d olestra group · Normal healthy adults | 20 mcg | 8 weeks | — |
| Olestra dose response on fat-soluble and water-soluble nutrients in humans 1997 · 8 g/d olestra group · Normal healthy adults | 20 mcg | 8 weeks | — |
| Olestra dose response on fat-soluble and water-soluble nutrients in humans 1997 · 20 g/d olestra group · Normal healthy adults | 20 mcg | 8 weeks | — |
| Olestra dose response on fat-soluble and water-soluble nutrients in humans 1997 · 32 g/d olestra group · Normal healthy adults | 20 mcg | 8 weeks | — |
| Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men 1998 · vitamin D3 250 micrograms/day · healthy men, mean age 28 years | 250 mcg | 8 weeks | — |
| Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men 1998 · 25(OH)D3 20 micrograms/day · healthy men, mean age 28 years | 20 mcg | 4 weeks | — |
| Effect of vitamin D supplementation during pregnancy on mid-to-late gestational blood pressure in a randomized controlled trial in Bangladesh 2021 · 4200 IU/week vitamin D group · Pregnant women aged 18 years and older, generally healthy, enrolled at 17–24 weeks of gestation | 600 IU | — | 252 |
| Effect of vitamin D supplementation during pregnancy on mid-to-late gestational blood pressure in a randomized controlled trial in Bangladesh 2021 · 16800 IU/week vitamin D group · Pregnant women aged 18 years and older, generally healthy, enrolled at 17–24 weeks of gestation | 2,400 IU | — | 251 |
| [Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial] 2004 · Group 1: Vitrum Osteomag · Postmenopausal women with osteopenia; age range not reported | 400 IU | 1 year | 125 |
| A 2-Year Randomized Controlled Trial With Low-Dose B-Vitamin Supplementation Shows Benefits on Bone Mineral Density in Adults With Lower B12 Status 2022 · B-vitamin treatment · Community-dwelling adults aged 50 years or older; men and women; no specific diagnosed condition, and not currently taking B-vitamin supplements at screening | 10 mcg | 2 years | 103 |
| Calcium and vitamin D fortified milk reduces bone turnover and improves bone density in postmenopausal women over 1 year 2018 · intervention · Chinese postmenopausal women in Malaysia; mean age 59 years | 15 mcg | 1 year | 61 |
| Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study 2013 · geniVida bone blend (GBB) · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding | 800 IU | 26 weeks | 31 |
| Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation 2015 · standard PN · Children aged 6 years or older undergoing first myeloablative allogeneic hematopoietic cell transplantation; ages 6–11 or over 11, with diagnoses including leukemia | 7,143 IU | — | — |
| Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation 2015 · experimental PN · Children aged 6 years or older undergoing first myeloablative allogeneic hematopoietic cell transplantation; ages 6–11 or over 11, with diagnoses including leukemia | 7,143 IU | — | — |
| The Impact of Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After Bariatric Surgery: The BABS Study 2016 · intervention group · Women and similarly aged men with BMI >38 kg/m² after Roux-en-Y gastric bypass or sleeve gastrectomy; median age 40.7 years | 6,286 IU | 2 years | — |
| High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT 2024 · Arm 1 (high-dose vitamin D) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL | 7,943 IU | 24 weeks | — |
| BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial 2006 · BXL628 group · Men aged 50 years or older with benign prostatic hyperplasia and prostate volume of at least 40 ml | 150 mcg | 12 weeks | 57 |
| The Effectiveness of Vitamin D Supplementation on Oxidative and Inflammatory Markers in Patients Suffering from End-stage Renal Disease, a Randomized Controlled Trial 2022 · vitamin D · Patients with end-stage renal disease, categorised by severity of vitamin D deficiency | 250 mcg | 8 weeks | 51 |
| Vitamin D(3) reduces risk of cardiovascular and liver diseases by lowering homocysteine levels: double-blinded, randomised, placebo-controlled trial 2021 · vitamin D · Overweight women with vitamin D deficiency | 179 mcg | 60 days | 50 |
| Effect of vitamin D(3) vs. calcifediol on VDR concentration and fiber size in skeletal muscle 2023 · HyD group · Postmenopausal women; mean age 61 ± 4 years | 20 mcg | 26 weeks | 11 |
| The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion 2006 · vitamin D group · Patients with pulmonary tuberculosis and moderately advanced pulmonary tuberculous lesions | 250 mcg | 6 weeks | — |
| Maintenance of wintertime vitamin D status with cholecalciferol supplementation is not associated with alterations in serum cytokine concentrations among apparently healthy younger or older adults 2011 · 15 μg/d cholecalciferol (D3) group · Apparently healthy younger adults aged 20–40 years and older adults aged ≥64 years | 15 mcg | 22 weeks | — |
| Associations Between Change in Total and Free 25-Hydroxyvitamin D With 24,25-Dihydroxyvitamin D and Parathyroid Hormone 2018 · 25(OH)D3 group · Adults aged 18 years or older with 25(OH)D levels below 20 ng/mL | 20 mcg | 16 weeks | — |
| Vitamin D3 supplementation for 8 weeks leads to improved haematological status following the consumption of an iron-fortified breakfast cereal: a double-blind randomised controlled trial in iron-deficient women 2019 · vitamin D3 group · Fe-deficient women; mean age 27.4 years | 38 mcg | 8 weeks | — |
| Vitamins D(2) and D(3) Have Overlapping But Different Effects on the Human Immune System Revealed Through Analysis of the Blood Transcriptome 2022 · vitamin D2 treatment group · Women aged 20–64, South Asian and white European, described as healthy | 15 mcg | 12 weeks | — |
| Vitamins D(2) and D(3) Have Overlapping But Different Effects on the Human Immune System Revealed Through Analysis of the Blood Transcriptome 2022 · vitamin D3 treatment group · Women aged 20–64, South Asian and white European, described as healthy | 15 mcg | 12 weeks | — |
| An investigation of sources of variation in calcium absorption efficiency 1995 · 25OHD pretreatment group · Healthy premenopausal women, mean age 36.4 years | 20 mcg | 34 days | — |
| Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study 2023 · vitamin D · Adults with prediabetes meeting at least two of three glycemic criteria and no diagnostic criteria for diabetes | 4,000 IU | 913 days | 1,211 |
| Associations of vitamin D binding protein variants with the vitamin D-induced increase in serum 25-hydroxyvitamin D 2019 · Vitamin D3 supplementation · Healthy adolescent Iranian girls | 7,143 IU | 9 weeks | 619 |
| Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation During Pregnancy 2016 · 1000-IU/d cholecalciferol · Pregnant women aged over 18 years with singleton pregnancies and serum 25(OH)D of 25–100 nmol/L | 1,000 IU | — | 407 |
| Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial 2006 · ALN + D · Men and postmenopausal women with osteoporosis and serum 25OHD ≥9 ng/mL | 10 mcg | 15 weeks | 360 |
| Impact of three different daily doses of vitamin D3 supplementation in healthy schoolchildren and adolescents from North India: a single-blind prospective randomised clinical trial 2019 · Group A · Vitamin D-deficient children aged 6–16 years | 600 IU | 26 weeks | 344 |
| Impact of three different daily doses of vitamin D3 supplementation in healthy schoolchildren and adolescents from North India: a single-blind prospective randomised clinical trial 2019 · Group B · Vitamin D-deficient children aged 6–16 years | 1,000 IU | 26 weeks | 341 |
| Response to Antenatal Cholecalciferol Supplementation Is Associated With Common Vitamin D-Related Genetic Variants 2017 · Cholecalciferol 1000 IU/d · White pregnant women aged over 18 years with singleton pregnancies, enrolled before 17 weeks' gestation and with 25(OH)D of 25–100 nmol/L | 1,000 IU | — | 331 |
| A genetic variant in the cytochrome P450 family 2 subfamily R member 1 determines response to vitamin D supplementation 2019 · Vitamin D3 supplementation · 253 healthy Iranian girls; age not reported | 7,143 IU | 9 weeks | 253 |
| Impact of vitamin D fortified milk supplementation on vitamin D status of healthy school children aged 10-14 years 2013 · Group B · Healthy school children aged 10–14 years, boys and girls | 600 IU | 12 weeks | 243 |
| Impact of vitamin D fortified milk supplementation on vitamin D status of healthy school children aged 10-14 years 2013 · Group C · Healthy school children aged 10–14 years, boys and girls | 1,000 IU | 12 weeks | 233 |
| Impact of three different daily doses of vitamin D3 supplementation in healthy schoolchildren and adolescents from North India: a single-blind prospective randomised clinical trial 2019 · Group C · Vitamin D-deficient children aged 6–16 years | 2,000 IU | 26 weeks | 232 |
| A randomized clinical trial comparing 3 different replacement regimens of vitamin D in clinically asymptomatic pediatrics and adolescents with vitamin D insufficiency 2016 · Group 1 · Children and adolescents aged 2–18 years with vitamin D below 30 ng/mL, clinically asymptomatic | 400 IU | 1 year | 196 |
| Relationship between vitamin D status and the vaginal microbiome during pregnancy 2019 · Group B: 4,400 IU/day · Pregnant women enrolled in the first trimester, with singleton pregnancies | 4,400 IU | — | 196 |
| Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis 2016 · Vitamin D supplementation during screening · Korean postmenopausal women aged 60–90 years with osteoporosis and vitamin D deficiency (serum 25(OH)D <50 nmol/L) | 2,000 IU | 31 days | 191 |
| Relationship between vitamin D status and the vaginal microbiome during pregnancy 2019 · Group A: 400 IU vitamin D3/day—Standard dose treatment · Pregnant women enrolled in the first trimester, with singleton pregnancies | 400 IU | — | 191 |
| Effects of different vitamin D supplementation strategies in reversing metabolic syndrome and its component risk factors in adolescents 2019 · vitamin D tablet · Saudi adolescents aged 12–18 years, boys and girls; apparently healthy | 1,000 IU | 212 days | 180 |
| Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness 2011 · 4000 IU group · Pregnant women aged 16 years or older with singleton pregnancies, enrolled before 16 weeks’ gestation | 4,000 IU | — | 169 |
| Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness 2011 · 2000 IU group · Pregnant women aged 16 years or older with singleton pregnancies, enrolled before 16 weeks’ gestation | 2,000 IU | — | 167 |
| Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness 2011 · 400 IU group · Pregnant women aged 16 years or older with singleton pregnancies, enrolled before 16 weeks’ gestation | 400 IU | — | 166 |
| Vitamin D supplementation and growth in urban Mongol school children: Results from two randomized clinical trials 2017 · Vitamin D3-fortified milk group (Fortification Study) · Children aged 9–11 years in Ulaanbaatar, Mongolia; most analyzed children had serum 25(OH)D below 20 ng/ml | 300 IU | 7 weeks | 138 |
| Effects of long-term vitamin D supplementation on metabolic profile in middle-aged and elderly patients with type 2 diabetes 2023 · vitamin D group · Patients aged 50–70 years with type 2 diabetes | 800 IU | 900 days | 135 |
| The relationship between physical activity and vitamin D status in postpartum lactating and formula-feeding women 2018 · 6400 IU vitamin D3 per day · Healthy postpartum women who were lactating; age range not reported | 6,400 IU | 213 days | 127 |
| The relationship between physical activity and vitamin D status in postpartum lactating and formula-feeding women 2018 · 400 IU vitamin D3 per day (control group) · Healthy postpartum women who were lactating; age range not reported | 400 IU | 213 days | 121 |
| 25-Hydroxyvitamin D in Cancer Patients Admitted to Palliative Care: A Post-Hoc Analysis of the Swedish Trial 'Palliative-D' 2022 · vitamin D3 oil drops (Detremin) · Adults with advanced or metastatic cancer in palliative care and serum 25-OHD ≤50 nmol/L | 4,000 IU | 12 weeks | 121 |
| Maternal obesity and baseline vitamin D insufficiency alter the response to vitamin D supplementation: a double-blind, randomized trial in pregnant women 2021 · 10 µg/d group · Pregnant women aged 18 years or older, from 12 gestational weeks through delivery; normal weight, overweight, and obese participants, including women with and without baseline vitamin D insufficiency. | 10 mcg | 28 weeks | 119 |
| Efficacy of Daily Supplementation of Milk Fortified With Vitamin D2 for Three Months in Healthy School Children: A Randomized Placebo Controlled Trial 2021 · Intervention group · Healthy schoolchildren aged 10–14 years with vitamin D deficiency | 240 IU | 90 days | 119 |
| Measurements of the Vitamin D Metabolome in the Calgary Vitamin D Study: Relationship of Vitamin D Metabolites to Bone Loss 2023 · 400 IU daily · Healthy males and females aged 55–70 years without vitamin D deficiency and with DXA T-scores > -2.5 | 400 IU | 1096 days | 109 |
| Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care 2017 · 4000 IU/day · Men and women aged 65 years or older living in the community; not currently taking more than 400 IU/day vitamin D3 | 4,000 IU | 1 year | 102 |
| Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care 2017 · 2000 IU/day · Men and women aged 65 years or older living in the community; not currently taking more than 400 IU/day vitamin D3 | 2,000 IU | 1 year | 102 |
| Measurements of the Vitamin D Metabolome in the Calgary Vitamin D Study: Relationship of Vitamin D Metabolites to Bone Loss 2023 · 10,000 IU daily · Healthy males and females aged 55–70 years without vitamin D deficiency and with DXA T-scores > -2.5 | 10,000 IU | 1096 days | 102 |
| Hormonal Contraceptive Use Is Associated With Higher Total but Unaltered Free 25-Hydroxyvitamin D Serum Concentrations 2018 · 800 IU vitamin D3 group · Apparently healthy women of childbearing age | 800 IU | 8 weeks | 101 |
| Hormonal Contraceptive Use Is Associated With Higher Total but Unaltered Free 25-Hydroxyvitamin D Serum Concentrations 2018 · 200 IU vitamin D3 group · Apparently healthy women of childbearing age | 200 IU | 8 weeks | 100 |
| Clinical effect of alfacalcidol in children with Henoch-Schönlein purpura: a prospective randomized controlled trial 2021 · observation group · Children with Henoch-Schönlein purpura | 0.25 mcg | 4 weeks | 100 |
| Measurements of the Vitamin D Metabolome in the Calgary Vitamin D Study: Relationship of Vitamin D Metabolites to Bone Loss 2023 · 4000 IU daily · Healthy males and females aged 55–70 years without vitamin D deficiency and with DXA T-scores > -2.5 | 4,000 IU | 1096 days | 100 |
| Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Tromsø study 2010 · Vitamin D supplementation (40,000 IU per week) · Adults in a population-based study; age and health condition not specified | 5,714 IU | 1 year | 93 |
| Effect of vitamin D on oxidative stress and serum inflammatory factors in the patients with type 2 diabetes 2022 · Vitamin D supplement group (VitD group) · Adults with type 2 diabetes; age range and sex not specified | 400 IU | 90 days | 86 |
| A randomized trial of vitamin D supplementation in 2 community health center networks in South Carolina 2013 · 2000 IU group · Pregnant women aged 16 years or older, enrolled before 16 weeks’ gestation; diverse community health center population, many African American or Hispanic | 2,000 IU | 26 weeks | 83 |
| Safety and effectiveness of stoss therapy in children with vitamin D deficiency 2020 · stoss · Children aged 2–16 years with 25OHD <50 nmol/L | 14,286 IU | 4 weeks | 83 |
| Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial 2013 · vitamin D3 group · Pregnant women aged 18 to under 35 years, enrolled at 26 to under 30 weeks’ gestation | 5,000 IU | 10 weeks | 80 |
| Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial 2018 · VD group · Women aged 50–65 years, postmenopausal for at least 12 months, with normal bone mineral density and vitamin D deficiency | 1,000 IU | 270 days | 80 |
| Isolated vitamin D supplementation improves the adipokine profile of postmenopausal women: a randomized clinical trial 2023 · vitamin D group · Postmenopausal women aged 50–65 years | 1,000 IU | 39 weeks | 80 |
| A randomized trial of vitamin D supplementation in 2 community health center networks in South Carolina 2013 · 4000 IU group · Pregnant women aged 16 years or older, enrolled before 16 weeks’ gestation; diverse community health center population, many African American or Hispanic | 4,000 IU | 26 weeks | 78 |
| Comparison between daily supplementation doses of 200 versus 400 IU of vitamin D in infants 2013 · group 1, 200 IU/day · infants; age and health status not further specified | 200 IU | — | 75 |
| Vitamin D Metabolism Varies among Women in Different Reproductive States Consuming the Same Intakes of Vitamin D and Related Nutrients 2016 · Vitamin D intake · Healthy women of childbearing age: pregnant women at 26–29 weeks’ gestation, lactating women at 5 weeks postpartum, and nonpregnant, nonlactating controls | 200 IU | 10 weeks | 75 |
| Supplementation with Three Different Daily Doses of Vitamin D3 in Healthy Pre-pubertal School Girls: A Cluster Randomized Trial 2018 · 2000 IU group · Healthy pre-pubertal girls aged 6.1–11.8 years | 2,000 IU | 26 weeks | 75 |
| Supplementation with Three Different Daily Doses of Vitamin D3 in Healthy Pre-pubertal School Girls: A Cluster Randomized Trial 2018 · 600 IU group · Healthy pre-pubertal girls aged 6.1–11.8 years | 600 IU | 26 weeks | 74 |
| Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants: a randomized clinical trial 2011 · Capsules 800 IU · Non-western immigrant adults aged 18–65 with documented vitamin D deficiency | 800 IU | 26 weeks | 72 |
| Safety and effectiveness of stoss therapy in children with vitamin D deficiency 2020 · standard · Children aged 2–16 years with 25OHD <50 nmol/L | 5,000 IU | 80 days | 68 |
| A randomized, double-blind, placebo-controlled trial of vitamin D supplementation with or without calcium in community-dwelling vitamin D deficient subjects 2022 · Vitamin D3 · Adults aged 18 years and over, men and women, with vitamin D deficiency; apparently healthy community-dwelling UAE residents and expatriates | 2,000 IU | 26 weeks | 68 |
| Supplementation with Three Different Daily Doses of Vitamin D3 in Healthy Pre-pubertal School Girls: A Cluster Randomized Trial 2018 · 1000 IU group · Healthy pre-pubertal girls aged 6.1–11.8 years | 1,000 IU | 26 weeks | 67 |
| A randomized trial of vitamin D₃ supplementation in children: dose-response effects on vitamin D metabolites and calcium absorption 2013 · 1000 IU group · Males and females aged 9–13 years; healthy children without a stated diagnosed condition | 1,000 IU | 12 weeks | 65 |
| High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients 2008 · replenishment phase · Haemodialysis patients with vitamin D deficiency | 2,857 IU | 39 weeks | 64 |
| Comparison between daily supplementation doses of 200 versus 400 IU of vitamin D in infants 2013 · group 2, 400 IU/day · infants; age and health status not further specified | 400 IU | — | 64 |
| A randomized trial of vitamin D₃ supplementation in children: dose-response effects on vitamin D metabolites and calcium absorption 2013 · 400 IU group · Males and females aged 9–13 years; healthy children without a stated diagnosed condition | 400 IU | 12 weeks | 64 |
| A randomized trial of vitamin D₃ supplementation in children: dose-response effects on vitamin D metabolites and calcium absorption 2013 · 2000 IU group · Males and females aged 9–13 years; healthy children without a stated diagnosed condition | 2,000 IU | 12 weeks | 64 |
| A randomized trial of vitamin D₃ supplementation in children: dose-response effects on vitamin D metabolites and calcium absorption 2013 · 4000 IU group · Males and females aged 9–13 years; healthy children without a stated diagnosed condition | 4,000 IU | 12 weeks | 64 |
| Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial 2014 · Oral cholecalciferol (D3) · Adults aged 18 years or older receiving hemodialysis for at least 2 months, with serum 25(OH)D below 25 ng/mL | 7,143 IU | 1 year | 62 |
| A randomized double-blind controlled trial comparing two regimens of vitamin D supplementation in preterm neonates 2016 · 400 IU group · Preterm neonates born at 27 to 34 weeks gestation | 400 IU | — | 60 |
| A randomized double-blind controlled trial comparing two regimens of vitamin D supplementation in preterm neonates 2016 · 1000 IU group · Preterm neonates born at 27 to 34 weeks gestation | 1,000 IU | — | 60 |
| Vitamin D(3) supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: Results of an open label randomized clinical trial 2017 · daily vitamin D3 group · Adults aged 18–80 with diabetes and chronic kidney disease stages 1–4 | 2,000 IU | 26 weeks | 60 |
| Differences in vitamin D3 dosing regimens in a geriatric community-dwelling population 2012 · 2,000 IU vitamin D3 daily · Adults aged 65 years and older, with baseline 25(OH)D levels below or at/above 30 ng/mL | 2,000 IU | 26 weeks | 59 |
| Influence of a single oral dose of vitamin D(2) on serum 25-hydroxyvitamin D concentrations in tuberculosis patients 2009 · vitamin D(2) group, healthy adults · Healthy adults; age and sex not reported | 2.5 mg | 1 day | 56 |
| Vitamin D supplementation and growth in urban Mongol school children: Results from two randomized clinical trials 2017 · Vitamin D3 group (Supplementation Study) · Children aged 12–15 years living in Ulaanbaatar, Mongolia; all analyzed children had serum 25(OH)D below 20 ng/ml | 800 IU | 26 weeks | 56 |
| Effect of Vitamin D Supplementation on (25(OH)D) Status in Children 12-30 Months of Age: A Randomized Clinical Trial 2023 · Vitamin D2 (Ergocalciferol) 400 IU/day · Healthy children aged 12–30 months, both sexes | 400 IU | 90 days | 56 |
| Effect of Vitamin D Supplementation on (25(OH)D) Status in Children 12-30 Months of Age: A Randomized Clinical Trial 2023 · Vitamin D3 (Cholecalciferol) 1000 IU/day · Healthy children aged 12–30 months, both sexes | 1,000 IU | 90 days | 56 |
| Effect of vitamin D(3) supplementation in winter on physical performance of university students: a one-month randomized controlled trial 2023 · vitamin D group · Chinese university undergraduates; men and women, mean age 19 years; no stated diagnosed condition | 1,000 IU | 30 days | 56 |
| Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents 2008 · Vitamin D3 daily · Men and women aged 70 years or older living in nursing homes; mean age 84 years, with low vitamin D status | 600 IU | 120 days | 55 |
| [Effect of vitamin D supplementation and outdoor time on the 25(OH)D level in adolescents] 2017 · VD supplementation group · Adolescents with vitamin D deficiency at baseline; age range and sex not specified | 800 IU | 4 weeks | 55 |
| Effects of a single dose of vitamin D in septic children: a randomized, double-blinded, controlled trial 2020 · treatment group · Children aged 14 years or younger with sepsis and vitamin D deficiency | 150,000 IU | 1 day | 55 |
| Monitored Supplementation of Vitamin D in Preterm Infants: A Randomized Controlled Trial 2021 · standard vitamin D supplementation group (control group) · Preterm infants born at 24–32 weeks of gestation | 500 IU | 52 weeks | 55 |
| Effect of Vitamin D Supplementation on (25(OH)D) Status in Children 12-30 Months of Age: A Randomized Clinical Trial 2023 · Vitamin D2 (Ergocalciferol) 800 IU/day · Healthy children aged 12–30 months, both sexes | 800 IU | 90 days | 55 |
| Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2 1998 · vitamin D3 · Subjects; age, sex, and health condition not stated | 4,000 IU | 2 weeks | 55 |
| Impact of a single oral dose of 100,000 IU vitamin D3 on profiles of serum 25(OH)D3 and its metabolites 24,25(OH)2D3, 3-epi-25(OH)D3, and 1,25(OH)2D3 in adults with vitamin D insufficiency 2017 · vitamin D3 · Adults aged 20–50 with self-perceived fatigue and vitamin D insufficiency | 100,000 IU | 1 day | 52 |
| Estimations of dietary vitamin D requirements in black and white children 2016 · vitamin D-supplemented group · Healthy children aged 8–14 years, black and white; sex not specified | 1,000 IU | 26 weeks | 51 |
| The interactive effect of improvement of vitamin D status and VDR FokI variants on oxidative stress in type 2 diabetic subjects: a randomized controlled trial 2015 · vitamin D3-fortified doogh (FD) · people with type 2 diabetes; age and sex not stated | 1,000 IU | 12 weeks | 50 |
| Effect of sun exposure versus oral vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in young adults: A randomized clinical trial 2020 · oral vitamin D3 group · Young vitamin D-deficient adults in Seoul, Korea; sex and age range not stated | 500 IU | 8 weeks | 50 |
| Bioavailability and Safety of Vitamin D3 from Pizza Baked with Fortified Mozzarella Cheese: A Randomized Controlled Trial 2015 · high-dose group · Apparently healthy, ethnically diverse adults | 4,000 IU | 8 weeks | 49 |
| Randomized trial of two maintenance doses of vitamin D in children with chronic kidney disease 2022 · 1000 IU group · Children aged 9 years or older with CKD stages 3–5 or kidney transplant recipients | 1,000 IU | 26 weeks | 49 |
| Randomized trial of two maintenance doses of vitamin D in children with chronic kidney disease 2022 · 4000 IU group · Children aged 9 years or older with CKD stages 3–5 or kidney transplant recipients | 4,000 IU | 26 weeks | 49 |
| Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial 2025 · Randomized trial, denosumab group · Infertile men; mean age approximately 34 years | 25 mcg | 160 days | 49 |
| Trial of daily vitamin D supplementation in preterm infants 2014 · 800-IU group · Preterm infants born at 28 to 34 weeks' gestation | 800 IU | — | 48 |
| Trial of daily vitamin D supplementation in preterm infants 2014 · 400-IU group · Preterm infants born at 28 to 34 weeks' gestation | 400 IU | — | 48 |
| Estimation of the maternal vitamin D intake that maintains circulating 25-hydroxyvitamin D in late gestation at a concentration sufficient to keep umbilical cord sera ≥25-30 nmol/L: a dose-response, double-blind, randomized placebo-controlled trial in pregnant women at northern latitude 2018 · 10 µg vitamin D3 group · White-skinned pregnant adults aged 21–41 years, enrolled by 18 weeks’ gestation and without a stated high-risk pregnancy | 10 mcg | 22 weeks | 48 |
| Bioavailability and Safety of Vitamin D3 from Pizza Baked with Fortified Mozzarella Cheese: A Randomized Controlled Trial 2015 · low-dose group · Apparently healthy, ethnically diverse adults | 28.6 IU | 8 weeks | 47 |
| Evolution of Serum 25OHD in Response to Vitamin D(3)-Fortified Yogurts Consumed by Healthy Menopausal Women: A 6-Month Randomized Controlled Trial Assessing the Interactions between Doses, Baseline Vitamin D Status, and Seasonality 2018 · Gr.Suppl.5 · Healthy menopausal women aged 55–75 years; no diagnosed condition stated, with screening serum 25OHD from 25 to 75 nmol/L | 5 mcg | 16 weeks | 47 |
| Evolution of Serum 25OHD in Response to Vitamin D(3)-Fortified Yogurts Consumed by Healthy Menopausal Women: A 6-Month Randomized Controlled Trial Assessing the Interactions between Doses, Baseline Vitamin D Status, and Seasonality 2018 · Gr.Suppl.10 · Healthy menopausal women aged 55–75 years; no diagnosed condition stated, with screening serum 25OHD from 25 to 75 nmol/L | 10 mcg | 16 weeks | 47 |
| Late-onset hypogonadism: beyond testosterone 2015 · calcidiol · Men aged 34.5 ± 6.8 years with classic or subclinical hypogonadism and low 25-hydroxyvitamin D; infertility evaluation patients | 571 IU | 90 days | 46 |
| Effect of Oral Vitamin D3 Supplementation in Exclusively Breastfed Newborns: Prospective, Randomized, Double-Blind, Placebo-Controlled Trial 2022 · vD-400 group · Exclusively breastfed term newborns, enrolled at 10 days of age; healthy infants without severe vitamin D deficiency at birth | 400 IU | 120 days | 46 |
| Long-term effects of giving nursing home residents bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving 2009 · Vitamin D- and calcium-fortified bun · Older nursing home residents; sex and age range not reported; vitamin D-deficient | 125 mcg | 1 year | 45 |
| The impact of vitamin D supplementation on VDR gene expression and body composition in monozygotic twins: randomized controlled trial 2020 · Supplemented group (SG) · Adults aged 18–45 years, women and men, without diagnosed chronic non-communicable diseases; members of monozygotic twin pairs | 2,000 IU | 60 days | 45 |
| The effect of vitamin D supplementation on glycemic status of elderly people with prediabetes: a 12-month open-label, randomized-controlled study 2022 · weekly vitamin D 3 dose of 25,000 IU · Greek adults aged 60 years or above with prediabetes | 3,571 IU | 1 year | 45 |
| Vitamin D status in full-term exclusively breastfed infants versus full-term breastfed infants receiving vitamin D supplementation in Thailand: a randomized controlled trial 2021 · Intervention group · Full-term exclusively breastfed infants aged 6–12 weeks at enrollment, without a stated health condition | 400 IU | 120 days | 43 |
| Effects of a single, high oral dose of 25-hydroxycholecalciferol on the mineral metabolism markers in hemodialysis patients 2015 · treated group · Adults with vitamin D deficiency receiving chronic hemodialysis | 3 mg | 1 day | 42 |
| Does high dose vitamin D supplementation enhance cognition?: A randomized trial in healthy adults 2017 · High Dose · Healthy adults from northern British Columbia with baseline 25(OH)D levels ≤100 nmol/L | 4,000 IU | 18 weeks | 42 |
| Vitamin D Stored in Fat Tissue During a 5-Year Intervention Affects Serum 25-Hydroxyvitamin D Levels the Following Year 2017 · vitamin D group · Adults who participated in a prevention study for type 2 diabetes; age and sex not reported | 2,857 IU | — | 42 |
| Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial 2020 · Vitamin D group · Adults aged 25–65 with overweight or obesity and type 2 diabetes; vitamin D deficient | 7,143 IU | 8 weeks | 42 |
| Prophylactic vitamin D in healthy infants: assessing the need 2011 · Vitamin D prophylaxis · Healthy full-term infants, assigned at 1 month of age | 402 IU | 1 year | 41 |
| Reduced-fat Gouda-type cheese enriched with vitamin D(3) effectively prevents vitamin D deficiency during winter months in postmenopausal women in Greece 2017 · intervention group · Postmenopausal women aged 55–75 years | 5.7 mcg | 8 weeks | 40 |
| Does high dose vitamin D supplementation enhance cognition?: A randomized trial in healthy adults 2017 · Low Dose · Healthy adults from northern British Columbia with baseline 25(OH)D levels ≤100 nmol/L | 400 IU | 18 weeks | 40 |
| Bioequivalence Studies of Vitamin D Gummies and Tablets in Healthy Adults: Results of a Cross-Over Study 2019 · gummy vitamin D3 · Healthy adults aged 18–45 years | 20,000 IU | 1 day | 40 |
| Bioequivalence Studies of Vitamin D Gummies and Tablets in Healthy Adults: Results of a Cross-Over Study 2019 · tablet vitamin D3 · Healthy adults aged 18–45 years | 20,000 IU | 1 day | 40 |
| Effect of Vitamin D-Enriched Gouda-Type Cheese Consumption on Biochemical Markers of Bone Metabolism in Postmenopausal Women in Greece 2021 · intervention group (IG) · Postmenopausal women aged 55–75 years in Greece, including women with sufficient or insufficient vitamin D status | 5.7 mcg | 8 weeks | 40 |
| Sunlight Exposure vs Oral Vitamin D Supplementation for Prevention of Vitamin D Deficiency in Infancy: A Randomized Controlled Trial 2022 · oral vitamin D3 supplementation · Breastfed infants aged 6–8 weeks at enrollment | 400 IU | — | 40 |
| Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial 2013 · 400 IU/d group · Healthy, term, breastfed infants enrolled at 1 month of age | 400 IU | 335 days | 39 |
| Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial 2013 · 800 IU/d group · Healthy, term, breastfed infants enrolled at 1 month of age | 800 IU | 335 days | 39 |
| Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial 2013 · 1200 IU/d group · Healthy, term, breastfed infants enrolled at 1 month of age | 1,200 IU | 335 days | 38 |
| 300,000 IU or 600,000 IU of oral vitamin D3 for treatment of nutritional rickets: a randomized controlled trial 2014 · Group 1 · Children under five with clinical and radiologically confirmed nutritional rickets; median age 12 months; sex not reported | 300,000 IU | 1 day | 38 |
| 300,000 IU or 600,000 IU of oral vitamin D3 for treatment of nutritional rickets: a randomized controlled trial 2014 · Group 2 · Children under five with clinical and radiologically confirmed nutritional rickets; median age 12 months; sex not reported | 600,000 IU | 1 day | 38 |
| The relationship between physical activity and vitamin D status in postpartum lactating and formula-feeding women 2018 · 2400 IU vitamin D3 per day · Healthy postpartum women who were lactating; age range not reported | 2,400 IU | 213 days | 38 |
| Colorectal cancer, Vitamin D and microbiota: A double-blind Phase II randomized trial (ColoViD) in colorectal cancer patients 2022 · Vitamin D supplementation · Adults aged 35–75 with resected stage I–III colorectal cancer after standard treatment; baseline 25(OH)D below 30 ng/ml | 2,000 IU | 1 year | 38 |
| Evaluation of the efficacy of two doses of vitamin D supplementation on glycemic, lipidemic and oxidative stress biomarkers during pregnancy: a randomized clinical trial 2020 · 1000 IU/d group · Pregnant women enrolled in the first trimester without stated clinical disease; many had vitamin D deficiency or insufficiency | 1,000 IU | 25 weeks | 37 |
| Efficacy of vitamin D supplementation among persons living with HIV/AIDS in São Paulo city, Brazil 2021 · Vitamin D (group 1; active group) · Adults with HIV-1 infection and vitamin D levels of 10–30 ng/mL; both sexes | 714 IU | 26 weeks | 37 |
| Daily Vitamin D3 Versus Stoss Vitamin D3 for Correction of 25OHD Deficiency in Children with Inflammatory Bowel Disease, a Randomised Controlled Trial 2025 · Daily vitamin D · Children aged 5–17 years with inflammatory bowel disease and vitamin D deficiency | 2,000 IU | 1 year | 37 |
| Nutritional vitamin D supplementation in dialysis: a randomized trial 2015 · 50,000 IU weekly · Adults receiving hemodialysis with 25(OH)D levels ≤32 ng/ml | 7,143 IU | 12 weeks | 36 |
| Vitamin D in newborns. A randomised controlled trial comparing daily and single oral bolus vitamin D in infants 2017 · daily dose · Newborn infants of vitamin D-deficient mothers | 400 IU | — | 36 |
| Evaluation of the efficacy of two doses of vitamin D supplementation on glycemic, lipidemic and oxidative stress biomarkers during pregnancy: a randomized clinical trial 2020 · 2000 IU/d group · Pregnant women enrolled in the first trimester without stated clinical disease; many had vitamin D deficiency or insufficiency | 2,000 IU | 25 weeks | 36 |
| Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial 2017 · D2 daily · Healthy adults aged 18–60 years with serum 25(OH)D of 20–50 nmol/L | 2,000 IU | 20 weeks | 35 |
| Controlled randomized open label clinical study comparing the safety and efficacy of loading schedules in vitamin D deficient patients 2023 · Slower Loading Dose (SLD) · Vitamin D-deficient patients; age and sex not specified | 4,286 IU | 14 weeks | 35 |
| Loading dose vitamin D3 improves vitamin D insufficiency in adults undergoing hematopoietic stem cell transplantation: A randomized controlled trial 2023 · Control group · Adults aged 18 or older undergoing allogeneic hematopoietic stem cell transplantation | 2,000 IU | 100 days | 35 |
| A Comparison of 3 Vitamin D Dosing Regimens in Extremely Preterm Infants: A Randomized Controlled Trial 2016 · 200 IU supplement · Extremely preterm infants born at 23–27 completed weeks’ gestation | 200 IU | 4 weeks | 34 |
| Vitamin D in newborns. A randomised controlled trial comparing daily and single oral bolus vitamin D in infants 2017 · single high-dose cholecalciferol · Newborn infants of vitamin D-deficient mothers | 50,000 IU | 1 day | 34 |
| Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial 2017 · D3 daily · Healthy adults aged 18–60 years with serum 25(OH)D of 20–50 nmol/L | 2,000 IU | 20 weeks | 34 |
| Controlled randomized open label clinical study comparing the safety and efficacy of loading schedules in vitamin D deficient patients 2023 · Moderate Loading Dose (MLD) · Vitamin D-deficient patients; age and sex not specified | 4,286 IU | 9 weeks | 34 |
| Vitamin D-vitamin K interaction: effect of vitamin D supplementation on serum percentage undercarboxylated osteocalcin, a sensitive measure of vitamin K status, in Danish girls 2010 · 10 μg vitamin D3 per d · Healthy Danish girls aged 11–12 years | 10 mcg | 1 year | 33 |
| Oral vitamin D3 5000 IU/day as an adjuvant in the treatment of atopic dermatitis: a randomized control trial 2018 · vitamin D3 group · Patients with atopic dermatitis diagnosed according to Hanifin-Rajka criteria; age and sex not specified | 5,000 IU | 90 days | 33 |
| Differences in vitamin D3 dosing regimens in a geriatric community-dwelling population 2012 · 400 IU vitamin D3 daily · Adults aged 65 years and older, with baseline 25(OH)D levels below or at/above 30 ng/mL | 400 IU | 26 weeks | 32 |
| Comparison of the pharmacokinetics, safety, and tolerability of vitamin D3 in DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet) and as monotherapy (24,000 iu) in healthy male Korean adults 2014 · DP-R206 test drug · Healthy adult male Korean volunteers, mean age 25.8 years | 24,000 IU | 1 day | 32 |
| Evaluation of vitamin D supplementation doses during pregnancy in a population at high risk for deficiency 2014 · group 3 · Pregnant women aged 16–42 years at high risk for vitamin D deficiency | 2,000 IU | — | 32 |
| Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens 2014 · Arm A · Children and adolescents aged 8–18 years with inflammatory bowel disease and baseline 25OHD greater than 20 ng/mL | 400 IU | 1 year | 32 |
| The effects of single high-dose or daily low-dosage oral colecalciferol treatment on vitamin D levels and muscle strength in postmenopausal women 2018 · daily dosage group · Postmenopausal women aged 50–68 with vitamin D levels below 20 ng/mL | 800 IU | 90 days | 32 |
| Evaluation of vitamin D supplementation doses during pregnancy in a population at high risk for deficiency 2014 · group 1 (control group) · Pregnant women aged 16–42 years at high risk for vitamin D deficiency | 600 IU | — | 31 |
| Evaluation of vitamin D supplementation doses during pregnancy in a population at high risk for deficiency 2014 · group 2 · Pregnant women aged 16–42 years at high risk for vitamin D deficiency | 1,200 IU | — | 31 |
| Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens 2014 · Arm B · Children and adolescents aged 8–18 years with inflammatory bowel disease and baseline 25OHD greater than 20 ng/mL | 1,000 IU | 1 year | 31 |
| Effects of vitamin D-fortified oil intake versus vitamin D supplementation on vitamin D status and bone turnover factors: A double blind randomized clinical trial 2022 · supplement · Healthy adults aged 18–30 years | 1,000 IU | 12 weeks | 31 |
| Pharmacokinetics of a single, large dose of cholecalciferol 2008 · cholecalciferol group · Healthy adults with limited sun exposure and milk consumption | 100,000 IU | 1 day | 30 |
| Comparative efficacy and safety of different doses of ergocalciferol supplementation in patients with metabolic syndrome 2014 · Group 2 · Patients with metabolic syndrome and vitamin D deficiency (serum 25(OH)D <20 ng/mL); age and sex not stated | 2,857 IU | 8 weeks | 30 |
| Comparative efficacy and safety of different doses of ergocalciferol supplementation in patients with metabolic syndrome 2014 · Group 3 · Patients with metabolic syndrome and vitamin D deficiency (serum 25(OH)D <20 ng/mL); age and sex not stated | 5,714 IU | 8 weeks | 30 |
| High-dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial 2015 · vitamin D3 supplementation · Children and young adults aged 5.0–24.9 years with perinatally acquired HIV or aged 15.0–24.9 years with behaviorally acquired HIV | 7,000 IU | 1 year | 30 |
| Vitamin D₃supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial 2015 · 4000 IU/d group · Children and adults aged 5.0–50.9 years with HIV receiving first-line antiretroviral therapy | 4,000 IU | 12 weeks | 30 |
| Vitamin D₃supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial 2015 · 7000 IU/d group · Children and adults aged 5.0–50.9 years with HIV receiving first-line antiretroviral therapy | 7,000 IU | 12 weeks | 30 |
| A Comparison of 3 Vitamin D Dosing Regimens in Extremely Preterm Infants: A Randomized Controlled Trial 2016 · 800 IU supplement · Extremely preterm infants born at 23–27 completed weeks’ gestation | 800 IU | 4 weeks | 30 |
| Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome 2017 · high-dose vitamin D + metformin · Women aged 18–40 with insulin-resistant PCOS | 4,000 IU | 12 weeks | 30 |
| Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome 2017 · low-dose vitamin D + metformin · Women aged 18–40 with insulin-resistant PCOS | 1,000 IU | 12 weeks | 30 |
| Determining the optimal cholecalciferol dosing regimen in children with CKD: a randomized controlled trial 2022 · Daily treatment group · Children with CKD stages 2–4 and 25OHD concentrations <30 ng/mL | 3,000 IU | 1 year | 30 |
| Investigating the Efficiency of Vitamin D Administration with Buccal Spray in the Treatment of Vitamin D Deficiency in Children and Adolescents 2021 · Group I (buccal spray) · Children and adolescents aged 3–18 years with vitamin D deficiency | 2,000 IU | 6 weeks | 30 |
| Investigating the Efficiency of Vitamin D Administration with Buccal Spray in the Treatment of Vitamin D Deficiency in Children and Adolescents 2021 · Group 2 (oral drops) · Children and adolescents aged 3–18 years with vitamin D deficiency | 2,000 IU | 6 weeks | 30 |
| The effect of vitamin D supplementation on tobacco-related disorders in individuals with a tobacco use disorder: a randomized clinical trial 2022 · vitamin D supplements · Adults who smoke cigarettes and have a tobacco use disorder; age and sex not reported | 3,570 IU | 24 weeks | 30 |
| Effects of vitamin D-fortified oil intake versus vitamin D supplementation on vitamin D status and bone turnover factors: A double blind randomized clinical trial 2022 · fortified oil · Healthy adults aged 18–30 years | 1,000 IU | 12 weeks | 30 |
| The short-term effect of high dose vitamin D3 supplementation in improving hypovitaminosis in patients with type 2 diabetes - A randomized clinical trial 2022 · vitamin D3 group · patients with type 2 diabetes and hypovitaminosis D3 | 7,143 IU | 8 weeks | 30 |
| Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects 2022 · Test formulation (T), fed trial · Healthy Chinese men and women aged 18 years or older | 0.75 mcg | 1 day | 30 |
| Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects 2022 · Reference formulation (R), fed trial · Healthy Chinese men and women aged 18 years or older | 0.75 mcg | 1 day | 30 |
| Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial Study 2022 · cholecalciferol group · Females aged 18–60 years with systemic lupus erythematosus | 5,000 IU | 12 weeks | 30 |
| Concurrent effects of high-intensity interval training and vitamin D supplementation on bone metabolism among women diagnosed with osteoporosis: a randomized controlled trial 2025 · vitamin D group (VD) · Women aged 30–50 with osteoporosis; premenopausal | 800 IU | 16 weeks | 30 |
| Concurrent effects of high-intensity interval training and vitamin D supplementation on bone metabolism among women diagnosed with osteoporosis: a randomized controlled trial 2025 · concurrent group (HIIT-VD) · Women aged 30–50 with osteoporosis; premenopausal | 800 IU | 16 weeks | 30 |
| Comparison of the pharmacokinetics, safety, and tolerability of vitamin D3 in DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet) and as monotherapy (24,000 iu) in healthy male Korean adults 2014 · Reference drug: vitamin D3 tablet · Healthy adult male Korean volunteers, mean age 25.8 years | 24,000 IU | 1 day | 29 |
| The impact of vitamin D3 supplementation on muscle function among HIV-infected children and young adults: a randomized controlled trial 2015 · Vitamin D supplementation · HIV-infected children and young adults aged 9.6–24.9 years, with perinatally or behaviorally acquired HIV | 7,000 IU | 1 year | 29 |
| Weekly regimen of vitamin D supplementation is more efficacious than stoss regimen for treatment of vitamin D deficiency in children with chronic liver diseases 2018 · weekly regimen · Children aged 1–18 years with chronic liver disease and hypovitaminosis D | 8,571 IU | 26 weeks | 28 |
| The effects of single high-dose or daily low-dosage oral colecalciferol treatment on vitamin D levels and muscle strength in postmenopausal women 2018 · single-dose group · Postmenopausal women aged 50–68 with vitamin D levels below 20 ng/mL | 300,000 IU | 90 days | 28 |
| Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial 2019 · Vitamin D3 · Women with breast cancer, mean age 47 years; participants were undergoing chemotherapy | 7,143 IU | 8 weeks | 28 |
| Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects 2022 · Test formulation (T), fasting trial · Healthy Chinese men and women aged 18 years or older | 0.75 mcg | 1 day | 28 |
| Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects 2022 · Reference formulation (R), fasting trial · Healthy Chinese men and women aged 18 years or older | 0.75 mcg | 1 day | 28 |
| Effects of vitamin D supplementation on metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial 2024 · vitamin D group · Women aged 21–34 years with PCOS and vitamin D deficiency or insufficiency | 2,000 IU | 12 weeks | 28 |
| Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial 2016 · 4000 IU/day vitamin D3 group · Adults older than 65 years who were clinically stable long-term nursing-home residents without sun exposure | 4,000 IU | 16 weeks | 27 |
| Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule 2019 · Group 1 (KIPOS) · Healthy adults aged 18–45 years, men and women; vitamin D deficient at baseline | 100,000 IU | 1 day | 27 |
| Seven-month wintertime supplementation of 1200 IU vitamin D has no effect on hand grip strength in young, physically active males: A randomized, controlled study 2022 · intervention group · Young male military conscripts aged 19–27 years; physically active, with no stated diagnosed condition | 1,200 IU | 30 weeks | 27 |
| The change in plasma 25-hydroxyvitamin D did not differ between breast-fed infants that received a daily supplement of ergocalciferol or cholecalciferol for 3 months 2013 · D2 group · Healthy, breast-fed term newborns, enrolled at about 1 month of age | 10 mcg | 90 days | 26 |
| The change in plasma 25-hydroxyvitamin D did not differ between breast-fed infants that received a daily supplement of ergocalciferol or cholecalciferol for 3 months 2013 · D3 group · Healthy, breast-fed term newborns, enrolled at about 1 month of age | 10 mcg | 90 days | 26 |
| Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule 2019 · Group 2 (UVEDOSE) · Healthy adults aged 18–45 years, men and women; vitamin D deficient at baseline | 100,000 IU | 1 day | 26 |
| No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes 2010 · open safety study · Adults aged 18–39 with recent-onset type 1 diabetes | 0.25 mcg | 39 weeks | 25 |
| A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness 2010 · experimental group · Black boys and girls, mean age 16.3 ± 1.4 years, normotensive, with vitamin D insufficiency/deficiency commonly observed in this population | 2,000 IU | 16 weeks | 25 |
| Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis 2012 · cholecalciferol · Adults receiving hemodialysis for stage 5D chronic kidney disease; most had vitamin D insufficiency or deficiency | 28,571 IU | 3 weeks | 25 |
| Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D 2012 · Cholecalciferol group · Haemodialysis and non-haemodialysis patients with chronic kidney disease and 25-OHD <50 nmol/L at screening | 5,714 IU | 8 weeks | 25 |
| The effects of vitamin D supplementation on lipid profiles and oxidative indices among diabetic nephropathy patients with marginal vitamin D status 2019 · Intervention group · Patients with diabetic nephropathy and marginal serum vitamin D status | 7,143 IU | 8 weeks | 25 |
| The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status 2019 · low dose group · Adults over 18 with vitamin D deficiency and active mild to moderate ulcerative colitis | 1,000 IU | 12 weeks | 25 |
| Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study 2020 · Group B · Healthy vitamin D-deficient Caucasian men and women aged 18–60 years | 7,143 IU | 12 weeks | 25 |
| Pharmacodynamics of Oral Cholecalciferol in Healthy Individuals with Vitamin D Deficiency: A Randomized Open-Label Study 2021 · Group B · Caucasian healthy males and females aged 18–60 years with 25OHD below 20 ng/mL | 7,143 IU | 12 weeks | 25 |
| Assessment of the effect of routine-dose vitamin D3 supplementation in Chinese women of childbearing age with vitamin D insufficiency 2025 · 800 IU/day vitamin D3 group · Women aged 18–50 with vitamin D insufficiency (serum total 25(OH)D <20 ng/mL) | 800 IU | 26 weeks | 25 |
| A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness 2010 · control group · Black boys and girls, mean age 16.3 ± 1.4 years, normotensive, with vitamin D insufficiency/deficiency commonly observed in this population | 400 IU | 16 weeks | 24 |
| Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency 2013 · vitamin D · Women aged 20–40 with polycystic ovary syndrome and vitamin D deficiency | 2,500 IU | 60 days | 24 |
| Placental vitamin D metabolism and its associations with circulating vitamin D metabolites in pregnant women 2017 · single vitamin D intake · Healthy pregnant women at 26–29 weeks of gestation | 511 IU | 10 weeks | 24 |
| The interaction of vitamin D supplementation with Omentin-1 gene polymorphism on metabolic biomarkers, omentin-1 levels and anthropometric measures in women with prediabetes: A double-blind randomized controlled trial 2025 · Vitamin D intervention, AT genotype · Women aged 18–65 with prediabetes and the Omentin-1 AT genotype | 3,571 IU | 12 weeks | 24 |
| The interaction of vitamin D supplementation with Omentin-1 gene polymorphism on metabolic biomarkers, omentin-1 levels and anthropometric measures in women with prediabetes: A double-blind randomized controlled trial 2025 · Vitamin D intervention, TT genotype · Women aged 18–65 with prediabetes and the Omentin-1 TT genotype | 3,571 IU | 12 weeks | 24 |
| Vitamin D intervention by pharmacists in geriatric outpatients 2008 · educational intervention · Geriatric outpatients aged 65 to 89 years with insufficient vitamin D (12–31 ng/mL) | 1,200 IU | 12 weeks | 23 |
| Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial 2024 · vitamin D group · Adults aged 20–60 with MASLD and NASH | 4,000 IU | 12 weeks | 23 |
| The Effect of High Dose Cholecalciferol on Arterial Stiffness and Peripheral and Central Blood Pressure in Healthy Humans: A Randomized Controlled Trial 2016 · Cholecalciferol group · Healthy adults older than 18 years with serum 25-OH vitamin D ≤50 nmol/L | 3,000 IU | 16 weeks | 22 |
| Response to vitamin D replacement therapy in obese children and adolescents with vitamin D deficiency: a randomized controlled trial 2023 · Group 1 · Children and adolescents aged 12–18 years with obesity and vitamin D deficiency | 6,000 IU | 12 weeks | 22 |
| Effects of vitamin D supplementation on metabolic parameters, serum irisin and obesity values in women with subclinical hypothyroidism: a double-blind randomized controlled trial 2023 · vitamin D supplement group · Women aged 20–65 with subclinical hypothyroidism (TSH 5–10 µIU/mL), normal fT4, and BMI 25–37 kg/m² | 7,143 IU | 12 weeks | 22 |
| A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation 2011 · Placebo bolus · Men and women over age 50 with an acute fragility hip fracture | 1,000 IU | 90 days | 21 |
| Effects of vitamin D3 and calcium supplementation on serum levels of tocopherols, retinol, and specific vitamin D metabolites 2012 · vitamin D3 · Adults aged 30–75 in general health with a history of at least one pathology-confirmed adenomatous colorectal polyp within the previous 36 months | 800 IU | 26 weeks | 21 |
| The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis 2013 · low-dose group · Patients with multiple sclerosis treated with IFN-β; age and sex not specified | 800 IU | 1 year | 21 |
| Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial 2024 · Cohort F (part 2, standard of care) · Children aged 6 to under 18 with physician-diagnosed asthma, BMI at or above the 85th percentile, and screening serum 25(OH)D of 10–30 ng/mL | 600 IU | 16 weeks | 21 |
| Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults 2024 · vitamin D group · Healthy adults aged 18–53 years, with no underlying health conditions | 4,000 IU | 12 weeks | 21 |
| The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults 2008 · fortified cheddar cheese (DC) · Adults; age range, sex, and health condition not specified | 4,000 IU | 8 weeks | 20 |
| The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults 2008 · liquid vitamin D supplement taken with food (DS+) · Adults; age range, sex, and health condition not specified | 4,000 IU | 8 weeks | 20 |
| Maternal vitamin D supplementation to improve the vitamin D status of breast-fed infants: a randomized controlled trial 2013 · single dose group · Healthy lactating women aged 18 years or older, exclusively breastfeeding a healthy infant aged 1–6 months | 150,000 IU | 4 weeks | 20 |
| Maternal vitamin D supplementation to improve the vitamin D status of breast-fed infants: a randomized controlled trial 2013 · daily dose group · Healthy lactating women aged 18 years or older, exclusively breastfeeding a healthy infant aged 1–6 months | 5,000 IU | 4 weeks | 20 |
| Pharmacokinetics of daily versus monthly vitamin D3 supplementation in non-lactating women 2014 · 150,000 IU group · Healthy non-pregnant, non-lactating women aged 18–40 years | 150,000 IU | 4 weeks | 20 |
| The efficacy of vitamin D supplementation during a prolonged submarine patrol 2014 · 1,000 IU/day · Submariners on a prolonged submarine patrol; adult age and sex not specified | 1,000 IU | 90 days | 20 |
| Late-onset hypogonadism: beyond testosterone 2015 · cholecalciferol · Men aged 34.5 ± 6.8 years with classic or subclinical hypogonadism and low 25-hydroxyvitamin D; infertility evaluation patients | 714 IU | 90 days | 20 |
| Effect of vitamin D3 supplementation and influence of BsmI polymorphism of the VDR gene of the inflammatory profile and oxidative stress in elderly women with vitamin D insufficiency: Vitamin D3 megadose reduces inflammatory markers 2015 · supplementation group (SG) · Elderly women aged 68±6 years with vitamin D insufficiency | 200,000 IU | 4 weeks | 20 |
| Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial 2016 · juvenile-onset SLE-VitD · juvenile-onset systemic lupus erythematosus patients; ages and sex not stated | 7,143 IU | 24 weeks | 20 |
| Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial 2016 · 800 IU/day vitamin D3 group · Adults older than 65 years who were clinically stable long-term nursing-home residents without sun exposure | 800 IU | 16 weeks | 20 |
| Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial 2016 · 2000 IU/day vitamin D3 group · Adults older than 65 years who were clinically stable long-term nursing-home residents without sun exposure | 2,000 IU | 16 weeks | 20 |
| Comparison of the effect of daily versus bolus dose maternal vitamin D(3) supplementation on the 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) ratio 2018 · daily-dose group · Lactating females aged 24–40 years with a singleton infant aged 1–6 months | 5,000 IU | 4 weeks | 20 |
| Vitamin D Daily versus Monthly Administration: Bone Turnover and Adipose Tissue Influences 2018 · daily dose group · Men and women aged 77 ± 8 years with hypovitaminosis D (serum 25(OH) vitamin D3 between 10 and 30 ng/mL) | 1,750 IU | 26 weeks | 20 |
| Comparison of two vitamin D supplementation strategies in children with sickle cell disease: a randomized controlled trial 2021 · Placebo bolus group (daily vitamin D3 prescription) · Children aged 5–17 years with sickle cell disease, all genotypes; the study notes many children with SCD were vitamin D-deficient | 1,000 IU | 90 days | 20 |
| Effect of Daily Vitamin D Supplementation on Serum Vitamin D Levels in Children with Epilepsy Receiving Sodium Valproate Monotherapy: A Randomized, Controlled Trial 2023 · intervention group · Children aged 2–12 years with newly diagnosed epilepsy, vitamin D-sufficient status, receiving sodium valproate monotherapy | 600 IU | 90 days | 20 |
| Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma 2023 · Cohort F · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL | 600 IU | 16 weeks | 20 |
| Vitamin D supplementation during Antarctic winter 2009 · 1000 IU/d group · Adults with limited ultraviolet B exposure wintering at McMurdo Station in Antarctica | 1,000 IU | 150 days | 19 |
| The effects of season-long vitamin D supplementation on collegiate swimmers and divers 2013 · VIT D · Men and women collegiate NCAA Division I swimmers and divers, generally healthy and aged 18 or older | 4,000 IU | 26 weeks | 19 |
| The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis 2013 · high-dose group · Patients with multiple sclerosis treated with IFN-β; age and sex not specified | 4,370 IU | 1 year | 19 |
| Pharmacokinetics of daily versus monthly vitamin D3 supplementation in non-lactating women 2014 · daily group · Healthy non-pregnant, non-lactating women aged 18–40 years | 5,000 IU | 4 weeks | 19 |
| The Effect of Vitamin D Supplementation on Metabolic Phenotypes in Thais with Prediabetes 2015 · vitamin D₂ · Thai adults with impaired fasting glucose and/or impaired glucose tolerance | 2,857 IU | 90 days | 19 |
| A single mega dose of vitamin D(3) improves selected physical variables in vitamin D-deficient young amateur soccer players: a randomized controlled trial 2020 · single dose · Vitamin D-deficient, mildly trained recreational soccer-playing boys; age not stated | 200,000 IU | 12 weeks | 19 |
| Improving Vitamin D Status in Preterm Newborns: A Randomized Trial of 800 vs. 400 IU/Day 2025 · 400 IU/day group · Preterm newborns with gestational age ≤32 weeks or birth weight ≤1500 g | 400 IU | 6 weeks | 19 |
| Improving Vitamin D Status in Preterm Newborns: A Randomized Trial of 800 vs. 400 IU/Day 2025 · 800 IU/day group · Preterm newborns with gestational age ≤32 weeks or birth weight ≤1500 g | 800 IU | 6 weeks | 19 |
| Vitamin D supplementation during Antarctic winter 2009 · 2000 IU/d group · Adults with limited ultraviolet B exposure wintering at McMurdo Station in Antarctica | 2,000 IU | 150 days | 18 |
| Vitamin D supplementation during Antarctic winter 2009 · 400 IU/d group · Adults with limited ultraviolet B exposure wintering at McMurdo Station in Antarctica | 400 IU | 150 days | 18 |
| Effects of Vitamin D Supplementation on Serum 25-Hydroxyvitamin D Concentrations in Cirrhotic Patients: A Randomized Controlled Trial 2016 · Vitamin D group · Adults aged 18–75 with compensated cirrhosis and serum 25(OH)D below 30 ng/mL | 2,800 IU | 8 weeks | 18 |
| Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn's Disease in Remission: A Pilot Randomized Double-Blind Controlled Study 2017 · High-dose vitamin D3 · Patients with Crohn's disease in remission; age and sex not stated | 10,000 IU | 1 year | 18 |
| Effects of Vitamin D Supplementation on Haematological Values and Muscle Recovery in Elite Male Traditional Rowers 2018 · Group treated with 3000 IU/day of vitamin D3 (VD3G) · Elite male rowers, mean age 27 ± 6 years, without disease | 3,000 IU | 8 weeks | 18 |
| Four weeks of vitamin D supplementation improves nitric oxide-mediated microvascular function in college-aged African Americans 2020 · vitamin D supplementation · Healthy college-aged adults, 21 ± 2 years; African American and European American men and women | 2,000 IU | 4 weeks | 18 |
| Changes of 25(OH)D Concentration, Bone Resorption Markers and Physical Performance as an Effect of Sun Exposure, Supplementation of Vitamin D and Lockdown among Young Soccer Players during a One-Year Training Season 2022 · supplemented group (GS) · Male young elite soccer players, mean age 17.2 years, competing in the Polish Central Junior League | 5,000 IU | 8 weeks | 18 |
| Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study 2008 · cholecalciferol treatment group · Adults aged 18–85 with stage 3 or 4 chronic kidney disease, serum 25(OH)D concentrations of 30 ng/mL or less, and PTH levels greater than 70 pg/mL | 7,143 IU | 12 weeks | 17 |
| The response of elderly veterans to daily vitamin D3 supplementation of 2,000 IU: a pilot efficacy study 2011 · cholecalciferol group · Veterans aged 70 and older | 2,000 IU | 26 weeks | 17 |
| The efficacy of vitamin D supplementation during a prolonged submarine patrol 2014 · 2,000 IU/day · Submariners on a prolonged submarine patrol; adult age and sex not specified | 2,000 IU | 90 days | 17 |
| Supplemental vitamin D increases serum cytokines in those with initially low 25-hydroxyvitamin D: a randomized, double blind, placebo-controlled study 2015 · 8000 IU vitamin D group · Healthy adults, mean age 32 years; both sexes, with varying baseline vitamin D status | 8,000 IU | 5 weeks | 17 |
| Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2 1998 · vitamin D2 · Subjects; age, sex, and health condition not stated | 4,000 IU | 2 weeks | 17 |
| Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study 2013 · cholecalciferol · Haemodialysis patients with end-stage renal disease and low baseline serum 25(OH)D | 1,785 IU | 1 year | 16 |
| Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial 2013 · 1600 IU/d group · Healthy, term, breastfed infants enrolled at 1 month of age | 1,600 IU | — | 16 |
| Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn's Disease in Remission: A Pilot Randomized Double-Blind Controlled Study 2017 · Low-dose vitamin D3 · Patients with Crohn's disease in remission; age and sex not stated | 1,000 IU | 1 year | 16 |
| Randomized trial of two doses of vitamin D3 in preterm infants <32 weeks: Dose impact on achieving desired serum 25(OH)D3 in a NICU population 2017 · 400 IU group · Preterm infants born at less than 32 weeks’ gestational age | 400 IU | 8 weeks | 16 |
| Randomized trial of two doses of vitamin D3 in preterm infants <32 weeks: Dose impact on achieving desired serum 25(OH)D3 in a NICU population 2017 · 800 IU group · Preterm infants born at less than 32 weeks’ gestational age | 800 IU | 8 weeks | 16 |
| A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption 2021 · vitamin D3 · Healthy adults with differing BMI and adults with intestinal malabsorption | 900 mcg | 1 day | 16 |
| A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption 2021 · 25(OH)D3 · Healthy adults with differing BMI and adults with intestinal malabsorption | 900 mcg | 1 day | 16 |
| Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers 2022 · Test_fast (vitamin D3 ODF under fasting conditions) · Healthy male and female volunteers aged 40–70 years | 25,000 IU | 1 day | 16 |
| Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers 2022 · Test_fed (vitamin D3 ODF under fed conditions) · Healthy male and female volunteers aged 40–70 years | 25,000 IU | 1 day | 16 |
| Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers 2022 · Reference_fed (vitamin D3 oral solution under fed conditions) · Healthy male and female volunteers aged 40–70 years | 25,000 IU | 1 day | 16 |
| Direct Effects of Vitamin D Supplementation on Ultramarathon-Induced Changes in Kynurenine Metabolism 2022 · experimental (supplementation, S) · Adult male amateur ultramarathon runners with no reported known disease; mean age 42.40 ± 7.59 years | 150,000 IU | 1 day | 16 |
| Effect of oral cholecalciferol 2,000 versus 5,000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency 2013 · 2,000-IU group · Vitamin D-deficient patients with serum 25OHD ≤ 50 nmol/L | 2,000 IU | 90 days | 15 |
| Effect of oral cholecalciferol 2,000 versus 5,000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency 2013 · 5,000-IU group · Vitamin D-deficient patients with serum 25OHD ≤ 50 nmol/L | 5,000 IU | 90 days | 15 |
| Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial 2024 · Cohort D (part 1, standard of care) · Children aged 6 to under 18 with physician-diagnosed asthma, BMI at or above the 85th percentile, and screening serum 25(OH)D of 10–30 ng/mL | 600 IU | 16 weeks | 15 |
| Assessment of the effect of routine-dose vitamin D3 supplementation in Chinese women of childbearing age with vitamin D insufficiency 2025 · 400 IU/day vitamin D3 group · Women aged 18–50 with vitamin D insufficiency (serum total 25(OH)D <20 ng/mL) | 400 IU | 26 weeks | 15 |
| Fortification of orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health 2003 · Vitamin D-fortified orange juice · Adults; age range and sex not reported | 1,000 IU | 12 weeks | 14 |
| Pharmacokinetics of high-dose weekly oral vitamin D3 supplementation during the third trimester of pregnancy in Dhaka, Bangladesh 2013 · PL (pregnant, lower dose) · Pregnant women aged 18 to under 35 years, enrolled at 27 to under 31 weeks of gestation in Bangladesh | 2,000 IU | — | 14 |
| Vitamin D deficiency, serum leptin and osteoprotegerin levels in older diabetic patients: an input to new research avenues 2014 · Vitamin D3 · Patients aged 60 years or older with type 2 diabetes mellitus and diabetic foot complications | 300,000 IU | 1 day | 14 |
| Supplemental vitamin D increases serum cytokines in those with initially low 25-hydroxyvitamin D: a randomized, double blind, placebo-controlled study 2015 · 4000 IU vitamin D group · Healthy adults, mean age 32 years; both sexes, with varying baseline vitamin D status | 4,000 IU | 5 weeks | 14 |
| Vitamin D supplementation in nursing home patients: randomized controlled trial of standard daily dose versus individualized loading dose regimen 2015 · Daily dose regimen (DD) · Nursing home patients with severe 25-hydroxyvitamin D deficiency | 800 IU | 26 weeks | 14 |
| Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial 2016 · 50,000 IU/week vitamin D3 group · Adults older than 65 years who were clinically stable long-term nursing-home residents without sun exposure | 7,143 IU | 16 weeks | 14 |
| Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women 2006 · 125 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years | 125 mcg | 90 days | 13 |
| The effect of high-dose vitamin D supplementation on serum vitamin D levels and milk calcium concentration in lactating women and their infants 2006 · 4000 IU/day vitamin D group · Fully breastfeeding mothers, randomized at 1 month postpartum; age not reported | 4,000 IU | 90 days | 13 |
| [Is daily supplementation with vitamin D2 equivalent to daily supplementation with vitamin D3 in the elderly?] 2012 · GD2 · Ambulatory postmenopausal women, mean age 77.1 years; most had deficient baseline 25OHD levels | 800 IU | 45 days | 13 |
| Impact of Vitamin D Replacement on Markers of Glucose Metabolism and Cardio-Metabolic Risk in Women with Former Gestational Diabetes--A Double-Blind, Randomized Controlled Trial 2015 · vitamin D group · Malaysian women with former gestational diabetes, 6–48 months postpartum, and plasma 25(OH)D of 15–50 nmol/L without overt diabetes | 4,000 IU | 26 weeks | 13 |
| A randomized two way cross over study for comparison of absorption of vitamin D3 buccal spray and soft gelatin capsule formulation in healthy subjects and in patients with intestinal malabsorption 2015 · Healthy subjects—soft gelatin capsule formulation · Adults aged 18–65, healthy subjects, either sex | 1,000 IU | 30 days | 13 |
| A randomized two way cross over study for comparison of absorption of vitamin D3 buccal spray and soft gelatin capsule formulation in healthy subjects and in patients with intestinal malabsorption 2015 · Patients with malabsorption syndrome—soft gelatin capsule formulation · Adults aged 18–65 with ulcerative colitis, Crohn’s disease, or steatorrhea, either sex | 1,000 IU | 30 days | 13 |
| Vitamin D Repletion in Kidney Stone Formers: A Randomized Controlled Trial 2017 · 50,000 IU weekly · Patients with a history of calcium stones and vitamin D deficiency (less than 30 ng/ml) | 7,143 IU | 6 weeks | 13 |
| High-dose vitamin D in Addison's disease regulates T-cells and monocytes: A pilot trial 2018 · cholecalciferol treatment · Patients with Addison's disease; age and sex not specified | 4,000 IU | 90 days | 13 |
| The influence of vitamin D supplementation on local and systemic inflammatory markers in periodontitis patients: A pilot study 2019 · vitamin D group · Dark-skinned adults aged 18 years or older with generalized chronic moderate-to-severe periodontitis; participants were not initially vitamin D deficient | 4,000 IU | 16 weeks | 13 |
| Disassociation of Vitamin D's Calcemic Activity and Non-calcemic Genomic Activity and Individual Responsiveness: A Randomized Controlled Double-Blind Clinical Trial 2019 · 4000 IU/d · Healthy young adult Black and White adults with BMI <30 and serum 25(OH)D below 30 ng/mL; men and non-pregnant women | 4,000 IU | 24 weeks | 13 |
| Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women 2006 · 250 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years | 250 mcg | 90 days | 12 |
| The effect of high-dose vitamin D supplementation on serum vitamin D levels and milk calcium concentration in lactating women and their infants 2006 · 2000 IU/day vitamin D group · Fully breastfeeding mothers, randomized at 1 month postpartum; age not reported | 2,000 IU | 90 days | 12 |
| Short-Term Vitamin D3 Supplementation in Children with Neurodisabilities: Comparison of Two Delivery Methods 2017 · Vitamin D3 buccal spray · Children aged 5–17 years with neurodisabilities and vitamin D deficiency (25(OH)D ≤20 ng/mL) | 800 IU | 90 days | 12 |
| Short-Term Vitamin D3 Supplementation in Children with Neurodisabilities: Comparison of Two Delivery Methods 2017 · Vitamin D3 oral drops · Children aged 5–17 years with neurodisabilities and vitamin D deficiency (25(OH)D ≤20 ng/mL) | 750 IU | 90 days | 12 |
| Vitamin D Vitamers Affect Vitamin D Status Differently in Young Healthy Males 2017 · vitD3 treatment · Healthy men aged 20–30 years | 10 mcg | 6 weeks | 12 |
| Vitamin D Vitamers Affect Vitamin D Status Differently in Young Healthy Males 2017 · vitD2 treatment · Healthy men aged 20–30 years | 10 mcg | 6 weeks | 12 |
| Vitamin D Vitamers Affect Vitamin D Status Differently in Young Healthy Males 2017 · 25OH-D3 treatment · Healthy men aged 20–30 years | 10 mcg | 6 weeks | 12 |
| Plasma 25-hydroxyvitamin D responses of younger and older men to three weeks of supplementation with 1800 IU/day of vitamin D 1999 · Vitamin D2 supplementation group · Men aged 22–73 years with self-reported vitamin D intakes below 200 IU/day | 1,800 IU | 3 weeks | 11 |
| Influence of a single oral dose of vitamin D(2) on serum 25-hydroxyvitamin D concentrations in tuberculosis patients 2009 · vitamin D(2) group · Tuberculosis patients with hypovitaminosis D; age and sex not reported | 2.5 mg | 1 day | 11 |
| Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma 2023 · Cohort D · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL | 600 IU | 16 weeks | 11 |
| The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults 2008 · fortified low-fat cheese (DLF) · Adults; age range, sex, and health condition not specified | 4,000 IU | 8 weeks | 10 |
| The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults 2008 · liquid vitamin D supplement taken without food (DS-) · Adults; age range, sex, and health condition not specified | 4,000 IU | 8 weeks | 10 |
| Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial 2015 · 200,000 IU cholecalciferol group · Adults aged 18 years or older with severe sepsis or septic shock | 200,000 IU | 1 day | 10 |
| Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial 2015 · 400,000 IU cholecalciferol group · Adults aged 18 years or older with severe sepsis or septic shock | 400,000 IU | 1 day | 10 |
| The Effect of Vitamin D Supplementation on Metabolic Phenotypes in Thais with Prediabetes 2015 · vitamin D₃ · Thai adults with impaired fasting glucose and/or impaired glucose tolerance | 2,143 IU | 90 days | 10 |
| Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma 2023 · Cohort C · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL | 6,000 IU | 16 weeks | 10 |
| Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial 2024 · Cohort C (part 1) · Children aged 6 to under 18 with physician-diagnosed asthma, BMI at or above the 85th percentile, and screening serum 25(OH)D of 10–30 ng/mL | 6,000 IU | 16 weeks | 10 |
| Prospective, Randomized, Double-Blind, Parallel-Group, Comparative Effectiveness Clinical Trial Comparing a Powder Vehicle Compound of Vitamin D With an Oil Vehicle Compound in Adults With Cystic Fibrosis 2017 · Oil group · Adults aged 18 or older with cystic fibrosis admitted to hospital for a pulmonary exacerbation | 100,000 IU | 1 day | 9 |
| Cholecalciferol Injections Are Effective in Hypovitaminosis D After Duodenal Switch: a Randomized Controlled Study 2018 · Control group · Adults with hypovitaminosis D after biliopancreatic diversion with duodenal switch (BPD/DS), despite oral vitamin D supplementation; age range not stated | 1,400 IU | 26 weeks | 9 |
| Disassociation of Vitamin D's Calcemic Activity and Non-calcemic Genomic Activity and Individual Responsiveness: A Randomized Controlled Double-Blind Clinical Trial 2019 · 600 IU/d · Healthy young adult Black and White adults with BMI <30 and serum 25(OH)D below 30 ng/mL; men and non-pregnant women | 600 IU | 24 weeks | 9 |
| Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly 2005 · Vitamin D2-fortified cheese feeding · Younger adults aged 23 to 50 years and older adults aged 72 to 84 years | 5,880 IU | 1 day | 8 |
| Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly 2005 · Vitamin D2-fortified water feeding · Younger adults aged 23 to 50 years and older adults aged 72 to 84 years | 32,750 IU | 1 day | 8 |
| Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly 2008 · Ergocalciferol oral · Women aged 66–97 years with vitamin D deficiency | 300,000 IU | 1 day | 8 |
| Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly 2008 · Cholecalciferol oral · Women aged 66–97 years with vitamin D deficiency | 300,000 IU | 1 day | 8 |
| [Is daily supplementation with vitamin D2 equivalent to daily supplementation with vitamin D3 in the elderly?] 2012 · GD3 · Ambulatory postmenopausal women, mean age 77.1 years; most had deficient baseline 25OHD levels | 800 IU | 45 days | 8 |
| Vitamin D Repletion in Kidney Stone Formers: A Randomized Controlled Trial 2017 · 1,000 IU daily · Patients with a history of calcium stones and vitamin D deficiency (less than 30 ng/ml) | 1,000 IU | 6 weeks | 8 |
| Disassociation of Vitamin D's Calcemic Activity and Non-calcemic Genomic Activity and Individual Responsiveness: A Randomized Controlled Double-Blind Clinical Trial 2019 · 10,000 IU/d · Healthy young adult Black and White adults with BMI <30 and serum 25(OH)D below 30 ng/mL; men and non-pregnant women | 10,000 IU | 24 weeks | 8 |
| Effect of 12-Week BMI-Based Vitamin D(3) Supplementation in Parkinson's Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites 2023 · Vitamin D group, BMI 25 to 30 · Adults with Parkinson’s disease treated with deep brain stimulation, BMI between 25 and 30 | 5,000 IU | 12 weeks | 8 |
| Exploration of smart adherence-monitoring methods in vitamin D-deficient patients: A pilot feasibility clinical study 2023 · App − only · Adults aged 19–64 years with serum 25(OH) vitamin D below 20 ng/mL; predominantly female | 1,000 IU | 12 weeks | 8 |
| Exploration of smart adherence-monitoring methods in vitamin D-deficient patients: A pilot feasibility clinical study 2023 · App + Watch · Adults aged 19–64 years with serum 25(OH) vitamin D below 20 ng/mL; predominantly female | 1,000 IU | 12 weeks | 8 |
| Impact of dietary and lifestyle on vitamin D in healthy student girls aged 11-15 years 2006 · vitamin D supplementation group · Girls aged 11–15 years with hypovitaminosis D | 50,000 IU | 20 days | 7 |
| Prospective, Randomized, Double-Blind, Parallel-Group, Comparative Effectiveness Clinical Trial Comparing a Powder Vehicle Compound of Vitamin D With an Oil Vehicle Compound in Adults With Cystic Fibrosis 2017 · Powder group · Adults aged 18 or older with cystic fibrosis admitted to hospital for a pulmonary exacerbation | 100,000 IU | 1 day | 6 |
| Pharmacokinetics of oral vitamin D(3) and calcifediol 2014 · single bolus calcifediol plus vitamin D(3) group · healthy females aged 50–70 years | 280 mcg | 1 day | 5 |
| Effect of 12-Week BMI-Based Vitamin D(3) Supplementation in Parkinson's Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites 2023 · Vitamin D group, BMI under 25 · Adults with Parkinson’s disease treated with deep brain stimulation, BMI under 25 | 4,000 IU | 12 weeks | 3 |
| Effect of 12-Week BMI-Based Vitamin D(3) Supplementation in Parkinson's Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites 2023 · Vitamin D group, BMI over 30 · Adults with Parkinson’s disease treated with deep brain stimulation, BMI over 30 | 6,000 IU | 12 weeks | 2 |
| Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin 2000 · vitamin D(3) · Postmenopausal women about 60 years old with normal or low bone mineral density | 350 IU | 1 year | — |
| Serum levels of 1,25-(OH)2-vitamin D are not altered by long-term supplementation with alphacalcidol (1-OH-vitamin D3). A double-blind, placebo-controlled study 1992 · alphacalcidol · non-vitamin D deficient subjects | 1 mcg | 120 days | — |
| Lack of effect of calcium intake on the 25-hydroxyvitamin d response to oral vitamin D3 2005 · Control group · Healthy older men and women | 800 IU | 90 days | — |
| Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly 2005 · Vitamin D3-fortified cheese group · Men and women aged 60 years or older | 600 IU | 60 days | — |
| Bread fortified with cholecalciferol increases the serum 25-hydroxyvitamin D concentration in women as effectively as a cholecalciferol supplement 2006 · fortified wheat bread · Healthy women aged 25–45 years with low baseline serum 25-hydroxyvitamin D concentrations | 10 mcg | 3 weeks | — |
| Bread fortified with cholecalciferol increases the serum 25-hydroxyvitamin D concentration in women as effectively as a cholecalciferol supplement 2006 · fortified rye bread · Healthy women aged 25–45 years with low baseline serum 25-hydroxyvitamin D concentrations | 10 mcg | 3 weeks | — |
| Bread fortified with cholecalciferol increases the serum 25-hydroxyvitamin D concentration in women as effectively as a cholecalciferol supplement 2006 · regular wheat bread and cholecalciferol supplement (vitamin D control) · Healthy women aged 25–45 years with low baseline serum 25-hydroxyvitamin D concentrations | 10 mcg | 3 weeks | — |
| How much vitamin D3 do the elderly need? 2006 · 5 microg vitamin D3 group · Women aged 65–85 years | 5 mcg | 12 weeks | — |
| How much vitamin D3 do the elderly need? 2006 · 10 microg vitamin D3 group · Women aged 65–85 years | 10 mcg | 12 weeks | — |
| Efficacy of daily and monthly high-dose calciferol in vitamin D-deficient nulliparous and lactating women 2007 · 2000 IU vitamin D2/d · Healthy vitamin D-deficient lactating and nulliparous women residing in the United Arab Emirates | 2,000 IU | 90 days | — |
| Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D 2008 · 1000 IU vitamin D3 · Healthy adults aged 18–84 years; 60% of the study population were vitamin D deficient at baseline | 1,000 IU | 11 weeks | — |
| Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D 2008 · 1000 IU vitamin D2 · Healthy adults aged 18–84 years; 60% of the study population were vitamin D deficient at baseline | 1,000 IU | 11 weeks | — |
| Effect of free vitamin D(2) drops on serum 25-hydroxyvitamin D in infants with immigrant origin: a cluster randomized controlled trial 2009 · intervention group · Healthy 6-week-old infants with Pakistani, Turkish or Somali background | 10 mcg | 7 weeks | — |
| Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children 2008 · short-term vitamin D3 group · Apparently healthy schoolchildren; age range and sex not reported | 2,000 IU | 8 weeks | — |
| Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children 2008 · long-term vitamin D3 group, 1,400 IU/wk · Apparently healthy schoolchildren; age range and sex not reported | 200 IU | 1 year | — |
| Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children 2008 · long-term vitamin D3 group, 14,000 IU/wk · Apparently healthy schoolchildren; age range and sex not reported | 2,000 IU | 1 year | — |
| Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients 2008 · daily group · Women, mean age 81 ± 8 years, who had undergone surgery to repair a hip fracture | 1,500 IU | 60 days | — |
| High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients 2008 · treated group (maintenance phase) · Haemodialysis patients who had received cholecalciferol during the replenishment phase | 2,857 IU | 65 weeks | — |
| Vitamin D deficiency and supplementation during pregnancy 2009 · single oral dose · Pregnant women from Indian Asian, Middle Eastern, Black and Caucasian backgrounds, recruited at 27 weeks’ gestation | 200,000 IU | 1 day | — |
| Vitamin D deficiency and supplementation during pregnancy 2009 · daily supplement · Pregnant women from Indian Asian, Middle Eastern, Black and Caucasian backgrounds, recruited at 27 weeks’ gestation | 800 IU | — | — |
| Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial 2009 · 800-IU group · Patients undergoing Roux-en-Y gastric bypass; age and sex not reported | 800 IU | 2 years | — |
| Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial 2009 · 2,000-IU group · Patients undergoing Roux-en-Y gastric bypass; age and sex not reported | 2,000 IU | 2 years | — |
| Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial 2009 · 5,000-IU group · Patients undergoing Roux-en-Y gastric bypass; age and sex not reported | 5,000 IU | 2 years | — |
| Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease 2008 · 5,000 IU/week cholecalciferol group · Adults with chronic kidney disease stages 2–4; mean age 66 years; 33 men and 54 women across the trial | 714 IU | 1 year | — |
| Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease 2008 · 20,000 IU/week cholecalciferol group · Adults with chronic kidney disease stages 2–4; mean age 66 years; 33 men and 54 women across the trial | 2,857 IU | 1 year | — |
| Wintertime vitamin D supplementation inhibits seasonal variation of calcitropic hormones and maintains bone turnover in healthy men 2009 · 10 microg (400 IU) group · Healthy white men aged 21–49 years | 10 mcg | 26 weeks | — |
| Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study 2009 · ergocalciferol group · Men and women aged 18–65 with 25OHD below 62 nmol/l who were severely obese and awaiting bariatric surgery | 7,143 IU | 8 weeks | — |
| Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study 2009 · cholecalciferol group · Men and women aged 18–65 with 25OHD below 62 nmol/l who were severely obese and awaiting bariatric surgery | 1,143 IU | 8 weeks | — |
| Estimation of the dietary requirement for vitamin D in healthy adults 2008 · 5 microg/d vitamin D3 · Men and women aged 20–40 years; healthy adults | 5 mcg | 22 weeks | — |
| Estimation of the dietary requirement for vitamin D in healthy adults 2008 · 10 microg/d vitamin D3 · Men and women aged 20–40 years; healthy adults | 10 mcg | 22 weeks | — |
| High-dose oral vitamin D3 supplementation in the elderly 2009 · Loading · Elderly participants; described as frail elderly, with no age range or condition specified | 500,000 IU | — | — |
| How much vitamin D for neonates? 1991 · 10 micrograms/d (400 IU/d) vitamin D · Neonates, including low-birth-weight and full-term well infants | 10 mcg | 16 weeks | — |
| How much vitamin D for neonates? 1991 · 0.85 micrograms/d 25-hydroxyvitamin D3 · Low-birth-weight and full-term well neonates | 0.85 mcg | 16 weeks | — |
| How much vitamin D for neonates? 1991 · 1.5 micrograms/d 25-hydroxyvitamin D3 · Low-birth-weight and full-term well neonates | 1.5 mcg | 16 weeks | — |
| Estimation of the dietary requirement for vitamin D in free-living adults >=64 y of age 2009 · 5 microg vitamin D(3)/d · men and women aged ≥64 years | 5 mcg | 22 weeks | — |
| Estimation of the dietary requirement for vitamin D in free-living adults >=64 y of age 2009 · 10 microg vitamin D(3)/d · men and women aged ≥64 years | 10 mcg | 22 weeks | — |
| Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light 2009 · D3 · Adults with cystic fibrosis and vitamin D insufficiency | 7,143 IU | 12 weeks | — |
| Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light 2009 · D2 · Adults with cystic fibrosis and vitamin D insufficiency | 7,143 IU | 12 weeks | — |
| Does vitamin D supplementation of healthy Danish Caucasian girls affect bone turnover and bone mineralization? 2010 · 5 microg/day vitamin D(3) · Healthy Danish Caucasian girls aged 11–12 years | 5 mcg | 1 year | — |
| Does vitamin D supplementation of healthy Danish Caucasian girls affect bone turnover and bone mineralization? 2010 · 10 microg/day vitamin D(3) · Healthy Danish Caucasian girls aged 11–12 years | 10 mcg | 1 year | — |
| Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults 2010 · Young adults, 5 microg/day · Healthy adults aged 20–40 years | 5 mcg | — | — |
| Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults 2010 · Young adults, 10 microg/day · Healthy adults aged 20–40 years | 10 mcg | — | — |
| Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults 2010 · Elderly adults, 5 microg/day · Healthy adults aged 64 years or older | 5 mcg | — | — |
| Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults 2010 · Elderly adults, 10 microg/day · Healthy adults aged 64 years or older | 10 mcg | — | — |
| Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention 2010 · VD group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D | 10 mcg | 1 year | — |
| Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults 2010 · vitamin D(3)-fortified orange juice · Healthy adults aged 18–84 years; vitamin D deficiency was present in 64% of participants at baseline. | 1,000 IU | 11 weeks | — |
| Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults 2010 · vitamin D(2)-fortified orange juice · Healthy adults aged 18–84 years; vitamin D deficiency was present in 64% of participants at baseline. | 1,000 IU | 11 weeks | — |
| Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults 2010 · vitamin D(3) capsule · Healthy adults aged 18–84 years; vitamin D deficiency was present in 64% of participants at baseline. | 1,000 IU | 11 weeks | — |
| Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults 2010 · vitamin D(2) capsule · Healthy adults aged 18–84 years; vitamin D deficiency was present in 64% of participants at baseline. | 1,000 IU | 11 weeks | — |
| Milk fortified with the current adequate intake for vitamin D (5 microg) increases serum 25-hydroxyvitamin D compared to control milk but is not sufficient to prevent a seasonal decline in young women 2010 · fortified milk group · Non-pregnant women aged 18–47 years living in Dunedin, New Zealand | 5 mcg | 12 weeks | — |
| Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States 2009 · 800 IU vitamin D daily · Adults aged 30–74 with a history of at least one pathologically confirmed adenomatous colonic polyp within the previous 36 months | 800 IU | 26 weeks | — |
| Combination of bolus dose vitamin D with routine vaccination in infants: a randomised trial 2010 · 200 IU daily · Healthy breastfed infants, assessed at six months of age | 200 IU | 26 weeks | — |
| Combination of bolus dose vitamin D with routine vaccination in infants: a randomised trial 2010 · 400 IU daily · Healthy breastfed infants, assessed at six months of age | 400 IU | 26 weeks | — |
| Heterogeneity in serum 25-hydroxy-vitamin D response to cholecalciferol in elderly women with secondary hyperparathyroidism and vitamin D deficiency 2010 · daily D(3) group · Women aged 65 and older with secondary hyperparathyroidism and vitamin D deficiency | 1,000 IU | 26 weeks | — |
| The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol 2011 · Calcitriol alone · Healthy volunteers aged 19–45 years | 1 mcg | 3 days | — |
| The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol 2011 · Calcitriol with lanthanum carbonate · Healthy volunteers aged 19–45 years | 1 mcg | 3 days | — |
| The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol 2011 · Calcitriol with sevelamer carbonate · Healthy volunteers aged 19–45 years | 1 mcg | 3 days | — |
| Vitamin D(3) is more potent than vitamin D(2) in humans 2011 · D2-treated group · Healthy adults; age and sex not specified | 7,143 IU | 12 weeks | — |
| Vitamin D(3) is more potent than vitamin D(2) in humans 2011 · D3-treated group · Healthy adults; age and sex not specified | 7,143 IU | 12 weeks | — |
| Estimation of the dietary requirement for vitamin D in healthy adolescent white girls 2011 · 5 μg/d vitamin D3 group · Healthy white girls, mean age 11.3 years, in Denmark and Finland | 5 mcg | 1 year | — |
| Estimation of the dietary requirement for vitamin D in healthy adolescent white girls 2011 · 10 μg/d vitamin D3 group · Healthy white girls, mean age 11.3 years, in Denmark and Finland | 10 mcg | 1 year | — |
| Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults 2011 · daily D(2) · Community-dwelling adults aged 65 years and older | 1,600 IU | 1 year | — |
| Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults 2011 · daily D(3) · Community-dwelling adults aged 65 years and older | 1,600 IU | 1 year | — |
| Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis 2011 · RSD+ · Adults with osteoporosis; sex and age range not specified | 800 IU | 16 weeks | — |
| Randomized trial of fortified milk and supplements to raise 25-hydroxyvitamin D concentrations in schoolchildren in Mongolia 2011 · one-time seasonal supplement · Children aged 9–11 years in Mongolia with very low baseline 25(OH)D concentrations | 13,700 IU | — | — |
| Randomized trial of fortified milk and supplements to raise 25-hydroxyvitamin D concentrations in schoolchildren in Mongolia 2011 · daily supplements · Children aged 9–11 years in Mongolia with very low baseline 25(OH)D concentrations | 300 IU | — | — |
| Randomized trial of fortified milk and supplements to raise 25-hydroxyvitamin D concentrations in schoolchildren in Mongolia 2011 · fortified ultra-high-temperature pasteurized milk from the United States · Children aged 9–11 years in Mongolia with very low baseline 25(OH)D concentrations | 300 IU | — | — |
| Randomized trial of fortified milk and supplements to raise 25-hydroxyvitamin D concentrations in schoolchildren in Mongolia 2011 · fortified pasteurized Mongolian milk · Children aged 9–11 years in Mongolia with very low baseline 25(OH)D concentrations | 300 IU | — | — |
| Vitamin D-fortified milk achieves the targeted serum 25-hydroxyvitamin D concentration without affecting that of parathyroid hormone in New Zealand toddlers 2011 · Fortified toddler milk group(s) · Healthy toddlers aged 12–20 months | 3.7 mcg | 20 weeks | — |
| Oral cholecalciferol versus ultraviolet radiation B: effect on vitamin D metabolites in patients with chronic pancreatitis and fat malabsorption - a randomized clinical trial 2011 · vitamin D supplement · Patients with chronic pancreatitis and fat malabsorption | 1,520 IU | 10 weeks | — |
| Vitamin D status and associations in newborn formula-fed infants during initial hospitalization 2011 · supplemented group · Hospitalized formula-fed infants born at less than 32 weeks' gestational age | 400 IU | — | — |
| Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults 2012 · 7 μg 25-hydroxyvitamin D3 group · Adults aged 50 years or older, apparently healthy | 7 mcg | 10 weeks | — |
| Stability and bioavailability of vitamin D nanoencapsulated in casein micelles 2012 · Aqueous Tween-80-emulsified vitamin D3 supplement · Human volunteers; age, sex, and health status not specified | 50,000 IU | 1 day | — |
| Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly 2012 · Oral group · Ambulatory nursing-home residents aged 65 years or older with vitamin D deficiency or insufficiency (25(OH)D <30 ng/ml) | 600,000 IU | 12 weeks | — |
| Fortified malted milk drinks containing low-dose ergocalciferol and cholecalciferol do not differ in their capacity to raise serum 25-hydroxyvitamin D concentrations in healthy men and women not exposed to UV-B 2012 · D2 at 5 μg/d · Healthy men and women | 5 mcg | 4 weeks | — |
| Fortified malted milk drinks containing low-dose ergocalciferol and cholecalciferol do not differ in their capacity to raise serum 25-hydroxyvitamin D concentrations in healthy men and women not exposed to UV-B 2012 · D2 at 10 μg/d · Healthy men and women | 10 mcg | 4 weeks | — |
| Fortified malted milk drinks containing low-dose ergocalciferol and cholecalciferol do not differ in their capacity to raise serum 25-hydroxyvitamin D concentrations in healthy men and women not exposed to UV-B 2012 · D3 at 5 μg/d · Healthy men and women | 5 mcg | 4 weeks | — |
| Fortified malted milk drinks containing low-dose ergocalciferol and cholecalciferol do not differ in their capacity to raise serum 25-hydroxyvitamin D concentrations in healthy men and women not exposed to UV-B 2012 · D3 at 10 μg/d · Healthy men and women | 10 mcg | 4 weeks | — |
| 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis 2012 · cholecalciferol treatment group · Adults with stage 5 CKD receiving maintenance hemodialysis; age and sex not specified | 1,476 IU | 15 weeks | — |
| High-dose vitamin d intervention in infants--effects on vitamin d status, calcium homeostasis, and bone strength 2012 · 10 μg group · Infants receiving supplementation from age 2 weeks to 3 months | 10 mcg | 10 weeks | — |
| Assessment of vitamin D concentration in non-supplemented professional athletes and healthy adults during the winter months in the UK: implications for skeletal muscle function 2013 · vitamin D group · Professional athletes; age and sex not specified | 5,000 IU | 8 weeks | — |
| Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial 2013 · vitamin D3 · Obese adolescents with low vitamin D status; mean age 14.1 years | 4,000 IU | 26 weeks | — |
| Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients 2013 · 400 IU/d vitamin D3 group · Prostate cancer patients with Gleason score 6 or 7 undergoing radical prostatectomy | 400 IU | — | — |
| Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients 2013 · 10 000 IU/d vitamin D3 group · Prostate cancer patients with Gleason score 6 or 7 undergoing radical prostatectomy | 10,000 IU | — | — |
| Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients 2013 · 40 000 IU/d vitamin D3 group · Prostate cancer patients with Gleason score 6 or 7 undergoing radical prostatectomy | 40,000 IU | — | — |
| Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial 2013 · Vitamin D supplementation phase · Healthy volunteers | 2,000 IU | 30 days | — |
| Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency 2013 · 400 IU/d group · Arab women with pregnancy, randomized at 12–16 weeks of gestation in a population with endemic vitamin D deficiency | 400 IU | — | — |
| Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency 2013 · 2000 IU/d group · Arab women with pregnancy, randomized at 12–16 weeks of gestation in a population with endemic vitamin D deficiency | 2,000 IU | — | — |
| Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency 2013 · 4000 IU/d group · Arab women with pregnancy, randomized at 12–16 weeks of gestation in a population with endemic vitamin D deficiency | 4,000 IU | — | — |
| The effect of high-dose vitamin D supplementation on calciotropic hormones and bone mineral density in obese subjects with low levels of circulating 25-hydroxyvitamin d: results from a randomized controlled study 2013 · cholecalciferol group · healthy obese men and women aged 18–50 years with plasma 25-hydroxyvitamin D below 50 nmol/L | 7,000 IU | 26 weeks | — |
| A randomized clinical trial of vitamin D supplementation in healthy adolescents 2013 · 200 IU group · Healthy adolescents aged 11–19 years with baseline vitamin D sufficiency | 200 IU | 11 weeks | — |
| A randomized clinical trial of vitamin D supplementation in healthy adolescents 2013 · 1000 IU group · Healthy adolescents aged 11–19 years with baseline vitamin D sufficiency | 1,000 IU | 11 weeks | — |
| Vitamin D favorably alters the cancer promoting prostaglandin cascade 2013 · 2,000 IU vitamin D-3 plus 400 mg celecoxib · Healthy women; age range and other characteristics not specified | 2,000 IU | 30 days | — |
| 25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults 2013 · 1000 IU/d group · Obese adults | 1,000 IU | 21 weeks | — |
| 25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults 2013 · 5000 IU/d group · Obese adults | 5,000 IU | 21 weeks | — |
| 25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults 2013 · 10,000 IU/d group · Obese adults | 10,000 IU | 21 weeks | — |
| Vitamin D3 dose requirement to raise 25-hydroxyvitamin D to desirable levels in adolescents: results from a randomized controlled trial 2014 · low-dose group · Lebanese adolescents aged 13 ± 2 years | 200 IU | 1 year | — |
| Vitamin D3 dose requirement to raise 25-hydroxyvitamin D to desirable levels in adolescents: results from a randomized controlled trial 2014 · high-dose group · Lebanese adolescents aged 13 ± 2 years | 2,000 IU | 1 year | — |
| Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial 2014 · 1000 IU vitamin D₃/d · African American adults in Boston; ages and health condition not stated | 1,000 IU | 90 days | — |
| Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial 2014 · 2000 IU vitamin D₃/d · African American adults in Boston; ages and health condition not stated | 2,000 IU | 90 days | — |
| Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial 2014 · 4000 IU vitamin D₃/d · African American adults in Boston; ages and health condition not stated | 4,000 IU | 90 days | — |
| 25-Hydroxyvitamin D concentrations in children with Crohn's disease supplemented with either 2000 or 400 IU daily for 6 months: a randomized controlled study 2014 · 400 IU group · Children aged 8–18 years with quiescent Crohn's disease | 400 IU | 26 weeks | — |
| 25-Hydroxyvitamin D concentrations in children with Crohn's disease supplemented with either 2000 or 400 IU daily for 6 months: a randomized controlled study 2014 · 2000 IU group · Children aged 8–18 years with quiescent Crohn's disease | 2,000 IU | 26 weeks | — |
| Obstetric and neonatal outcomes of maternal vitamin D supplementation: results of an open-label, randomized controlled trial of antenatal vitamin D supplementation in Pakistani women 2014 · Group B (vitamin D supplementation) · Pregnant women in Karachi, Pakistan; age range and vitamin D status not specified | 4,000 IU | — | — |
| Impact of vitamin D3 dietary supplement matrix on clinical response 2014 · chewable tablet (TAB) · Healthy adults with serum 25(OH)D <33 ng/mL | 10,000 IU | 12 weeks | — |
| Impact of vitamin D3 dietary supplement matrix on clinical response 2014 · oil-emulsified drop (DROP) · Healthy adults with serum 25(OH)D <33 ng/mL | 10,000 IU | 12 weeks | — |
| Impact of vitamin D3 dietary supplement matrix on clinical response 2014 · encapsulated powder (CAP) · Healthy adults with serum 25(OH)D <33 ng/mL | 10,000 IU | 12 weeks | — |
| Vitamin D-binding protein levels do not influence the effect of vitamin D repletion on serum PTH and calcium: data from a randomized, controlled trial 2014 · vitamin D3 · Vitamin D-deficient adults with serum 25(OH)D <20 ng/mL | 7,143 IU | 8 weeks | — |
| Effect of fat on serum 25-hydroxyvitamin D levels after a single oral dose of vitamin D in young healthy adults: a double-blind randomized placebo-controlled study 2015 · Group 1 (0 g fat) · Healthy medical residents or students; age and sex not specified | 50,000 IU | 2 weeks | — |
| Effect of fat on serum 25-hydroxyvitamin D levels after a single oral dose of vitamin D in young healthy adults: a double-blind randomized placebo-controlled study 2015 · Group 2 (15 g fat) · Healthy medical residents or students; age and sex not specified | 50,000 IU | 2 weeks | — |
| Effect of fat on serum 25-hydroxyvitamin D levels after a single oral dose of vitamin D in young healthy adults: a double-blind randomized placebo-controlled study 2015 · Group 3 (30 g fat) · Healthy medical residents or students; age and sex not specified | 50,000 IU | 2 weeks | — |
| Iron stores of breastfed infants during the first year of life 2014 · 200 IU/day Vitamin D · Full-term breastfed infants, enrolled at 1 month of age | 200 IU | 243 days | — |
| Iron stores of breastfed infants during the first year of life 2014 · 400 IU/day Vitamin D · Full-term breastfed infants, enrolled at 1 month of age | 400 IU | 243 days | — |
| Iron stores of breastfed infants during the first year of life 2014 · 600 IU/day Vitamin D · Full-term breastfed infants, enrolled at 1 month of age | 600 IU | 243 days | — |
| Iron stores of breastfed infants during the first year of life 2014 · 800 IU/day Vitamin D · Full-term breastfed infants, enrolled at 1 month of age | 800 IU | 243 days | — |
| Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial 2014 · Cholecalciferol group · Adults receiving maintenance hemodialysis with 25(OH)D levels below 30 ng/mL | 3,571 IU | 13 weeks | — |
| Vitamin D supplementation of breastfed infants: a randomized dose-response trial 2014 · 200 IU/day vitamin D group · Term, exclusively breastfed infants enrolled at 1 month of age | 200 IU | 36 weeks | — |
| Vitamin D supplementation of breastfed infants: a randomized dose-response trial 2014 · 400 IU/day vitamin D group · Term, exclusively breastfed infants enrolled at 1 month of age | 400 IU | 36 weeks | — |
| Vitamin D supplementation of breastfed infants: a randomized dose-response trial 2014 · 600 IU/day vitamin D group · Term, exclusively breastfed infants enrolled at 1 month of age | 600 IU | 36 weeks | — |
| Vitamin D supplementation of breastfed infants: a randomized dose-response trial 2014 · 800 IU/day vitamin D group · Term, exclusively breastfed infants enrolled at 1 month of age | 800 IU | 36 weeks | — |
| Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial 2014 · vitamin D3 · Healthy non-Hispanic white adults aged 45–75 years | 1,000 IU | 1 year | — |
| Dietary fat increases vitamin D-3 absorption 2015 · Fat-free meal group · Healthy older men and women | 50,000 IU | 1 day | — |
| Dietary fat increases vitamin D-3 absorption 2015 · Low MUFA:PUFA meal group (1:4) · Healthy older men and women | 50,000 IU | 1 day | — |
| Dietary fat increases vitamin D-3 absorption 2015 · High MUFA:PUFA meal group (4:1) · Healthy older men and women | 50,000 IU | 1 day | — |
| Single high-dose vitamin D at birth corrects vitamin D deficiency in infants in Mexico 2015 · vitamin D3 group · Healthy term newborn infants enrolled within 24 hours after birth; infants were not selected for a diagnosed condition | 50,000 IU | 1 day | — |
| A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial 2016 · 400 IU/d vitamin D3 · Healthy Chinese adults | 400 IU | 16 weeks | — |
| A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial 2016 · 800 IU/d vitamin D3 · Healthy Chinese adults | 800 IU | 16 weeks | — |
| A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial 2016 · 1200 IU/d vitamin D3 · Healthy Chinese adults | 1,200 IU | 16 weeks | — |
| A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial 2016 · 2000 IU/d vitamin D3 · Healthy Chinese adults | 2,000 IU | 16 weeks | — |
| Large Individual Differences in Serum 25-Hydroxyvitamin D Response to Vitamin D Supplementation: Effects of Genetic Factors, Body Mass Index, and Baseline Concentration. Results from a Randomized Controlled Trial 2016 · vitamin D3 group · People with prediabetes; age and sex not specified | 2,857 IU | 1 year | — |
| Effects of vitamin D-fortified low fat yogurt on glycemic status, anthropometric indexes, inflammation, and bone turnover in diabetic postmenopausal women: A randomised controlled clinical trial 2016 · fortified yogurt (FY) · Postmenopausal women with type 2 diabetes; age range not reported | 2,000 IU | 12 weeks | — |
| Safety and Efficacy of High-dose Daily Vitamin D3 Supplementation in Children and Young Adults With Sickle Cell Disease 2015 · 4,000 IU/day vitamin D3 — SCD-SS group · African-American children and young adults aged 5–20 years with sickle cell disease, homozygous SS | 4,000 IU | 12 weeks | — |
| Safety and Efficacy of High-dose Daily Vitamin D3 Supplementation in Children and Young Adults With Sickle Cell Disease 2015 · 7,000 IU/day vitamin D3 — SCD-SS group · African-American children and young adults aged 5–20 years with sickle cell disease, homozygous SS | 7,000 IU | 12 weeks | — |
| Safety and Efficacy of High-dose Daily Vitamin D3 Supplementation in Children and Young Adults With Sickle Cell Disease 2015 · 4,000 IU/day vitamin D3 — healthy control group · African-American healthy children and young adults aged 5–20 years | 4,000 IU | 12 weeks | — |
| Safety and Efficacy of High-dose Daily Vitamin D3 Supplementation in Children and Young Adults With Sickle Cell Disease 2015 · 7,000 IU/day vitamin D3 — healthy control group · African-American healthy children and young adults aged 5–20 years | 7,000 IU | 12 weeks | — |
| Response of vitamin D binding protein and free vitamin D concentrations to vitamin D supplementation in hospitalized premature infants 2015 · 400 IU/day vitamin D3 group · Premature infants born before 32 weeks' gestation | 400 IU | 8 weeks | — |
| Response of vitamin D binding protein and free vitamin D concentrations to vitamin D supplementation in hospitalized premature infants 2015 · 800 IU/day vitamin D3 group · Premature infants born before 32 weeks' gestation | 800 IU | 8 weeks | — |
| Effect of Vitamin D3 Supplementation in Black and in White Children: A Randomized, Placebo-Controlled Trial 2015 · vitamin D3 group · Healthy Black and White children aged 8–14 years; mean baseline 25(OH)D was below 20 ng/mL | 1,000 IU | 26 weeks | — |
| Maternal vitamin D₃ supplementation at 50 μg/d protects against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized controlled trial of 3 doses of vitamin D beginning in gestation and continued in lactation 2015 · 10 μg vitamin D₃/d group · Pregnant women, supplementation begun during gestation and continued through 8 weeks postpartum; breastfed infants received no supplementation | 10 mcg | — | — |
| Vitamin D metabolism in the premature newborn: A randomized trial 2016 · 400 IU/day vitamin D3 · Premature infants born at less than 32 weeks’ gestation | 400 IU | 8 weeks | — |
| Vitamin D metabolism in the premature newborn: A randomized trial 2016 · 800 IU/day vitamin D3 · Premature infants born at less than 32 weeks’ gestation | 800 IU | 8 weeks | — |
| Free 25(OH)D and Calcium Absorption, PTH, and Markers of Bone Turnover 2015 · 4000-IU dose arm · Adults; age, sex, and health condition are not specified in the abstract. | 4,000 IU | 10 weeks | — |
| Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial 2015 · 400 IU maternal group · Exclusively lactating women 4 to 6 weeks postpartum | 400 IU | 26 weeks | — |
| Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial 2015 · 6400 IU maternal group · Exclusively lactating women 4 to 6 weeks postpartum | 6,400 IU | 26 weeks | — |
| Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial 2015 · Infant 400 IU group · Breastfeeding infants of lactating women assigned to the 400 IU maternal group | 400 IU | 26 weeks | — |
| [Effect of supplementation with a single dose of vitamin D in children with cerebral palsy. Preliminary randomised controlled study] 2015 · supplemented (S) group · Children with cerebral palsy; median age 9.9 years (range 6.2–13.5); both sexes | 100,000 IU | 8 weeks | — |
| Dietary vitamin D dose-response in healthy children 2 to 8 y of age: a 12-wk randomized controlled trial using fortified foods 2016 · EAR: 400 IU/d · Children aged 2–8 years | 400 IU | 12 weeks | — |
| Dietary vitamin D dose-response in healthy children 2 to 8 y of age: a 12-wk randomized controlled trial using fortified foods 2016 · RDA: 600 IU/d · Children aged 2–8 years | 600 IU | 12 weeks | — |
| Vitamin D activity of breast milk in women randomly assigned to vitamin D3 supplementation during pregnancy 2016 · 1000-IU group · Pregnant women enrolled at 27 weeks of gestation who were breastfeeding postpartum | 1,000 IU | — | — |
| Vitamin D activity of breast milk in women randomly assigned to vitamin D3 supplementation during pregnancy 2016 · 2000-IU group · Pregnant women enrolled at 27 weeks of gestation who were breastfeeding postpartum | 2,000 IU | — | — |
| Treatment of Vitamin D Deficiency in Predominantly Hispanic and Black Adolescents: A Randomized Clinical Trial 2016 · 50,000 IU/week · Adolescents aged 13–20 years with vitamin D deficiency; predominantly Hispanic and Black | 7,143 IU | 8 weeks | — |
| Treatment of Vitamin D Deficiency in Predominantly Hispanic and Black Adolescents: A Randomized Clinical Trial 2016 · 5,000 IU/day · Adolescents aged 13–20 years with vitamin D deficiency; predominantly Hispanic and Black | 5,000 IU | 8 weeks | — |
| Treatment of Vitamin D Deficiency in Predominantly Hispanic and Black Adolescents: A Randomized Clinical Trial 2016 · 1,000 IU/day · Adolescents aged 13–20 years with vitamin D deficiency; predominantly Hispanic and Black | 1,000 IU | 8 weeks | — |
| Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis 2016 · high-dose group · Adults with relapsing-remitting multiple sclerosis; age and sex not reported | 10,400 IU | 26 weeks | — |
| Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis 2016 · low-dose group · Adults with relapsing-remitting multiple sclerosis; age and sex not reported | 800 IU | 26 weeks | — |
| Effect of weekly high-dose vitamin D3 supplementation on serum cholecalciferol concentrations in pregnant women 2016 · Vitamin D3 (VitD) · Pregnant women enrolled at 26–29 weeks’ gestation in Dhaka, Bangladesh | 5,000 IU | 8 weeks | — |
| Vitamin D Dosing Strategies Among Jordanians With Hypovitaminosis D 2017 · group A · Volunteers with hypovitaminosis D; age and sex not reported | 7,143 IU | 26 weeks | — |
| Vitamin D Dosing Strategies Among Jordanians With Hypovitaminosis D 2017 · group B · Volunteers with hypovitaminosis D; age and sex not reported | 7,000 IU | 26 weeks | — |
| Vitamin D3 for uncontrolled childhood asthma: A pilot study 2016 · vitamin D3 group · Children with asthma; age and sex not specified | 2,000 IU | 15 weeks | — |
| Vitamin D treatment in Somali women living in Sweden - Two randomized, placebo-controlled studies 2016 · 800 IU/day cholecalciferol · Somali women living in Sweden, mean age 34; most were vitamin D-deficient | 800 IU | 12 weeks | — |
| Vitamin D treatment in Somali women living in Sweden - Two randomized, placebo-controlled studies 2016 · 1600 IU/day cholecalciferol · Somali women living in Sweden, mean age 34; most were vitamin D-deficient | 1,600 IU | 12 weeks | — |
| Short-term Administration of Alphacalcidol is Associated with More Significant Improvement of Muscular Performance in Women with Vitamin D Deficiency Compared to Native Vitamin D 2016 · cholecalciferol · Women with vitamin D deficiency | 1,000 IU | 26 weeks | — |
| Short-term Administration of Alphacalcidol is Associated with More Significant Improvement of Muscular Performance in Women with Vitamin D Deficiency Compared to Native Vitamin D 2016 · alphacalcidol · Women with vitamin D deficiency | 1 mcg | 26 weeks | — |
| Effect of vitamin D supplementation, directly or via breast milk for term infants, on serum 25 hydroxyvitamin D and related biochemistry, and propensity to infection: a randomised placebo-controlled trial 2016 · group B · Term newborn infants | 10 mcg | 39 weeks | — |
| Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation 2016 · 2000 IU cholecalciferol group · Adults with prediabetes or well-controlled diabetes; mean age 59.1 years | 2,000 IU | 16 weeks | — |
| Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation 2016 · 4000 IU cholecalciferol group · Adults with prediabetes or well-controlled diabetes; mean age 59.1 years | 4,000 IU | 16 weeks | — |
| Effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome: a randomized controlled double-blind clinical trial 2016 · vitamin D intervention group · Adults with metabolic syndrome; mean age 40.49 years, 49% male; all intervention participants were vitamin D deficient or insufficient | 7,143 IU | 16 weeks | — |
| The impact of 1-year vitamin D supplementation on vitamin D status in athletes: a dose-response study 2016 · 400 IU vitamin D3 per day · Male and female athletes aged 18–32 with deficient or insufficient baseline 25(OH)D concentrations | 400 IU | 1 year | — |
| The impact of 1-year vitamin D supplementation on vitamin D status in athletes: a dose-response study 2016 · 1100 IU vitamin D3 per day · Male and female athletes aged 18–32 with deficient or insufficient baseline 25(OH)D concentrations | 1,100 IU | 1 year | — |
| The impact of 1-year vitamin D supplementation on vitamin D status in athletes: a dose-response study 2016 · 2200 IU vitamin D3 per day · Male and female athletes aged 18–32 with deficient or insufficient baseline 25(OH)D concentrations | 2,200 IU | 1 year | — |
| CYP2R1 polymorphisms are important modulators of circulating 25-hydroxyvitamin D levels in elderly females with vitamin insufficiency, but not of the response to vitamin D supplementation 2017 · 600 IU daily · Lebanese elderly overweight adults; mean age 71 years; men and women, with vitamin D insufficiency | 600 IU | 1 year | — |
| CYP2R1 polymorphisms are important modulators of circulating 25-hydroxyvitamin D levels in elderly females with vitamin insufficiency, but not of the response to vitamin D supplementation 2017 · dose equivalent to 3750 IU daily · Lebanese elderly overweight adults; mean age 71 years; men and women, with vitamin D insufficiency | 3,750 IU | 1 year | — |
| The relationship between maternal self-efficacy, compliance and outcome in a trial of vitamin D supplementation in pregnancy 2017 · cholecalciferol group · Pregnant women aged over 18 years with a singleton pregnancy, recruited before 17 weeks’ gestation and with baseline 25(OH)D of 25–100 nmol/L | 1,000 IU | — | — |
| Estimation of the dietary requirement for vitamin D in adolescents aged 14-18 y: a dose-response, double-blind, randomized placebo-controlled trial 2016 · 10 μg/d group · White male and female adolescents aged 14–18 years in the United Kingdom during winter | 10 mcg | 20 weeks | — |
| Daily Cholecalciferol Supplementation during Pregnancy Alters Markers of Regulatory Immunity, Inflammation, and Clinical Outcomes in a Randomized Controlled Trial 2016 · 400 IU/d group · Pregnant women; supplementation began before 20 weeks of pregnancy and continued to delivery | 400 IU | — | — |
| Daily Cholecalciferol Supplementation during Pregnancy Alters Markers of Regulatory Immunity, Inflammation, and Clinical Outcomes in a Randomized Controlled Trial 2016 · 2000 IU/d group · Pregnant women; supplementation began before 20 weeks of pregnancy and continued to delivery | 2,000 IU | — | — |
| Vitamin D Improves Selected Metabolic Parameters but Not Neuropsychological or Quality of Life Indices in OSA: A Pilot Study 2017 · D3 group · Caucasian adults with obstructive sleep apnea; mean age 55 years | 4,000 IU | 15 weeks | — |
| Randomized clinical trial to comparing efficacy of daily, weekly and monthly administration of vitamin D(3) 2017 · group A · adult subjects with vitamin D deficiency | 1,000 IU | 90 days | — |
| Randomized clinical trial to comparing efficacy of daily, weekly and monthly administration of vitamin D(3) 2017 · group B · adult subjects with vitamin D deficiency | 1,000 IU | 90 days | — |
| Vitamin D3 supplementation in healthy adults: a comparison between capsule and oral spray solution as a method of delivery in a wintertime, randomised, open-label, cross-over study 2016 · Vitamin D3 liquid capsule · Healthy adults; age range and sex not specified | 3,000 IU | 4 weeks | — |
| Vitamin D3 supplementation in healthy adults: a comparison between capsule and oral spray solution as a method of delivery in a wintertime, randomised, open-label, cross-over study 2016 · Oral spray vitamin D3 · Healthy adults; age range and sex not specified | 3,000 IU | 4 weeks | — |
| Estimation of the dietary requirement for vitamin D in white children aged 4-8 y: a randomized, controlled, dose-response trial 2016 · 10 μg vitamin D3/d supplementation · White Danish children aged 4–8 years | 10 mcg | 20 weeks | — |
| Effects of Genetic and Nongenetic Factors on Total and Bioavailable 25(OH)D Responses to Vitamin D Supplementation 2017 · vitamin D3 group · Chinese participants with vitamin D deficiency; age and sex not specified | 2,000 IU | 20 weeks | — |
| Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial 2017 · vitamin D2 · People with cystic fibrosis; age range and sex not reported | 15,650 IU | 90 days | — |
| Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial 2017 · vitamin D3 · People with cystic fibrosis; age range and sex not reported | 8,184 IU | 90 days | — |
| Effect of Two Different Multimicronutrient Supplements on Vitamin D Status in Women of Childbearing Age: A Randomized Trial 2017 · 200 IU group (Elevit gynvital) · Apparently healthy women aged 18–45 years | 200 IU | 8 weeks | — |
| Effect of Two Different Multimicronutrient Supplements on Vitamin D Status in Women of Childbearing Age: A Randomized Trial 2017 · 800 IU group (Femibion 1) · Apparently healthy women aged 18–45 years | 800 IU | 8 weeks | — |
| DOES VITAMIN D METABOLITE MEASUREMENT HELP PREDICT 25(OH)D CHANGE FOLLOWING VITAMIN D SUPPLEMENTATION? 2017 · daily vitamin D3 · postmenopausal women | 1,800 IU | 120 days | — |
| Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone 2017 · D3 group · Adults aged 18 years or older with 25-hydroxyvitamin D levels below 20 ng/mL | 2,400 IU | 16 weeks | — |
| Changes in pro-inflammatory markers and leucine concentrations in response to Nordic Walking training combined with vitamin D supplementation in elderly women 2017 · 800 IU/day vitamin D3 group · Elderly women, mean age 67 ± 8 years; subgroup sizes and age ranges not reported | 800 IU | 12 weeks | — |
| Changes in pro-inflammatory markers and leucine concentrations in response to Nordic Walking training combined with vitamin D supplementation in elderly women 2017 · 4000 IU/day vitamin D3 group · Elderly women, mean age 67 ± 8 years; subgroup sizes and age ranges not reported | 4,000 IU | 12 weeks | — |
| Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults 2018 · 5 μg calcifediol group · Men and women aged 65 years or older; no condition specified | 5 mcg | 24 weeks | — |
| Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults 2018 · 10 μg calcifediol group · Men and women aged 65 years or older; no condition specified | 10 mcg | 24 weeks | — |
| The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial 2017 · vitamin D · People with metabolic syndrome; age and sex not specified | 7,143 IU | 16 weeks | — |
| Impact of high-dose vitamin D(3) on plasma free 25-hydroxyvitamin D concentrations and antimicrobial peptides in critically ill mechanically ventilated adults 2017 · 50,000 IU vitamin D3 group · Adults older than 18 years with respiratory failure requiring mechanical ventilation, critically ill in the ICU | 50,000 IU | 5 days | — |
| Impact of high-dose vitamin D(3) on plasma free 25-hydroxyvitamin D concentrations and antimicrobial peptides in critically ill mechanically ventilated adults 2017 · 100,000 IU vitamin D3 group · Adults older than 18 years with respiratory failure requiring mechanical ventilation, critically ill in the ICU | 100,000 IU | 5 days | — |
| Increased vitamin D intake differentiated according to skin color is needed to meet requirements in young Swedish children during winter: a double-blind randomized clinical trial 2017 · 10 μg/d vitamin D3 group · Children aged 5–7 years in Sweden with fair or dark skin | 10 mcg | 90 days | — |
| Multi-dose vitamin d supplementation in stable very preterm infants: Prospective randomized trial response to three different vitamin D supplementation doses 2017 · 400 IU/d group · Preterm infants born at 24–32 weeks’ gestation | 400 IU | — | — |
| Multi-dose vitamin d supplementation in stable very preterm infants: Prospective randomized trial response to three different vitamin D supplementation doses 2017 · 800 IU/d group · Preterm infants born at 24–32 weeks’ gestation | 800 IU | — | — |
| Multi-dose vitamin d supplementation in stable very preterm infants: Prospective randomized trial response to three different vitamin D supplementation doses 2017 · 1000 IU/d group · Preterm infants born at 24–32 weeks’ gestation | 1,000 IU | — | — |
| Longevity of daily oral vitamin D3 supplementation: differences in 25OHD and 24,25(OH)2D observed 2 years after cessation of a 1-year randomised controlled trial (VICtORy RECALL) 2017 · 400 IU daily vitamin D3 group · Caucasian, non-smoking postmenopausal women | 400 IU | 1 year | — |
| Longevity of daily oral vitamin D3 supplementation: differences in 25OHD and 24,25(OH)2D observed 2 years after cessation of a 1-year randomised controlled trial (VICtORy RECALL) 2017 · 1000 IU daily vitamin D3 group · Caucasian, non-smoking postmenopausal women | 1,000 IU | 1 year | — |
| Oral Supplementation of Parturient Mothers with Vitamin D and Its Effect on 25OHD Status of Exclusively Breastfed Infants at 6 Months of Age: A Double-Blind Randomized Placebo Controlled Trial 2017 · Intervention (A) · Exclusively breastfeeding term mothers in the early postpartum period | 60,000 IU | 10 days | — |
| Impact of Three Doses of Vitamin D3 on Serum 25(OH)D Deficiency and Insufficiency in At-Risk Schoolchildren 2017 · 600 IU/d group · Schoolchildren at risk for vitamin D deficiency; age and sex not specified | 600 IU | 26 weeks | — |
| Impact of Three Doses of Vitamin D3 on Serum 25(OH)D Deficiency and Insufficiency in At-Risk Schoolchildren 2017 · 1000 IU/d group · Schoolchildren at risk for vitamin D deficiency; age and sex not specified | 1,000 IU | 26 weeks | — |
| Impact of Three Doses of Vitamin D3 on Serum 25(OH)D Deficiency and Insufficiency in At-Risk Schoolchildren 2017 · 2000 IU/d group · Schoolchildren at risk for vitamin D deficiency; age and sex not specified | 2,000 IU | 26 weeks | — |
| The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial 2018 · weight-loss intervention + vitamin D3 · Overweight or obese women of reproductive age with PCOS and vitamin D insufficiency | 7,143 IU | 12 weeks | — |
| Vitamin D status and functional health outcomes in children aged 2-8 y: a 6-mo vitamin D randomized controlled trial 2018 · intervention group · Healthy children aged 2–8 y | 400 IU | 26 weeks | — |
| Vitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children 2018 · 400 IU/day (EAR) · Healthy, prepubertal children aged 2–8 years | 400 IU | 12 weeks | — |
| Vitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children 2018 · 600 IU/day (RDA) · Healthy, prepubertal children aged 2–8 years | 600 IU | 12 weeks | — |
| A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D₃ Supplementation 2018 · daily regimen treatment group · Caucasian men and women aged 18–55 with vitamin D deficiency and BMI 18–25 kg/m² | 2,000 IU | 75 days | — |
| Winter Cholecalciferol Supplementation at 55°N Has No Effect on Markers of Cardiometabolic Risk in Healthy Children Aged 4-8 Years 2018 · 10 µg/d vitamin D3 group · Healthy white Danish children aged 4–8 years | 10 mcg | 20 weeks | — |
| Correlation of 25-Hydroxyvitamin D Levels in Serum vs. Breastmilk in Vitamin D-Supplementation Breastfeeding Women during Lactation: Randomized Double Blinded Control Trial 2017 · vitamin D group · Thai breastfeeding women with maternal 25-hydroxyvitamin D levels of 10–30 ng/mL | 1,800 IU | 6 weeks | — |
| The Effect of Nordic Walking Training Combined with Vitamin D Supplementation on Postural Control and Muscle Strength in Elderly People-A Randomized Controlled Trial 2018 · HI-NW low-dose vitamin D subgroup · Women aged 69.02 ± 5.57 years on average with insufficient 25(OH)D levels, assigned to high-intensity interval Nordic Walking training | 800 IU | 12 weeks | — |
| The Effect of Nordic Walking Training Combined with Vitamin D Supplementation on Postural Control and Muscle Strength in Elderly People-A Randomized Controlled Trial 2018 · HI-NW high-dose vitamin D subgroup · Women aged 69.02 ± 5.57 years on average with insufficient 25(OH)D levels, assigned to high-intensity interval Nordic Walking training | 4,000 IU | 12 weeks | — |
| The Effect of Nordic Walking Training Combined with Vitamin D Supplementation on Postural Control and Muscle Strength in Elderly People-A Randomized Controlled Trial 2018 · MI-NW low-dose vitamin D subgroup · Women aged 69.02 ± 5.57 years on average with insufficient 25(OH)D levels, assigned to moderate-intensity continuous Nordic Walking training | 800 IU | 12 weeks | — |
| The Effect of Nordic Walking Training Combined with Vitamin D Supplementation on Postural Control and Muscle Strength in Elderly People-A Randomized Controlled Trial 2018 · MI-NW high-dose vitamin D subgroup · Women aged 69.02 ± 5.57 years on average with insufficient 25(OH)D levels, assigned to moderate-intensity continuous Nordic Walking training | 4,000 IU | 12 weeks | — |
| Effects of sunlight exposure and vitamin D supplementation on vitamin D levels in postmenopausal women in rural Thailand: A randomized controlled trial 2018 · sunlight exposure with vitamin D supplementation group · Postmenopausal women aged 50–70 years in rural Thailand | 2,857 IU | 12 weeks | — |
| Effect of vitamin D supplementation along with weight loss diet on meta-inflammation and fat mass in obese subjects with vitamin D deficiency: A double-blind placebo-controlled randomized clinical trial 2019 · vitamin D group · obese subjects with vitamin D deficiency (25OHD < 50 nmol/L); age and sex not stated | 7,143 IU | 12 weeks | — |
| Sunshine is an Important Determinant of Vitamin D Status Even Among High-dose Supplement Users: Secondary Analysis of a Randomized Controlled Trial in Crohn's Disease Patients 2019 · vitamin D3 group · Adults with Crohn's disease in remission; median age 44 years, 49% female | 2,000 IU | 1 year | — |
| A randomized double-blinded placebo controlled trial of ergocalciferol 40,000 versus 100,000 IU per week for vitamin D inadequacy in institutionalized postmenopausal women 2020 · standard dose group · Institutionalized postmenopausal women with baseline 25(OH)D levels below 30 ng/mL | 5,714 IU | 12 weeks | — |
| A randomized double-blinded placebo controlled trial of ergocalciferol 40,000 versus 100,000 IU per week for vitamin D inadequacy in institutionalized postmenopausal women 2020 · high dose group · Institutionalized postmenopausal women with baseline 25(OH)D levels below 30 ng/mL | 14,286 IU | 12 weeks | — |
| Can Supplementation with Vitamin D Modify Thyroid Autoantibodies (Anti-TPO Ab, Anti-Tg Ab) and Thyroid Profile (T3, T4, TSH) in Hashimoto's Thyroiditis? A Double Blind, Randomized Clinical Trial 2019 · vitamin D group · Women with Hashimoto's thyroiditis | 7,143 IU | 90 days | — |
| Efficacy of two different doses of oral vitamin D supplementation on inflammatory biomarkers and maternal and neonatal outcomes 2019 · 1,000 IU/d group · Pregnant women; age and condition details beyond pregnancy not stated | 1,000 IU | — | — |
| Efficacy of two different doses of oral vitamin D supplementation on inflammatory biomarkers and maternal and neonatal outcomes 2019 · 2,000 IU/d group · Pregnant women; age and condition details beyond pregnancy not stated | 2,000 IU | — | — |
| The Effect of High-Dose Postpartum Maternal Vitamin D Supplementation Alone Compared with Maternal Plus Infant Vitamin D Supplementation in Breastfeeding Infants in a High-Risk Population. A Randomized Controlled Trial 2019 · High-dose maternal supplementation: mother received 6000 IU/day vitamin D3 and infant received placebo · Arab breastfeeding mothers enrolled within four weeks postpartum and their term infants, in Doha and Al-Wakra, Qatar | 6,000 IU | 26 weeks | — |
| Genetic Variation of the Vitamin D Binding Protein Affects Vitamin D Status and Response to Supplementation in Infants 2019 · 10 μg/d vitamin D3 group · Healthy term infants | 10 mcg | 716 days | — |
| Effect of Oral Versus Intramuscular Vitamin D Replacement on Oxidative Stress and Outcomes in Traumatic Mechanical Ventilated Patients Admitted to Intensive Care Unit 2020 · oral vitamin D group · Patients with traumatic injury and vitamin D deficiency requiring mechanical ventilation; age and sex not reported | 50,000 IU | 6 days | — |
| Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults 2020 · 25(OH)D3 10 µg group · Older adults, mean age 63.3 ± 7.9 years; no specific condition stated | 10 mcg | 26 weeks | — |
| Rate of change of circulating 25-hydroxyvitamin D following sublingual and capsular vitamin D preparations 2019 · capsule · healthy volunteers | 3,000 IU | 6 weeks | — |
| Rate of change of circulating 25-hydroxyvitamin D following sublingual and capsular vitamin D preparations 2019 · sublingual spray · healthy volunteers | 3,000 IU | 6 weeks | — |
| Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients 2019 · vitamin D group · Patients with non-alcoholic fatty liver disease diagnosed by abdominal ultrasound and liver enzymes; age and sex not reported | 7,143 IU | 12 weeks | — |
| The Effect of Vitamin D Supplementation on its Metabolism and the Vitamin D Metabolite Ratio 2019 · vitamin-D-treated group · Adults over 18 with hypertension and 25(OH)D levels below 75 nmol/L | 2,800 IU | 8 weeks | — |
| Epigenetics Predicts Serum 25-Hydroxyvitamin D Response to Vitamin D(3) Supplementation in African Americans 2020 · 600 IU/day vitamin D3 · African Americans; age and sex not specified; no condition stated | 600 IU | 16 weeks | — |
| Epigenetics Predicts Serum 25-Hydroxyvitamin D Response to Vitamin D(3) Supplementation in African Americans 2020 · 2000 IU/day vitamin D3 · African Americans; age and sex not specified; no condition stated | 2,000 IU | 16 weeks | — |
| Epigenetics Predicts Serum 25-Hydroxyvitamin D Response to Vitamin D(3) Supplementation in African Americans 2020 · 4000 IU/day vitamin D3 · African Americans; age and sex not specified; no condition stated | 4,000 IU | 16 weeks | — |
| Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment 2019 · vitamin D treatment group · Men aged 50 years and older and women aged 55 years and older | 2,000 IU | 1 year | — |
| Effectiveness of vitamin D supplementation in Swedish children may be negatively impacted by BMI and serum fructose 2020 · 10 μg vitamin D group · children aged 5–7 years in northern and southern Sweden; no condition stated | 10 mcg | 90 days | — |
| Effects of Weekly Supplementation of Cholecalciferol and Calcifediol Among the Oldest-Old People: Findings From a Randomized Pragmatic Clinical Trial 2019 · Group A (25D3) · Community-dwelling women and men aged over 75 years, hospitalized in a geriatric acute-care ward; many had vitamin D deficiency or insufficiency | 21.4 mcg | 30 weeks | — |
| Effects of Weekly Supplementation of Cholecalciferol and Calcifediol Among the Oldest-Old People: Findings From a Randomized Pragmatic Clinical Trial 2019 · Group B (D3) · Community-dwelling women and men aged over 75 years, hospitalized in a geriatric acute-care ward; many had vitamin D deficiency or insufficiency | 21.4 mcg | 30 weeks | — |
| The impact of active vitamin D administration on the clinical outcomes of acne vulgaris 2021 · study group · Patients with acne vulgaris; age and sex not reported | 0.25 mcg | 90 days | — |
| Effects of vitamin D3 supplementation for 12 weeks on serum levels of anabolic hormones, anaerobic power, and aerobic performance in active male subjects: A randomized, double-blind, placebo-controlled trial 2020 · vitamin D3 supplement (VDS) · Active males | 2,000 IU | 12 weeks | — |
| Effects of vitamin D supplementation on circulating concentrations of growth factors and immune-mediators in healthy women during pregnancy 2021 · 400 IU vitamin D3/day · Pregnant women of Hispanic, African-American, or Caucasian ethnicity; age range not reported | 400 IU | — | — |
| Effects of vitamin D supplementation on circulating concentrations of growth factors and immune-mediators in healthy women during pregnancy 2021 · 4400 IU vitamin D3/day · Pregnant women of Hispanic, African-American, or Caucasian ethnicity; age range not reported | 4,400 IU | — | — |
| Efficacy and safety of active vitamin D supplementation in chronic spontaneous urticaria patients 2022 · study group · Patients with chronic spontaneous urticaria (age and sex not reported) | 0.25 mcg | 12 weeks | — |
| Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation 2020 · 2000 IU per day group · Patients with inflammatory bowel disease (IBD) | 2,000 IU | 12 weeks | — |
| Safety Aspects of a Randomized Clinical Trial of Maternal and Infant Vitamin D Supplementation by Feeding Type Through 7 Months Postpartum 2020 · 6,400 IU/day group · Postpartum mothers aged not reported, breastfeeding or formula-feeding | 6,400 IU | 26 weeks | — |
| Oral Vitamin D supplementation impacts gene expression in granulosa cells in women undergoing IVF 2021 · Vitamin D group · Women aged 18–39 with vitamin D deficiency undergoing IVF, normal BMI (18–25 kg/m²), and fewer than 3 previous IVF cycles | 600,000 IU | 12 weeks | — |
| Daily vitamin D(3) in overweight and obese children and adolescents: a randomized controlled trial 2021 · 600 IU vitamin D3 group · Children and adolescents aged 6–13 years who were overweight or obese | 600 IU | 1 year | — |
| Daily vitamin D(3) in overweight and obese children and adolescents: a randomized controlled trial 2021 · 1000 IU vitamin D3 group · Children and adolescents aged 6–13 years who were overweight or obese | 1,000 IU | 1 year | — |
| Daily vitamin D(3) in overweight and obese children and adolescents: a randomized controlled trial 2021 · 2000 IU vitamin D3 group · Children and adolescents aged 6–13 years who were overweight or obese | 2,000 IU | 1 year | — |
| Effect of low-fat dairy products fortified with 1500IU nano encapsulated vitamin D(3) on cardiometabolic indicators in adults with abdominal obesity: a total blinded randomized controlled trial 2021 · fortified low-fat yogurt (FY) · Adults with abdominal obesity | 1,500 IU | 10 weeks | — |
| Effect of low-fat dairy products fortified with 1500IU nano encapsulated vitamin D(3) on cardiometabolic indicators in adults with abdominal obesity: a total blinded randomized controlled trial 2021 · fortified low-fat milk (FM) · Adults with abdominal obesity | 1,500 IU | 10 weeks | — |
| 25-OHD response to vitamin D supplementation in children: effect of dose but not GC haplotype 2021 · standard dose group · Healthy urban-dwelling children aged 7 months to 10 years, largely from a Hispanic/LatinX community | 400 IU | 26 weeks | — |
| 25-OHD response to vitamin D supplementation in children: effect of dose but not GC haplotype 2021 · higher dose group · Healthy urban-dwelling children aged 7 months to 10 years, largely from a Hispanic/LatinX community | 1,000 IU | 26 weeks | — |
| Vitamin D(3) supplementation reduces serum markers of bone resorption and muscle damage in female basketball players with vitamin D inadequacy 2022 · vitamin D group · Female basketball players aged 15–30 with inadequate vitamin D status | 4,000 IU | 6 weeks | — |
| Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD 2022 · vitamin D3 supplementation · Adults with type 2 diabetes; mean age 70 ± 6 years; 66% male | 2,000 IU | 2 years | — |
| Vitamin D supplementation and cardiometabolic risk factors among diverse schoolchildren: a randomized clinical trial 2022 · 600 IU/d group · Racially diverse schoolchildren aged 8–15 years at risk of vitamin D deficiency | 600 IU | 26 weeks | — |
| Vitamin D supplementation and cardiometabolic risk factors among diverse schoolchildren: a randomized clinical trial 2022 · 1000 IU/d group · Racially diverse schoolchildren aged 8–15 years at risk of vitamin D deficiency | 1,000 IU | 26 weeks | — |
| Vitamin D supplementation and cardiometabolic risk factors among diverse schoolchildren: a randomized clinical trial 2022 · 2000 IU/d group · Racially diverse schoolchildren aged 8–15 years at risk of vitamin D deficiency | 2,000 IU | 26 weeks | — |
| Effectiveness of three Vitamin D dosing protocols on raising and maintaining blood serum levels of 25-hydroxyvitamin D over a three-month period: a randomized, prospective study 2023 · Group 2 · Patients with baseline total 25-hydroxyvitamin D below 30.0 ng/mL; age and sex not reported | 14,286 IU | 12 weeks | — |
| The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trial 2022 · vitamin D only (VitD) · Overweight or obese participants; age and sex not reported | 3,000 IU | 12 weeks | — |
| 800 IU versus 400 IU per day of vitamin D(3) in term breastfed infants: a randomized controlled trial from an LMIC 2022 · 800 IU/day vitamin D3 · Healthy term breastfed infants, supplemented from the first week of life until 14 weeks of age | 800 IU | 14 weeks | — |
| 800 IU versus 400 IU per day of vitamin D(3) in term breastfed infants: a randomized controlled trial from an LMIC 2022 · 400 IU/day vitamin D3 · Healthy term breastfed infants, supplemented from the first week of life until 14 weeks of age | 400 IU | 14 weeks | — |
| Safety and Efficacy of Early Vitamin D Supplementation in Critically Ill Extremely Preterm Infants: An Ancillary Study of a Randomized Trial 2023 · 200 IU group · Extremely preterm infants born at ≤28 weeks' gestation | 200 IU | 4 weeks | — |
| Safety and Efficacy of Early Vitamin D Supplementation in Critically Ill Extremely Preterm Infants: An Ancillary Study of a Randomized Trial 2023 · 800 IU group · Extremely preterm infants born at ≤28 weeks' gestation | 800 IU | 4 weeks | — |
| Vitamin D Supplementation and Its Relationship with Loss of Visceral Adiposity 2022 · G1 (800 IU/day) · Patients who underwent bariatric surgery; age and sex not specified | 800 IU | 1 year | — |
| Vitamin D Supplementation and Its Relationship with Loss of Visceral Adiposity 2022 · G2 (1800 IU/day) · Patients who underwent bariatric surgery; age and sex not specified | 1,800 IU | 1 year | — |
| The Effect of a Single High Dose of Vitamin D on Serum Levels of Its Metabolites in the Elderly 2022 · Vitamin D3 group · Adults aged 61–96 years; no specific condition reported | 120,000 IU | 1 day | — |
| [Vitamin D level in umbilical cord blood of late preterm infants and the effect of vitamin D(3) supplementation on the behavioral development of infants and young children: a prospective randomized controlled study] 2022 · Sufficiency group, subgroup A · Late preterm infants with sufficient umbilical-cord-blood 25(OH)D | 800 IU | — | — |
| [Vitamin D level in umbilical cord blood of late preterm infants and the effect of vitamin D(3) supplementation on the behavioral development of infants and young children: a prospective randomized controlled study] 2022 · Insufficiency group, subgroup A · Late preterm infants with insufficient umbilical-cord-blood 25(OH)D | 800 IU | — | — |
| [Vitamin D level in umbilical cord blood of late preterm infants and the effect of vitamin D(3) supplementation on the behavioral development of infants and young children: a prospective randomized controlled study] 2022 · Deficiency group, subgroup A · Late preterm infants with deficient umbilical-cord-blood 25(OH)D | 800 IU | — | — |
| Association of Body Weight With Response to Vitamin D Supplementation and Metabolism 2023 · Vitamin D3 (cholecalciferol) · Men aged 50 years or older and women aged 55 years or older, free of cancer and cardiovascular disease at baseline | 2,000 IU | 2 years | — |
| Vitamin D Status of Infants of Mothers with Gestational Diabetes: Status at Birth and a Randomized Controlled Trial of Vitamin D Supplementation across Infancy 2022 · 400 IU/d vitamin D group · Infants born to mothers with gestational diabetes and serum 25(OH)D below 50 nmol/L | 400 IU | 1 year | — |
| Vitamin D Status of Infants of Mothers with Gestational Diabetes: Status at Birth and a Randomized Controlled Trial of Vitamin D Supplementation across Infancy 2022 · 1000 IU/d vitamin D group · Infants born to mothers with gestational diabetes and serum 25(OH)D below 50 nmol/L | 1,000 IU | 1 year | — |
| Increased Serum Total and Free 25-Hydroxyvitamin D with Daily Intake of Cholecalciferol-Fortified Skim Milk: A Randomized Controlled Trial in Colombian Adolescents 2023 · cholecalciferol-fortified skim milk · Colombian adolescents aged 12–14.5 years and their mothers | 2,400 IU | 6 weeks | — |
| Effects of an Individualized vs. Standardized Vitamin D Supplementation on the 25(OH)D Level in Athletes 2023 · individualized supplementation (INDV) · Athletes aged 18–50 with insufficient vitamin D status (25(OH)D3 <30 ng/mL), exercising at least five hours per week | 4,000 IU | 10 weeks | — |
| Effects of an Individualized vs. Standardized Vitamin D Supplementation on the 25(OH)D Level in Athletes 2023 · standardized supplementation (STAD) · Athletes aged 18–50 with insufficient vitamin D status (25(OH)D3 <30 ng/mL), exercising at least five hours per week | 2,000 IU | 10 weeks | — |
| The Effect of Vitamin D Supplementation in Pregnant Women with Overweight and Obesity: A Randomised Controlled Trial 2023 · Control group · Pregnant women aged 21–45 years with pre-pregnancy BMI ≥25 kg/m², recruited at up to 16 weeks’ gestation | 400 IU | — | — |
| An 8-Week Vitamin D3-Fortified Fruit Drink Supplementation Increases Serum Ferritin Concentration: A Randomized Controlled Trial in Malaysian Women With Low Iron Stores 2024 · vitamin D3-fortified fruit drink · Nonpregnant, nonlactating women aged 18–40 years with low iron stores (serum ferritin <20 μg/L) | 4,000 IU | 8 weeks | — |
| Effect of Antenatal Oral Vitamin D Supplementation on Serum 25(OH)D Concentration in Exclusively Breastfed Infants at 6 Months of age - A Randomized Double-Blind Placebo-Controlled Trial 2024 · Vitamin D3 group · Pregnant women recruited at 30–32 weeks gestation who intended to exclusively breastfeed their infants for 6 months | 8,571 IU | 5 weeks | — |
| A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D(3) Oral Supplementation in a Randomized, Double-Blind Human Pilot Study 2024 · STD1000 (regular/standard Vitamin D3 1000 IU) · Healthy adults aged 21–65 years; men and women | 1,000 IU | 30 days | — |
| A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D(3) Oral Supplementation in a Randomized, Double-Blind Human Pilot Study 2024 · LMD1000 (LipoMicel Vitamin D3 1000 IU) · Healthy adults aged 21–65 years; men and women | 1,000 IU | 30 days | — |
| A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D(3) Oral Supplementation in a Randomized, Double-Blind Human Pilot Study 2024 · STD2500 (regular/standard Vitamin D3 2500 IU) · Healthy adults aged 21–65 years; men and women | 2,500 IU | 30 days | — |
| A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D(3) Oral Supplementation in a Randomized, Double-Blind Human Pilot Study 2024 · LMD2500 (LipoMicel Vitamin D3 2500 IU) · Healthy adults aged 21–65 years; men and women | 2,500 IU | 30 days | — |
| Effects of High-Dose Vitamin D Supplementation on Placental Vitamin D Metabolism and Neonatal Vitamin D Status 2024 · 10 µg vitamin D group · Pregnant women enrolled at gestational weeks 11–16; no specific pregnancy complication required | 10 mcg | 26 weeks | — |
| Oral vs. injected: which vitamin D boost works best for low levels? 2024 · Group A · Adults aged 18–60 with initial serum vitamin D levels below 30 ng/mL | 800 IU | 12 weeks | — |
| Oral vs. injected: which vitamin D boost works best for low levels? 2024 · Group B · Adults aged 18–60 with initial serum vitamin D levels below 30 ng/mL | 8,571 IU | 12 weeks | — |
| Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial 2024 · calcifediol 75 µg group · Adults aged 18 years or older with vitamin D deficiency, serum 25(OH)D >10 and <20 ng/mL; males and females | 10.7 mcg | 52 weeks | — |
| Cutoff levels of serum 25-OH-D for defining vitamin D deficiency in early infancy 2025 · 800 IU/day · Healthy, term, breastfed infants from 48 hours after birth to 14 weeks of age | 800 IU | 14 weeks | — |
| Cutoff levels of serum 25-OH-D for defining vitamin D deficiency in early infancy 2025 · 400 IU/day · Healthy, term, breastfed infants from 48 hours after birth to 14 weeks of age | 400 IU | 14 weeks | — |
| Effect of CYP2R1 and GC gene polymorphisms on serum 25(OH)D response to vitamin D(3) supplementation in prediabetes 2025 · Vitamin D3 group · Adults with prediabetes; age and sex not specified | 1,600 IU | 24 weeks | — |
| Relationship between Circulating Vitamin D Concentration and the Maternal Gut Microbiota during Early Pregnancy in Japanese Women: Results of a Pilot Study of Antenatal Vitamin D(3) Supplementation 2025 · low-dose group · Pregnant Japanese women, starting in the first trimester; participants were predominantly vitamin D-deficient | 200 IU | 8 weeks | — |
| Relationship between Circulating Vitamin D Concentration and the Maternal Gut Microbiota during Early Pregnancy in Japanese Women: Results of a Pilot Study of Antenatal Vitamin D(3) Supplementation 2025 · medium-dose group · Pregnant Japanese women, starting in the first trimester; participants were predominantly vitamin D-deficient | 400 IU | 8 weeks | — |
| Relationship between Circulating Vitamin D Concentration and the Maternal Gut Microbiota during Early Pregnancy in Japanese Women: Results of a Pilot Study of Antenatal Vitamin D(3) Supplementation 2025 · high-dose group · Pregnant Japanese women, starting in the first trimester; participants were predominantly vitamin D-deficient | 1,000 IU | 8 weeks | — |
| Impact of almond milk fortified with vitamin D3-loaded soy protein nanoparticles on serum 25(OH)D3 concentrations in adults with CKD: a pilot double-blind randomized controlled trial 2025 · Intervention group · Adults with advanced-stage chronic kidney disease; age range and sex not reported | 4,000 IU | 3 weeks | — |
| Effects of weekly cholecalciferol supplementation of lactating mothers on vitamin D status, and infant growth and gross motor development: a randomized controlled trial in rural Ethiopia 2025 · weekly cholecalciferol group · Lactating mothers in rural Ethiopia; age not reported | 2,143 IU | 1 year | — |
| Differences in the bioavailability of dihydrotachysterol preparations 1994 · Capsule preparation 1 · Healthy volunteers; age and sex not reported | 1 mg | 1 day | — |
| Differences in the bioavailability of dihydrotachysterol preparations 1994 · Capsule preparation 2 · Healthy volunteers; age and sex not reported | 1 mg | 1 day | — |
| Differences in the bioavailability of dihydrotachysterol preparations 1994 · Oral solution preparation 1 · Healthy volunteers; age and sex not reported | 1 mg | 1 day | — |
| Differences in the bioavailability of dihydrotachysterol preparations 1994 · A.T.10 oral solution · Healthy volunteers; age and sex not reported | 1 mg | 1 day | — |
| Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males 1996 · A · Normal males aged 21–54 years | 2 mcg | 7 days | — |
| Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males 1996 · B · Normal males aged 21–54 years | 1 mcg | 7 days | — |
| Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin D3) on vitamin D photosynthesis in patients with psoriasis 1996 · calcitriol · Patients with psoriasis; age and sex not reported | 0.5 mcg | 8 weeks | — |
| Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly 1998 · VIT-D · Female psychogeriatric nursing-home patients, mean age 85 years, predominantly with low serum 25-hydroxyvitamin D | 400 IU | 12 weeks | — |
| Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men 1998 · vitamin D3 1250 micrograms/day · healthy men, mean age 28 years | 1.25 mg | 8 weeks | — |
| Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men 1998 · 25(OH)D3 10 micrograms/day · healthy men, mean age 28 years | 10 mcg | 4 weeks | — |
| Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men 1998 · 1,25(OH)2D3 0.5 microgram/day · healthy men, mean age 28 years | 0.5 mcg | 2 weeks | — |
| Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men 1998 · 1,25(OH)2D3 1.0 microgram/day (first group) · healthy men, mean age 28 years | 1 mcg | 2 weeks | — |
| Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men 1998 · 1,25(OH)2D3 1.0 microgram/day (second group) · healthy men, mean age 28 years | 1 mcg | 2 weeks | — |
| Effects of vitamin D, omega-3 and a simple strength exercise programme in cardiovascular disease prevention: The DO-HEALTH randomized controlled trial 2024 · Vitamin D3 · Community-dwelling adults aged 70 years and older, generally healthy and active, without major chronic conditions | 2,000 IU | 3 years | 1,076 |
| High Dose Supplementation of Vitamin D Affects Measures of Systemic Inflammation: Reductions in High Sensitivity C-Reactive Protein Level and Neutrophil to Lymphocyte Ratio (NLR) Distribution 2017 · Vitamin D supplementation · Adolescent girls | 7,143 IU | 9 weeks | 580 |
| Clinical and biomarker modifiers of vitamin D treatment response: the Multi-Ethnic Study of Atherosclerosis 2022 · vitamin D3 · Older adults in MESA; mean age 72 years; 53% female; no specific disease stated | 2,000 IU | 16 weeks | 499 |
| Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial 2025 · Vitamin D group · Generally healthy, community-dwelling adults aged 70 years and older; Swiss subgroup with DNA methylation measures at baseline and 3 years | 2,000 IU | 3 years | 397 |
| Process evaluation of a randomised controlled trial aimed at improving health behaviours and vitamin D status during pregnancy: Implementation of the SPRING trial 2025 · Vitamin D supplementation group · Pregnant women aged over 18 years with a singleton pregnancy of less than 17 weeks’ gestation | 1,000 IU | — | 321 |
| Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial 2020 · Vitamin D · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified | 2,400 IU | 17 weeks | 294 |
| Phosphate Concentrations and Modifying Factors in Healthy Children From 12 to 24 Months of Age 2021 · Group10 · Healthy infants; sex not specified for this arm; no stated condition | 10 mcg | 670 days | 257 |
| Vitamin D Supplementation Regulates Postoperative Serum Levels of PD-L1 in Patients with Digestive Tract Cancer and Improves Survivals in the Highest Quintile of PD-L1: A Post Hoc Analysis of the AMATERASU Randomized Controlled Trial 2021 · vitamin D group · Adults with stage I–III digestive tract cancer (esophageal, gastric, small intestinal, or colorectal) who underwent curative surgery; median age 66 years; both sexes | 2,000 IU | 1 year | 251 |
| Gestational Vitamin D Supplementation Leads to Reduced Perinatal RXRA DNA Methylation: Results From the MAVIDOS Trial 2019 · Cholecalciferol 1000 IU/day · Pregnant women aged over 18 years with singleton pregnancies, enrolled before 17 weeks’ gestation and eligible serum 25(OH)D status of 25–100 nmol/L | 1,000 IU | — | 225 |
| Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial 2020 · vitamin D · Adults with non-alcoholic fatty liver disease (NAFLD) | 1,000 IU | 360 days | 201 |
| Healthcare Costs and Healthcare Utilization Outcomes of Vitamin D3 Supplementation at 5000 IU Daily during a 10.9 Month Observation Period within a Pragmatic Randomized Clinical Trial 2023 · intervention group · Adults aged 18 years or older who were employees of an inner-city university hospital; no specific condition stated | 5,000 IU | 39 weeks | 196 |
| Bone turnover in pregnancy, measured by urinary CTX, is influenced by vitamin D supplementation and is associated with maternal bone health: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial 2021 · cholecalciferol · Pregnant women receiving supplementation from 14 weeks of gestation to birth | 1,000 IU | — | 184 |
| The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial 2021 · Vitamin D · Premenopausal women aged 22–59 with breast density of at least 25% | 2,000 IU | 1 year | 140 |
| Effect of vitamin D(3) on antiphospholipid antibodies in hospitalized patients with moderate to severe COVID-19 2024 · vitamin D3 group · Adults aged 18 or older hospitalized with moderate to severe COVID-19 | 200,000 IU | 1 day | 120 |
| Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: a randomized-controlled trial 2019 · Vitamin D · Premenopausal women aged 18 years or older with PCOS and serum 25(OH)D below 75 nmol/L | 2,857 IU | 24 weeks | 119 |
| Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial 2012 · paricalcitol group · Patients with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved left ventricular ejection fraction; estimated GFR 15 to 60 mL/min/1.73 m² | 2 mcg | 48 weeks | 115 |
| Effect of Vitamin D3 Supplementation in Combination with Weight Loss on Inflammatory Biomarkers in Postmenopausal Women: A Randomized Controlled Trial 2015 · Vitamin D · Postmenopausal women aged 50–75 with overweight or obesity and insufficient serum 25(OH)D (≥10 to <32 ng/mL) | 2,000 IU | 1 year | 109 |
| Effects of vitamin D supplementation during weight loss on sex hormones in postmenopausal women 2016 · Vitamin D · Postmenopausal women aged 50–75 with BMI ≥25 kg/m² and serum 25(OH)D ≥10 and <32 ng/mL, participating in a lifestyle-based weight-loss program | 2,000 IU | 1 year | 109 |
| Antiproteinuric effect of oral paricalcitol in chronic kidney disease 2005 · oral paricalcitol · Patients with CKD stage 3 or 4 and secondary hyperparathyroidism | 1.36 mcg | 24 weeks | 107 |
| Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial 2018 · 2000 IU vitamin D · Community-dwelling, ambulatory adults aged 65 years or older | 2,000 IU | 1 year | 102 |
| Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial 2018 · 4000 IU vitamin D · Community-dwelling, ambulatory adults aged 65 years or older | 4,000 IU | 1 year | 102 |
| Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial 2025 · 4000 IU vitamin D3 · Community-dwelling men and women aged 65 years and older; generally healthy older adults | 4,000 IU | 1 year | 102 |
| Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial 2025 · 2000 IU vitamin D3 · Community-dwelling men and women aged 65 years and older; generally healthy older adults | 2,000 IU | 1 year | 102 |
| Effects of Vitamin D Supplementation on Bone Turnover and Bone Mineral Density in Healthy Men: A Post-Hoc Analysis of a Randomized Controlled Trial 2019 · vitamin D group · Men aged 18 to under 70 years with serum 25(OH)D below 75 nmol/L; described as healthy | 2,857 IU | 12 weeks | 100 |
| Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study 2013 · Paricalcitol 2 μg/day · Men and women aged 20 years or older with type 2 diabetes, diabetic nephropathy, CKD stages 2–4, and PTH concentrations of 35–500 pg/mL | 2 mcg | 24 weeks | 95 |
| Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study 2013 · Paricalcitol 1 μg/day · Men and women aged 20 years or older with type 2 diabetes, diabetic nephropathy, CKD stages 2–4, and PTH concentrations of 35–500 pg/mL | 1 mcg | 24 weeks | 93 |
| The effect of cholecalciferol supplementation on allograft function in incident kidney transplant recipients: A randomized controlled study 2021 · Cholecalciferol · Adults aged 20–80 who were 1 month after living kidney transplantation; incident kidney transplant recipients | 4,000 IU | 335 days | 92 |
| Vitamin D supplementation and the effects on glucose metabolism during pregnancy: a randomized controlled trial 2014 · low-dose (LD) · Pregnant women with plasma 25-hydroxyvitamin D levels below 32 ng/mL before 20 weeks' gestation | 400 IU | — | 90 |
| Effects of vitamin D supplementation on FGF23: a randomized-controlled trial 2019 · Vitamin D · Adults aged 18 years or older with arterial hypertension and serum 25(OH)D below 30 ng/mL | 2,800 IU | 8 weeks | 90 |
| Vitamin D supplementation and the effects on glucose metabolism during pregnancy: a randomized controlled trial 2014 · high-dose (HD) · Pregnant women with plasma 25-hydroxyvitamin D levels below 32 ng/mL before 20 weeks' gestation | 5,000 IU | — | 89 |
| Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study 2017 · rhPTH(1–84) group · Adults aged 18–85 with hypoparathyroidism | 400 IU | 24 weeks | 84 |
| Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial 2018 · paricalcitol · Kidney transplant recipients with urinary protein-to-creatinine ratio ≥20 mg/mmol despite optimized RAAS blockade | 2 mcg | 24 weeks | 83 |
| Isolated vitamin D supplementation improves the immune-inflammatory biomarkers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial 2018 · VitD group · Postmenopausal women aged 50 to 65 years with amenorrhea for at least 12 months | 1,000 IU | 39 weeks | 80 |
| Impact of vitamin D supplementation on modulating heat-shock proteins in postmenopausal women: a randomized, double-blind, placebo-controlled study 2023 · VitD group · Postmenopausal women aged 45 to 65 years with amenorrhea for 12 months or more | 1,000 IU | 304 days | 80 |
| The Cardioprotective Effect of Vitamin D in Breast Cancer Patients Receiving Adjuvant Doxorubicin Based Chemotherapy 2022 · Vit D group · Women with newly diagnosed breast cancer receiving adjuvant doxorubicin-based chemotherapy | 0.5 mcg | 12 weeks | 75 |
| The effects of low-fat dairy products fortified with 1500 IU vitamin D(3) on serum liver function biomarkers in adults with abdominal obesity: a randomized controlled trial 2023 · fortified milk (FM) · Adults aged 30–50 years with abdominal obesity; men and women | 1,500 IU | 10 weeks | 73 |
| Positive effect of low dose vitamin D supplementation on growth of fetal bones: A randomized prospective study 2019 · intervention group · Pregnant patients; age and pregnancy-stage ranges not reported | 1,000 IU | — | 70 |
| Vitamin D status and cardiometabolic risk markers in young Swedish children: a double-blind randomized clinical trial comparing different doses of vitamin D supplements 2020 · 10 µg group · Healthy children aged 5–7 years, including fair- and dark-skinned children | 10 mcg | 90 days | 70 |
| The effects of low-fat dairy products fortified with 1500 IU vitamin D(3) on serum liver function biomarkers in adults with abdominal obesity: a randomized controlled trial 2023 · fortified yogurt (FY) · Adults aged 30–50 years with abdominal obesity; men and women | 1,500 IU | 10 weeks | 69 |
| Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study 2005 · daily group · Maintenance hemodialysis patients of both sexes with secondary hyperparathyroidism and intact parathyroid hormone (iPTH) above 200 pg/mL | 0.5 mcg | 20 weeks | 67 |
| The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism 2021 · Calcitriol group · Adults aged 18–60 with non-alcoholic fatty liver disease and below-20 ng/ml baseline vitamin D; men and women | 0.25 mcg | 17 weeks | 64 |
| Impact of treatment with active vitamin D calcitriol on bone turnover markers in people with type 2 diabetes and stage 3 chronic kidney disease 2023 · calcitriol · People with type 2 diabetes and stage 3 chronic kidney disease with intact parathyroid hormone >30 pg/ml; median age 67 years | 0.25 mcg | 48 weeks | 64 |
| Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial 2025 · calcitriol · Adults aged 18–70 with type 2 diabetes and early diabetic kidney disease | 0.25 mcg | 26 weeks | 60 |
| Association of Vitamin D Level and Maternal Gut Microbiome during Pregnancy: Findings from a Randomized Controlled Trial of Antenatal Vitamin D Supplementation 2023 · high-dose treatment group · Pregnant women enrolled at 10–18 weeks of gestation | 4,400 IU | — | 59 |
| Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans 2015 · placebo group · African American male veterans aged 35–85 with dysglycemia and hypovitaminosis D | 400 IU | 1 year | 55 |
| Association of Vitamin D Level and Maternal Gut Microbiome during Pregnancy: Findings from a Randomized Controlled Trial of Antenatal Vitamin D Supplementation 2023 · placebo group (400 IU daily cholecalciferol) · Pregnant women enrolled at 10–18 weeks of gestation | 400 IU | — | 55 |
| Vitamin D Supplementation Modestly Reduces Serum Iron Indices of Healthy Arab Adolescents 2018 · tablet group · Saudi boys and girls aged 13–17 years with vitamin D deficiency at baseline; participants with severe deficiency were excluded from the analysis | 1,000 IU | 26 weeks | 53 |
| The effect of vitamin D supplementation on serum lipids in postmenopausal women with diabetes: A randomized controlled trial 2015 · vitamin D group · Postmenopausal women with type 2 diabetes | 4,000 IU | 26 weeks | 52 |
| Effect of vitamin D adjuvant therapy on the proportion of regulatory T cells in peripheral blood and pregnancy outcome of patients with recurrent miscarriage 2025 · Vitamin D group (VDG) · Women aged 22–35 with recurrent miscarriage and singleton pregnancy | 800 IU | 12 weeks | 52 |
| Effect of vitamin D adjuvant therapy on the proportion of regulatory T cells in peripheral blood and pregnancy outcome of patients with recurrent miscarriage 2025 · Vitamin D group (VDG) · Women aged 22–35 with recurrent miscarriage and singleton pregnancy | 800 IU | 12 weeks | 52 |
| Vitamin D(3) prevents cardiovascular diseases by lowering serum total homocysteine concentrations in overweight reproductive women: A randomized, placebo-controlled clinical trial 2018 · treatment group · Overweight women of reproductive age | 7,143 IU | 60 days | 50 |
| A Randomized Double-Blind Placebo-Controlled Trial Evaluating the Efficacy of Oral Cholecalciferol in Improving Renal and Vascular Functions in Vitamin D-Deficient Patients With Type 2 Diabetes Mellitus 2023 · Group A · Adults aged 18–65 with type 2 diabetes, stage IIIA or IIIB chronic kidney disease, and hypovitaminosis D | 8,571 IU | 8 weeks | 50 |
| Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease 2016 · calcitriol · Patients with type 2 diabetes and albuminuria treated with RAAS inhibitors | 0.25 mcg | 24 weeks | 48 |
| Vitamin D Supplementation Reduces Both Oxidative DNA Damage and Insulin Resistance in the Elderly with Metabolic Disorders 2019 · intervention group · Adults older than 45 years with serum vitamin D below 30 ng/mL; participants included people with and without type 2 diabetes | 2,000 IU | 90 days | 48 |
| Changes in the human transcriptome upon vitamin D supplementation 2017 · vitamin D3 · Adults; sex and age range not specified, with no condition stated | 2,857 IU | 5 years | 47 |
| High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study 2018 · cholecalciferol group · Adults aged 18–85 with CKD stages 3–4, secondary hyperparathyroidism, and 25(OH)D below 75 nmol/L | 8,000 IU | 12 weeks | 47 |
| Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial 2023 · Vit.D3 group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified | 7,143 IU | 8 weeks | 47 |
| Vitamin D supplementation in obese type 2 diabetes subjects in Ajman, UAE: a randomized controlled double-blinded clinical trial 2015 · Vitamin D-group, phase 1 · UAE-national men and women aged 30–60 with obesity (BMI ≥30 kg/m²), type 2 diabetes, and serum 25(OH)D <50 nmol/L | 6,000 IU | 90 days | 45 |
| Vitamin D supplementation in obese type 2 diabetes subjects in Ajman, UAE: a randomized controlled double-blinded clinical trial 2015 · Vitamin D-group, phase 2 · UAE-national men and women aged 30–60 with obesity (BMI ≥30 kg/m²), type 2 diabetes, and serum 25(OH)D <50 nmol/L | 3,000 IU | 90 days | 45 |
| Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial 2015 · Vitamin D group · Vitamin D-deficient women with PCOS who were not pregnant or taking exogenous hormones | 7,143 IU | 8 weeks | 45 |
| Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease 2021 · VD group (experimental group) · Adults over 18 years with confirmed mild-to-moderate COVID-19 and hypovitaminosis D (serum vitamin D below 30 ng/mL); men and women | 60,000 IU | 10 days | 44 |
| Vitamin D supplementation reduces serum lipids of children with hypertriacylglycerolemia: A randomized, triple-masked, placebo-controlled crossover trial 2021 · supplemented group · Children aged 4–11 years with hypertriacylglycerolemia | 1,000 IU | 12 weeks | 44 |
| The Effects of Cholecalciferol Supplementation on FGF23 and α-Klotho in Hemodialysis Patients With Hypovitaminosis D: A Randomized, Double-Blind, Placebo-Controlled Trial 2022 · cholecalciferol group · Patients with hypovitaminosis D requiring hemodialysis | 7,143 IU | 12 weeks | 43 |
| Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial 2014 · vitamin D supplementation · Patients with chronic HCV genotype 1b | 1,000 IU | — | 42 |
| The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease 2023 · Cholecalciferol · Adults aged 18–85 with CKD stages G3–G4 and secondary hyperparathyroidism, with 25(OH)D below 75 nmol/L | 8,000 IU | 12 weeks | 42 |
| Insulin resistance via modification of PGC1α function identifying a possible preventive role of vitamin D analogues in chronic inflammatory state of obesity. A double blind clinical trial study 2014 · intervention group (alfacalcidol) · Obese participants (BMI ≥30); age and sex not specified | 1 mcg | 8 weeks | 40 |
| Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D 2014 · VD group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 22.1 years | 400 IU | 1 year | 40 |
| Prenatal high-dose vitamin D3 supplementation has balanced effects on cord blood Th1 and Th2 responses 2016 · vitD group · Pregnant women aged 18 to under 35 years, enrolled at 26–29 weeks of gestation in Dhaka | 5,000 IU | — | 40 |
| Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study 2017 · Placebo group · Adults aged 18–85 with hypoparathyroidism | 400 IU | 24 weeks | 40 |
| Calcitriol Reduces Albuminuria and Urinary Angiotensinogen Level in Renal Transplant Recipients 2018 · calcitriol group · Renal transplant recipients with low 25-(OH)D levels; nondiabetic | 0.25 mcg | 1 year | 40 |
| Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial 2019 · calcitriol group · Adults aged 18–68 years with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma in complete remission after autologous peripheral blood hematopoietic stem cell transplantation | 0.75 mcg | 30 days | 40 |
| Calcitriol supplementation before parathyroidectomy and calcium level after surgery in parathyroid adenoma patients: a randomized controlled trial 2023 · intervention group · Adults with primary hyperparathyroidism undergoing parathyroidectomy | 0.25 mcg | 7 days | 40 |
| Effect of vitamin D on endothelial and ventricular function in chronic heart failure patients: A prospective, randomized, placebo-controlled trial 2022 · vitamin D group · Adults with vitamin D-deficient, stable chronic heart failure; mean age about 66 years; both sexes | 4,000 IU | 26 weeks | 39 |
| Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients 2011 · treatment group · Adults with treatment-naïve chronic hepatitis C genotype 1 infection | 2,000 IU | — | 36 |
| Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth 2008 · daily orally calcitriol (DO group) · Adults receiving haemodialysis for more than 6 months with secondary hyperparathyroidism and intact PTH 100–300 pg/ml | 0.25 mcg | 1 year | 35 |
| A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men 2009 · supplemented group · Men aged 35 years or older who were apparently healthy and centrally obese | 60,000 IU | 6 weeks | 35 |
| 1,25-Dihydroxyvitamin D3 stimulation test and the effect of a prostaglandin synthesis inhibitor (piroxicam) in young adults 1991 · 1,25(OH)2 vitamin D3 (Rocaltrol) stimulation test · Healthy young adult men | 4 mcg | 4 days | 34 |
| Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study 2013 · Cinacalcet group · Adults aged 18–70 receiving peritoneal dialysis with secondary hyperparathyroidism | 0.13 mcg | 16 weeks | 33 |
| Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study 2013 · Control group · Adults aged 18–70 receiving peritoneal dialysis with secondary hyperparathyroidism | 0.27 mcg | 16 weeks | 33 |
| Vitamin D to Prevent Lung Injury Following Esophagectomy-A Randomized, Placebo-Controlled Trial 2018 · cholecalciferol arm · Adults undergoing planned esophagectomy for malignancy; men aged 18 or older and women aged 55 or older or more than 2 years post-menopause | 300,000 IU | 1 day | 33 |
| Vitamin D supplementation in obese Sri Lankan children: a randomized controlled trial 2020 · Supplementation Group · Children aged 5–15 years with obesity and vitamin D deficiency | 357 IU | 24 weeks | 33 |
| Supplementation with 1000 IU vitamin D/d leads to parathyroid hormone suppression, but not increased fractional calcium absorption, in 4-8-y-old children: a double-blind randomized controlled trial 2013 · 1000 IU vitamin D(3)/d · Healthy prepubertal children aged 4–8 years | 1,000 IU | 8 weeks | 32 |
| Vitamin D supplementation in obese Sri Lankan children: a randomized controlled trial 2020 · Treatment Group · Children aged 5–15 years with obesity and vitamin D deficiency | 7,143 IU | 24 weeks | 32 |
| Impact of high-dose vitamin D supplementation initiated shortly after diagnosis on residual beta cell function and partial remission rates in children with type 1 diabetes 2025 · Cases · Children aged 2–12 years with newly diagnosed type 1 diabetes | 4,286 IU | 26 weeks | 32 |
| High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients 2020 · Group I · Men and women aged 18–65 years with type 2 diabetes mellitus and diabetic peripheral neuropathy; most had vitamin D deficiency or insufficiency | 714 IU | 24 weeks | 31 |
| High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients 2020 · Group II · Men and women aged 18–65 years with type 2 diabetes mellitus and diabetic peripheral neuropathy; most had vitamin D deficiency or insufficiency | 5,714 IU | 24 weeks | 31 |
| Low-Dose Vitamin D(3) Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-γ: Results From the D-SIRe2 Randomized Controlled Trial 2021 · VitD3 group · Healthy adults older than 18 years | 400 IU | 43 weeks | 31 |
| Oral vitamin D supplementation on the prevention of peritoneal dialysis-related peritonitis: A pilot randomised controlled trial 2024 · Vitamin D group · Patients receiving peritoneal dialysis who had recovered from a recent episode of peritonitis; age and sex not stated | 2,000 IU | 1 year | 31 |
| Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial 2014 · paricalcitol · Adults with stages 3–5 chronic kidney disease and left ventricular hypertrophy | 1 mcg | 52 weeks | 30 |
| Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 2015 · Group Paricalcitol · Adults over 18 with stage 3b–5 chronic kidney disease and hemoglobin levels of 10–12.5 g/dL | 1 mcg | 26 weeks | 30 |
| Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 2015 · Group Calcitriol · Adults over 18 with stage 3b–5 chronic kidney disease and hemoglobin levels of 10–12.5 g/dL | 0.25 mcg | 26 weeks | 30 |
| Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients 2016 · Paricalcitol plus cholecalciferol (study group) · Adults aged 18 years or older receiving hemodialysis, with stage 5D chronic kidney disease, secondary hyperparathyroidism and low serum 25(OH)D3 | 714 IU | 16 weeks | 30 |
| Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · 4 000 IU vitamin D group · Insulin-resistant patients with PCOS aged 18–40 years | 4,000 IU | 12 weeks | 30 |
| Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · 1 000 IU vitamin D group · Insulin-resistant patients with PCOS aged 18–40 years | 1,000 IU | 12 weeks | 30 |
| Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients 2018 · CCC (study group) · Adults over 18 years receiving maintenance hemodialysis with severe secondary hyperparathyroidism | 5,000 IU | 24 weeks | 30 |
| Effects of active vitamin D on insulin resistance and islet β-cell function in non-diabetic chronic kidney disease patients: a randomized controlled study 2022 · Non-dialysis experimental group · Adults with non-diabetic chronic kidney disease receiving non-dialysis treatment; mean age 53.45 years in the non-dialysis group | 0.5 mcg | 26 weeks | 30 |
| Vitamin D Supplementation Modulates Platelet-Mediated Inflammation in Subjects With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial 2022 · vitamin D3 group · Adults aged 35–65 with vitamin-D-deficient, uncontrolled type 2 diabetes | 8,571 IU | 26 weeks | 30 |
| The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial 2025 · UDCA + VitD group · Adults aged 18 years or older with treatment-naive primary biliary cholangitis; 70% female in the initial group | 1,200 IU | 2 years | 30 |
| Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial 2009 · paricalcitol group · Patients with proteinuric chronic kidney disease and eGFR of 15 to 90 mL/min/1.73 m² | 1 mcg | 26 weeks | 28 |
| Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: A randomized placebo-controlled trial 2015 · vitamin D · Patients with hypercholesterolemia receiving statin treatment | 2,000 IU | 26 weeks | 28 |
| Effects of 1α-Calcidol (Alfacalcidol) on Microvascular Endothelial Function, Arterial Stiffness, and Blood Pressure in Type II Diabetic Nephropathy Patients 2016 · alfacalcidol group · Patients with type II diabetic nephropathy; age and sex not reported | 0.25 mcg | 26 weeks | 28 |
| Effect of two vitamin D repletion protocols on 24-h urine calcium in patients with recurrent calcium kidney stones and vitamin D deficiency: a randomized clinical trial 2023 · 2000 IU/daily · Adults aged 18–70 with recurrent calcium kidney stones and vitamin D deficiency (25(OH)D 10–20 ng/mL) | 2,000 IU | 12 weeks | 28 |
| The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients 2015 · vitamin D3 supplementation group · Adults with multiple sclerosis; some had deficient or insufficient 25-hydroxyvitamin D levels | 7,143 IU | 26 weeks | 27 |
| Vitamin D binding protein is not affected by high-dose vitamin D supplementation: a post hoc analysis of a randomised, placebo-controlled study 2018 · vitamin D treated group · Persistent MRSA carriers; age and sex not stated; generally healthy | 4,000 IU | 1 year | 27 |
| Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial 2013 · paricalcitol · Adults with stage III-IV chronic kidney disease and micro- or macroalbuminuria; age >18 years | 2 mcg | 6 weeks | 26 |
| Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial 2015 · Group B · Overweight, vitamin D-deficient women aged 18–40 years with PCOS | 7,143 IU | 8 weeks | 26 |
| Vitamin D supplementation during pregnancy: Effect on the neonatal immune system in a randomized controlled trial 2018 · 4400 IU/d vitamin D3 · Pregnant women; age and pregnancy condition details beyond pregnancy are not reported. | 4,400 IU | — | 26 |
| Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial 2021 · Calcitriol (switched from alfacalcidol) · Patients with idiopathic hypoparathyroidism who had optimal calcemic control on alfacalcidol | 0.75 mcg | 26 weeks | 25 |
| The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes 2021 · D-yogurt drink (DY) · Adults aged 30–60 years with confirmed type 2 diabetes | 1,000 IU | 12 weeks | 25 |
| Vitamin D supplementation affects serum high-sensitivity C-reactive protein, insulin resistance, and biomarkers of oxidative stress in pregnant women 2013 · vitamin D group · Pregnant women aged 18–40 years at 25 weeks of gestation; described as healthy | 400 IU | 9 weeks | 24 |
| Acute Supplementation with High Dose Vitamin D3 Increases Serum Anti-Müllerian Hormone in Young Women 2017 · Vitamin D3 group · Women aged 19–25 years with regular menstrual cycles and no known ovarian conditions | 50,000 IU | 7 days | 24 |
| Effects of vitamin D supplements on frequency of CD4(+) T-cell subsets in women with Hashimoto's thyroiditis: a double-blind placebo-controlled study 2019 · vitamin D group · Women with Hashimoto's thyroiditis | 7,143 IU | 90 days | 24 |
| Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial 1994 · continuous calcitriol group · Dialysis patients with elevated 1,84-iPTH levels | 0.75 mcg | 12 weeks | 24 |
| Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial 2009 · 800 IU vitamin D3 supplementation · Adults aged 30–75 in generally good health with at least one pathology-confirmed sporadic colon or rectal adenoma in the previous 36 months | 800 IU | 26 weeks | 23 |
| Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial 2009 · vitamin D supplementation group · Adults aged 30–75 in general good health with a history of at least one pathology-confirmed colorectal adenoma within the past 36 months | 800 IU | 26 weeks | 23 |
| Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients 2010 · 800 IU vitamin D3 supplementation group · Adults aged 30–75 with a history of at least one adenomatous colonic or rectal polyp within the past 36 months | 800 IU | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients 2011 · vitamin D3 group · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp in the preceding 36 months | 800 IU | 180 days | 23 |
| Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial 2011 · 800 IU vitamin D3 group · Adults aged 30–75 with a history of sporadic colorectal adenoma | 800 IU | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients 2012 · 800 IU vitamin D3 supplementation · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp within the past 36 months | 800 IU | 26 weeks | 23 |
| Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: a randomized controlled trial 2015 · vitamin D3 group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp within the past 36 months; both sexes | 800 IU | 26 weeks | 23 |
| Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by Pseudomonas aeruginosa- pilot study 2019 · calcitriol group · Children and adolescents aged 6–19 years with cystic fibrosis and chronic Pseudomonas aeruginosa infection | 0.5 mcg | 90 days | 23 |
| Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by Pseudomonas aeruginosa- pilot study 2019 · cholecalciferol group · Children and adolescents aged 6–19 years with cystic fibrosis and chronic Pseudomonas aeruginosa infection | 1,000 IU | 90 days | 23 |
| The effects of chromium and vitamin D(3) co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial 2020 · vitamin D3 supplement · patients with type 2 diabetes mellitus; age and sex not stated | 7,143 IU | 120 days | 23 |
| The effect of vitamin D supplementation on flow-mediated dilatation, oxidized LDL and intracellular adhesion molecule 1 on type 2 diabetic patients with hypertension: A randomized, placebo-controlled, double-blind trial 2021 · vitamin D group · Patients with type 2 diabetes and hypertension; age and sex not reported | 2,000 IU | 12 weeks | 23 |
| Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia 2006 · Group 1 · Patients undergoing total thyroidectomy; age and sex not reported | 1.5 mcg | 7 days | 22 |
| A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease 2010 · cholecalciferol · Adults with vitamin D-deficient stage 3 or 4 chronic kidney disease and parathyroid hormone values above the Kidney Disease Outcomes Quality Initiative target | 4,000 IU | 90 days | 22 |
| No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes 2010 · 1,25(OH)2D3 treatment group · Adults with recent-onset type 1 diabetes; randomized efficacy phase participants | 0.25 mcg | 39 weeks | 22 |
| Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial 2014 · Cholecalciferol group · Healthy men and women older than 18 years with vitamin D insufficiency (serum 25(OH)vitamin D ≤50 nmol/L) | 3,000 IU | 16 weeks | 22 |
| Acute Effects of Single Doses of Bonito Fish Peptides and Vitamin D on Whole Blood Gene Expression Levels: A Randomized Controlled Trial 2019 · VitD3 · Overweight or obese adults aged 18–65 years, without metabolic disorders requiring treatment | 1,000 IU | 1 day | 22 |
| Effect of high-dose vitamin D supplementation in combination with weight loss diet on glucose homeostasis, insulin resistance, and matrix metalloproteinases in obese subjects with vitamin D deficiency: a double-blind, placebo-controlled, randomized clinical trial 2020 · Vitamin D group · Obese participants with vitamin D deficiency, BMI 30–40 kg/m² and serum 25(OH)D ≤50 nmol/L; age and sex not specified | 7,143 IU | 12 weeks | 22 |
| Effects of cholecalciferol supplementation on serum angiogenic biomarkers in breast cancer patients treated with tamoxifen: A controlled randomized clinical trial 2020 · cholecalciferol intervention group · Women with breast cancer treated with tamoxifen; age range and menopausal status not specified | 7,143 IU | 8 weeks | 22 |
| Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial 2025 · Vit D 1000 (D1) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m² | 1,000 IU | 8 weeks | 22 |
| Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial 2025 · Vit D 5000 (D5) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m² | 5,000 IU | 8 weeks | 22 |
| Effect of vitamins on the lipid profile of patients on regular hemodialysis 2000 · vitamin D3 · hemodialysis patients; age and sex not reported | 50,000 IU | 90 days | 21 |
| Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial 1994 · intermittent calcitriol group · Dialysis patients with elevated 1,84-iPTH levels | 0.75 mcg | 12 weeks | 21 |
| [Treatment of secondary hyperparathyroidism with vitamin D metabolites] 1994 · 1-alpha-OHD3 plus placebo · Adults aged 19–67 with secondary hyperparathyroidism receiving chronic haemodialysis | 0.25 mcg | 13 weeks | 20 |
| The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial 2010 · 200,000 IU vitamin D(3) · Patients with type 2 diabetes and baseline 25-hydroxyvitamin D levels <100 nmol/l | 200,000 IU | 1 day | 20 |
| Vitamin D(3) repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial 2017 · Vitamin D3 treatment · Adults aged 18 years or older with NYHA class II or III heart failure and baseline 25(OH)D ≤32 ng/ml | 10,000 IU | 26 weeks | 20 |
| A randomized double-blind placebo-controlled trial of vitamin D supplementation in juvenile-onset systemic lupus erythematosus: positive effect on trabecular microarchitecture using HR-pQCT 2018 · JoSLE-VitD · Female patients with juvenile-onset systemic lupus erythematosus | 7,143 IU | 24 weeks | 20 |
| Vitamin D3 supplementation improves serum SFRP5 and Wnt5a levels in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial 2018 · Vitamin D group · Adults with type 2 diabetes; 16 women and 24 men across the trial; age range not reported | 4,000 IU | 8 weeks | 20 |
| Vitamin D Supplementation and T Cell Regulation in Preterm Infants: A Randomized Controlled Trial 2019 · 400 IU/day vitamin D3 group · Preterm infants born at 28–33 weeks’ gestation | 400 IU | 4 weeks | 20 |
| Vitamin D Supplementation and T Cell Regulation in Preterm Infants: A Randomized Controlled Trial 2019 · 800 IU/day vitamin D3 group · Preterm infants born at 28–33 weeks’ gestation | 800 IU | 4 weeks | 20 |
| Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial 2021 · Alfacalcidol (continued same treatment) · Patients with idiopathic hypoparathyroidism who had optimal calcemic control on alfacalcidol | 2 mcg | 26 weeks | 20 |
| Vitamin D supplementation during pregnancy inhibits the activation of fetal membrane NF-κB pathway 2022 · Group 1 · Pregnant women with vitamin D insufficiency (serum vitamin D 20–30 ng/mL), supplemented from week 14 of pregnancy until delivery | 500 IU | — | 20 |
| Vitamin D supplementation during pregnancy inhibits the activation of fetal membrane NF-κB pathway 2022 · Group 2 · Pregnant women with vitamin D insufficiency (serum vitamin D 20–30 ng/mL), supplemented from week 14 of pregnancy until delivery | 1,000 IU | — | 20 |
| The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial 2010 · 100,000 IU vitamin D(3) · Patients with type 2 diabetes and baseline 25-hydroxyvitamin D levels <100 nmol/l | 100,000 IU | 1 day | 19 |
| Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients 2018 · Vitamin D (2-arm randomization) · Women aged 45–75 with a removed histologically verified colorectal adenoma who declined to forego calcium supplementation | 1,000 IU | 1 year | 19 |
| Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study 2020 · Group C · Patients with latent autoimmune diabetes in adults (LADA) | 2,000 IU | 1 year | 19 |
| Effects of active vitamin D on insulin resistance and islet β-cell function in non-diabetic chronic kidney disease patients: a randomized controlled study 2022 · Peritoneal dialysis experimental group · Adults with non-diabetic chronic kidney disease receiving peritoneal dialysis; mean age 49.95 years in the peritoneal dialysis group | 0.5 mcg | 26 weeks | 19 |
| A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome 2019 · vitamin D group · Women aged 18–45 with PCOS who were overweight or obese and vitamin D deficient | 3,200 IU | 90 days | 18 |
| Effects of active vitamin D on insulin resistance and islet β-cell function in non-diabetic chronic kidney disease patients: a randomized controlled study 2022 · Hemodialysis experimental group · Adults with non-diabetic chronic kidney disease receiving hemodialysis; mean age 48.75 years in the hemodialysis group | 0.5 mcg | 26 weeks | 18 |
| Effect of Ergocalciferol on β-Cell Function in New-Onset Type 1 Diabetes: A Secondary Analysis of a Randomized Clinical Trial 2024 · Ergocalciferol · Youths aged 10–21 years with newly diagnosed type 1 diabetes | 7,143 IU | 1 year | 18 |
| Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial 2017 · intervention group · Children and young people aged 1 to under 21 years with stage 2–5 non-dialysis chronic kidney disease | 4,000 IU | 12 weeks | 17 |
| Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial 2017 · control group · Children and young people aged 1 to under 21 years with stage 2–5 non-dialysis chronic kidney disease | 400 IU | 12 weeks | 17 |
| Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients 2018 · Vitamin D (4-arm randomization) · Adults aged 45–75 with a removed histologically verified colorectal adenoma; men and women | 1,000 IU | 1 year | 17 |
| Effect of Vitamin D Supplementation on Faecal Microbiota: A Randomised Clinical Trial 2019 · vitamin D group · Adults aged 18–60 with vitamin D deficiency and overweight or obesity | 4,000 IU | 16 weeks | 17 |
| Effect of 1,25 (OH)2D3 treatment on glucose intolerance in uraemia 1992 · oral calcitriol · Adults receiving haemodialysis with uraemia | 0.5 mcg | 8 weeks | 16 |
| Effects of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis patients 1992 · calcitriol treatment · Uremic hemodialysis patients | 0.5 mcg | 8 weeks | 16 |
| Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma 2010 · 1,25(OH)2D3-treated patients · Adults aged 45–92 with newly diagnosed head and neck squamous cell carcinoma scheduled for surgery | 4 mcg | 3 weeks | 16 |
| Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients 2011 · calcitriol group · Haemodialysis patients with secondary hyperparathyroidism and intact parathyroid hormone >32 pmol/L | 0.586 mcg | 24 weeks | 16 |
| Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients 2011 · alfacalcidol group · Haemodialysis patients with secondary hyperparathyroidism and intact parathyroid hormone >32 pmol/L | 0.986 mcg | 24 weeks | 16 |
| Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study) 2022 · intervention group · Vitamin D-deficient adults with asymptomatic or mildly symptomatic SARS-CoV-2 infection; age and sex not reported | 60,000 IU | 7 days | 16 |
| Single High-Dose Vitamin D Supplementation as an Approach for Reducing Ultramarathon-Induced Inflammation: A Double-Blind Randomized Controlled Trial 2021 · supplementation group (S) · Healthy male semi-professional ultramarathon runners aged 30 years or older | 150,000 IU | 1 day | 16 |
| Effects of Endurance Exercise and Vitamin D Supplementation on Insulin Resistance and Plasma Lipidome in Middle-Aged Adults with Type 2 Diabetes 2023 · EX + VD group · Middle-aged adults with type 2 diabetes mellitus, not receiving insulin treatment | 1,000 IU | 12 weeks | 16 |
| Effects of Endurance Exercise and Vitamin D Supplementation on Insulin Resistance and Plasma Lipidome in Middle-Aged Adults with Type 2 Diabetes 2023 · VD group · Middle-aged adults with type 2 diabetes mellitus, not receiving insulin treatment | 1,000 IU | 12 weeks | 16 |
| Vitamin D Supplementation Influences Ultramarathon-Induced Changes in Serum Amino Acid Levels, Tryptophan/Branched-Chain Amino Acid Ratio, and Arginine/Asymmetric Dimethylarginine Ratio 2023 · experimental (supplemented, S) group · Semi-professional male ultramarathon runners with previous ultramarathon experience (at least 5 starts); age range not reported | 150,000 IU | 1 day | 16 |
| Effect of Single High-Dose Vitamin D(3) Supplementation on Post-Ultra Mountain Running Heart Damage and Iron Metabolism Changes: A Double-Blind Randomized Controlled Trial 2024 · supplementation group (S) · Healthy semi-professional male ultramarathon runners aged 30 years or older with at least five previous ultramarathon finishes | 150,000 IU | 1 day | 16 |
| Plasma Lipidomic Profiles Improve upon Traditional Risk Factors for the Prediction of Arterial Stiffness Among Patients with Type 2 Diabetes Mellitum: A Randomized, Placebo-Controlled Trial 2024 · EX + VD group · Adults aged 33–65 with type 2 diabetes, not treated with insulin | 1,000 IU | 12 weeks | 16 |
| Plasma Lipidomic Profiles Improve upon Traditional Risk Factors for the Prediction of Arterial Stiffness Among Patients with Type 2 Diabetes Mellitum: A Randomized, Placebo-Controlled Trial 2024 · VD group · Adults aged 33–65 with type 2 diabetes, not treated with insulin | 1,000 IU | 12 weeks | 16 |
| Single high-dose vitamin D supplementation impacts ultramarathon-induced changes in serum levels of bone turnover markers: a double-blind randomized controlled trial 2025 · supplemented group · Semiprofessional male ultramarathon runners who intended to complete a 240 km ultramarathon; ages 42.40 ± 7.59 years in the supplemented group | 150,000 IU | 1 day | 16 |
| The effect of 1,25(OH)2 vitamin D3 on CD4+/CD8+ subsets of T lymphocytes in postmenopausal women 1997 · Group one (1 ug/day) · Postmenopausal women | 1 mcg | 2 weeks | 16 |
| Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure 1998 · Treatment A · Adults with predialytic chronic renal failure and secondary hyperparathyroidism | 0.5 mcg | 90 days | 16 |
| Effect of Vitamin D Supplementation on Muscle Status in Old Patients Recovering from COVID-19 Infection 2021 · vitamin D (VD) group · Older male patients recovering from recent PCR-confirmed COVID-19 infection, without stated comorbidities | 2,000 IU | 6 weeks | 15 |
| Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease 1997 · Group B · Patients with untreated Graves' disease; age and sex not stated | 1.5 mcg | 24 weeks | 15 |
| Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study 2014 · ACD group · Hemodialysis patients with mild secondary hyperparathyroidism whose intact PTH had decreased to the target range | 0.5 mcg | 12 weeks | 14 |
| High-dose vitamin D(3) reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults 2017 · vitamin D group · Healthy adults aged 18–65; most were vitamin D deficient at baseline | 250,000 IU | 1 day | 14 |
| The effect of 1,25(OH)2 vitamin D3 on CD4+/CD8+ subsets of T lymphocytes in postmenopausal women 1997 · Group two (2 ug/day) · Postmenopausal women | 2 mcg | 2 weeks | 14 |
| Vitamin D2 supplementation amplifies eccentric exercise-induced muscle damage in NASCAR pit crew athletes 2013 · Vitamin D group · Adult NASCAR pit crew athletes; sex not stated; not selected for a diagnosed condition or vitamin D deficiency | 3,800 IU | 6 weeks | 13 |
| The effect of short-term vitamin D on the antioxidant capacity following exhaustive aerobic exercise 2023 · Experimental (Exp) · Men aged 20–30 with vitamin D deficiency, without underlying disease; non-athletes | 2,000 IU | 6 weeks | 13 |
| Effect of 24,25-dihydroxycholecalciferol on intestinal absorption of calcium and phosphate and on parathyroid hormone secretion in chronic renal failure 1992 · 24,25-dihydroxycholecalciferol treatment · Patients with chronic renal failure requiring dialysis; 7 of the 12 were hypercalcaemic | 10 mcg | 90 days | 12 |
| Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease 2017 · Stage 3/4 CKD Part 1 paricalcitol · Children aged 10–16 years with stage 3 or 4 chronic kidney disease | 3 mcg | 1 day | 12 |
| Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial 2017 · Paricalcitol 1 μg · Adults over 20 years with moderate chronic kidney disease (eGFR 15–59 mL/min/1.73 m²) | 1 mcg | 12 weeks | 12 |
| Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial 2017 · Paricalcitol 2 μg · Adults over 20 years with moderate chronic kidney disease (eGFR 15–59 mL/min/1.73 m²) | 2 mcg | 12 weeks | 12 |
| Oxidative stress in critically ill ventilated adults: effects of vitamin D(3) and associations with alveolar macrophage function 2018 · 50,000 IU vitamin D3 group · Adults older than 18 years with critical illness and respiratory failure requiring mechanical ventilation | 50,000 IU | 5 days | 12 |
| Oxidative stress in critically ill ventilated adults: effects of vitamin D(3) and associations with alveolar macrophage function 2018 · 100,000 IU vitamin D3 group · Adults older than 18 years with critical illness and respiratory failure requiring mechanical ventilation | 100,000 IU | 5 days | 12 |
| Effect of Vitamin D(3) on the Postprandial Lipid Profile in Obese Patients: A Non-Targeted Lipidomics Study 2019 · low-dose cholecalciferol group · Obese, pre-menopausal, vitamin D-deficient women | 75,000 IU | 7 days | 12 |
| Effect of Vitamin D(3) on the Postprandial Lipid Profile in Obese Patients: A Non-Targeted Lipidomics Study 2019 · high-dose cholecalciferol group · Obese, pre-menopausal, vitamin D-deficient women | 300,000 IU | 7 days | 12 |
| Effect of vitamin D(3) vs. calcifediol on VDR concentration and fiber size in skeletal muscle 2023 · VD3 group · Postmenopausal women; mean age 61 ± 4 years | 3,200 IU | 26 weeks | 12 |
| Randomized controlled trial of vitamin d supplementation on toll-like receptor-2 (tlr-2) and toll-like receptor-4 (tlr-4) in tuberculosis spondylitis patients 2023 · 10,000 IU/day group · Patients aged 19–50 with tuberculosis spondylitis | 10,000 IU | 8 weeks | 12 |
| Randomized controlled trial of vitamin d supplementation on toll-like receptor-2 (tlr-2) and toll-like receptor-4 (tlr-4) in tuberculosis spondylitis patients 2023 · 5,000 IU/day group · Patients aged 19–50 with tuberculosis spondylitis | 5,000 IU | 8 weeks | 12 |
| Randomized controlled trial of vitamin d supplementation on toll-like receptor-2 (tlr-2) and toll-like receptor-4 (tlr-4) in tuberculosis spondylitis patients 2023 · 400 IU/day group · Patients aged 19–50 with tuberculosis spondylitis | 400 IU | 8 weeks | 12 |
| Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial 2025 · Pilot cohort · Infertile men; mean age 33.4 years | 25 mcg | 270 days | 12 |
| Effects of Resistance Training Combined with Vitamin D Supplementation on Health-Related Variables in the Elderly: Muscle Strength, Body Composition, and Inflammatory Status 2025 · experimental group (EG) · Men and women aged 60 or older without a stated diagnosed condition; participants had adequate vitamin D levels | 2,000 IU | 12 weeks | 12 |
| Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone 1995 · Group A · Adults with chronic renal insufficiency who were not receiving dialysis | 0.55 mcg | 39 weeks | 12 |
| 1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells 2009 · 1,25(OH)2D3-treated patients · Adults aged 42–77 with newly diagnosed stage II–IV head and neck squamous cell carcinoma scheduled for surgery | 4 mcg | 3 weeks | 11 |
| Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial 2012 · Group-1: alphacalcidol first · Adults aged 18 years or older with chronic kidney disease stage 3b | 0.25 mcg | 2 weeks | 11 |
| Maternal pregnancy vitamin D supplementation increases offspring bone formation in response to mechanical loading: Findings from a MAVIDOS Trial sub-study 2020 · Intervention group (children whose mothers received antenatal vitamin D) · Pregnant women with baseline 25(OH)D of 25–100 nmol/L at 11–14 weeks’ gestation; their offspring were aged 4–5 years at the sub-study | 1,000 IU | — | 11 |
| Alterations of liver enzymes and lipid profile in response to exhaustive eccentric exercise: vitamin D supplementation trial in overweight females with non-alcoholic fatty liver disease 2022 · experimental group · Women aged 20–40 years with overweight and ultrasound-diagnosed non-alcoholic fatty liver disease | 2,000 IU | 6 weeks | 11 |
| Vitamin D3 supplementation in COVID-19 patients with cardiovascular disease and gut dysbiosis 2024 · vitamin D3 group · Adults hospitalized with mild COVID-19 and a history of cardiovascular disease | 10,000 IU | — | 11 |
| Calcitriol per os once, twice or three times a week: effect of different schedules of administration in hemodialysis patients 2000 · Group A · Patients on hemodialysis with secondary hyperparathyroidism; age and sex not reported | 0.0000114 mg/kg | 60 days | 10 |
| Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis 2003 · Adults with cystic fibrosis · Adults with cystic fibrosis | 1 mcg | 2 weeks | 10 |
| Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis 2003 · Age-, sex- and BMI-matched controls · Adult age-, sex- and BMI-matched controls without stated cystic fibrosis | 1 mcg | 2 weeks | 10 |
| Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial 2012 · Group-2: sevelamer carbonate first · Adults aged 18 years or older with chronic kidney disease stage 3b | 0.25 mcg | 2 weeks | 10 |
| Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis 2018 · Plain vitamin D3 treatment · Post-menopausal women with osteoporosis, approximately 73 years old | 800 IU | 27 days | 10 |
| Home-based aerobic training and vitamin D improve neurotrophins and inflammatory biomarkers in MS patients 2022 · AT+Vit D · Females aged 20–40 with multiple sclerosis (EDSS 3–5) and BMI 25–30 kg/m² | 7,143 IU | 8 weeks | 10 |
| Concurrent alteration in inflammatory biomarker gene expression and oxidative stress: how aerobic training and vitamin D improve T2DM 2022 · AT+Vit D · Males aged 35–50 years with type 2 diabetes mellitus | 7,143 IU | 8 weeks | 10 |
| Concurrent alteration in inflammatory biomarker gene expression and oxidative stress: how aerobic training and vitamin D improve T2DM 2022 · Vit D · Males aged 35–50 years with type 2 diabetes mellitus | 7,143 IU | 8 weeks | 10 |
| Decreased inflammatory gene expression accompanies the improvement of liver enzyme and lipid profile following aerobic training and vitamin D supplementation in T2DM patients 2022 · AT+Vit D · Men aged 35–50 with type 2 diabetes mellitus | 7,143 IU | 8 weeks | 10 |
| Decreased inflammatory gene expression accompanies the improvement of liver enzyme and lipid profile following aerobic training and vitamin D supplementation in T2DM patients 2022 · Vit D · Men aged 35–50 with type 2 diabetes mellitus | 7,143 IU | 8 weeks | 10 |
| [Effect of 1 alpha-OH-D3 on the bone metabolism after high tibial osteotomy] 1993 · 1 alpha-OH-D3 treated group · Female patients with gonarthrosis undergoing high tibial osteotomy | 1 mcg | — | 10 |
| Changes in 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D are associated with maturation of regulatory T lymphocytes in patients with chronic pancreatitis: a randomized controlled trial 2012 · group B · Patients with chronic pancreatitis and fat malabsorption; age and sex not reported | 1,520 IU | 10 weeks | 9 |
| Effects of 1,25-dihydroxyvitamin D3 and vitamin D3 on the expression of the vitamin d receptor in human skeletal muscle cells 2015 · vitamin D3-supplemented women · Women aged 65 years and older with mobility limitations and moderately low baseline 25OHD | 4,000 IU | 16 weeks | 9 |
| Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis 2018 · ELD treatment · Post-menopausal women with osteoporosis, approximately 74 years old | 0.75 mcg | 27 days | 9 |
| Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis 2018 · ALF treatment · Post-menopausal women with osteoporosis, approximately 75 years old | 1 mcg | 27 days | 9 |
| Home-based aerobic training and vitamin D improve neurotrophins and inflammatory biomarkers in MS patients 2022 · Vit D · Females aged 20–40 with multiple sclerosis (EDSS 3–5) and BMI 25–30 kg/m² | 7,143 IU | 8 weeks | 9 |
| Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism 1995 · intermittent oral calcitriol · Adults with secondary hyperparathyroidism receiving chronic haemodialysis | 0.0000064 mg/kg | 10 weeks | 8 |
| Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial 1998 · daily · CAPD patients with mild to moderate secondary hyperparathyroidism | 0.75 mcg | 85 days | 8 |
| Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients 2021 · ASC + VIT D group · Patients aged 16–35 years with recent-onset type 1 diabetes (<4 months) and positive GADA; both sexes | 2,000 IU | 26 weeks | 7 |
| Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism 1995 · daily oral calcitriol · Adults with secondary hyperparathyroidism receiving chronic haemodialysis | 0.0000064 mg/kg | 10 weeks | 7 |
| Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial 2013 · Group II (2,000 IU/d) · Healthy adults aged 18 or older, men and women; included participants with vitamin D deficiency and participants with insufficient or sufficient status | 2,000 IU | 8 weeks | 5 |
| Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial 2013 · Group I (400 IU/d) · Healthy adults aged 18 or older, men and women; included participants with vitamin D deficiency and participants with insufficient or sufficient status | 400 IU | 8 weeks | 3 |
| Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy 2004 · calcitriol · Patients with histologically confirmed prostate adenocarcinoma scheduled for radical prostatectomy; age and sex range not reported | 0.0000714 mg/kg | 4 weeks | — |
| Calcemic response to magnesium or 1-alpha-hydroxycholecalciferol treatment in intestinal hypomagnesemia 1991 · Group II (1-alpha-hydroxycholecalciferol) · Gastroenterological patients with intestinal hypomagnesemia; age and sex not reported | 1 mcg | 7 days | — |
| A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease 2006 · continuous group · Patients with end-stage renal disease on hemodialysis and secondary hyperparathyroidism | 1 mcg | 12 weeks | — |
| A single dose of vitamin D enhances immunity to mycobacteria 2007 · vitamin D · Healthy adult tuberculosis contacts in London, United Kingdom | 2.5 mg | 1 day | — |
| Combined calcium and vitamin D supplementation is not superior to calcium supplementation alone in improving disturbed bone metabolism in patients with congestive heart failure 2008 · CaD group · Ambulatory men with congestive heart failure, low vitamin D status, and insufficient dietary calcium intake | 50 mcg | 270 days | — |
| Calcium balance during calcitriol and paricalcitol administration in healthy humans 2008 · paricalcitol · Healthy individuals with normal renal function; age and sex not reported | 1.5 mcg | 6 days | — |
| Calcium balance during calcitriol and paricalcitol administration in healthy humans 2008 · calcitriol · Healthy individuals with normal renal function; age and sex not reported | 0.5 mcg | 6 days | — |
| Reduction in serum alkaline phosphatase levels by treatment with active vitamin D (alphacalcidol) in primary and secondary hyperparathyroidism and in euparathyroid individuals 1991 · Oral alphacalcidol group · People with mild primary hyperparathyroidism | 1 mcg | 26 weeks | — |
| Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women 2010 · D group · Postmenopausal Japanese women aged 49–81 years with osteoporosis or osteopenia | 1 mcg | 1 year | — |
| Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women 2010 · D + R group · Postmenopausal Japanese women aged 49–81 years with osteoporosis or osteopenia | 1 mcg | 1 year | — |
| Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial 2010 · vitamin D supplementation group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp | 800 IU | 26 weeks | — |
| Effects of 25-hydroxyvitamin D level and its change on parathyroid hormone in premenopausal Chinese women 2010 · vitamin D3 dairy product group · Premenopausal Chinese women aged 28.0±4.4 years | 200 IU | 90 days | — |
| Efficient tetanus toxoid immunization on vitamin D supplementation 2011 · vitamin D group · 32 individuals; age, sex, and health condition not specified | 2,000 IU | 10 weeks | — |
| Maintenance of wintertime vitamin D status with cholecalciferol supplementation is not associated with alterations in serum cytokine concentrations among apparently healthy younger or older adults 2011 · 5 μg/d cholecalciferol (D3) group · Apparently healthy younger adults aged 20–40 years and older adults aged ≥64 years | 5 mcg | 22 weeks | — |
| Maintenance of wintertime vitamin D status with cholecalciferol supplementation is not associated with alterations in serum cytokine concentrations among apparently healthy younger or older adults 2011 · 10 μg/d cholecalciferol (D3) group · Apparently healthy younger adults aged 20–40 years and older adults aged ≥64 years | 10 mcg | 22 weeks | — |
| Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women 2011 · alendronate plus vitamin D3 (ALN + D) · Postmenopausal women with low bone mineral density and 25(OH)D concentrations of 25 ng/mL or less | 400 IU | 30 days | — |
| The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation 2011 · vitamin D3-treated subjects · Trial participants; age, sex, and health condition are not specified in the abstract. | 4,000 IU | 6 weeks | — |
| Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients 2011 · calcitriol group · Adults aged 30–75 years with type 2 diabetes | 0.5 mcg | 12 weeks | — |
| Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23 2012 · ergocalciferol treatment · Adults aged 18–45 with vitamin D deficiency (25-hydroxyvitamin D ≤20 ng/ml) | 7,143 IU | 12 weeks | — |
| Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus 2012 · cholecalciferol group · Patients with new-onset type 1 diabetes mellitus and fasting serum C-peptide levels ≥0.6 ng/mL | 2,000 IU | 540 days | — |
| High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial 2012 · vitamin D group · Adults with early chronic kidney disease, stages 2–3; age and sex not specified | 7,143 IU | 52 weeks | — |
| Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects 2012 · 40,000 IU vitamin D per week · Overweight and obese subjects; age and sex not specified | 5,714 IU | 1 year | — |
| Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects 2012 · 20,000 IU vitamin D per week · Overweight and obese subjects; age and sex not specified | 2,857 IU | 1 year | — |
| Blood lead concentration is not altered by high-dose vitamin D supplementation in children and young adults with HIV 2013 · 4000 IU/day group · Children and young adults aged 8–24 years with HIV | 4,000 IU | 12 weeks | — |
| Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects 2013 · 40,000 IU cholecalciferol per week · Middle-aged overweight and obese subjects | 5,714 IU | 1 year | — |
| Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects 2013 · 20,000 IU cholecalciferol per week · Middle-aged overweight and obese subjects | 2,857 IU | 1 year | — |
| The effect of different doses of vitamin D supplementation on insulin resistance during pregnancy 2013 · Group A · Pregnant women enrolled before 12 weeks of gestation | 200 IU | — | — |
| A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes 2013 · intervention group · Children aged 8–15 with newly diagnosed type 1 diabetes of less than 8 weeks’ duration | 0.5 mcg | 26 weeks | — |
| Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue 2013 · 400 IU/day group · Men aged 42–67 with prostate cancer undergoing radical prostatectomy | 400 IU | 8 weeks | — |
| Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue 2013 · 10,000 IU/day group · Men aged 42–67 with prostate cancer undergoing radical prostatectomy | 10,000 IU | 8 weeks | — |
| Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue 2013 · 40,000 IU/day group · Men aged 42–67 with prostate cancer undergoing radical prostatectomy | 40,000 IU | 8 weeks | — |
| Effect of vitamin D administration in vitamin D-deficient pregnant women on maternal and neonatal serum calcium and vitamin D concentrations: a randomised clinical trial 2013 · Treatment group · Vitamin D-deficient pregnant women recruited at 26–28 weeks of pregnancy | 7,143 IU | 8 weeks | — |
| A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis 2014 · Vitamin D3, atopic dermatitis subjects · Adults with moderate-to-severe atopic dermatitis; mean age 31.2 years | 4,000 IU | 3 weeks | — |
| A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis 2014 · Vitamin D3, non-atopic control subjects · Non-atopic adults; mean age 31.9 years | 4,000 IU | 3 weeks | — |
| A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis 2014 · Vitamin D3, psoriasis subjects · Adults with mild psoriasis; mean age 38.8 years | 4,000 IU | 3 weeks | — |
| Effect of vitamin D replacement on hip structural geometry in adolescents: a randomized controlled trial 2013 · 1400 IU vitamin D3 group · Adolescent girls and boys; mean age 13.1 years for girls and 12.7 years for boys | 200 IU | 1 year | — |
| Effect of vitamin D replacement on hip structural geometry in adolescents: a randomized controlled trial 2013 · 14,000 IU vitamin D3 group · Adolescent girls and boys; mean age 13.1 years for girls and 12.7 years for boys | 2,000 IU | 1 year | — |
| Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial) 2013 · VitD3 treatment group · Adults with stable chronic heart failure and reduced left ventricular ejection fraction; mean age 64 years, 93% male | 2,000 IU | 6 weeks | — |
| Vitamin D favorably alters the cancer promoting prostaglandin cascade 2013 · 2,000 IU vitamin D-3 · Healthy women; age range and other characteristics not specified | 2,000 IU | 30 days | — |
| Serum IL-18 and hsCRP correlate with insulin resistance without effect of calcitriol treatment on type 2 diabetes 2013 · Calcitriol group · Adults with type 2 diabetes | 0.5 mcg | 12 weeks | — |
| A randomized study on the effect of vitamin D₃ supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women 2013 · vitamin D (VD) · Women aged 65 years or older with mobility limitations and serum 25-hydroxyvitamin D levels of 22.5 to 60 nmol/L | 4,000 IU | 120 days | — |
| A Randomized controlled trial on safety and efficacy of single intramuscular versus staggered oral dose of 600 000IU Vitamin D in treatment of nutritional rickets 2014 · 60 000 IU oral vitamin D once a week for 10 weeks · Children aged 0.5–5 years with nutritional rickets | 8,571 IU | 10 weeks | — |
| Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23 2014 · cholecalciferol · Patients with chronic kidney disease, stages 1–5; age and sex not specified | 5,714 IU | 8 weeks | — |
| Vitamin D and fetal-neonatal calcium homeostasis: findings from a randomized controlled trial of high-dose antenatal vitamin D supplementation 2014 · oral vitamin D3 · Pregnant women in Bangladesh, enrolled at 26–29 weeks of gestation | 5,000 IU | — | — |
| Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial 2014 · vitamin D group · Adults with vitamin D insufficiency and type 2 diabetes; age and sex range not stated | 7,143 IU | 8 weeks | — |
| Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model 2015 · 400 IU/day vitamin D3 group · Men with prostate cancer scheduled for radical prostatectomy | 400 IU | 8 weeks | — |
| Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model 2015 · 10,000 IU/day vitamin D3 group · Men with prostate cancer scheduled for radical prostatectomy | 10,000 IU | 8 weeks | — |
| Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model 2015 · 40,000 IU/day vitamin D3 group · Men with prostate cancer scheduled for radical prostatectomy | 40,000 IU | 8 weeks | — |
| Calcium supplementation increases blood creatinine concentration in a randomized controlled trial 2014 · Vitamin D3 alone · Adults aged 45–75 in generally good health with a previously removed large bowel adenoma; predominantly male | 1,000 IU | 5 years | — |
| [Effects of vitamin D supplementation on insulin resistance in patients with type 2 diabetes mellitus] 2014 · intervention group · Adults aged 30–75 years with type 2 diabetes mellitus | 0.5 mcg | 12 weeks | — |
| Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: Potential benefits of calcitriol 2015 · calcitriol · Adults with steroid-resistant asthma | 0.5 mcg | 4 weeks | — |
| Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta 2015 · cholecalciferol 20,000 IU/week · Patients with relapsing-remitting multiple sclerosis, all using IFN-beta-1b; age and sex not specified | 2,857 IU | 1 year | — |
| Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C 2015 · Cholecalciferol group · Patients with genotype 1b chronic hepatitis C and serum HCV-RNA levels greater than 5 Log IU/mL | 2,000 IU | 76 weeks | — |
| Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C 2015 · Alfacalcidol group · Patients with genotype 1b chronic hepatitis C and serum HCV-RNA levels greater than 5 Log IU/mL | 0.5 mcg | 76 weeks | — |
| The effect of 14 weeks of vitamin D3 supplementation on antimicrobial peptides and proteins in athletes 2016 · vitamin D3 supplement · Healthy male athletes during a winter training period | 5,000 IU | 14 weeks | — |
| Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial 2015 · low-dose vitamin D arm · Postmenopausal women with vitamin D insufficiency (serum 25(OH)D >14 and ≤27 ng/mL); women with osteoporosis were excluded. | 800 IU | 1 year | — |
| Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial 2015 · intervention group · Patients with relapsing-remitting multiple sclerosis | 10,000 IU | 90 days | — |
| Effects of vitamin D supplementation as an adjuvant therapy in coronary artery disease patients 2016 · vitamin D supplementation group · Adults with stable coronary artery disease residing in Beijing | 0.5 mcg | 26 weeks | — |
| High-Dose versus Low-Dose Vitamin D Supplementation and Arterial Stiffness among Individuals with Prehypertension and Vitamin D Deficiency 2015 · low-dose vitamin D group · Adults aged 18–50 with prehypertension or elevated untreated blood pressure and vitamin D deficiency | 400 IU | 26 weeks | — |
| High-Dose versus Low-Dose Vitamin D Supplementation and Arterial Stiffness among Individuals with Prehypertension and Vitamin D Deficiency 2015 · high-dose vitamin D group · Adults aged 18–50 with prehypertension or elevated untreated blood pressure and vitamin D deficiency | 4,000 IU | 26 weeks | — |
| Vitamin D Supplementation Modulates T Cell-Mediated Immunity in Humans: Results from a Randomized Control Trial 2016 · high-dose vitamin D3 · Adults with vitamin D deficiency and untreated pre- or early stage I hypertension | 4,000 IU | 26 weeks | — |
| Vitamin D Supplementation Modulates T Cell-Mediated Immunity in Humans: Results from a Randomized Control Trial 2016 · low-dose vitamin D3 · Adults with vitamin D deficiency and untreated pre- or early stage I hypertension | 400 IU | 26 weeks | — |
| A Vitamin D-Calcium-Fortified Yogurt Drink Decreased Serum PTH but did not Affect Osteocalcin in Subjects with Type 2 Diabetes 2015 · Group 2 (DD) · Women and men aged 30–50 years with type 2 diabetes | 1,000 IU | 12 weeks | — |
| Persistent Effect of Vitamin D Supplementation on Musculoskeletal Parameters in Adolescents One Year After Trial Completion 2016 · 200 IU/day vitamin D group · Adolescents, mean age 13.9 ± 2 years; girls and boys | 200 IU | 1 year | — |
| Persistent Effect of Vitamin D Supplementation on Musculoskeletal Parameters in Adolescents One Year After Trial Completion 2016 · 2000 IU/day vitamin D group · Adolescents, mean age 13.9 ± 2 years; girls and boys | 2,000 IU | 1 year | — |
| Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial 2016 · cholecalciferol group · Pregnant women aged over 18 years with singleton pregnancies, recruited before 17 weeks’ gestation; eligible maternal serum 25(OH)D was 25–100 nmol/L. | 1,000 IU | — | — |
| Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients 2017 · 1,000 IU/day vitamin D3 supplementation · Adults aged 45–75 with a history of colorectal adenomas | 1,000 IU | 1 year | — |
| Assessment of Adequacy of Supplementation of Vitamin D in Very Low Birth Weight Preterm Neonates: A Randomized Controlled Trial 2016 · Group 1 · Very low birth weight preterm neonates | 400 IU | 6 weeks | — |
| Assessment of Adequacy of Supplementation of Vitamin D in Very Low Birth Weight Preterm Neonates: A Randomized Controlled Trial 2016 · Group 2 · Very low birth weight preterm neonates | 1,000 IU | 6 weeks | — |
| Effects of vitamin D supplementation on glycated haemoglobin and fasting glucose levels in hypertensive patients: a randomized controlled trial 2016 · vitamin D group · Adults with arterial hypertension and 25(OH)D concentrations below 30 ng/mL | 2,800 IU | 8 weeks | — |
| T-lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossover 2017 · cholecalciferol followed by placebo sequence · Adults with type 1 diabetes; sex breakdown was 19 women and 20 men | 4,000 IU | 90 days | — |
| Vitamin D supplementation reduces insulin resistance in Japanese adults: a secondary analysis of a double-blind, randomized, placebo-controlled trial 2016 · vitamin D3 group · Healthy Japanese adults; age range and sex not reported | 420 IU | 1 year | — |
| Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D(3) administration 2017 · vitamin D3 treatment group · Adults aged 18 years or older with cystic fibrosis hospitalized for an acute pulmonary exacerbation | 250,000 IU | 7 days | — |
| Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial 2017 · vitamin D group · Adults aged 18 or older with arterial hypertension and low serum 25(OH)D | 2,800 IU | 8 weeks | — |
| Effect of Cholecalciferol therapy on serum FGF(23) in vitamin D deficient patients: a randomized clinical trial 2018 · Cholecalciferol treatment group · Vitamin D deficient patients; age and sex not specified | 7,143 IU | 12 weeks | — |
| Bolus Weekly Vitamin D3 Supplementation Impacts Gut and Airway Microbiota in Adults With Cystic Fibrosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial 2018 · vitamin D3 · Adults with cystic fibrosis and vitamin D insufficiency (25-hydroxyvitamin D < 30 ng/mL) | 7,143 IU | 12 weeks | — |
| Expression and shedding of CD44 in the endometrium of women with endometriosis and modulating effects of vitamin D: A randomized exploratory trial 2018 · Vitamin D alongside routine protocol · Women with endometriosis; age and sex beyond the stated population not reported | 7,143 IU | 13 weeks | — |
| The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial 2018 · intervention group · Women aged 20–38 years with PCOS and plasma 25OHD <20 ng/mL | 7,143 IU | 8 weeks | — |
| Effectiveness of vitamin D therapy in improving metabolomic biomarkers in obesity phenotypes: Two randomized clinical trials 2018 · MHO vitamin D group · Adults with metabolically healthy obesity and sub-optimal vitamin D levels | 4,000 IU | 120 days | — |
| Effectiveness of vitamin D therapy in improving metabolomic biomarkers in obesity phenotypes: Two randomized clinical trials 2018 · MUHO vitamin D group · Adults with metabolically unhealthy obesity and sub-optimal vitamin D levels | 4,000 IU | 120 days | — |
| Cholecalciferol Supplementation Promotes Bone Turnover in Chinese Adults with Vitamin D Deficiency 2018 · cholecalciferol · Chinese adults with vitamin D deficiency; mean age 31.9 years, 69% women | 2,000 IU | 20 weeks | — |
| Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males 2018 · 0.5-μg group · Healthy Chinese adult males | 0.5 mcg | 1 day | — |
| Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males 2018 · 0.75-μg group · Healthy Chinese adult males | 0.75 mcg | 1 day | — |
| Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial 2019 · 600 IU/d vitamin D3 · Overweight or obese African American adults with serum 25(OH)D below 50 nmol/L; mean age 26.1 years in the analysed sample, 16% male | 600 IU | 16 weeks | — |
| Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial 2019 · 2,000 IU/d vitamin D3 · Overweight or obese African American adults with serum 25(OH)D below 50 nmol/L; mean age 26.1 years in the analysed sample, 16% male | 2,000 IU | 16 weeks | — |
| Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial 2019 · 4,000 IU/d vitamin D3 · Overweight or obese African American adults with serum 25(OH)D below 50 nmol/L; mean age 26.1 years in the analysed sample, 16% male | 4,000 IU | 16 weeks | — |
| Effects of vitamin D and calcium on expression of MSH2 and transforming growth factors in normal-appearing colorectal mucosa of sporadic colorectal adenoma patients: A randomized clinical trial 2019 · vitamin D3 group · People with sporadic colorectal adenomas; age and sex not specified | 1,000 IU | 1 year | — |
| Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol 2018 · calcitriol group · Postmenopausal women with osteopenia or osteoporosis and low bone mass; ages not specified | 0.5 mcg | 12 weeks | — |
| The effects of vitamin D(3) supplementation on some metabolic and inflammatory markers in diabetic nephropathy patients with marginal status of vitamin D: A randomized double blind placebo controlled clinical trial 2019 · intervention group · Patients with diabetic nephropathy and marginal vitamin D status; age and sex not reported | 7,143 IU | 8 weeks | — |
| Effects of supplemental calcium and vitamin D on tight-junction proteins and mucin-12 expression in the normal rectal mucosa of colorectal adenoma patients 2019 · vitamin D supplementation · Adults aged 45–75 with a removed colorectal adenoma and no remaining polyps after colonoscopy; patients at increased risk for colorectal neoplasms | 1,000 IU | 1 year | — |
| Local In Vivo Measures of Muscle Lipid and Oxygen Consumption Change in Response to Combined Vitamin D Repletion and Aerobic Training in Older Adults 2019 · vitamin D repletion alone (D) · Adults aged 60–80 years with serum 25(OH)D ≤32 ng/mL and BMI 18.5–34.9 kg/m² | 10,000 IU | 13 weeks | — |
| Local In Vivo Measures of Muscle Lipid and Oxygen Consumption Change in Response to Combined Vitamin D Repletion and Aerobic Training in Older Adults 2019 · vitamin D repletion plus aerobic training (DAT) · Adults aged 60–80 years with serum 25(OH)D ≤32 ng/mL and BMI 18.5–34.9 kg/m² | 10,000 IU | 13 weeks | — |
| Randomized Study of the Effect of Vitamin D and Omega-3 Fatty Acids Cosupplementation as Adjuvant Chemotherapy on Inflammation and Nutritional Status in Colorectal Cancer Patients 2020 · vitamin D group · Colorectal cancer patients | 7,143 IU | 8 weeks | — |
| Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease - a randomized trial 2019 · 1 μg paricalcitol daily · Adults older than 20 years with stage 3–4 chronic kidney disease (eGFR 15–59 mL/min/1.73 m²) | 1 mcg | 12 weeks | — |
| Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease - a randomized trial 2019 · 2 μg paricalcitol daily · Adults older than 20 years with stage 3–4 chronic kidney disease (eGFR 15–59 mL/min/1.73 m²) | 2 mcg | 12 weeks | — |
| Effect of vitamin D3 supplementation on vascular and metabolic health of vitamin D-deficient overweight and obese children: a randomized clinical trial 2020 · 600-IU group · Vitamin D-deficient overweight or obese children aged 10–18 years | 600 IU | 26 weeks | — |
| Effect of vitamin D3 supplementation on vascular and metabolic health of vitamin D-deficient overweight and obese children: a randomized clinical trial 2020 · 1000-IU group · Vitamin D-deficient overweight or obese children aged 10–18 years | 1,000 IU | 26 weeks | — |
| Effect of vitamin D3 supplementation on vascular and metabolic health of vitamin D-deficient overweight and obese children: a randomized clinical trial 2020 · 2000-IU group · Vitamin D-deficient overweight or obese children aged 10–18 years | 2,000 IU | 26 weeks | — |
| Inflammatory biomarkers response to two dosages of vitamin D supplementation in patients with ulcerative colitis: A randomized, double-blind, placebo-controlled pilot study 2020 · 2000 IU/day vitamin D group · Patients with mild to moderate active ulcerative colitis; age and sex not reported | 2,000 IU | 12 weeks | — |
| Inflammatory biomarkers response to two dosages of vitamin D supplementation in patients with ulcerative colitis: A randomized, double-blind, placebo-controlled pilot study 2020 · 1000 IU/day vitamin D group · Patients with mild to moderate active ulcerative colitis; age and sex not reported | 1,000 IU | 12 weeks | — |
| In infants with sufficient vitamin D status at birth, vitamin D supplementation does not impact immune development 2020 · vitamin D supplementation · Infants sufficient in vitamin D at birth | 400 IU | 26 weeks | — |
| Vitamin D(3) Supplementation Increases Long-Chain Ceramide Levels in Overweight/Obese African Americans: A Post-Hoc Analysis of a Randomized Controlled Trial 2020 · 18,000 IU/month (~600 IU/day) vitamin D3 · African-American participants aged 13–45 years with overweight or obesity and vitamin D insufficiency | 600 IU | 16 weeks | — |
| Vitamin D(3) Supplementation Increases Long-Chain Ceramide Levels in Overweight/Obese African Americans: A Post-Hoc Analysis of a Randomized Controlled Trial 2020 · 60,000 IU/month (~2000 IU/day) vitamin D3 · African-American participants aged 13–45 years with overweight or obesity and vitamin D insufficiency | 2,000 IU | 16 weeks | — |
| Vitamin D(3) Supplementation Increases Long-Chain Ceramide Levels in Overweight/Obese African Americans: A Post-Hoc Analysis of a Randomized Controlled Trial 2020 · 120,000 IU/month (~4000 IU/day) vitamin D3 · African-American participants aged 13–45 years with overweight or obesity and vitamin D insufficiency | 4,000 IU | 16 weeks | — |
| Vitamin D Treatment Attenuates Heart Apoptosis After Coronary Artery Bypass Surgery: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial 2020 · Vitamin D group · Patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass | 150,000 IU | 3 days | — |
| Effects of Vitamin D and Omega-3 Fatty Acids Co-Supplementation on Inflammatory Factors and Tumor Marker CEA in Colorectal Cancer Patients Undergoing Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2020 · vitamin D · Patients with stage II or III colorectal cancer undergoing chemotherapy | 7,143 IU | 8 weeks | — |
| Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS 2020 · high-dose arm · Adults aged 18–65 with relapsing-remitting multiple sclerosis on stable IFNβ-1b treatment | 10,200 IU | 547 days | — |
| Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS 2020 · low-dose arm · Adults aged 18–65 with relapsing-remitting multiple sclerosis on stable IFNβ-1b treatment | 200 IU | 547 days | — |
| Seasonal Antimicrobial Activity of the Airway: Post-Hoc Analysis of a Randomized Placebo-Controlled Double-Blind Trial 2020 · vitamin D3 group · Adults aged 18–60 years recruited from the community, without the listed exclusionary illnesses; winter–spring participants had generally suboptimal vitamin D levels | 1,000 IU | 90 days | — |
| Safety Aspects of a Randomized Clinical Trial of Maternal and Infant Vitamin D Supplementation by Feeding Type Through 7 Months Postpartum 2020 · 400 IU/day group · Postpartum mothers aged not reported, breastfeeding or formula-feeding; breastfeeding infants in this group also received vitamin D | 400 IU | 26 weeks | — |
| Safety Aspects of a Randomized Clinical Trial of Maternal and Infant Vitamin D Supplementation by Feeding Type Through 7 Months Postpartum 2020 · 2,400 IU/day group · Postpartum mothers aged not reported, breastfeeding or formula-feeding | 2,400 IU | 26 weeks | — |
| Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial 2021 · vitamin D group · Adults aged 45–75 with a histologically verified colorectal adenoma | 1,000 IU | 1 year | — |
| Fibroblast growth factor 23 concentrations and modifying factors in children from age 12 to 24 months 2020 · 10 μg/day vitamin D3 group · Healthy infants, enrolled at approximately 2 weeks of age and followed to 24 months | 10 mcg | — | — |
| Improving the endothelial dysfunction in type 2 diabetes with chromium and vitamin D(3) byreducing homocysteine and oxidative stress: A randomized placebo-controlled trial 2020 · group II: D 3 · People with type 2 diabetes mellitus; age and sex not stated | 7,143 IU | 120 days | — |
| Changes in Bone Turnover, Inflammatory, Oxidative Stress, and Metabolic Markers in Women Consuming Iron plus Vitamin D Supplements: a Randomized Clinical Trial 2021 · D-P · Women aged 18–45 years with hemoglobin ≤12.7 g/dL and 25OHD ≤29 ng/mL | 1,000 IU | 12 weeks | — |
| The modulating effects of vitamin D on the activity of β-catenin in the endometrium of women with endometriosis: a randomized exploratory trial 2021 · treatment group · Infertile women with stage III or IV endometriosis | 7,143 IU | 13 weeks | — |
| A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease 2021 · calcitriol · Patients with non-alcoholic fatty liver disease and vitamin D deficiency or insufficiency | 1 mcg | 8 weeks | — |
| A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease 2021 · cholecalciferol · Patients with non-alcoholic fatty liver disease and vitamin D deficiency or insufficiency | 7,143 IU | 8 weeks | — |
| The effect of vitamin D supplementation on circulating osteoprogenitor cells: A pilot randomized controlled trial 2021 · 1000 IU supplement alone · Healthy older adults, stratified by baseline vitamin D level into deficient and non-deficient groups | 1,000 IU | 6 weeks | — |
| Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial 2022 · treatment group · Children with biopsy-proven nonalcoholic fatty liver disease (NAFLD) | 2,000 IU | 26 weeks | — |
| The Effects of Vitamin D Supplementation on Metabolic and Oxidative Stress Markers in Patients With Type 2 Diabetes: A 6-Month Follow Up Randomized Controlled Study 2021 · Vitamin D3 group, participants with baseline 25(OH)D ≤ 50 nmol/L · Adults aged 30 years or older with type 2 diabetes treated with metformin and baseline 25(OH)D ≤ 50 nmol/L | 7,143 IU | 26 weeks | — |
| The Effects of Vitamin D Supplementation on Metabolic and Oxidative Stress Markers in Patients With Type 2 Diabetes: A 6-Month Follow Up Randomized Controlled Study 2021 · Vitamin D3 group, participants with baseline 25(OH)D > 50 nmol/L · Adults aged 30 years or older with type 2 diabetes treated with metformin and baseline 25(OH)D > 50 nmol/L | 2,000 IU | 26 weeks | — |
| Efficacy of low-fat milk and yogurt fortified with vitamin D(3) on systemic inflammation in adults with abdominal obesity 2022 · Fortified low-fat milk · Adults aged 30–50 years with abdominal obesity | 1,500 IU | 10 weeks | — |
| Efficacy of low-fat milk and yogurt fortified with vitamin D(3) on systemic inflammation in adults with abdominal obesity 2022 · Fortified low-fat yogurt · Adults aged 30–50 years with abdominal obesity | 1,500 IU | 10 weeks | — |
| Maternal Vitamin D Status Correlates to Leukocyte Antigenic Responses in Breastfeeding Infants 2022 · control group · Exclusively breastfeeding mothers and their 1-month-old infants | 400 IU | 90 days | — |
| Maternal Vitamin D Status Correlates to Leukocyte Antigenic Responses in Breastfeeding Infants 2022 · treatment group · Exclusively breastfeeding mothers and their 1-month-old infants | 6,400 IU | 90 days | — |
| An Open-Label, Randomized Pharmacokinetic Study of 2 Formulations of Eldecalcitol Capsules Following Single Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions 2022 · Test formulation · Healthy Chinese male and female volunteers under fasting and fed conditions | 0.75 mcg | 1 day | — |
| An Open-Label, Randomized Pharmacokinetic Study of 2 Formulations of Eldecalcitol Capsules Following Single Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions 2022 · Reference formulation · Healthy Chinese male and female volunteers under fasting and fed conditions | 0.75 mcg | 1 day | — |
| Effect of Vitamin D and/or Calcium Supplementation on Pancreatic β-Cell Function in Subjects with Prediabetes: A Randomized, Controlled Trial 2023 · vitamin D group · Chinese adults with prediabetes | 1,600 IU | 24 weeks | — |
| Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial 2022 · Vitamin D3 active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization | 2,000 IU | 1935 days | — |
| Vitamin D3 and deconvoluting a rash 2023 · VitD(+) group · Healthy adults; exact age range and sex distribution not stated | 200,000 IU | 1 day | — |
| Does maternal vitamin D status influence placental weight or vascular and inflammatory pathology? Secondary analysis from the Kellogg Pregnancy Study 2023 · daily placebo group · Women aged 18–45 with singleton pregnancies, enrolled at 10–14 weeks’ gestation; generally healthy, with a sub-cohort with specified chronic conditions | 400 IU | — | — |
| Low-grade inflammation from prenatal period to age 6-8 years in a Vitamin D trial 2024 · group 10 · Healthy full-term infants, from age 2 weeks to 2 years | 10 mcg | 2 years | — |
| Racial differences in measures of glycemia in the Vitamin D and Type 2 Diabetes (D2d) Study: a secondary analysis of a randomized trial 2024 · vitamin D group · Adults aged 30 years or older (25 years or older for specified Indigenous and Pacific Islander groups), at high risk of diabetes with prediabetes | 4,000 IU | 913 days | — |
| Effects of Vitamin D-3 Supplementation During Pregnancy and Lactation on Maternal and Infant Biomarkers of Environmental Enteric Dysfunction, Systemic Inflammation, and Growth: A Secondary Analysis of a Randomized Controlled Trial 2024 · vitamin D-3 group · Pregnant and lactating women living with HIV in Dar es Salaam, Tanzania | 3,000 IU | — | — |
| Calcium plus vitamin D supplementation during pregnancy has no impact on postpartum transient longitudinal changes in hip geometry in adolescent mothers: a secondary analysis of a randomised controlled trial 2024 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low daily calcium intake (approximately 600 mg/day); lactating postpartum adolescents were assessed | 200 mcg | — | — |
| The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial 2025 · vitamin D (VitD) group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported | 7,143 IU | 9 weeks | — |
| High-dose vitamin D supplementation in pregnancy ameliorates obesity-induced increase in maternal IL-1β level without affecting obesity-induced increase in IL-6 and MCP 2025 · 400 IU/day group · Pregnant women, with results analysed by pre-pregnancy BMI | 400 IU | — | — |
| High-dose vitamin D supplementation in pregnancy ameliorates obesity-induced increase in maternal IL-1β level without affecting obesity-induced increase in IL-6 and MCP 2025 · 3600 IU/day group · Pregnant women, with results analysed by pre-pregnancy BMI | 3,600 IU | — | — |
| Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial 2025 · Vitamin D3 only · Females aged 55 years or older and males aged 50 years or older; no specific condition stated | 2,000 IU | 5 years | — |
| Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients 1994 · oral calcitriol (ORC) · 10 hemodialysis patients with secondary hyperparathyroidism; age and sex not reported | 0.69 mcg | 12 weeks | — |
| Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial 1994 · cholecalciferol group · Healthy men and women aged 63–76 years | 2.5 mg | 1 day | — |
| Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial) 1995 · Calcitriol · Adults with mild to moderate renal failure and elevated 1,84 iPTH | 0.125 mcg | 1 year | — |
| A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures 1996 · alfacalcidol treatment · Elderly women aged 64–79 years with radiological evidence of vertebral fractures | 0.5 mcg | 26 weeks | — |
| Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis 1997 · calcitriol alone · Patients with Schistosoma haematobium infection; age and sex not reported | 1 mcg | 5 days | — |
| Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis 1997 · praziquantel plus calcitriol · Patients with Schistosoma haematobium infection; age and sex not reported | 1 mcg | 5 days | — |
| Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men 1998 · prednisolone and calcitriol · Healthy men aged 21–54 years | 2 mcg | 7 days | — |
| Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men 1998 · calcitriol · Healthy men aged 21–54 years | 2 mg | 7 days | — |
| SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial 2017 · D&Cancer Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health | 2,000 IU | 1 year | 915 |
| Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients 2014 · strontium ranelate 2 g/vitamin D₃ 1000 IU daily · Men and postmenopausal women aged 50 years or older with primary osteoporosis and serum 25(OH)D >22.5 nmol/l | 1,000 IU | 26 weeks | 413 |
| Factors predicting vitamin D response variation in non-Hispanic white postmenopausal women 2012 · calcium and vitamin D supplementation · Non-Hispanic white postmenopausal women | 1,100 IU | 4 years | 392 |
| A randomized clinical trial comparing 3 different replacement regimens of vitamin D in clinically asymptomatic pediatrics and adolescents with vitamin D insufficiency 2016 · Group 2 · Children and adolescents aged 2–18 years with inadequate vitamin D, clinically asymptomatic | 6,829 IU | 1 year | 247 |
| Does Vitamin D3 Supplementation Improve Depression Scores among Rural Adolescents? A Randomized Controlled Trial 2024 · calcium intervention arm · Rural adolescent boys and girls aged 14–19 years with any form of depression | 250 IU | 9 weeks | 216 |
| SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial 2017 · CaMEWS Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health | 1,100 IU | 1 year | 203 |
| Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study 2002 · calcium-vitamin D3 fixed combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population | 800 IU | 2 years | 199 |
| A randomized clinical trial comparing 3 different replacement regimens of vitamin D in clinically asymptomatic pediatrics and adolescents with vitamin D insufficiency 2016 · Group 3 · Children and adolescents aged 2–18 years with inadequate vitamin D, clinically asymptomatic | 3,000 IU | 1 year | 194 |
| Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study 2002 · calcium plus vitamin D3 separate combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population | 800 IU | 2 years | 190 |
| Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial 2014 · ALN/D5600 group · Postmenopausal women with osteoporosis and serum 25(OH)D ≥9 ng/mL | 800 IU | 16 weeks | 173 |
| Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation 2011 · active treatment arm · Healthy men and women aged 65 and older | 700 IU | 2 years | 152 |
| Impact of Maternal Daily Oral Low-Dose Vitamin A Supplementation on the Mother-Infant Pair: A Randomised Placebo-Controlled Trial in China 2021 · supplementation group · Lactating mothers aged 20–40 years, 30–45 days postpartum, breastfeeding healthy full-term singleton infants | 600 IU | 60 days | 144 |
| Vitamin D Receptor Fok-I polymorphism modulates diabetic host response to vitamin D intake: need for a nutrigenetic approach 2013 · vitamin D–fortified doogh group · Adults aged 29–67 with type 2 diabetes | 1,000 IU | 12 weeks | 140 |
| Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older adults 2008 · calcium-vitamin D supplementation treatment group · Men and women aged 65 years or older; healthy and ambulatory | 700 IU | 3 years | 132 |
| Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial 2020 · vitamin D3 4 000 IU/day · Healthy adults aged 55–70 years with serum 25-hydroxyvitamin D of 30–125 nmol/L | 4,000 IU | 3 years | 125 |
| Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial 2020 · vitamin D3 400 IU/day · Healthy adults aged 55–70 years with serum 25-hydroxyvitamin D of 30–125 nmol/L | 400 IU | 3 years | 124 |
| Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial 2020 · vitamin D3 10 000 IU/day · Healthy adults aged 55–70 years with serum 25-hydroxyvitamin D of 30–125 nmol/L | 10,000 IU | 3 years | 124 |
| Randomized trial of three doses of vitamin D to reduce deficiency in pregnant Mongolian women 2019 · 2000 IU · Women aged 18 years or older, pregnant at 12–16 weeks’ gestation, in Mongolia; no stated disease requirement | 2,000 IU | — | 121 |
| Time out: should vitamin D dosing be based on patient's body mass index (BMI): a prospective controlled study 2021 · Group A (2000 IU) · Women with vitamin D deficiency and BMI ≥30 kg/m²; mean age 50 years; treated in orthopaedic, obstetrics and gynaecology clinics | 2,000 IU | 90 days | 121 |
| Randomized trial of three doses of vitamin D to reduce deficiency in pregnant Mongolian women 2019 · 4000 IU · Women aged 18 years or older, pregnant at 12–16 weeks’ gestation, in Mongolia; no stated disease requirement | 4,000 IU | — | 120 |
| Randomized trial of three doses of vitamin D to reduce deficiency in pregnant Mongolian women 2019 · 600 IU · Women aged 18 years or older, pregnant at 12–16 weeks’ gestation, in Mongolia; no stated disease requirement | 600 IU | — | 119 |
| Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D(3) combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal 2018 · ALN/D5600 · Postmenopausal women in China aged over 55 with postmenopausal osteoporosis | 800 IU | 1 year | 111 |
| Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly 2021 · Low dose (600 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL | 600 IU | 1 year | 111 |
| Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly 2021 · High dose (3750 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL | 3,750 IU | 1 year | 110 |
| A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency 2025 · calcifediol 125 µg · Adults aged 18 years or older with severe vitamin D deficiency (serum 25(OH)D ≤10 ng/mL), male or female | 17.9 mcg | 52 weeks | 110 |
| Response of serum 25(OH)D to Vitamin D and calcium supplementation in school-children from a semi-rural setting in India 2018 · Daily vitamin D and calcium supplementation · Schoolchildren aged 6–12 years, boys and girls, from a semi-rural setting in India; baseline vitamin D status varied | 1,000 IU | 26 weeks | 106 |
| Dose response to vitamin D supplementation among postmenopausal African American women 2007 · Vitamin D group, 20 μg/day phase · Healthy postmenopausal African American women not receiving hormone replacement therapy | 20 mcg | 2 years | 104 |
| Dose response to vitamin D supplementation among postmenopausal African American women 2007 · Vitamin D group, 50 μg/day phase · Healthy postmenopausal African American women not receiving hormone replacement therapy | 50 mcg | 1 year | 104 |
| A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency 2025 · calcifediol 100 µg · Adults aged 18 years or older with severe vitamin D deficiency (serum 25(OH)D ≤10 ng/mL), male or female | 800 IU | 52 weeks | 104 |
| REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients 2023 · extended-release calcifediol (ERC) · Adults aged 18 years or older with mild to moderate symptomatic COVID-19 | 3.12 mg | 4 weeks | 80 |
| High-dose versus low-dose ergocalciferol for correcting hypovitaminosis D after fragility hip fracture: a randomized controlled trial 2021 · Low-dose vitamin D group · Adults older than 50 years with fragility hip fracture and hypovitaminosis D; mean age in the study was 78.9 years overall | 2,857 IU | 12 weeks | 70 |
| High-dose versus low-dose ergocalciferol for correcting hypovitaminosis D after fragility hip fracture: a randomized controlled trial 2021 · High-dose vitamin D group · Adults older than 50 years with fragility hip fracture and hypovitaminosis D; mean age in the study was 78.9 years overall | 8,571 IU | 12 weeks | 70 |
| A randomized, double-blind, placebo-controlled trial of vitamin D supplementation with or without calcium in community-dwelling vitamin D deficient subjects 2022 · Vitamin D3 + Calcium · Adults aged 18 years and over, men and women, with vitamin D deficiency; apparently healthy community-dwelling UAE residents and expatriates | 2,000 IU | 26 weeks | 68 |
| Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial 2014 · 400 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months | 400 IU | 26 weeks | 67 |
| Effects of a Novel Dispersible Supplement Containing 2500 IU of Vitamin D and 1000 µg of B12 in Restoring Vitamin D and B12 Insufficiency: A Multicenter, Randomized Controlled Trial 2025 · Group A · Adults aged over 20 and under 80 with vitamin D concentration below 20 ng/mL and vitamin B12 concentration below 250 ng/L | 2,500 IU | 12 weeks | 62 |
| Effects of a Novel Dispersible Supplement Containing 2500 IU of Vitamin D and 1000 µg of B12 in Restoring Vitamin D and B12 Insufficiency: A Multicenter, Randomized Controlled Trial 2025 · Group B · Adults aged over 20 and under 80 with vitamin D concentration below 20 ng/mL and vitamin B12 concentration below 250 ng/L | 2,000 IU | 12 weeks | 62 |
| Changes in blood pressure and lipid levels in young women consuming a vitamin D-fortified skimmed milk: a randomised controlled trial 2013 · D-fortified · Women aged 18–35 with low iron stores; healthy, non-pregnant, and non-breast-feeding | 200 IU | 16 weeks | 55 |
| Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial 2011 · vitamin D3-fortified doogh (FYD) · Adults aged 29–67 years with type 2 diabetes; 57 women and 43 men overall | 1,000 IU | 12 weeks | 50 |
| Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes 2012 · vitamin D3-fortified doogh (FD) · People with type 2 diabetes | 1,000 IU | 12 weeks | 50 |
| Daily vs. monthly oral vitamin D(3) for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial 2023 · Daily (D) group · Infants with symptomatic vitamin D deficiency | 2,000 IU | 90 days | 46 |
| Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents 1995 · G1 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure | 800 IU | 26 weeks | 46 |
| Efficacy of daily 4,000 International Units (IU) versus 6,000 IU of oral vitamin D(3) in vitamin D deficient children with overweight and obesity: An open-label randomized controlled trial 2025 · Group A · Children aged 5–18 years with overweight or obesity and vitamin D deficiency | 4,000 IU | 12 weeks | 45 |
| Efficacy of daily 4,000 International Units (IU) versus 6,000 IU of oral vitamin D(3) in vitamin D deficient children with overweight and obesity: An open-label randomized controlled trial 2025 · Group B · Children aged 5–18 years with overweight or obesity and vitamin D deficiency | 6,000 IU | 12 weeks | 45 |
| Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents 1995 · G2 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure | 800 IU | 26 weeks | 45 |
| Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma 2023 · Cohort E · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL | 58,000 IU | 16 weeks | 43 |
| Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial 2024 · Cohort E (part 2, replacement dose) · Children aged 6 to under 18 with physician-diagnosed asthma, BMI at or above the 85th percentile, and screening serum 25(OH)D of 10–30 ng/mL | 8,000 IU | 16 weeks | 43 |
| Effect of Vitamin D and Docosahexaenoic Acid Co-Supplementation on Vitamin D Status, Body Composition, and Metabolic Markers in Obese Children: A Randomized, Double Blind, Controlled Study 2022 · GROUP II (vitamin D + wheat germ oil) · Children aged 6–14 years with obesity and vitamin D deficiency | 1,200 IU | 26 weeks | 41 |
| Daily versus fortnightly oral vitamin D(3) in treatment of symptomatic vitamin D deficiency in children aged 1-10 years: An open labelled randomized controlled trial 2024 · group daily (D) · Children aged 1–10 years with symptomatic vitamin D deficiency | 4,000 IU | 12 weeks | 40 |
| 25 hydroxy vitamin D is higher when a renal multivitamin is given with cholecalciferol at hemodialysis 2016 · multivitamin with vitamin D (MVD) group · Adults receiving hemodialysis; age and sex not specified | 1,714 IU | 20 weeks | 39 |
| Loading dose vitamin D3 improves vitamin D insufficiency in adults undergoing hematopoietic stem cell transplantation: A randomized controlled trial 2023 · High vitamin D (intervention) group · Adults aged 18 or older undergoing allogeneic hematopoietic stem cell transplantation | 102,000 IU | 100 days | 39 |
| Efficacy and Safety of a Personalized Vitamin D(3) Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial 2022 · vitamin D3 arm · Adults aged 18 years or older with nonmetastatic colorectal cancer, recent tumor surgery, and vitamin D insufficiency (25(OH)D <50 nmol/L) | 2,000 IU | 12 weeks | 38 |
| Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial 2017 · D2/D3 daily · Healthy adults aged 18–60 years with serum 25(OH)D of 20–50 nmol/L | 2,000 IU | 20 weeks | 35 |
| Effect of Vitamin D and Docosahexaenoic Acid Co-Supplementation on Vitamin D Status, Body Composition, and Metabolic Markers in Obese Children: A Randomized, Double Blind, Controlled Study 2022 · GROUP I (vitamin D + DHA) · Children aged 6–14 years with obesity and vitamin D deficiency | 1,200 IU | 26 weeks | 33 |
| Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial 2009 · group 1 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass | 7,943 IU | 1 year | 30 |
| Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial 2009 · group 2 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass | 800 IU | 1 year | 30 |
| Effects of Vitamin D3 Supplementation and Resistance Training on 25-Hydroxyvitamin D Status and Functional Performance of Older Adults: A Randomized Placebo-Controlled Trial 2021 · vitamin D3 daily group (VDD) · Adults aged 65–85 years, community-dwelling, with low-to-moderate baseline vitamin D levels; independent lifestyle | 800 IU | 14 weeks | 30 |
| Influence of food matrix delivery system on the bioavailability of vitamin D(3): A randomized crossover trial in postmenopausal women 2023 · Apple juice with whey protein isolate (WPI) · Postmenopausal women aged 60–80 years with vitamin D insufficiency | 200 mcg | 1 day | 30 |
| A randomised comparison of increase in serum 25-hydroxyvitamin D concentration after 4 weeks of daily oral intake of 10 microg cholecalciferol from multivitamin tablets or fish oil capsules in healthy young adults 2007 · multivitamin tablets · Healthy adults aged 19–49 years | 10 mcg | 4 weeks | 28 |
| Fortification of Yogurts with Vitamin D and Calcium Enhances the Inhibition of Serum Parathyroid Hormone and Bone Resorption Markers: A Double Blind Randomized Controlled Trial in Women over 60 Living in a Community Dwelling Home 2015 · Fortified Yogurt (FY) · Women aged 61–90 with serum 25OHD ≤20 ng/mL, living in community sheltered accommodation | 10 mcg | 12 weeks | 28 |
| A randomised comparison of increase in serum 25-hydroxyvitamin D concentration after 4 weeks of daily oral intake of 10 microg cholecalciferol from multivitamin tablets or fish oil capsules in healthy young adults 2007 · fish oil capsules · Healthy adults aged 19–49 years | 10 mcg | 4 weeks | 27 |
| Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome 2015 · 1000 mg calcium/d + 50,000 IU/wk vitamin D · Overweight and obese vitamin D deficient women diagnosed with PCOS | 7,143 IU | 8 weeks | 26 |
| Vitamin D(3) Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial 2017 · intervention group · Men and women aged 18–100 years with vitamin D deficiency (serum 25(OH)D <75 nmol/L), morbid obesity, and planned omega-loop gastric bypass surgery | 3,420 IU | 26 weeks | 25 |
| Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study 2020 · Group A · Healthy vitamin D-deficient Caucasian men and women aged 18–60 years | 11,000 IU | 12 weeks | 25 |
| A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation 2011 · 50,000 IU vitamin D2 loading dose · Men and women over age 50 with an acute fragility hip fracture | 51,000 IU | 90 days | 22 |
| A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation 2011 · 100,000 IU vitamin D2 loading dose · Men and women over age 50 with an acute fragility hip fracture | 101,000 IU | 90 days | 22 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight loss and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss | 10 mcg | 6 weeks | 22 |
| Effects of vitamin D3 and calcium supplementation on serum levels of tocopherols, retinol, and specific vitamin D metabolites 2012 · calcium plus vitamin D3 · Adults aged 30–75 in general health with a history of at least one pathology-confirmed adenomatous colorectal polyp within the previous 36 months | 800 IU | 26 weeks | 21 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight maintenance and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance | 10 mcg | 6 weeks | 21 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight maintenance and vitamin D3-supplementation (WM-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance | 63.6 mcg | 6 weeks | 20 |
| Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation 2013 · Vitamin D3 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency | 400 IU | 90 days | 20 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight loss and vitamin D3-supplementation (WL-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss | 63.6 mcg | 6 weeks | 19 |
| Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation 2013 · Vitamin D2 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency | 400 IU | 90 days | 19 |
| Treatment Effect of Ergocalciferol on Bone Metabolism Indexes and Parathyroid Hormone in Hemodialysis Patients 2018 · Intervention · Hemodialysis patients with vitamin D deficiency; ages and sex not reported | 7,143 IU | 90 days | 19 |
| Oral vitamin D supplemental therapy to attain a desired serum 25-hydroxyvitamin D concentration in essential healthcare teams 2022 · Intervention · Healthcare workers aged 18–69 working in settings with high risk of contact with people with COVID-19; adults, predominantly female, with most participants below the study’s vitamin D sufficiency threshold at baseline | 1,429 IU | 10 weeks | 19 |
| Comparison of two vitamin D supplementation strategies in children with sickle cell disease: a randomized controlled trial 2021 · Vitamin D3 bolus · Children aged 5–17 years with sickle cell disease, all genotypes; the study notes many children with SCD were vitamin D-deficient | 301,000 IU | 90 days | 18 |
| Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women 2006 · vitamin K2 plus vitamin D3 · Postmenopausal women, mean age 53, with osteopenia or osteoporosis and BMD below 0.809 g/cm2 | 0.75 mcg | 2 years | 17 |
| Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation 2025 · VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase | 4,000 IU | 6 weeks | 17 |
| Narrowband ultraviolet B three times per week is more effective in treating vitamin D deficiency than 1600 IU oral vitamin D₃ per day: a randomized clinical trial 2012 · oral vitamin D(3) and calcium group · Participants with vitamin D deficiency (25(OH)D(3) ≤ 25 nmol L(-1)); age and sex not reported | 1,600 IU | 6 weeks | 16 |
| Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma 2023 · Cohort A · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL | 56,000 IU | 16 weeks | 12 |
| Influence of daily 10-85 μg vitamin D supplements during pregnancy and lactation on maternal vitamin D status and mature milk antirachitic activity 2019 · 35 µg vitamin D3/d · Healthy pregnant women, from 20 gestational weeks through 4 weeks postpartum | 35 mcg | — | 11 |
| Influence of daily 10-85 μg vitamin D supplements during pregnancy and lactation on maternal vitamin D status and mature milk antirachitic activity 2019 · 60 µg vitamin D3/d · Healthy pregnant women, from 20 gestational weeks through 4 weeks postpartum | 60 mcg | — | 11 |
| Influence of daily 10-85 μg vitamin D supplements during pregnancy and lactation on maternal vitamin D status and mature milk antirachitic activity 2019 · 85 µg vitamin D3/d · Healthy pregnant women, from 20 gestational weeks through 4 weeks postpartum | 85 mcg | — | 11 |
| Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma 2023 · Cohort B · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL | 60,000 IU | 16 weeks | 11 |
| Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study 2010 · Silicon-rich Water (SW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA | 800 IU | 14 weeks | 10 |
| Calcium and vitamin D intakes in children: a randomized controlled trial 2013 · Group 1 (dietary counseling plus Ca and Vitamin D supplementation) · Children aged 9.7–11.4 years with dietary calcium and vitamin D intake below 70% of the recommended intake | 400 IU | 120 days | 10 |
| Influence of daily 10-85 μg vitamin D supplements during pregnancy and lactation on maternal vitamin D status and mature milk antirachitic activity 2019 · 10 µg vitamin D3/d · Healthy pregnant women, from 20 gestational weeks through 4 weeks postpartum | 10 mcg | — | 10 |
| Vitamin A and D Absorption in Adults with Metabolic Syndrome versus Healthy Controls: A Pilot Study Utilizing Targeted and Untargeted LC-MS Lipidomics 2021 · MetS adults · Adults aged 24–40 with metabolic syndrome; 5 men and 5 women | 119 IU | 1 day | 10 |
| Vitamin A and D Absorption in Adults with Metabolic Syndrome versus Healthy Controls: A Pilot Study Utilizing Targeted and Untargeted LC-MS Lipidomics 2021 · Healthy controls · Healthy adults aged 24–40; 5 men and 5 women | 119 IU | 1 day | 10 |
| Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study 2010 · Purified Water (PW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA | 800 IU | 14 weeks | 9 |
| The effects of omega-3 fatty acid on vitamin D activation in hemodialysis patients: a pilot study 2015 · Cholecalciferol with omega-3 FA group · Hemodialysis patients with baseline 25(OH)D levels below 30 ng/mL; mean age 62.1 years; 33.3% men | 7,143 IU | 12 weeks | 8 |
| Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin 2000 · vitamins K(1)+D(3) · Postmenopausal women about 60 years old with normal or low bone mineral density | 350 IU | 1 year | — |
| Lack of effect of calcium intake on the 25-hydroxyvitamin d response to oral vitamin D3 2005 · Calcium group · Healthy older men and women | 800 IU | 90 days | — |
| Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant 2004 · 1600 IU vitamin D2 and 400 IU vitamin D3 (prenatal vitamin) · Fully lactating women enrolled 1 month after birth | 2,000 IU | 90 days | — |
| Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant 2004 · 3600 IU vitamin D2 and 400 IU vitamin D3 · Fully lactating women enrolled 1 month after birth | 4,000 IU | 90 days | — |
| Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults 2006 · vitamin D group · Healthy university students aged 18–27 years, male and female | 15 mcg | 8 weeks | — |
| Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women 2007 · 200 microg phylloquinone/d · Postmenopausal women | 10 mcg | 6 weeks | — |
| Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women 2007 · 500 microg phylloquinone/d · Postmenopausal women | 10 mcg | 6 weeks | — |
| High-dose vitamin D3 supplementation in a cohort of breastfeeding mothers and their infants: a 6-month follow-up pilot study 2006 · High-dose group · Fully breastfeeding women enrolled at 1 month postpartum and their infants | 6,000 IU | 26 weeks | — |
| Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients 2008 · Group II (400 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent | 400 IU | 26 weeks | — |
| Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients 2008 · Group III (1200 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent | 1,200 IU | 26 weeks | — |
| Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D 2008 · 500 IU vitamin D2 plus 500 IU vitamin D3 · Healthy adults aged 18–84 years; 60% of the study population were vitamin D deficient at baseline | 1,000 IU | 11 weeks | — |
| Treatment of hypovitaminosis D in infants and toddlers 2008 · Vitamin D2 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported | 2,000 IU | 6 weeks | — |
| Treatment of hypovitaminosis D in infants and toddlers 2008 · Vitamin D2 weekly · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported | 7,143 IU | 6 weeks | — |
| Treatment of hypovitaminosis D in infants and toddlers 2008 · Vitamin D3 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported | 2,000 IU | 6 weeks | — |
| The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit 2008 · group 1 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit | 300,000 IU | 39 weeks | — |
| The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit 2008 · group 2 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit | 800 IU | 39 weeks | — |
| High-dose oral vitamin D3 supplementation in the elderly 2009 · Loading + Monthly · Elderly participants; described as frail elderly, with no age range or condition specified | 500,000 IU | — | — |
| Effect of combined maternal and infant vitamin D supplementation on vitamin D status of exclusively breastfed infants 2009 · group 1 · Healthy breastfeeding mothers and their exclusively breastfed infants | 2,400 IU | 90 days | — |
| Effect of combined maternal and infant vitamin D supplementation on vitamin D status of exclusively breastfed infants 2009 · group 2 · Healthy breastfeeding mothers and their exclusively breastfed infants | 400 IU | 90 days | — |
| Effect of vitamin D supplementation in the institutionalized elderly 2009 · group (B) · Institutionalized elderly with low baseline vitamin D status | 5 mcg | 30 days | — |
| The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function 2010 · D group · Women aged 69.3–78.8 years | 800 IU | 1 year | — |
| Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol 2009 · Ergocalciferol group · Hip fracture inpatients with vitamin D insufficiency | 1,000 IU | 90 days | — |
| Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol 2009 · Cholecalciferol group · Hip fracture inpatients with vitamin D insufficiency | 1,000 IU | 90 days | — |
| Is a lower dose of vitamin D supplementation enough to increase 25(OH)D status in a sunny country? 2010 · supplement group · Postmenopausal women with osteoporosis, mean age 62 ± 8 years | 400 IU | 90 days | — |
| Improvement of vitamin D status in Japanese institutionalized elderly by supplementation with 800 IU of vitamin D(3) 2009 · Ca+VD group · Institutionalized elderly; age and sex not specified; baseline serum 25-hydroxyvitamin D was in the hypovitaminosis D range | 800 IU | 30 days | — |
| Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention 2010 · VD and Ca (VD-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D | 10 mcg | 1 year | — |
| Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention 2010 · Multiple micronutrient and Ca (MMN-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D | 10 mcg | 1 year | — |
| Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States 2009 · 2,000 mg calcium plus 800 IU vitamin D daily · Adults aged 30–74 with a history of at least one pathologically confirmed adenomatous colonic polyp within the previous 36 months | 800 IU | 26 weeks | — |
| Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting 2010 · high-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L | 50,000 IU | 10 days | — |
| Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting 2010 · continuous low-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L | 4,000 IU | 90 days | — |
| Is a daily supplementation with 40 microgram vitamin D3 sufficient? A randomised controlled trial 2012 · vitamin D(3) plus calcium group · Community-dwelling adults aged 55–84 years | 40 mcg | 1 year | — |
| Dose response to vitamin D supplementation in postmenopausal women: a randomized trial 2012 · Vitamin D(3) 400 IU once daily · Postmenopausal white women with vitamin D insufficiency | 400 IU | 1 year | — |
| Dose response to vitamin D supplementation in postmenopausal women: a randomized trial 2012 · Vitamin D(3) 800 IU once daily · Postmenopausal white women with vitamin D insufficiency | 800 IU | 1 year | — |
| Dose response to vitamin D supplementation in postmenopausal women: a randomized trial 2012 · Vitamin D(3) 1600 IU once daily · Postmenopausal white women with vitamin D insufficiency | 1,600 IU | 1 year | — |
| Dose response to vitamin D supplementation in postmenopausal women: a randomized trial 2012 · Vitamin D(3) 2400 IU once daily · Postmenopausal white women with vitamin D insufficiency | 2,400 IU | 1 year | — |
| Dose response to vitamin D supplementation in postmenopausal women: a randomized trial 2012 · Vitamin D(3) 3200 IU once daily · Postmenopausal white women with vitamin D insufficiency | 3,200 IU | 1 year | — |
| Dose response to vitamin D supplementation in postmenopausal women: a randomized trial 2012 · Vitamin D(3) 4000 IU once daily · Postmenopausal white women with vitamin D insufficiency | 4,000 IU | 1 year | — |
| Dose response to vitamin D supplementation in postmenopausal women: a randomized trial 2012 · Vitamin D(3) 4800 IU once daily · Postmenopausal white women with vitamin D insufficiency | 4,800 IU | 1 year | — |
| Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens 2012 · Arm A · Children and adolescents aged 5–21 with inflammatory bowel disease and serum 25OHD below 20 ng/ml | 2,000 IU | 6 weeks | — |
| Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens 2012 · Arm B · Children and adolescents aged 5–21 with inflammatory bowel disease and serum 25OHD below 20 ng/ml | 2,000 IU | 6 weeks | — |
| Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens 2012 · Arm C · Children and adolescents aged 5–21 with inflammatory bowel disease and serum 25OHD below 20 ng/ml | 7,143 IU | 6 weeks | — |
| Stability and bioavailability of vitamin D nanoencapsulated in casein micelles 2012 · Vitamin D3 encapsulated in re-assembled casein micelles · Human volunteers; age, sex, and health status not specified | 50,000 IU | 1 day | — |
| The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women 2013 · 400 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL) | 400 IU | 1 year | — |
| The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women 2013 · 800 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL) | 800 IU | 1 year | — |
| The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women 2013 · 1600 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL) | 1,600 IU | 1 year | — |
| The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women 2013 · 2400 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL) | 2,400 IU | 1 year | — |
| The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women 2013 · 3200 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL) | 3,200 IU | 1 year | — |
| The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women 2013 · 4000 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL) | 4,000 IU | 1 year | — |
| The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women 2013 · 4800 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL) | 4,800 IU | 1 year | — |
| Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis 2013 · Group 1 (G1) · Adults receiving haemodialysis with chronic kidney disease and secondary hyperparathyroidism; age and sex not reported | 1 mcg | 26 weeks | — |
| Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis 2013 · Group 2 (G2) · Adults receiving haemodialysis with chronic kidney disease and secondary hyperparathyroidism; age and sex not reported | 38 mcg | 26 weeks | — |
| Effects of vitamin D supplementation in older African American women 2013 · Vitamin D3 400 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL | 400 IU | 1 year | — |
| Effects of vitamin D supplementation in older African American women 2013 · Vitamin D3 800 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL | 800 IU | 1 year | — |
| Effects of vitamin D supplementation in older African American women 2013 · Vitamin D3 1600 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL | 1,600 IU | 1 year | — |
| Effects of vitamin D supplementation in older African American women 2013 · Vitamin D3 2400 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL | 2,400 IU | 1 year | — |
| Effects of vitamin D supplementation in older African American women 2013 · Vitamin D3 3200 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL | 3,200 IU | 1 year | — |
| Effects of vitamin D supplementation in older African American women 2013 · Vitamin D3 4000 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL | 4,000 IU | 1 year | — |
| Effects of vitamin D supplementation in older African American women 2013 · Vitamin D3 4800 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL | 4,800 IU | 1 year | — |
| A 250 μg/week dose of vitamin D was as effective as a 50 μg/d dose in healthy adults, but a regimen of four weekly followed by monthly doses of 1250 μg raised the risk of hypercalciuria 2013 · 1250 μg/week for 4 weeks, then 1250 μg/month for 2 months · Healthy adults | 179 mcg | 90 days | — |
| Vitamin D supplementation in young White and African American women 2014 · 400 IU vitamin D3 daily · Women aged 25–45 with vitamin D insufficiency (serum 25OHD ≤20 ng/mL), healthy; White and African American | 400 IU | 1 year | — |
| Vitamin D supplementation in young White and African American women 2014 · 800 IU vitamin D3 daily · Women aged 25–45 with vitamin D insufficiency (serum 25OHD ≤20 ng/mL), healthy; White and African American | 800 IU | 1 year | — |
| Vitamin D supplementation in young White and African American women 2014 · 1600 IU vitamin D3 daily · Women aged 25–45 with vitamin D insufficiency (serum 25OHD ≤20 ng/mL), healthy; White and African American | 1,600 IU | 1 year | — |
| Vitamin D supplementation in young White and African American women 2014 · 2400 IU vitamin D3 daily · Women aged 25–45 with vitamin D insufficiency (serum 25OHD ≤20 ng/mL), healthy; White and African American | 2,400 IU | 1 year | — |
| The necessity and safety of calcium and vitamin D in the elderly 1990 · Treatment group, independently living elderly women · Independently living elderly women | 45 mcg | 11 weeks | — |
| The necessity and safety of calcium and vitamin D in the elderly 1990 · Treatment group, institutionalized elderly women · Institutionalized elderly women | 45 mcg | 11 weeks | — |
| Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial 2014 · CaD · Children aged approximately 8 years | 200 IU | 12 weeks | — |
| Calcium-vitamin D-fortified milk is as effective on circulating bone biomarkers as fortified juice and supplement but has less acceptance: a randomised controlled school-based trial 2014 · supplement · Children aged 9–12 years, both sexes, in Tehran | 200 IU | 12 weeks | — |
| Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women 2014 · vitamin D3 400 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency | 400 IU | 1 year | — |
| Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women 2014 · vitamin D3 800 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency | 800 IU | 1 year | — |
| Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women 2014 · vitamin D3 1600 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency | 1,600 IU | 1 year | — |
| Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women 2014 · vitamin D3 2400 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency | 2,400 IU | 1 year | — |
| Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women 2014 · vitamin D3 3200 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency | 3,200 IU | 1 year | — |
| Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women 2014 · vitamin D3 4000 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency | 4,000 IU | 1 year | — |
| Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women 2014 · vitamin D3 4800 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency | 4,800 IU | 1 year | — |
| Association Between Single Gene Polymorphisms and Bone Biomarkers and Response to Calcium and Vitamin D Supplementation in Young Adults Undergoing Military Training 2017 · calcium and vitamin D · Young adults undergoing Army or Air Force initial military training | 1,000 IU | 9 weeks | — |
| A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia 2017 · Initial daily Vitamin D3 + calcium citrate formulation · Adolescents aged 10–21 years with newly diagnosed B-ALL or T-ALL and Vitamin D insufficiency or deficiency | 2,000 IU | — | — |
| The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome 2017 · treatment group · children with steroid-sensitive nephrotic syndrome, after achieving remission | 8,571 IU | 90 days | — |
| Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation 2017 · VitD/Ca arm · HIV-infected, ART-naive participants with 25-(OH)D ≥10 and <75 ng/mL, CrCl ≥60 mL/min, and serum calcium <10.5 mg/dL; age and sex not specified | 4,000 IU | 48 weeks | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D3 2,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 2,000 IU | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D3 3,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 3,000 IU | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D2 50,000 IU weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 7,143 IU | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D2 50,000 IU twice weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 7,143 IU | 1 year | — |
| Effect of 6-Month Vitamin D Supplementation on Plasma Matrix Gla Protein in Older Adults 2019 · Vitamin D3 group · Adults aged 60–80 with low serum 25(OH)D, clinically relevant depressive symptoms, and at least one functional limitation | 1,200 IU | 26 weeks | — |
| Calcium and vitamin D supplementation and bone health in Marine recruits: Effect of season 2019 · Ca + D fortified snack bars · Male and female Marine recruits, mean age 18.9 years, undergoing 12 weeks of initial military training | 1,000 IU | 12 weeks | — |
| The Effect of High-Dose Postpartum Maternal Vitamin D Supplementation Alone Compared with Maternal Plus Infant Vitamin D Supplementation in Breastfeeding Infants in a High-Risk Population. A Randomized Controlled Trial 2019 · Maternal plus infant supplementation: mother received 600 IU/day vitamin D3 and infant received 400 IU/day vitamin D3 · Arab breastfeeding mothers enrolled within four weeks postpartum and their term infants, in Doha and Al-Wakra, Qatar | 1,000 IU | 26 weeks | — |
| Total, Bioavailable, and Free 25(OH)D Relationship with Indices of Bone Health in Elderly: A Randomized Controlled Trial 2021 · 600 IU/day vitamin D3 group · Adults older than 65 years who were overweight and had baseline serum 25(OH)D of 10–30 ng/mL | 600 IU | 1 year | — |
| Total, Bioavailable, and Free 25(OH)D Relationship with Indices of Bone Health in Elderly: A Randomized Controlled Trial 2021 · 3750 IU/day vitamin D3 group · Adults older than 65 years who were overweight and had baseline serum 25(OH)D of 10–30 ng/mL | 3,750 IU | 1 year | — |
| Effectiveness of three Vitamin D dosing protocols on raising and maintaining blood serum levels of 25-hydroxyvitamin D over a three-month period: a randomized, prospective study 2023 · Group 3 · Patients with baseline total 25-hydroxyvitamin D below 30.0 ng/mL; age and sex not reported | 52,000 IU | 12 weeks | — |
| The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trial 2022 · magnesium + vitamin D (MagD) · Overweight or obese participants; age and sex not reported | 3,000 IU | 12 weeks | — |
| Vitamin D-A Risk Factor for Bone Fractures in Children: A Population-Based Prospective Case-Control Randomized Cross-Sectional Study 2023 · study group · Children aged 2–17 years with fractures; supplementation was given when serum 25-OH-vitamin D was below 30 ng/mL. | 2,000 IU | 26 weeks | — |
| High-dose cholecalciferol supplementation to obese infertile men is sufficient to reach adequate vitamin D status 2024 · active group · Infertile men, including men with normal weight, overweight, and obesity | 301 g | 150 days | — |
| The Effect of Vitamin D Supplementation in Pregnant Women with Overweight and Obesity: A Randomised Controlled Trial 2023 · Intervention group · Pregnant women aged 21–45 years with pre-pregnancy BMI ≥25 kg/m², recruited at up to 16 weeks’ gestation | 800 IU | — | — |
| Prophylactic effect of low dose vitamin D in osteopenia of prematurity: a clinical trial study 2014 · group one · Preterm newborns with birth weight under 2000 g and gestational age under 37 weeks | 200 IU | 8 weeks | 30 |
| Prophylactic effect of low dose vitamin D in osteopenia of prematurity: a clinical trial study 2014 · group two · Preterm newborns with birth weight under 2000 g and gestational age under 37 weeks | 400 IU | 8 weeks | 30 |
| Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial 2023 · Vitamin D3 only · Generally healthy, robust, community-dwelling adults aged 70 years or older | 2,000 IU | 3 years | — |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 10 mcg | — | 870 |
| Antenatal Multiple Micronutrient Supplementation Compared to Iron-Folic Acid Affects Micronutrient Status but Does Not Eliminate Deficiencies in a Randomized Controlled Trial Among Pregnant Women of Rural Bangladesh 2019 · MM · Pregnant women aged 12–45 years in rural Bangladesh | 5 mcg | 165 days | 749 |
| Effects of Oral Nutritional Supplement with β-Hydroxy-β-methylbutyrate (HMB) on Biochemical and Hematological Indices in Community-Dwelling Older Adults at Risk of Malnutrition: Findings from the SHIELD Study 2024 · specialized ONS · Community-dwelling men and women aged 65 years or older in Singapore, at medium or high risk of malnutrition | 15.5 mcg | 180 days | 401 |
| Enhancement of vitamin A combined vitamin D supplementation on immune response to Bacille Calmette-Guérin vaccine revaccinated in Chinese infants 2014 · supplementation group · Chinese infants who were revaccinated with BCG; age range and sex distribution not specified | 500 IU | 90 days | 307 |
| Thirteen weeks of supplementation of vitamin D and leucine-enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study 2019 · active group · Adults aged 65 years or older with mild to moderate physical-function limitations and class I or II sarcopenia | 1,600 IU | 13 weeks | 184 |
| Newborn micronutrient status biomarkers in a cluster-randomized trial of antenatal multiple micronutrient compared with iron folic acid supplementation in rural Bangladesh 2020 · MM · Pregnant women in rural Bangladesh; age range not specified; no disease condition specified | 5 mcg | — | 176 |
| Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study 2017 · vitamin D group · Adult critically ill ICU patients with serum 25(OH)D levels ≤20 ng/ml; ages and sex not restricted | 540,000 IU | 26 weeks | 153 |
| Vitamin D Supplementation Improves Fasting Insulin Levels and HDL Cholesterol in Infertile Men 2022 · Vitamin D and calcium group · Infertile men; age not stated | 1,400 IU | 150 days | 151 |
| Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism 2020 · high dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml | 3,750 IU | 1 year | 129 |
| Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism 2020 · low dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml | 600 IU | 1 year | 128 |
| Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis 2007 · PTH group · Postmenopausal women with low bone mineral density and osteoporosis | 400 IU | 1 year | 119 |
| Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy 2005 · Group B · Patients after total thyroidectomy | 2 mcg | — | 111 |
| Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy 2005 · Group A · Patients after total thyroidectomy | 1 mcg | — | 104 |
| A Combined Nutrition and Exercise Intervention Influences Serum Vitamin B-12 and 25-Hydroxyvitamin D and Bone Turnover of Healthy Chinese Middle-Aged and Older Adults 2020 · intervention group · Chinese men and women aged 50 years or older, apparently healthy and community-dwelling | 30 mcg | 24 weeks | 80 |
| The DALI vitamin D randomized controlled trial for gestational diabetes mellitus prevention: No major benefit shown besides vitamin D sufficiency 2020 · Vitamin D intervention arm · Pregnant women with prepregnancy BMI ≥29 kg/m², without gestational diabetes mellitus, enrolled by 19+6 weeks of gestation; overweight or obese | 1,600 IU | — | 79 |
| Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover 2004 · Calcitonin group · Women older than 65 with high bone turnover, at high risk of osteoporosis | 200 IU | 26 weeks | 75 |
| Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study 2013 · D+ group · Adults with primary hyperparathyroidism after parathyroidectomy | 1,600 IU | 1 year | 75 |
| Consumption of a calcium and vitamin D-fortified food product does not affect iron status during initial military training: a randomised, double-blind, placebo-controlled trial 2016 · Ca/vitamin D group · Young adult male and female volunteers enrolled in US Army basic combat training | 25 mcg | 9 weeks | 75 |
| Effects of vitamin D supplementation on salivary immune responses during Marine Corps basic training 2019 · Vitamin D3 + calcium group · Male and female US Marine Corps recruits entering basic training; ages and vitamin D status not specified | 1,000 IU | 12 weeks | 73 |
| Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial 2014 · 1200 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months | 800 IU | 26 weeks | 70 |
| Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial 2003 · mid-dose · Postmenopausal Chinese women aged 48–62 years | 125 IU | 1 year | 68 |
| Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial 2003 · high dose · Postmenopausal Chinese women aged 48–62 years | 125 IU | 1 year | 68 |
| Obesity and efficacy of vitamin D(3) supplementation in healthy black adults 2020 · 1000 IU/day vitamin D3 · African American men and women aged 30–80; healthy adults, including participants with and without obesity | 1,000 IU | 90 days | 65 |
| Obesity and efficacy of vitamin D(3) supplementation in healthy black adults 2020 · 4000 IU/day vitamin D3 · African American men and women aged 30–80; healthy adults, including participants with and without obesity | 4,000 IU | 90 days | 63 |
| Vitamin D Supplementation in Overweight/obese Asian Indian Women with Prediabetes Reduces Glycemic Measures and Truncal Subcutaneous Fat: A 78 Weeks Randomized Placebo-Controlled Trial (PREVENT-WIN Trial) 2020 · Group A (vitamin D supplementation) · Overweight/obese Asian Indian women aged 20–60 years with prediabetes and vitamin D deficiency | 8,571 IU | 78 weeks | 61 |
| Obesity and efficacy of vitamin D(3) supplementation in healthy black adults 2020 · 2000 IU/day vitamin D3 · African American men and women aged 30–80; healthy adults, including participants with and without obesity | 2,000 IU | 90 days | 61 |
| Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans 2015 · vitamin D2 group · African American male veterans aged 35–85 with dysglycemia and hypovitaminosis D | 7,543 IU | 1 year | 60 |
| Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 2019 · treated · Adults aged 18–80 with histologically diagnosed nonalcoholic fatty liver disease (NAFLD) | 20 mg | 26 weeks | 60 |
| Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis 2007 · PTH/alendronate combination group · Postmenopausal women with low bone mineral density and osteoporosis | 400 IU | 1 year | 59 |
| Low iron status as a factor of increased bone resorption and effects of an iron and vitamin D-fortified skimmed milk on bone remodelling in young Spanish women 2014 · Fe+D group · Young iron-deficient women | 5 mcg | 16 weeks | 55 |
| Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method 2005 · CaCO(3) + cholecalciferol · Healthy younger women and older women and men; median ages 30 and 66, respectively | 1,200 IU | 4 weeks | 53 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · ALN add TPTD · Postmenopausal women with osteoporosis previously treated with alendronate | 400 IU | 26 weeks | 52 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · ALN switch TPTD · Postmenopausal women with osteoporosis previously treated with alendronate | 400 IU | 26 weeks | 50 |
| Consumption of vitamin D-fortified yogurt drink increased leptin and ghrelin levels but reduced leptin to ghrelin ratio in type 2 diabetes patients: a single blind randomized controlled trial 2017 · Vitamin D3-fortified doogh (FD) · Adults with type 2 diabetes; age and sex not specified | 1,000 IU | 12 weeks | 50 |
| Once daily calcium (1000 mg) and vitamin D (1000 IU) supplementation during military training prevents increases in biochemical markers of bone resorption but does not affect tibial microarchitecture in Army recruits 2022 · Ca + D fortified food bar · Male and female Army recruits undergoing basic combat training; mean age 21.8 years | 1,000 IU | 8 weeks | 50 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · RLX switch TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene | 400 IU | 26 weeks | 49 |
| Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial 2023 · active treatment (probiotic) · Healthy adults aged 18–60 years without prior SARS-CoV-2 infection or seropositivity | 20 mcg | 26 weeks | 48 |
| Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] 2004 · Control group · Postmenopausal women aged 45–65 with active rheumatoid arthritis | 400 IU | 2 years | 47 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · RLX add TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene | 400 IU | 26 weeks | 47 |
| Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial 2023 · D+ group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified | 7,143 IU | 8 weeks | 47 |
| Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease 2014 · 1000 μg vitamin K/d plus calcium and vitamin D3 group (main RCT) · Adults with Crohn's disease, currently in remission | 10 mcg | 1 year | 43 |
| Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] 2004 · HRT group · Postmenopausal women aged 45–65 with active rheumatoid arthritis | 400 IU | 2 years | 41 |
| The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study 2009 · Group 1 · Postmenopausal women with osteoporosis | 400 IU | 1 year | 41 |
| Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D 2014 · VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 23.0 years | 400 IU | 1 year | 41 |
| The effect of high-dose vitamin D supplementation on insulin resistance and arterial stiffness in patients with type 2 diabetes 2014 · vitamin D group · Adults aged 30–69 with vitamin D-deficient type 2 diabetes | 2,000 IU | 24 weeks | 40 |
| Changes in biochemical indices of bone metabolism in post-menopausal women following a dietary intervention with fortified dairy products 2009 · dairy intervention group (IG) · Post-menopausal women | 7.5 mcg | 150 days | 39 |
| Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin 2011 · First group · Postmenopausal women with osteoporosis | 400 IU | 26 weeks | 37 |
| Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D 2014 · MMN-VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 22.4 years | 400 IU | 1 year | 37 |
| The effects of fish oil plus vitamin D(3) intervention on non-alcoholic fatty liver disease: a randomized controlled trial 2022 · FO + D group · Adults aged 56.0 ± 15.9 years with non-alcoholic fatty liver disease | 1,680 IU | 90 days | 37 |
| Consumption of vitamin D-and calcium-fortified soft white cheese lowers the biochemical marker of bone resorption TRAP 5b in postmenopausal women at moderate risk of osteoporosis fracture 2012 · treated · Healthy postmenopausal women aged 56.6 ± 3.9 years with low spontaneous calcium and vitamin D intake | 2.5 mcg | 6 weeks | 36 |
| Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial 2021 · group B · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet | 250 IU | 6 weeks | 36 |
| Multiple Micronutrients, Lutein, and Docosahexaenoic Acid Supplementation during Lactation: A Randomized Controlled Trial 2020 · MMS group · Healthy breastfeeding women, aged 18–45 years, beginning supplementation 4–6 weeks after delivery | 600 IU | 12 weeks | 35 |
| Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin 2011 · Second group · Postmenopausal women with osteoporosis | 400 IU | 26 weeks | 34 |
| Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China 2020 · low VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D <10 ng/mL | 0.25 mcg | 26 weeks | 34 |
| Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial 2021 · group A · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet | 1,000 IU | 6 weeks | 34 |
| Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial 2008 · ch-OSA 3 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy | 20 mcg | 1 year | 33 |
| Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial 2008 · ch-OSA 6 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy | 20 mcg | 1 year | 33 |
| Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial 2008 · ch-OSA 12 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy | 20 mcg | 1 year | 33 |
| The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD 2016 · vitamin D, vitamin K and calcium supplements · Overweight patients with type 2 diabetes and CHD; age and sex not specified | 10 mcg | 12 weeks | 33 |
| Vitamin D and the hepatitis B vaccine response: a prospective cohort study and a randomized, placebo-controlled oral vitamin D(3) and simulated sunlight supplementation trial in healthy adults 2021 · oral vitamin D3 (ORAL) · Healthy men aged 17 years or older entering the British Army Combat Infantryman’s Course; vitamin D status varied, with many below sufficiency at baseline. | 1,400 IU | 12 weeks | 32 |
| Between-meal risedronate does not alter bone turnover in nursing home residents 2006 · Risedronate group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline | 400 IU | 12 weeks | 31 |
| The effect of vitamin d on aldosterone and health status in patients with heart failure 2014 · vitamin D3 group · Adults aged 50 years or older with NYHA class II–IV heart failure and serum 25OHD ≤37.5 ng/ml | 7,143 IU | 26 weeks | 31 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · HD/HK · Postmenopausal women aged 50–65 years | 16.3 mcg | 12 weeks | 31 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · HD/LK · Postmenopausal women aged 50–65 years | 15 mcg | 12 weeks | 31 |
| A pilot intervention to increase calcium intake in female collegiate athletes 2004 · treatment group · Female collegiate athletes with regular menstrual cycles; age not reported | 400 IU | 16 weeks | 30 |
| Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D 2014 · vitamin D-fortified doogh (DD) · Adults aged 30–50 of both sexes with type 2 diabetes | 1,000 IU | 12 weeks | 30 |
| Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D 2014 · calcium-vitamin D-fortified doogh (CDD) · Adults aged 30–50 of both sexes with type 2 diabetes | 1,000 IU | 12 weeks | 30 |
| The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2016 · vitamin D-K-calcium co-supplementation group · Vitamin D-deficient women aged 18–40 years with polycystic ovary syndrome | 400 IU | 8 weeks | 30 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · LD/HK · Postmenopausal women aged 50–65 years | 3.86 mcg | 12 weeks | 30 |
| Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome 2019 · vitamin D plus probiotic supplements · Women aged 18–40 with polycystic ovary syndrome | 3,571 IU | 12 weeks | 30 |
| Between-meal risedronate does not alter bone turnover in nursing home residents 2006 · Placebo group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline | 400 IU | 12 weeks | 29 |
| Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women 2013 · vitamin D- and calcium-fortified yogurt (FY) · Institutionalized women, mean age 85.5 years, at high risk for vitamin D deficiency and osteoporotic fracture | 10 mcg | 8 weeks | 29 |
| The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome 2017 · calcium, vitamin D and vitamin K group · Women aged 18–40 years with vitamin D deficiency and polycystic ovary syndrome | 400 IU | 8 weeks | 28 |
| Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial 2022 · 600 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline. | 600 IU | 16 weeks | 28 |
| Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins 2017 · vitamin D arm · Participants; age, sex, and health condition not specified | 1,200 IU | 1 year | 27 |
| Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia 2020 · Group B (control) · Postmenopausal women with osteopenia | 400 IU | 90 days | 27 |
| Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations 2020 · Nutrient supplement phase, healthy participants · Healthy adults aged 20–65 years | 1,000 IU | 4 weeks | 27 |
| Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial 2015 · Group C · Overweight, vitamin D-deficient women aged 18–40 years with PCOS | 7,143 IU | 8 weeks | 26 |
| Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial 2022 · 1200 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline. | 1,200 IU | 16 weeks | 26 |
| Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial 2022 · 4000 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline. | 4,000 IU | 16 weeks | 26 |
| Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women 2000 · calcium carbonate plus calcitriol · Thai postmenopausal women with osteoporosis, more than 10 years postmenopausal | 0.5 mcg | 90 days | 25 |
| A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis 2010 · Treatment group · Patients with multiple sclerosis; age and sex not specified | 40,000 IU | 52 weeks | 25 |
| Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China 2020 · high VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D ≥10 ng/mL | 0.25 mcg | 26 weeks | 25 |
| The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes 2021 · Ca+D-yogurt drink (CDY) · Adults aged 30–60 years with confirmed type 2 diabetes | 1,000 IU | 12 weeks | 25 |
| Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial 2012 · calcium-vitamin D supplements · Pregnant women aged 18–35 in the third trimester, primigravida, with singleton pregnancies and at risk for pre-eclampsia | 200 IU | 9 weeks | 24 |
| Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia 2020 · Group A · Postmenopausal women with osteopenia | 400 IU | 90 days | 24 |
| Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations 2020 · Nutrient supplement phase, participants with Crohn's disease · Adults aged 20–65 years with Crohn’s disease in remission | 1,000 IU | 6 weeks | 24 |
| Alfacalcidol (alpha D3) and calcium in osteoporosis 1994 · treatment group · Postmenopausal women with osteoporosis; mean age 67 years | 0.5 mcg | 3 years | 24 |
| Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover 2004 · Calcium and vitamin D control group · Women older than 65 with high bone turnover, at high risk of osteoporosis | 200 IU | 26 weeks | 23 |
| Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 2004 · No-alendronate group (controls) · HIV-infected men and women on stable HAART with osteopenia or osteoporosis | 500 IU | 52 weeks | 23 |
| [Treatment of secondary hyperparathyroidism with vitamin D metabolites] 1994 · 1-alpha-OHD3 plus 24,25(OH)2D3 · Adults aged 19–67 with secondary hyperparathyroidism receiving chronic haemodialysis | 10.3 mcg | 13 weeks | 23 |
| Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial 2009 · 2.0 g elemental calcium plus 800 IU vitamin D3 · Adults aged 30–75 in generally good health with at least one pathology-confirmed sporadic colon or rectal adenoma in the previous 36 months | 800 IU | 26 weeks | 23 |
| Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial 2009 · calcium plus vitamin D supplementation group · Adults aged 30–75 in general good health with a history of at least one pathology-confirmed colorectal adenoma within the past 36 months | 800 IU | 26 weeks | 23 |
| Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients 2010 · calcium plus vitamin D3 supplementation group · Adults aged 30–75 with a history of at least one adenomatous colonic or rectal polyp within the past 36 months | 800 IU | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients 2011 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp in the preceding 36 months | 800 IU | 180 days | 23 |
| Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial 2011 · 2.0 g elemental calcium plus 800 IU vitamin D3 group · Adults aged 30–75 with a history of sporadic colorectal adenoma | 800 IU | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients 2012 · 2.0 g elemental calcium plus 800 IU vitamin D3 supplementation · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp within the past 36 months | 800 IU | 26 weeks | 23 |
| Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: a randomized controlled trial 2015 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp within the past 36 months; both sexes | 800 IU | 26 weeks | 23 |
| The effects of chromium and vitamin D(3) co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial 2020 · both vitamin D3 and CrPic · patients with type 2 diabetes mellitus; age and sex not stated | 7,143 IU | 120 days | 23 |
| Acute Effects of Single Doses of Bonito Fish Peptides and Vitamin D on Whole Blood Gene Expression Levels: A Randomized Controlled Trial 2019 · VitD3 + BPH · Overweight or obese adults aged 18–65 years, without metabolic disorders requiring treatment | 1,000 IU | 1 day | 22 |
| Investigation of the Effect of Nutritional Supplementation with Whey Protein and Vitamin D on Muscle Mass and Muscle Quality in Subacute Post-Stroke Rehabilitation Patients: A Randomized, Single-Blinded, Placebo-Controlled Trial 2022 · HP group · Adults aged 40 years or older with ischemic or hemorrhagic stroke in subacute rehabilitation | 40 mcg | 16 weeks | 22 |
| Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial 2025 · Vit D 1000 + NAC (D1N) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m² | 1,000 IU | 8 weeks | 22 |
| Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial 2025 · Vit D 5000 + NAC (D5N) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m² | 5,000 IU | 8 weeks | 22 |
| Nutritional approach for inhibiting bone resorption in institutionalized elderly women with vitamin D insufficiency and high prevalence of fracture 2011 · Soft plain cheese consumption period · Institutionalized women aged 65 years or older with vitamin D insufficiency and low calcium intake | 2.5 mcg | 6 weeks | 21 |
| Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves' Disease Hyperthyroidism During Methimazole Treatment 2022 · MMI+Se+VitD (intervention group) · Adults aged 18–70 with newly diagnosed Graves’ disease and low or suboptimal selenium and vitamin D levels | 1,000 IU | 270 days | 21 |
| The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study 2009 · Group 2 (control group) · Postmenopausal women with osteoporosis | 400 IU | 1 year | 20 |
| Calcium and vitamin-D supplementation on bone structural properties in peripubertal female identical twins: a randomised controlled trial 2011 · calcium-supplemented group · Peripubertal girls aged 9 to 13 years | 400 IU | 26 weeks | 20 |
| Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial 2016 · Treatment arm · Children and adolescents aged 4–16 years with biopsy-proven NAFLD and serum vitamin D deficiency | 800 IU | 24 weeks | 20 |
| Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study 2018 · K citrate group · Postmenopausal women with osteopenia, more than 5 years post-menopause | 400 IU | 26 weeks | 20 |
| Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study 2018 · Placebo group with background supplements · Postmenopausal women with osteopenia, more than 5 years post-menopause | 400 IU | 26 weeks | 20 |
| Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D 1996 · three tablets containing 1000 mg CaCO3 plus 5 micrograms (200 IU) vitamin D/d · Healthy women aged 28–59 years | 5 mcg | 3 days | 20 |
| The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1-infected males: results of a clinical trial 2013 · A · HIV-1-infected males | 1,200 IU | 16 weeks | 19 |
| Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation 2025 · ω-3VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase | 4,000 IU | 6 weeks | 19 |
| Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 2004 · Alendronate-treatment group · HIV-infected men and women on stable HAART with osteopenia or osteoporosis | 500 IU | 52 weeks | 18 |
| Fortified breakfast cereal consumed daily for 12 wk leads to a significant improvement in micronutrient intake and micronutrient status in adolescent girls: a randomised controlled trial 2016 · Fortified cereal, morning · Females aged 16–19 years who regularly skipped breakfast and had low riboflavin status and haemoglobin; no diagnosed illness | 4.15 mcg | 12 weeks | 18 |
| Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients 2018 · Calcium + Vitamin D (4-arm randomization) · Adults aged 45–75 with a removed histologically verified colorectal adenoma; men and women | 1,000 IU | 1 year | 17 |
| Fortified breakfast cereal consumed daily for 12 wk leads to a significant improvement in micronutrient intake and micronutrient status in adolescent girls: a randomised controlled trial 2016 · Fortified cereal, evening · Females aged 16–19 years who regularly skipped breakfast and had low riboflavin status and haemoglobin; no diagnosed illness | 4.15 mcg | 12 weeks | 16 |
| Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial 2025 · ERC plus adjunctive doxercalciferol · Adults with non-dialysis chronic kidney disease, mild to moderate secondary hyperparathyroidism, and elevated iPTH; mean age 65.8 years in the combined adjunctive-AVD arm | 0.5 mcg | 52 weeks | 14 |
| Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial 2025 · ERC plus adjunctive paricalcitol · Adults with non-dialysis chronic kidney disease, mild to moderate secondary hyperparathyroidism, and elevated iPTH; mean age 65.8 years in the combined adjunctive-AVD arm | 1 mcg | 52 weeks | 14 |
| Effect of vitamin D and calcium supplementation on bone turnover in institutionalized adults with Down's Syndrome 2006 · supplementation group · Adults with Down's syndrome living in an institution | 800 IU | 1 year | 12 |
| [Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3] 1995 · 1-alpha(OH) vitamin D3 group · Postmenopausal women with osteoporosis | 0.5 mcg | 26 weeks | 12 |
| The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners 2021 · ω-3 PUFA group · Healthy physically active male recreational marathon runners, with no stated disease; age range not reported | 30 mcg | 3 weeks | 12 |
| Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial 2025 · ERC plus adjunctive calcitriol · Adults with non-dialysis chronic kidney disease, mild to moderate secondary hyperparathyroidism, and elevated iPTH; mean age 65.8 years in the combined adjunctive-AVD arm | 0.25 mcg | 52 weeks | 12 |
| Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone 1995 · Group B · Adults with chronic renal insufficiency who were not receiving dialysis | 0.55 mcg | 39 weeks | 12 |
| Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa 2006 · calcium plus vitamin D treatment group · Adults with adenomatous polyps; age and sex not stated | 400 IU | 26 weeks | 11 |
| Systemic vitamin D supplementation and local bone formation after maxillary sinus augmentation - a randomized, double-blind, placebo-controlled clinical investigation 2016 · vitamin D3 + calcium group · Adults undergoing maxillary sinus augmentation; age and sex not stated | 5,000 IU | 213 days | 10 |
| SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE? 2015 · Calcium citrate group (Group 1 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–55 | 800 IU | 60 days | 10 |
| SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE? 2015 · Calcium carbonate group (Group 2 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–68 | 800 IU | 60 days | 10 |
| Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3 1994 · group 1 · Adults aged 26–72 years receiving hemodialysis with secondary hyperparathyroidism resistant to long-term low-dose 1-alpha-OHD3 therapy | 10 mcg | 24 weeks | 10 |
| A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis 1993 · Study group: 2.5 mEq/L calcium dialysate with oral calcitriol · Patients on peritoneal dialysis | 0.25 mcg | 8 weeks | 9 |
| Tibial bone responses to 6-month calcium and vitamin D supplementation in young male jockeys: A randomised controlled trial 2015 · Supplemented group · Apprentice male jockeys, mean age 20.2 ± 3.2 years, engaged in caloric restriction and high volumes of physical activity | 400 IU | 26 weeks | 8 |
| The effect of calcium and vitamin D supplementation on bone health of male Jockeys 2017 · calcium and vitamin D group · Apprentice male jockeys; mean age 20.18 ± 3.23 years | 400 IU | 26 weeks | 8 |
| Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion 2001 · Two doses of Orocal D3 at a 6-hour interval · Healthy male volunteers; age not stated | 800 IU | 1 day | — |
| Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion 2001 · One morning dose of Cacit vitamin D3 · Healthy male volunteers; age not stated | 880 IU | 1 day | — |
| Absorbability and cost effectiveness in calcium supplementation 2001 · marketed calcium carbonate · Postmenopausal women | 10 mcg | 7 days | — |
| Absorbability and cost effectiveness in calcium supplementation 2001 · encapsulated calcium carbonate · Postmenopausal women | 10 mcg | 7 days | — |
| Absorbability and cost effectiveness in calcium supplementation 2001 · marketed calcium citrate · Postmenopausal women | 10 mcg | 7 days | — |
| Alendronate prevents further bone loss in renal transplant recipients 2001 · Group A · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier | 0.5 mcg | 1 year | — |
| Alendronate prevents further bone loss in renal transplant recipients 2001 · Group B · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier | 0.5 mcg | 1 year | — |
| Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion 2002 · Two doses of Orocal D3 · Healthy volunteers; age and sex not specified | 800 IU | 1 day | — |
| Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion 2002 · Single morning dose of Cacit D3 · Healthy volunteers; age and sex not specified | 880 IU | 1 day | — |
| Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels 2002 · calcium-vitamin D (CaD) group · postmenopausal women with serum 25(OH)vitamin D levels below 18 ng/mL | 200 IU | 90 days | — |
| Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women 2004 · calcium citrate · Older postmenopausal women | 900 IU | 12 weeks | — |
| Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women 2004 · calcium carbonate · Older postmenopausal women | 900 IU | 12 weeks | — |
| Mineral water fortified with folic acid, vitamins B6, B12, D and calcium improves folate status and decreases plasma homocysteine concentration in men and women 2004 · Fortified mineral water · Free-living men and women without folate deficiency or elevated homocysteine | 0.6 mcg | 8 weeks | — |
| Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis 2004 · group D · Elderly women with osteoporosis; mean age 77.4 years | 1 mcg | 26 weeks | — |
| Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial 2005 · group A · Postmenopausal women aged 49–71 years; healthy | 5.7 mcg | 26 weeks | — |
| Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial 2005 · group B · Postmenopausal women aged 49–71 years; healthy | 5.7 mcg | 26 weeks | — |
| Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake 2005 · High-calcium mineral water plus vitamin D · Postmenopausal women with dietary calcium intake below 700 mg/day; mean age 70.1 years | 400 IU | 26 weeks | — |
| Calcemic response to magnesium or 1-alpha-hydroxycholecalciferol treatment in intestinal hypomagnesemia 1991 · Combined 1-alpha-hydroxycholecalciferol and magnesium chloride treatment · Gastroenterological patients with intestinal hypomagnesemia; age and sex not reported | 1 mcg | 7 days | — |
| Dietary acid-base balance, bone resorption, and calcium excretion 2006 · Cereal (acidogenic) diet group · Healthy older men and women | 400 IU | 60 days | — |
| Dietary acid-base balance, bone resorption, and calcium excretion 2006 · Fruit and vegetable (alkalinogenic) diet group · Healthy older men and women | 400 IU | 60 days | — |
| Effect of calcium, vitamins K1 and D3 on bone in galactosemia 2006 · calcium, vitamins K1 and D3 supplementation · Children aged 3–17 years with classical galactosemia | 10 mcg | 2 years | — |
| The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults 2007 · calcium and vitamin D supplementation · Caucasian adults aged 65 years or older without diabetes; baseline fasting glucose was normal or impaired | 700 IU | 3 years | — |
| Biochemical short-term changes produced by hormonal replacement therapy 1991 · calcium · White postmenopausal women, 6 months to 6 years after menopause | 400 IU | 60 days | — |
| Biochemical short-term changes produced by hormonal replacement therapy 1991 · cyclic estrogen-progestin plus calcium · White postmenopausal women, 6 months to 6 years after menopause | 400 IU | 60 days | — |
| Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss 2008 · Placebo group · Postmenopausal Korean women aged 50–65 with moderate bone loss | 400 IU | 12 weeks | — |
| Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss 2008 · Alendronate group · Postmenopausal Korean women aged 50–65 with moderate bone loss | 400 IU | 12 weeks | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · placebo · Men and women aged 50 and older; described as healthy older adults | 525 IU | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · potassium bicarbonate group · Men and women aged 50 and older; described as healthy older adults | 525 IU | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · sodium bicarbonate group · Men and women aged 50 and older; described as healthy older adults | 525 IU | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · potassium chloride group · Men and women aged 50 and older; described as healthy older adults | 525 IU | 90 days | — |
| The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD 2009 · calcium-vitamin D(3) fixed combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease | 800 IU | 26 weeks | — |
| The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD 2009 · calcium plus vitamin D(3) separate combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease | 800 IU | 26 weeks | — |
| Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial 2010 · calcium plus vitamin D supplementation group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp | 800 IU | 26 weeks | — |
| Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D 2010 · group 1 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L | 1,000 IU | 8 weeks | — |
| Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D 2010 · group 2 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L | 1,000 IU | 8 weeks | — |
| The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design 2010 · vitamin D3 and calcium · Healthy men and women aged 20–80 years | 100 mcg | 90 days | — |
| Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial 2011 · vitamin D-fortified yogurt drink (DY) · people with type 2 diabetes; age and sex not stated | 1,000 IU | 12 weeks | — |
| Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial 2011 · vitamin D + calcium-fortified yogurt drink (DCY) · people with type 2 diabetes; age and sex not stated | 1,000 IU | 12 weeks | — |
| Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness 2012 · ibandronate group · Postmenopausal women with chronic critical illness | 2,000 IU | 11 days | — |
| Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness 2012 · placebo group · Postmenopausal women with chronic critical illness | 2,000 IU | 11 days | — |
| Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial 2011 · PRT + fortified milk supplement · Healthy men aged 50–79 years | 800 IU | 548 days | — |
| Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial 2011 · Fortified milk supplement · Healthy men aged 50–79 years | 800 IU | 548 days | — |
| Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes 2012 · vitamin D-fortified doogh (DD) · Adults aged 30–60 of both sexes with type 2 diabetes | 1,000 IU | 12 weeks | — |
| Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes 2012 · calcium + vitamin D3-fortified doogh (CDD) · Adults aged 30–60 of both sexes with type 2 diabetes | 1,000 IU | 12 weeks | — |
| Blood lead concentration is not altered by high-dose vitamin D supplementation in children and young adults with HIV 2013 · 7000 IU/day group · Children and young adults aged 8–24 years with HIV | 7,000 IU | 12 weeks | — |
| One year B and D vitamins supplementation improves metabolic bone markers 2013 · group B · Healthy adults older than 54 years | 1,200 IU | 1 year | — |
| Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial 2013 · vitamin D-fortified doogh (DD) · Men and women aged 30–60 years with type 2 diabetes | 1,000 IU | 12 weeks | — |
| Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial 2013 · calcium- and vitamin D-fortified doogh (CDD) · Men and women aged 30–60 years with type 2 diabetes | 1,000 IU | 12 weeks | — |
| Calcium and vitamin d supplementation in postmenopausal women 2013 · vitamin D3 and calcium · healthy postmenopausal white women | 100 mcg | 26 weeks | — |
| Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial 2014 · CaDEA · Children aged approximately 8 years | 200 IU | 12 weeks | — |
| Vitamin D does not increase calcium absorption in young women: a randomized clinical trial 2014 · vitamin D3 400 IU group · White and African American women aged 25 to 45 years with vitamin D insufficiency | 400 IU | 1 year | — |
| Vitamin D does not increase calcium absorption in young women: a randomized clinical trial 2014 · vitamin D3 800 IU group · White and African American women aged 25 to 45 years with vitamin D insufficiency | 800 IU | 1 year | — |
| Vitamin D does not increase calcium absorption in young women: a randomized clinical trial 2014 · vitamin D3 1600 IU group · White and African American women aged 25 to 45 years with vitamin D insufficiency | 1,600 IU | 1 year | — |
| Vitamin D does not increase calcium absorption in young women: a randomized clinical trial 2014 · vitamin D3 2400 IU group · White and African American women aged 25 to 45 years with vitamin D insufficiency | 2,400 IU | 1 year | — |
| Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial 2014 · 1,000 IU/day vitamin D3 · Black adults aged 30–80 years from a community-based healthy population | 1,000 IU | 90 days | — |
| Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial 2014 · 2,000 IU/day vitamin D3 · Black adults aged 30–80 years from a community-based healthy population | 2,000 IU | 90 days | — |
| Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial 2014 · 4,000 IU/day vitamin D3 · Black adults aged 30–80 years from a community-based healthy population | 4,000 IU | 90 days | — |
| Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study 2014 · intervention group (IG) · Steroid-naïve pre-pubertal children with new-onset nephrotic syndrome treated with glucocorticoids; boys and girls | 1,000 IU | 12 weeks | — |
| Calcium and vitamin D supplementation maintains parathyroid hormone and improves bone density during initial military training: a randomized, double-blind, placebo controlled trial 2014 · Ca+Vit D · Men and women undergoing Army initial military training (basic combat training); ages and health conditions not specified | 1,000 IU | 9 weeks | — |
| Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial 2014 · joint calcium-vitamin D group · Adults with vitamin D insufficiency and type 2 diabetes; age and sex range not stated | 7,143 IU | 8 weeks | — |
| Calcium supplementation increases blood creatinine concentration in a randomized controlled trial 2014 · Calcium plus vitamin D · Adults aged 45–75 in generally good health with a previously removed large bowel adenoma; predominantly male | 1,000 IU | 5 years | — |
| Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months 2015 · 1,000 IU/day · African-American adults aged 30–80 who were overweight or obese | 1,000 IU | 90 days | — |
| Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months 2015 · 2,000 IU/day · African-American adults aged 30–80 who were overweight or obese | 2,000 IU | 90 days | — |
| Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months 2015 · 4,000 IU/day · African-American adults aged 30–80 who were overweight or obese | 4,000 IU | 90 days | — |
| A Vitamin D-Calcium-Fortified Yogurt Drink Decreased Serum PTH but did not Affect Osteocalcin in Subjects with Type 2 Diabetes 2015 · Group 3 (CDD) · Women and men aged 30–50 years with type 2 diabetes | 1,000 IU | 12 weeks | — |
| Vitamin D and Evening Primrose Oil Administration Improve Glycemia and Lipid Profiles in Women with Gestational Diabetes 2016 · Vitamin D and EPO group · Pregnant women with gestational diabetes mellitus | 1,000 IU | 6 weeks | — |
| Vitamin D supplementation during pregnancy and infancy reduces aeroallergen sensitization: a randomized controlled trial 2016 · 1000 IU/400 IU · Pregnant women from 27 weeks’ gestation and their infants from birth to 6 months | 1,400 IU | — | — |
| Vitamin D supplementation during pregnancy and infancy reduces aeroallergen sensitization: a randomized controlled trial 2016 · 2000 IU/800 IU · Pregnant women from 27 weeks’ gestation and their infants from birth to 6 months | 2,800 IU | — | — |
| Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients 2017 · 1,200 mg/day elemental calcium plus 1,000 IU/day vitamin D3 supplementation · Adults aged 45–75 with a history of colorectal adenomas | 1,000 IU | 1 year | — |
| One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation 2017 · group B · Adults older than 54 years; no specific condition stated | 1,200 IU | 1 year | — |
| Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial 2017 · Calcium + vitamin D alone · Postmenopausal women aged 50–79 in the WHI hormone therapy trials | 400 IU | 5 years | — |
| Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial 2017 · Calcium + vitamin D plus hormone therapy · Postmenopausal women aged 50–79 in the WHI hormone therapy trials | 400 IU | 5 years | — |
| Maternal vitamin D sufficiency and reduced placental gene expression in angiogenic biomarkers related to comorbidities of pregnancy 2017 · 4000 IU/day vitamin D3 group · Pregnant women aged 18–45 with singleton pregnancies, enrolled at 8–14 weeks’ gestation | 4,400 IU | — | — |
| Vitamin D(3) supplementation decreases a unique circulating monocyte cholesterol pool in patients with type 2 diabetes 2018 · vitamin D3 group · Adults aged 25–80 with type 2 diabetes, hypertension, and serum 25(OH)D below 25 ng/mL | 4,000 IU | 120 days | — |
| Nutritional Supplementation With Physical Activity Improves Muscle Composition in Mobility-Limited Older Adults, The VIVE2 Study: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · daily nutritional supplement · Mobility-limited, vitamin D-insufficient older adults; mean age 78.5 years, 46.3% female | 800 IU | 26 weeks | — |
| Effects of Vitamin D Supplementation on Semen Quality, Reproductive Hormones, and Live Birth Rate: A Randomized Clinical Trial 2018 · active group · Infertile men with serum 25-hydroxyvitamin-D levels ≤50 nmol/L | 1,400 IU | 150 days | — |
| Safety of calcium and vitamin D supplements, a randomized controlled trial 2018 · CaCO3 1200 mg/day with 10 000 IU vitamin D3/day · Healthy, white postmenopausal women | 10,000 IU | 1 year | — |
| Safety of calcium and vitamin D supplements, a randomized controlled trial 2018 · CaCO3 1200 mg/day with 600 IU vitamin D3/day · Healthy, white postmenopausal women | 600 IU | 1 year | — |
| Effects of vitamin D and calcium on expression of MSH2 and transforming growth factors in normal-appearing colorectal mucosa of sporadic colorectal adenoma patients: A randomized clinical trial 2019 · vitamin D3 plus calcium group · People with sporadic colorectal adenomas; age and sex not specified | 1,000 IU | 1 year | — |
| Effects of supplemental calcium and vitamin D on tight-junction proteins and mucin-12 expression in the normal rectal mucosa of colorectal adenoma patients 2019 · calcium plus vitamin D supplementation · Adults aged 45–75 with a removed colorectal adenoma and no remaining polyps after colonoscopy; patients at increased risk for colorectal neoplasms | 1,000 IU | 1 year | — |
| Randomized Study of the Effect of Vitamin D and Omega-3 Fatty Acids Cosupplementation as Adjuvant Chemotherapy on Inflammation and Nutritional Status in Colorectal Cancer Patients 2020 · cosupplementation group · Colorectal cancer patients | 7,143 IU | 8 weeks | — |
| Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial 2020 · n-3 LCPUFA plus vitamin D · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified | 2,400 IU | 17 weeks | — |
| Effects of Maternal Vitamin D3 Supplementation on Offspring Epigenetic Clock of Gestational Age at Birth: A Post-hoc Analysis of a Randomized Controlled Trial 2020 · Vitamin D3 supplementation · Pregnant women; mean age 29.6 ± 4.8 years; multiethnic population | 4,400 IU | — | — |
| Effects of Vitamin D and Omega-3 Fatty Acids Co-Supplementation on Inflammatory Factors and Tumor Marker CEA in Colorectal Cancer Patients Undergoing Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2020 · co-supplementation · Patients with stage II or III colorectal cancer undergoing chemotherapy | 7,143 IU | 8 weeks | — |
| Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial 2021 · calcium plus vitamin D group · Adults aged 45–75 with a histologically verified colorectal adenoma | 1,000 IU | 1 year | — |
| Improving the endothelial dysfunction in type 2 diabetes with chromium and vitamin D(3) byreducing homocysteine and oxidative stress: A randomized placebo-controlled trial 2020 · group IV: vitamin D3 and CrPic · People with type 2 diabetes mellitus; age and sex not stated | 7,143 IU | 120 days | — |
| Changes in Bone Turnover, Inflammatory, Oxidative Stress, and Metabolic Markers in Women Consuming Iron plus Vitamin D Supplements: a Randomized Clinical Trial 2021 · D-Fe · Women aged 18–45 years with hemoglobin ≤12.7 g/dL and 25OHD ≤29 ng/mL | 1,000 IU | 12 weeks | — |
| Differential regulation of a placental SAM68 and sFLT1 gene pathway and the relevance to maternal vitamin D sufficiency 2020 · 4000 IU/day vitamin D3 plus standard prenatal vitamin · Pregnant women aged 18–45 years; placental samples were from term pregnancies | 4,400 IU | — | — |
| Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab 2020 · Infliximab and vitamin D (Ifx + VitD) · Adults aged 18–80 with active colonic and/or ileocecal Crohn’s disease | 20,000 IU | 7 weeks | — |
| Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab 2020 · Placebo infliximab and vitamin D (placeboIfx + VitD) · Adults aged 18–80 with active colonic and/or ileocecal Crohn’s disease | 20,000 IU | 7 weeks | — |
| Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial 2021 · MK-7 group · Postmenopausal women; the abstract describes them as healthy | 38 mcg | 1 year | — |
| The effect of vitamin D supplementation on circulating osteoprogenitor cells: A pilot randomized controlled trial 2021 · 50,000 IU bolus dose plus 1000 IU daily supplement · Healthy older adults, stratified by baseline vitamin D level into deficient and non-deficient groups | 51,000 IU | 6 weeks | — |
| The effect of combined supplementation with vitamin D and omega-3 fatty acids on blood glucose and blood lipid levels in patients with gestational diabetes 2021 · test group · Women aged 18–40 with gestational diabetes | 80,000 IU | 6 weeks | — |
| Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial 2022 · MK-7 plus vitamin D · Elderly men with an aortic valve calcification score >300 AU | 25 mcg | 2 years | — |
| Small-Scale Randomized Controlled Trial to Explore the Impact of β-Hydroxy-β-Methylbutyrate Plus Vitamin D(3) on Skeletal Muscle Health in Middle Aged Women 2022 · SED HMB + D · Women aged 45–60 years, apparently healthy, assigned to sedentary control; vitamin D status varied at baseline | 2,000 IU | 12 weeks | — |
| Small-Scale Randomized Controlled Trial to Explore the Impact of β-Hydroxy-β-Methylbutyrate Plus Vitamin D(3) on Skeletal Muscle Health in Middle Aged Women 2022 · RET HMB + D · Women aged 45–60 years, apparently healthy, assigned to resistance exercise training; vitamin D status varied at baseline | 2,000 IU | 12 weeks | — |
| Effect of Vitamin D and/or Calcium Supplementation on Pancreatic β-Cell Function in Subjects with Prediabetes: A Randomized, Controlled Trial 2023 · vitamin D plus calcium group · Chinese adults with prediabetes; the reported disposition-index result was for vitamin D-insufficient individuals | 1,600 IU | 24 weeks | — |
| Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial 2022 · Vitamin D3 and marine n-3 fatty acids active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization | 2,000 IU | 1935 days | — |
| Changes in bone turnover after high-dose vitamin D supplementation during acute pulmonary exacerbation in cystic fibrosis 2023 · Vitamin D3 · Adults aged 16 years or older with cystic fibrosis admitted to hospital for an acute pulmonary exacerbation | 250,000 IU | 1 year | — |
| Does maternal vitamin D status influence placental weight or vascular and inflammatory pathology? Secondary analysis from the Kellogg Pregnancy Study 2023 · 4000 IU vitamin D3 group · Women aged 18–45 with singleton pregnancies, enrolled at 10–14 weeks’ gestation; generally healthy, with a sub-cohort with specified chronic conditions | 4,000 IU | — | — |
| Effects of dietary supplementation of fish oil plus vitamin D(3) on gut microbiota and fecal metabolites, and their correlation with nonalcoholic fatty liver disease risk factors: a randomized controlled trial 2024 · FO + D group · Subjects studied in relation to nonalcoholic fatty liver disease risk factors; age and sex not reported | 1,680 IU | 90 days | — |
| Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial 2025 · Vitamin D3 plus marine n-3 fatty acids · Females aged 55 years or older and males aged 50 years or older; no specific condition stated | 2,000 IU | 5 years | — |
| Effects of vitamin K2 and D3 supplementation on epicardial adipose tissue and systemic inflammation: A substudy of the AVADEC trial 2025 · vitamin K2 and D3 group · Men aged 65–74 at cardiovascular risk | 25 mcg | 2 years | — |
| Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3 1998 · cholecalciferol group · Inpatients with hypovitaminosis D and secondary hyperparathyroidism | 800 IU | 26 weeks | — |
| Low dose estrogen and calcium have an additive effect on bone resorption in older women 1999 · Calcium plus vitamin D (Ca+D) · Healthy women over 70 years of age | 800 IU | 12 weeks | — |
| Low dose estrogen and calcium have an additive effect on bone resorption in older women 1999 · Combination Ca+D and E2 · Healthy women over 70 years of age | 800 IU | 12 weeks | — |
| Safety and tolerability of 6-month supplementation with a vitamin D, calcium and leucine-enriched whey protein medical nutrition drink in sarcopenic older adults 2020 · One-serving WP-MND group during the open-label extension · Adults aged 65 years or older with sarcopenia who continued from the RCT | 800 IU | 13 weeks | 133 |
| Effects of combined nutritional supplementation and exercise on proxy measures of muscle mass, strength, and function in older adults with sarcopenia: a 12-week multicentre RCT 2025 · intervention group · Adults aged 65 years or older with sarcopenia or possible sarcopenia; men and women | 400 IU | 12 weeks | 55 |
| Change in Micronutrient Intake among People with Relapsing-Remitting Multiple Sclerosis Adapting the Swank and Wahls Diets: An Analysis of Weighed Food Records 2021 · Wahls (modified Paleolithic elimination diet) group · Adults with relapsing-remitting multiple sclerosis and moderate to severe fatigue; age and sex range not specified | 5,000 IU | 12 weeks | 39 |
| Change in Micronutrient Intake among People with Relapsing-Remitting Multiple Sclerosis Adapting the Swank and Wahls Diets: An Analysis of Weighed Food Records 2021 · Swank (low-saturated fat diet) group · Adults with relapsing-remitting multiple sclerosis and moderate to severe fatigue; age and sex range not specified | 5,000 IU | 12 weeks | 38 |
| A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome 2017 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS) | 400 IU | 12 weeks | 30 |
| The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes 2019 · Magnesium-zinc-calcium-vitamin D group · Women aged 18–40 with gestational diabetes mellitus, at 24–28 weeks’ gestation at diagnosis | 400 IU | 6 weeks | 30 |
| Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome 2011 · intervention arm · Postmenopausal women with metabolic syndrome | 1,000 IU | 14 weeks | 25 |
| Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins 2017 · vitamin D + B arm · Participants; age, sex, and health condition not specified | 1,200 IU | 1 year | 25 |
| Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial 2010 · treatment arm · Healthy postmenopausal women | 1,000 IU | 14 weeks | 16 |
| Characterizing gut microbial dysbiosis and exploring the effect of prebiotic fiber supplementation in patients with COPD 2025 · nutritional supplement group · Adults with moderate to very severe, clinically stable COPD (GOLD II–IV); ages reported as 69.3 ± 7.4 years | 20 mcg | 90 days | 16 |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 0.15 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 400 IU | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 0.4 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 400 IU | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 1.0 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 400 IU | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 2.5 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 400 IU | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 1.0 mg intermittent sCT (every other day) · Healthy postmenopausal women aged 55–85 years | 400 IU | 90 days | — |
| Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women 2005 · KBC 30 mmol/d · Postmenopausal women | 400 IU | 3 years | — |
| Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women 2005 · KBC 60 mmol/d · Postmenopausal women | 400 IU | 3 years | — |
| Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women 2005 · KBC 90 mmol/d · Postmenopausal women | 400 IU | 3 years | — |
| One year B and D vitamins supplementation improves metabolic bone markers 2013 · group A · Healthy adults older than 54 years | 1,200 IU | 1 year | — |
| Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women 2016 · Intervention (Int), premenopausal women · Premenopausal women, mean age 41 years; no specific condition stated | 15 mcg | 12 weeks | — |
| Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women 2016 · Intervention (Int), postmenopausal women · Postmenopausal women, mean age 59 years; no specific condition stated | 15 mcg | 12 weeks | — |
| One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation 2017 · group A · Adults older than 54 years; no specific condition stated | 1,200 IU | 1 year | — |
| A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya 2017 · standard regimen · Pregnant women enrolled between 16 and 30 weeks of gestation | 200 IU | 8 weeks | — |
| A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya 2017 · low-dose regimen · Pregnant women enrolled between 16 and 30 weeks of gestation | 200 IU | 8 weeks | — |
| Multimicronutrient and omega-3 fatty acid supplementation reduces low-grade inflammation in older participants: An exploratory study 2025 · multimicronutrient and n-3 PUFA supplementation · Healthy, physically active older adults; mean age 75.6 ± 3.9 years; sex not specified | 50 mcg | 12 weeks | — |
| Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial 2023 · Vitamin D3 plus marine omega-3s · Generally healthy, robust, community-dwelling adults aged 70 years or older | 2,000 IU | 3 years | — |
| Predicting comorbidities of pregnancy: A comparison between total and free 25(OH)D and their associations with parathyroid hormone 2023 · prenatal plus extra supplementation · Pregnant women with singleton pregnancies | 4,400 IU | — | 196 |
| Predicting comorbidities of pregnancy: A comparison between total and free 25(OH)D and their associations with parathyroid hormone 2023 · group receiving a daily prenatal · Pregnant women with singleton pregnancies | 400 IU | — | 191 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · placebo · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 400 IU | 1 year | 88 |
| Standard versus distal Roux-en-Y gastric bypass in patients with BMI 50-60 kg/m2: 5-year outcomes of a double-blind, randomized clinical trial 2021 · Standard RYGB · Adults aged 20–60 years with BMI 50–60 kg/m² referred for bariatric surgery | 800 IU | 5 years | 57 |
| Standard versus distal Roux-en-Y gastric bypass in patients with BMI 50-60 kg/m2: 5-year outcomes of a double-blind, randomized clinical trial 2021 · Distal RYGB · Adults aged 20–60 years with BMI 50–60 kg/m² referred for bariatric surgery | 800 IU | 5 years | 56 |
| Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial 2025 · Randomized trial, placebo group · Infertile men; mean age approximately 34 years | 25 mcg | 160 days | 49 |
| The impact of supplemental n-3 long chain polyunsaturated fatty acids and dietary antioxidants on physical performance in postmenopausal women 2013 · Placebo group (background supplements) · Postmenopausal women over age 65 without the listed bone, cancer or liver diseases; most were prefrail or frail. | 1,000 IU | 180 days | 41 |
| Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome 2015 · 50,000 IU/wk vitamin D + calcium placebo · Overweight and obese vitamin D deficient women diagnosed with PCOS | 7,143 IU | 8 weeks | 26 |
| Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol 2008 · group 1 (alfacalcidol) · Kidney transplant recipients with low bone mineral density; 22 women and 42 men were recruited overall, but the arm's sex and age distribution are not reported. | 0.5 mcg | 1 year | 25 |
| Vitamin D supplementation during pregnancy: Effect on the neonatal immune system in a randomized controlled trial 2018 · 400 IU/d vitamin D3 · Pregnant women; age and pregnancy condition details beyond pregnancy are not reported. | 400 IU | — | 25 |
| Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial 2017 · placebo group · Postmenopausal women aged 50–72 years with osteopenia | 200 IU | 26 weeks | 25 |
| Effects of 12 Weeks of Whole-Body Vibration Training and Vitamin D Supplementation on Bone Density and Muscle Quality in the Aged with Osteosarcopenia: A Randomized Controlled Trial 2025 · control group · Older adults with osteosarcopenia; age range and sex not specified | 0.25 mcg | 90 days | 24 |
| The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1-infected males: results of a clinical trial 2013 · B · HIV-1-infected males | 1,200 IU | 16 weeks | 17 |
| Biochemical short-term changes produced by hormonal replacement therapy 1991 · placebo · White postmenopausal women, 6 months to 6 years after menopause | 400 IU | 60 days | — |
| Vitamin D supplementation for nonspecific musculoskeletal pain in non-Western immigrants: a randomized controlled trial 2012 · Original placebo group switched to vitamin D at week 6 · Vitamin D-deficient non-Western immigrants with nonspecific persistent musculoskeletal pain | 150,000 IU | 6 weeks | — |
| Vitamin D favorably alters the cancer promoting prostaglandin cascade 2013 · 400 IU vitamin D-3 · Healthy women; age range and other characteristics not specified | 400 IU | 30 days | — |
| Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial 2014 · vitamin D3 and calcium carbonate · Healthy non-Hispanic white adults aged 45–75 years | 1,000 IU | 1 year | — |
| Free 25(OH)D and Calcium Absorption, PTH, and Markers of Bone Turnover 2015 · 800-IU dose arm · Adults; age, sex, and health condition are not specified in the abstract. | 800 IU | 10 weeks | — |
| Free 25(OH)D and Calcium Absorption, PTH, and Markers of Bone Turnover 2015 · 2000-IU dose arm · Adults; age, sex, and health condition are not specified in the abstract. | 2,000 IU | 10 weeks | — |
| Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial 2015 · 2400 IU maternal group · Exclusively lactating women 4 to 6 weeks postpartum | 2,400 IU | 26 weeks | — |
| microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma 2017 · 400 IU/day group · Men with prostate cancer scheduled for prostatectomy; age not reported | 400 IU | 8 weeks | — |
| microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma 2017 · 10,000 IU/day group · Men with prostate cancer scheduled for prostatectomy; age not reported | 10,000 IU | 8 weeks | — |
| microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma 2017 · 40,000 IU/day group · Men with prostate cancer scheduled for prostatectomy; age not reported | 40,000 IU | 8 weeks | — |
| Maternal Obesity, 25-Hydroxy Vitamin D Concentration, and Bone Density in Breastfeeding Dyads 2017 · control group · Exclusively breastfeeding mother-infant dyads recruited 4–6 weeks postpartum; maternal age and infant age range not reported | 800 IU | — | — |
| Maternal Obesity, 25-Hydroxy Vitamin D Concentration, and Bone Density in Breastfeeding Dyads 2017 · intervention group · Exclusively breastfeeding mother-infant dyads recruited 4–6 weeks postpartum; maternal age and infant age range not reported | 6,400 IU | — | — |
| Body mass index, calcium supplementation and risk of colorectal adenomas 2019 · VCPPS vitamin D3 · People with a recently removed colorectal adenoma; sex and age range not specified | 1,000 IU | 1303 days | — |
| Body mass index, calcium supplementation and risk of colorectal adenomas 2019 · VCPPS calcium carbonate plus vitamin D3 · People with a recently removed colorectal adenoma; sex and age range not specified | 1,000 IU | 1303 days | — |
| A high weekly dose of cholecalciferol and calcium supplement enhances weight loss and improves health biomarkers in obese women 2018 · vitamin D3 (Diet/D) · Obese women with vitamin D deficiency | 7,143 IU | 90 days | — |
| Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia 2022 · Group B · Postmenopausal women with osteopenia | 400 IU | 1 year | — |
| Association of Body Weight With Response to Vitamin D Supplementation and Metabolism 2023 · Vitamin D3 plus marine omega-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, free of cancer and cardiovascular disease at baseline | 2,000 IU | 2 years | — |
| Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial 2024 · vitamin D · Men aged 50 years or older and women aged 55 years or older, free of cardiovascular disease and cancer at baseline | 2,000 IU | 1935 days | — |
| Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial 1998 · Control group · Postmenopausal women with osteoporosis, at least one prevalent vertebral fracture, and low bone mineral density; mean age 68.4 years | 400 IU | 1 year | — |